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Introduction and outline

CH
A
PT
ER 1
General introduction 
and outline of this thesis
The first chapter of this thesis presents an introduction with a description of the background, 
main concepts, aims, and outline of this study.
General introduction
Ehlers-Danlos syndrome (EDS) and Marfan syndrome are the two most common inherited 
connective tissue disorders (ICTDs).12 They are characterized by a wide variety of dermal, 
articular, orthopaedic, gastrointestinal, gynaecological, vascular, and cardiac symptoms due 
to an abnormal composition of the connective tissue. Neuromuscular symptoms, such as 
muscle weakness, fatigue, exercise intolerance, and muscle cramps are only sporadically 
reported and generally understood as secondary to reduced physical activity.
Our clinical interest in the neuromuscular features in EDS and Marfan syndrome was 
raised by the encounter with these patients at our outpatients department. They were 
referred diagnostic work-up with complaints of muscle weakness, fatigue or exercise 
intolerance, and pain (Box /). Ancillary investigations revealed no signs of a concomitant 
neuromuscular disorder, although these patients displayed mild muscle weakness or sensory 
disturbances or both. These encounters have put forth the hypothesis that neuromuscular 
symptoms might be an intrinsic part of the phenotype of these multisystem disorders. With 
a dense network of connective tissue present within muscle and peripheral nerve, this seems 
a plausible assumption.
Recent developments in neuromuscular research have further increased our attention 
on neuromuscular features in EDS and Marfan syndrome. Myopathies are generally 
understood to be caused by defects or deficiencies of molecules inside muscle cells or along 
the muscle membrane (sarcolemma). Over the last few years however, a number of 
myopathies have been found to be caused by mutations in the gene encoding the 
extracellular matrix (ECM) molecule collagen VI; both Bethlem myopathy and Ullrich 
Congenital Muscular Dystrophy (UCMD) are caused by mutations in collagen VI.3 Apparently, 
a primary change in the ECM which surrounds muscle cells is capable of influencing muscle 
function drastically. At the same time, these developments have raised our scientific interest 
into the physiological effect of alterations of the muscle ECM on quantitative muscle 
function. This interest has grown with current investigations on myofascial force transmission,4 
which suggests that the connective tissue within and between the muscles plays a role in 
force transmission.
Following the above, the focus of this thesis is dual. First, it aims to explore the occurrence 
of neuromuscular symptoms in two ICTDs: EDS and Marfan syndrome. Second, it endeavours 
to elucidate the role of the ECM in muscle function by investigating how quantitative 
muscle function changes in EDS. We will explain this inspiration and focus in this introduction. 
Next, we will present the objectives of this study and give an outline of the thesis.
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BOX 1 Three patients with Ehlers-Danlos syndrome.
Patient 1
A 58-year old male patient was referred for analysis of proximal weakness. EDS was diagnosed at 
the age of 46 following a knee haemorrhage. He also suffered from frequent subluxations of his 
shoulders, easy bruising, and hyperextensible skin. Later this was specified as the tenascin X (TNX)- 
deficient type EDS. His medical history further showed a gastric haemorrhage due to ulcers, mitral 
valve endocarditis and prolaps, renal insufficiency, and bilateral pneumothorax. Motor milestones 
were not delayed, but he had never been very good at sports. He reported limited physical fitness, 
reduced strength, and easy fatigability compared with peers. Walking stairs was difficult due to 
weakness and dyspnoea.
Physical examination revealed generalized joint hypermobility and a hyperextensible skin. Proximal 
muscle strength in arms was MRC 4/5, in legs MRC 3/5, and distal weakness was very mild (MRC 4/5). 
Creatine kinase was normal. Electromyography revealed myopathic units in proximal arm and leg 
muscles. Muscle biopsy revealed myopathic changes without signs of a specific myopathy.
At the age of 58, he was admitted at the ICU after replacement of the mitral valve. This was 
complicated by perforation ofthe piriformis sinus during introduction of a gastric tube. Subsequently, 
he developed sepsis with multi-organ failure and died.
Pa tien t 2
A 42-year old female patient was referred for analysis of proximal muscle weakness and impairments 
in daily life. Hypermobility type EDS was diagnosed at the age of 41. Motor development was 
normal, and she had been active in sports until adolescence. Her complaints started eight years ago, 
when she remarked soreness of her leg muscles after strenuous physical activity. Since an uterus 
extirpation seven years ago, she suffered from recurrent subluxations of her right hip, and walking 
became impaired. Walking distance was now limited to 10 minutes due to pain in her feet, in spite 
of orthopedic shoes. Riding a bicycle was only possible for 1 km due to difficulties holding the steer 
and fatigue in her legs. Driving a car with cruise control was possible for short distances only. She 
worked part time (50%) as a secretary at a social service and used voice recognition software. An 
extensive rehabilitation program focusing on improvement of her physical condition and increase 
of muscle strength had increased her articular complaints, but had not resulted in improvement of 
muscle strength.
Physical examination showed generalized joint hypermobility, mild proximal hip girdle weakness, 
and weakness in hands, wrists, and foot extensors (MRC 4). Provocation test showed no signs of 
myasthenia.
Creatine kinase was normal. Muscle ultrasound revealed mild increase of ultrasound intensity of the 
gastrocnemius muscle and carpal flexor muscles. Nerve conduction studies and electromyography 
were normal.
She was again referred to a rehabilitation centre, focusing on aids for her impairments and on 
finding a balance between her physical capacities and her daily activities, with good effect.
Pa tien t 3
A 32-year old female patient was referred for analysis of her exercise intolerance and mild distal 
muscle weakness. EDS of the hypermobility type was diagnosed at the age of 25. Three years later, 
cervical dystonia was diagnosed in her and in her father, but no DYT-// mutation was detected. 
Motor development was normal. During childhood, she suffered from easy bruising and frequent 
(sub)luxations. Exercise tolerance had always been reduced in comparison with peers. An extensive 
training program in a rehabilitation centre had not improved that. Fatigue had been a prominent 
complaint since adolescence. She slept well and was well rested in the morning, but fatigued easily
14
BOX 1 Continued.
during the day. She worked part time as a secretary at a law firm (60%) but was exhausted after work 
and had no energy left to participate in any recreation or social activities. Her main concern was 
the complete lack of knowledge of EDS among the health insurance doctors she had encountered. 
Physical examination revealed mild cervical torticollis, generalized joint hypermobility, and mild 
weakness of finger extensors muscles and of dorsal interosseous muscles on both sides. Creatine 
kinase was normal. Nerve conduction studies showed no signs of ulnar neuropathy. Muscle 
ultrasound revealed increased ultrasound intensity of the tibial anterior muscle and biceps brachii 
muscle. Needle biopsy was not performed. Psychological screening consisting of standardized 
questionnaires pointed to severe fatigue and severe impairments in daily functioning.
She was reassured with the explanation of the results of recent studies on neuromuscular features, 
pain, fatigue, and natural course of the hypermobility type of EDS.
Discussion
Patient 1 is one of the first patients who was referred to our department for neuromuscular work-up 
and as such contributed to the initiative of this study. His case is descriptive since the TNX-deficient 
type EDS can be accompanied by mild to moderate proximal muscle weakness and polyneuropathy, 
while no signs of a concomitant myopathy or underlying cause for a polyneuropathy were found. 
Furthermore, we have recently reported another severe complication during ICU admittance in a 
patient with this type EDS.5
Patient 2 and 3 are illustrative for the subsequent referrals of EDS patients to our department. 
The hypermobility type EDS is the most common type EDS, and most patients are female. Mild 
proximal and/or distal muscle weakness usually manifests after adolescence. Fatigue is a prominent 
feature. Ancillary investigations generally show mild abnormalities, but no signs of overt myopathy. 
Complaints of exercise intolerance and fatigue are often neglected by medical specialists and in 
insurance procedures. Rehabilitation programs focusing at improving muscle strength often result 
in increase of articular problems rather than in functional improvement. Furthermore, it has been 
shown that the lack of knowledge of EDS among physicians and the resulting memory of not being 
respected is substantial for individuals with EDS and can last for years.6,7
Connective tissue within muscle
Connective tissue is any type of biological tissue that forms a network composed of the ECM 
and of nerve branches, capillaries, fibroblasts, and macrophages that are embedded within 
this matrix. It supports, binds together, and protects virtually all organs. The ECM network is built 
up of two major structural protein molecules: collagen and elastin. Collagen is the main 
component of connective tissue, and is the most abundant protein in mammals, making up 
about 25% to 35% of the whole-body protein content. It forms elongated fibrils which are mostly 
found in fibrous tissues such as tendon, ligament and skin. Collagen generally constitutes 1% to 
2% of muscle tissue, and accounts for 6%  of the weight of strong, tendinous muscles. Elastin is 
the elastic protein in connective tissue which allows many tissues in the body to resume their 
shape after stretching or contracting. For example, elastin helps skin to return to its original 
position when it is poked or pinched. Elastin is also an important load-bearing tissue and used 
in places where mechanical energy is required to be stored, such as in fascia and tendons.
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Within muscle, connective tissue consists of endomysium, perimysium, and epimysium, 
surrounding the muscle fibres, fascicles, and the entire muscle respectively (Figure 1, 2). These 
connective tissue membranes are continuous with the tendons that connect the muscle to 
the bones. This continuity gives support to the muscle cells and enables a strong connection 
between the muscles and the bones, necessary to transmit force and to enable physiological 
movements. In general, the role of connective tissue within muscle has long been considered 
to be only mechanically supportive.
Figure 1 Cross section of a muscle with 
the connective tissue within 
muscle consisting of endo-, 
peri-, and epimysium. Reprinted 
with permission of the artist 
(K.Mount, www.gm-studio.com).
Figure 2 Close-up of a piece of pork muscle: 
muscle fibres (dark grey) sur­
rounded by the perimysium (light 
grey). Reprinted with permission 
of the photographer: D. Marshall 
and D. Gregory, Wellcome Images, 
London, UK (http://www.wellcome. 
ac.uk/en/bia/gallery.html).
However, recent insights underscore the importance of the ECM in developmental and 
regenerative processes, as well as in transmembrane signalling in various tissues.89 Hence, 
the ECM within muscle is gradually becoming recognized as a dynamic complex of molecules 
that interacts with sarcolemmal, cytoskeletal, and nuclear elements in order to maintain 
skeletal muscle integrity and to transmit forces.10 In fact, the muscle ECM is a very dynamic 
structure that easily adapts to changes in physiological demand. Constant remodelling 
modifies the mechanical and viscoelastic properties, decreases stress-susceptibility, and may 
increase load-resistance.11
A shift o f focus in neuromuscular research
The focus in neuromuscular research has gradually extended in line with these developments 
from the nucleus, contractile elements, and sarcolemma towards the ECM.12 The novelty of
16
this development is reflected by the lack of detail in which the ECM has generally been 
depicted in reviews on myopathies and muscular dystrophies so far (Figure3A). Our review in 
Chapter2, focusing on the myopathies and the ICTDs caused by defects or deficiencies of 
ECM molecules, presents a more detailed image of the ECM within muscle (Figure 3B).
As a result of this broadening of the scope in neuromuscular research, a number of 
myopathies have been identified that result from deficiencies of ECM molecules or trans- 
sarcolemmal molecules projecting into the ECM: Bethlem myopathy and UCMD are caused 
by mutations in the gene encoding collagen VI. These collagen VI myopathies are 
characterized by hypotonia, delayed motor milestones, and a variable degree and pattern of 
muscle weakness. In addition, abnormal scar formation, soft velvety skin, and a combination 
of joint contractures and joint hypermobility is observed. Limb girdle muscular dystrophy 2E 
with joint hyperlaxity and contractures is associated with mutations in SGCB encoding the 
transsarcolemmal molecule beta-sarcoglycan.31314 The dermal and articular features in these 
myopathies point to a clinical overlap with ICTDs such as EDS and Marfan syndrome.1516 
In fact, joint hypermobility can be useful in the differential diagnosis of myopathies.17
The role of the extracellular matrix in muscle function
The finding that a number of myopathies is caused by a deficiency of ECM molecules has 
raised our curiosity into the role of the ECM in muscle function. As a result, we became 
interested in studying the physiological mechanism in which alterations of the muscle ECM 
cause abnormal muscle function while the contractile elements within muscle cells seem to 
function normally. Recent research on myofascial force transmission offers a possible 
explanation; we will discuss this below.
The general view of skeletal muscle is that force is generated within its muscle fibres and 
then directly transmitted in-series, usually via tendon, onto the skeleton. However, muscle fibres 
are mechanically connected to surrounding structures and cannot be considered as independent 
actuators. This suggests that the connective tissue within and between the muscles plays a role 
in force transmission. Indeed, force transmission occurs not only through myotendinous 
pathways, but a proportion of the muscle force generated within a muscle is transmitted to the 
skeleton through intra-, inter- and extramuscular myofascial force transmission (Box2). Within 
muscles this occurs via the endo- and perimysium with its intramuscular continuations of 
neurovascular tracts in which nerve branches and blood vessels are embedded. The epimysium 
and fascia between muscle enable extramuscular force transmission. Force transmission via 
these pathways might be influenced by alterations of the ECM.
Inherited connective tissue disorders
ICTDs are a group of inherited multisystem disorders due to abnormal composition of the 
connective tissue. These disorders are characterized by a varying degree of dermal, skeletal,
17
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oo Figure 3 The focus in neuromuscular research has gradually extended from the nucleus, contractile elements, and sarcolemma towards the ECM.
The novelty of this development is reflected by gradual increase of detail in which the ECM is being depicted in reviews.
A: Image in a review on muscular dystrophies in 2006, representative of most reviews 
so far: the ECM is depicted as coiled lines representing the collagen fibres in the ECM. 
The transsarcolemmal molecules are presented in detail with their subunits whereas 
the collagens are depicted only collectively as curled lines. Reprinted by permission 
from Macmillan Publishers Ltd: Nat Rev Mol Cell Biol, copyright 2006.30
B: Image adapted from the image in our review on the clinical and molecular 
overlap of myopathies and inherited connective tissue disorders in 2008. The 
ECM is drawn in much more detail (DG = dystroglycan).31
■I band *1 A band H I band
BOX 2 Myofascial force transmission.
Muscle force is transmitted from the muscle fibre (M) in which it is generated onto the myotendinous 
junction (MTJ), and subsequently to the tendon (T) and skeleton (S): m yotend inous force 
transm ission (dashed line).
In addition, muscle force can also be transmitted through serial myofascial pathways:
1. In tram uscu lar m yofascial force transm ission: Force generated within muscle fibres can be 
transmitted via the network of intramuscular connective tissue.
Muscle force can also leave the muscle to be transmitted to the skeleton: Two epjmuscular pathways 
are distinguished:
2. In term uscular force transm ission: force transmission between two neighbouring muscles via 
the continuous intermuscular connective tissue at their muscle belly interface, and
3. Extram uscular: force transm ission between a muscle and adjacent non-muscular structures: 
extramuscular connective tissue of fascia, septa or neurovascular tracts (F).4,21
Myofascial force transmission thus contributes significantly to the total force generated in a muscle. 
Up to 40%  of muscle force can be transmitted in this way.22 Result of several studies on myofascial 
force transmission call for a new view of the locomotor apparatus, which needs to take into account 
the high interdependence of muscles and muscle fibres as force generators, as well as proximo-distal 
force differences and serial and parallel distributions of sarcomere lengths that are consequences 
of such interaction. If this is done, the effects of integrating a muscle fibre, muscle or muscle group 
into higher levels of organization of the body will become more clear.23
articular, orthopaedic, cardiovascular, gynaecological, and gastrointestinal symptoms. EDS 
and Marfan syndrome are the two most common ICTDs. They are caused by defects of 
collagen or TNX (EDS) and fibrillin (Marfan syndrome), the latter of which is one of the 
constituents of elastin. Among other ICTDs are osteogenesis imperfecta, cutis laxa, and 
Stickler syndrome.
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Ehlers-Danlos syndrome
The key features of EDS are joint hypermobility, skin hyperextensibility, and tissue fragility, 
resulting in easy bruising, abnormal scarring, and arterial rupture (Figure 4). The overall 
prevalence of this condition has been estimated at 1:5-10,000.18
Figure 4 Clinical features of EDS.
A  and B: Skin hyperextensibility and joint hypermobility in a 20-year-old male TNX-deficient EDS patient. 
C: W idened atrophic scars in a 34-year-old female patient with the classical type EDS.
Six major types of EDS are identified based upon clinical diagnostic criteria: the classical, 
hypermobility, vascular, kyphoscoliotic, arthrochalasia, and dermatosparaxis type, the latter 
three of which are very rare.1 In 2001, a clinically and genetically distinct type was identified, 
the TNX-deficient type.19 Table 1 in Chapter4 presents these diagnostic criteria. The clinical 
variability of each EDS subtype is extremely wide and the diagnosis is not always straight­
forward even for the experienced clinician.20 As a result, misdiagnosis or lack of diagnosis 
represents a major burden for patients with EDS.7 In fact, a recent survey by the The European 
Organization for Rare Diseases (http://www.eurordis.org) has demonstrated that among 
patients belonging to 16 major rare diseases, those affected with EDS have the longest delay 
in diagnosis and request consultation of up to 20 specialists before obtaining the correct 
diagnosis.
This has severe consequences on the quality of life of the patients, usually in terms of 
excessive financial and time expense, superfluous investigations, wrong therapies, delay of 
appropriate treatments, and preventable worsening of the disease state.20 Furthermore, it 
influences the attitude of patients towards medicine.7 This is illustrated by a recent patients' 
account of their disease in the British Medical Journal.6 These stories of three patients are 
similar in that symptoms have long been misunderstood, misinterpreted, and mishandled, 
and that their condition remained undiagnosed throughout childhood and adolescence.
The hypermobility type EDS is inherited as a dominant trait and is the most common 
type, with extreme hypermobility as its hallmark, and severe pain and fatigue developing 
later in life.24 The classical type is also autosomal dominantly inherited and forms the second
20
most common type. Together with the hypermobility type, it accounts for approximately 
90% of all EDS patients. It is characterized by joint hypermobility, skin hyperextensibility, 
and increased tissue fragility resulting in widened, atrophic scars. The vascular type EDS has 
thin, translucent skin, arterial/intestinal/uterine fragility or rupture, and extensive bruising as 
major diagnostic criteria. The phenotype of the TNX-deficient type is similar to that of the 
classical type, but inheritance is autosomal recessive and scars are not widened. The other 
types are much less common.
Muscle involvement in EDS can be expected based on interactions between muscle and 
the ECM molecules involved in the pathophysiology of EDS. Furthermore, muscle hypotonia 
and muscle rupture are part of the diagnostic criteria of EDS, and fatigue, musculoskeletal 
pain, and delayed gross motor development are described as associated features.1 However, 
muscle symptoms such as muscle weakness and exercise intolerance are only sporadically 
reported in case reports , and often explained as a result of exercise avoidance due to joint 
hypermobility.1-18-25-26
Marfan syndrome
Marfan syndrome is characterized by ocular, skeletal, and cardiovascular manifestations, with 
an estimated prevalence of 1 in 3-5,000.2 Mutations in the fibrillin-1 (FBN!) gene located at 
15q21.1 account for most of the cases.27 FBN1 encodes fibrillin-1, a widely distributed major 
component of microfibrils in the ECM. It has an important role in elastin deposition in elastic 
fibres. Joint hypermobility is usually most pronounced in distal joints and often accompanied 
by arachnodactyly ('spider fingers') (Figure 5). (Congenital) joint contractures, particularly of 
the elbow, occur with moderate frequency.2
Figure 5 Clinical features of Marfan syndrome.
A  and B: Arachnodactyly with positive thumb sign in a 27-year-old male Marfan syndrome patient. 
C: Distal joint hypermobility in a 28-year-old male Marfan syndrome patient.
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Marfan patients frequently report muscle fatigue, and to a lesser extent muscle weakness, 
muscle hypoplasia, myalgia, and cramps, but these features have long been neglected in 
clinical practice and research.
Aims of this study
These observations in EDS and Marfan patients, together with the developments in 
neuromuscular and experimental research described above have led to the design of this 
study on neuromuscular features in EDS and Marfan syndrome and on the role of the ECM in 
muscle function.
Theoretically, we could have investigated the role of the ECM in muscle function in 
patients with collagen VI myopathies (Bethlem myopathy and UCMD). This might even seem 
a more plausible approach, since muscular features are very apparent in these myopathies 
caused by an ECM defect. However, as described above, EDS patients with muscular 
symptoms were referred to our outpatients department and formed the inspiration for this 
study. In parallel, recent experimental studies have shown that the pathophysiology of 
Bethlem myopathy and UCMD involves various intracellular changes: mitochondrial 
dysfunction and spontaneous apoptosis, leading to myofibre degeneration.28 This probably 
results from defective autophagy.29 These intracellular processes are likely to significantly 
influence muscle function. Therefore, collagen VI myopathies were not considered to be a 
very suitable model to investigate the role of the ECM on muscle function.
In order to explore the occurrence of neuromuscular symptoms in EDS and Marfan 
syndrome and to study the role of the ECM in muscle function this thesis has the following 
aims (numbering corresponds with the parts of the outline):
(I) to present an overview of the clinical and molecular overlap of the ICTDs and myopathies;
(IIA) to study the occurrence and nature of neuromuscular features in EDS;
(IIB) to investigate the pathophysiological mechanisms of muscle weakness in EDS in order 
to explore the role of the ECM in muscle function, and;
(III) to examine the occurrence of neuromuscular features in Marfan syndrome, to find out 
whether the findings in part IIA are specific for EDS or can also be found in other ICTDs.
Table 1 gives a schematic representations of the content of this thesis.
Outline of this thesis
Part I: Introduction and outline
The first part of this thesis presents an introduction with a description of the main concepts, 
aims of the study, and outline (Chapter 1); and deals with the overlap of ICTDs and myopathies 
(Chapter2). Chapter2 presents an overview of neuromuscular involvement in ICTDs and of
22
myopathies with symptoms typically seen in ICTDs. As such, this review focuses on the 
molecular and clinical overlap between these disorders and myopathies. These ICTDs are 
caused by defects of matrix-embedded ECM molecules that are also present within muscle 
(collagen I, III, V, IX, lysylhydroxylase, tenascin, fibrillin, fibulin, elastin, and perlecan), and 
interact with trans-membrane glycoproteins. Insight in this clinical overlap can contribute to 
enhanced recognition of joint hypermobility as a distinctive feature in the differential 
diagnosis of myopathies.
Part II: Neuromuscular features o f Ehlers-Danlos syndrome 
Part IIA: Clinical evaluation o f Ehlers-Danlos syndrome patients
In part IIA, the reports of our initial clinical observations and the results of the subsequent 
systematic clinical and questionnaire studies on neuromuscular involvement, fatigue, and 
pain in EDS are presented.
Chapter 3 consists of three case reports of EDS patients with neuromuscular involvement. 
First, we describe a patient with the hypermobility type EDS who subsequently presented 
with an axillary neuropathy, a brachial plexopathy, and a sciatic neuropathy. We discuss the 
possible pathophysiological mechanisms. The second report in this chapter describes the 
neuromuscular features of an adolescent patient with the kyphoscoliotic type of EDS, 
consisting of myopathy and polyneuropathy. Muscle hypotonia and weakness have so far 
only been recognized in neonates, but has not been reported later in life. In the third report, 
we present a TNX-deficient type EDS patient, who presented with moderate proximal and 
severe distal muscle weakness. The muscle atrophy and contractures in her hands point to 
the clinical overlap with Bethlem myopathy described in part I of this thesis.
Chapter 4 is an observational study on neuromuscular features in four types of EDS. 
Standardized questionnaires, physical examination, laboratory investigations, nerve 
conduction studies, electromyography, muscle ultrasound, and muscle biopsy were 
performed in 40 EDS patients with the vascular, classical, TNX-deficient type EDS, and 
hypermobility type of EDS due to TNXB haploinsufficiency.
In addition to this clinical study, the results of a questionnaire study on neuromuscular 
features, fatigue, pain, and impairments are described (Chapter 5 and 6). We used a multidi­
mensional assessment method to measure fatigue, its clinical relevance, and possible 
determinants among 273 members of the Dutch Ehlers-Danlos syndrome patient 
organization. The following dimensions were assessed: fatigue severity, functional 
impairment in daily life, physical activity, psychological distress, sleep disturbances, 
concentration problems, social functioning, self efficacy concerning fatigue, causal 
attribution of fatigue, pain, and disease related factors (Chapter 5). Since pain severity was 
found to be one of the determinants of fatigue in EDS, we subsequently investigated various 
aspects of pain, functional impairment due to pain, and sleep disturbances (Chapter 6).
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Part IIB: Quantitative muscle function measurements o f tenascin X-deficient 
Ehlers-Danlos syndrome patients and tenascin xb knockout mice
The studies described in this part focus on the pathophysiological mechanisms contributing 
to the neuromuscular phenotype of EDS. These studies were performed on TNX-deficient 
EDS patients and on Tnxb knockout (KO) mice, an animal model of EDS.
We first performed a pilot study on two EDS patients (Chapter 7), consisting of clinical 
investigations, electromyography, muscle ultrasound, muscle biopsy, and quantitative 
muscle function tests on two EDS patients with deficiency of TNX. Based on the results, we 
hypothesized that alterations in the ECM modify myofascial force transmission (i.e. the 
transmission of generated force via connective tissue structures within and between muscles, 
enabling them to work together) and consequently influence muscle function in EDS.
To test this hypothesis, we subsequently performed an extensive quantitative muscle 
function study on Tnxb KO mice (Chapter 9). We first performed a study on the muscular 
phenotype of these Tnxb KO mice (Chapter 8). This consisted of standardized clinical 
assessment, muscle histology, and gene expression profiling of muscle tissue. Furthermore, 
peripheral nerve composition was studied by histology and electronmicroscopy. The 
quantitative muscle function study protocol (Chapter 9) focused on both intra- and 
intermuscular aspects of muscle force. Intramuscular aspects were studied during isometric 
contractions of isolated muscles, when the muscle-tendon complex length is fixed. In this 
situation, the actual active length of the muscle fibres is dependent on the properties of the 
series elastic components, consisting of the network of endo-, peri-, and epimysium, and of 
the tendon. Study of the intermuscular aspects of muscle force has proved to be an effective 
method to investigate myofascial force transmission.4
To confirm these findings in EDS patients, we finally performed a quantitative muscle 
function measurement on seven TNX-deficient EDS patients (Chapter 10). This consisted of 
measurements of knee flexion and extension at different joint angles and of an evaluation of 
voluntary activation capacity.
Part III: Neuromuscular features o f M arfan syndrome 
Clinical evaluation o f M arfan syndrome patients
In order to find out whether the clinical findings in EDS can be generalized to other ICTDs, an 
observational study on neuromuscular features in Marfan syndrome was performed, the 
results of which are described in Chapter 11. Neuromuscular involvement was evaluated in 
ten Marfan patients through a standardized questionnaire, physical examination, nerve 
conduction study, needle electromyography, muscle ultrasound, laboratory investigation, 
and muscle biopsy. Existing neuroimages were screened for dural ectasia and spinal 
meningeal cysts.
24
Since the results also showed signs of lumbosacral radiculopathy associated with dural 
ectasia in the elder Marfan patients, we investigated three patients with moderate to severe 
lumbosacral radiculopathy in more detail. This case series is presented in Chapter 12.
Part IV: Summary and outlook
Finally, part IV provides an overview of the results of the previously described chapters. 
General conclusions and directions for future research are formulated as well (Chapter 13).
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Table 1 Schematic presentation of the outline of this thesis.
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Clinical and molecular overlap 
between myopathies and inherited 
connective tissue diseases
Adapted from:
Voermans NC, Bönnemann CG, Huijing PA, Hamel BC, van Kuppevelt TH, 
de Haan A, Schalkwijk J, van Engelen BG, Jenniskens GJ.
Neuromuscul Disord. 2008;18:843-56.
Abstract
This review presents an overview of the myopathies and inherited connective tissue disorders 
that are caused by defects or deficiencies of molecules within the extracellular matrix (ECM). 
We will cover the myopathies caused by defects in transmembrane protein complexes 
(dystroglycan, sarcoglycan, and integrins), laminin, and collagens (collagen VI, XIII, and XV). 
Clinical characteristics of several of these myopathies imply skin or joint symptoms. We 
subsequently describe the inherited connective tissue disorders that are characterized by 
mild to moderate muscle involvement in addition to the dermal, vascular, or articular 
symptoms. These disorders are caused by defects of matrix-embedded ECM molecules that 
are also present within muscle (collagen I, III, V, IX, lysylhydroxylase, tenascin, fibrillin, fibulin, 
elastin, and perlecan).
By focusing on the structure and function of these ECM molecules, we aim to point out the 
clinical and molecular overlap between these disorders. We argue that clinicians and 
researchers dealing with myopathies and inherited connective tissue disorders should be 
aware of this overlap. Only a multi-disciplinary approach will allow a full recognition of the 
wide variety of symptoms present in the spectrum of ECM defects, which has important 
implications for scientific research, diagnosis, and for the treatment of these disorders.
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Introduction
Clinical overlap between myopathies and inherited connective tissue diseases
Over the past few years, a number of patients with Ehlers-Danlos syndrome (EDS) or Marfan 
syndrome were referred to our neuromuscular outpatients' clinic by the departments of 
Dermatology and Human Genetics. These patients suffered from muscle weakness, 
hypotonia, exercise intolerance, and / or easy fatigability. Concomitantly, patients with similar 
complaints were referred for neuromuscular work-up by their general practitioner or by 
other neurologists. None of these patients was diagnosed with a neuromuscular disorder. 
However, clinical investigations raised the suspicions of an inherited connective tissue 
disorder (ICTD), and most of these patients were diagnosed with EDS or Marfan syndrome.
Exposure to both patient groups has sparked our interest in the clinical overlap between 
certain myopathies and ICTDs. Scientific progress in various fields has contributed to the 
understanding of this overlap. First, biochemical research provides a growing insight in the 
structure and function of various extracellular matrix (ECM) molecules of skeletal muscle.1 
Furthermore, growth factors and cytokines are increasingly recognized as players in the field 
of muscular pathophysiology.2-4 Second, focus in neuromuscular research has gradually 
extended from the cytoskeleton and the sarcolemma towards the ECM.5 This results in an 
increased recognition of myopathies that result from defects in ECM molecules (e.g. Bethlem 
myopathy and Ullrich Congenital Muscular Dystrophy (UCMD)).6 Clinical characteristics of 
these myopathies also include skin and joint features, as seen in the ICTDs.7 Third, clinical 
research in the field of ICTDs has renewed interest for myopathic features.8-10 This has shed 
light on the roles of ECM molecules in pathophysiology and towards possible interventions.4
With this review, we aim to provide an overview of the myopathies and ICTDs that result 
from defective ECM molecules. A general awareness of the overlap in clinical features 
between these pathologies may have important implications for research, diagnosis, and 
therapy (for an overview of ECM molecules that are implicated in myopathies or ICTDs, see 
Table 2 and Figure I). Although certain clinical characteristics seen in the conditions under 
discussion also occur in disorders caused by defects of other molecules (e.g. contractures in 
Emery-Dreifuss Muscular Dystrophy caused by lamin or emerin mutations), this review will 
only focus on primary ECM defects. Nevertheless, future research into a possible pathophys­
iological role of the ECM in these myopathies would be very interesting. Furthermore, we will 
not discuss the disorders of the neuromuscular junction, although some of these are also 
caused by defects of ECM molecules.
Extracellular m atrix and connective tissue
The ECM of skeletal muscle refers to the extracellular network, which consists of non- 
collagenous glycoproteins and fibrous proteins (Figure I). This network can be compared to
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Figure 1 Schematic representation of the ECM surrounding skeletal muscle.
Individual molecules are depicted at their approximate location in relation to the sarcolemma. Well- 
established molecular interactions between individual ECM molecules are portrayed. Due to limitations 
in space, not all possible interactions are indicated. Names of ECM molecules of which no genetic 
mutations are associated with specific myopathies or inherited connective tissue disorders in human, 
are printed in Italic (DG = dystroglycan).
composite plastics or reinforced concrete: the amorphous matrix of non-collagenous 
glycoproteins and proteoglycans (formerly referred to as 'ground substance') is reinforced by 
stiffer fibrous proteins. This matrix yields a supramolecular network that can both withstand 
and transmit the contractile forces generated by muscle fibres. Most likely, the proteins and 
glycoproteins of the sarcolemma and the ECM most proximal to muscle fibres are 
predominantly produced by muscle cells. The other proteins and glycoproteins of the ECM 
are assumed to be produced by a combination of muscle cells and interstitial cells, including 
fibroblasts and/or myofibroblasts; however, much research needs to be done in this field.11 
The ECM provides intramuscular continuations of neurovascular tracts in which nerve 
branches and blood vessels are embedded (Figure 2).12 This integral network not only ensures 
the structural integrity and enables force transmission onto the skeleton; it also mediates the 
development and physiological behaviour of muscle cells.
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The ECM has long been viewed as an amorphous scaffold that provides mechanical 
support.13 Recent insights underscore the importance of the ECM in developmental and 
regenerative processes, as well as in transmembrane signalling and force transmission.214 In 
fact, the ECM is a very dynamic structure that easily adapts to changes in physiological 
demand. Constant remodelling modifies the mechanical and viscoelastic properties, 
decreases stress-susceptibility, and may increase load-resistance.1315
Classification of components of muscle ECM is based upon histological features (light 
microscopy), ultrastructural features (electron microscopy), or on molecular features. These 
classifications are overlapping to a certain extent (Table I). Connective tissue in skeletal 
muscle is histologically defined as the ECM with the nerve branches, capillaries, fibroblasts, 
and macrophages that are embedded within this matrix. The following structures within 
muscle connective tissue are recognized: (1) endomysium surrounding each muscle fibre, (2) 
perimysium surrounding groups of muscle fibres (so called fascicles), and (3) epimysium 
surrounding the muscle as a whole. The endo-, peri-, and epimysium form an intricate 
supporting network, which integrates muscular forces and connects muscle fibres to the 
tendon, which itself is attached to the bone (Figure 2). Myotendinous junctions are complex 
specializations of the sarcolemma and ECM that connect the ends of muscle fibres to 
tendons or aponeuroses.13 Ultrastructurally, the ECM of skeletal muscle adjacent to muscle 
cells is designated basement membrane. The basement membrane is composed of two 
layers: the basal lamina lies proximal to the sarcolemma, and the reticular lamina lies more 
distally. This is surrounded by more peripherally located ECM. A third classification can be 
made at the molecular level: ECM molecules that are directly associated with the sarcolemma 
('sarcolemma-associated ECM molecules') versus ECM molecules that are embedded within 
the collagen-reinforced matrix ('matrix-embedded ECM molecules').
In this review, we will focus on the structural proteins and glycoproteins of the ECM that 
are involved in muscular symptoms in humans or in animal models. Although equally 
important in muscle physiology and pathology, we will not discuss the more dynamic 
molecules that are involved in various muscle diseases (e.g. growth factors, cytokines, and 
matrix metalloproteinases).
Myopathies: 
from the sarcolemma towards the extracellular matrix
The major focus in neuromuscular research has long been the myofibrils, the cytoskeleton, 
and the cell membrane. Disorders of the contractile elements mostly belong to the 
congenital myopathies, whereas defects of the cell membrane and its connection to the 
cytoskeleton are associated with the muscular dystrophies.16,17
35
Ch
ap
te
r 
2 
Cl
in
ic
al
 a
nd
 
m
ol
ec
ul
ar
 o
ve
rla
p 
be
tw
ee
n 
m
yo
pa
th
ie
s 
an
d 
in
he
rit
ed
 
co
nn
ec
tiv
e 
tis
su
e 
di
se
as
es
Table 1 Definitions.
Histo logical classification
Connective tissue: matrix of extracellular material, consisting of the ECM and of the nerve branches, 
capillaries, fibroblasts, and macrophages that are embedded within this matrix (Figure 2)
Endomysium: the collagen reinforced ECM that surrounds individual muscle cells 
Perimysium: the collagen reinforced ECM that surrounds fascicles of muscle cells 
Epimysium: the collagen reinforced ECM that surrounds entire muscles 
U ltrastructu ra l classification
Sarcolemma: the plasma membrane of a muscle cell, with basal lamina receptors dystroglycan and 
sarcoglycan
Extracellular matrix (ECM): is the supramolecular, extracellular network that consists of non- 
collagenous proteoglycans and glycoproteins and is reinforced by stiffer collagenous proteins. The 
ECM includes the extracellular parts of transmembrane molecules, which protrude in the ECM and 
interact with other ECM molecules
Basement membrane: the ECM surrounding skeletal muscle cells. It is comprised of two layers: 
the inner basal lamina and the outer reticular lamina
Basal lamina: the ECM that is directly adjacent to the sarcolemma, which consists of the 
molecules that interact with the trans-sarcolemmal molecules
Reticular lamina: the ECM zone that is located adjacent to the basal lamina, which consists 
of various glycoproteins and collagens
More peripheral ECM that is found peripherally of the basement membrane
M o lecu la r classification
Sarcolemma-associated ECM molecules: ECM molecules that are located at or directly adjacent 
to the sarcolemma; including dystroglycan, sarcoglycan, integrins and their directly associated 
molecules (located in the basal lamina); they are part of the chain spanning the sarcolemma and 
enabling force transmission (Figure 1)
Matrix-embedded ECM molecules: the ECM molecules that are located more peripherally in 
the matrix and interact with each other (located in the reticular lamina and more peripherally in 
ECM)
In recent years, the focus of attention has gradually shifted towards the ECM.5 This was 
initiated by the growing insight that the ECM is an extremely dynamic complex of molecules 
that interacts with sarcolemmal, cytoskeletal, and nuclear elements in order to maintain 
skeletal muscle integrity and to transmit forces.18 Since then, myopathies have been identified 
that result from defects in or deficiencies of trans-sarcolemmal proteins (e.g. limb girdle 
muscular dystrophies) or ECM molecules (e.g. congenital muscular dystrophies, Bethlem 
myopathy and UCMD). Extramuscular characteristics of such myopathies, including joint and 
skin manifestations, are increasingly recognized.719
36
Figure 2 Structure of intramuscular connective tissue.
The skeletal muscle (bovine semitendinosus muscle) extracellular network is shown by scanning 
electron micrographs after removal of skeletal muscle fibres. A: The endomysium surrounding one 
individual skeletal muscle fibre. B: The epimysium (EP) surrounding the entire muscle. C: The perimysium 
(P), surrounding a fascicle, as well as the endomysium (E). Reprinted with permission from S. Karger AG, 
Basel.12
Sarcolemma-associated extracellular matrix molecules and myopathies
The trans-sarcolemmal molecules dystroglycan, sarcoglycan, and the associated molecule 
integrins are part of the complex of proteins that connects muscle cells to the surrounding 
ECM. Dystroglycans and sarcoglycans, together with dystrophin, form the dystrophin-glyco- 
protein complex (DGC). This complex has both mechanical and signalling roles in mediating 
interactions between the cytoskeleton, the sarcolemma, and the ECM. The proteins within 
the DGC are structurally organized into three distinct subcomplexes. These are the (1)
37
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intracellular proteins dystrophin, a-dystrobrevin, and the syntrophins (which will not be 
discussed in this review; we refer to a recent review by Laval et al);20 (2) the sarcolemmal 
dystroglycan (P subunit); and (3) the sarcoglycan-subcomplex (a, p, y, and 6 subunit) (Figure I). 
A second group of sarcolemma-associated ECM molecules forming a link to the more 
peripheral ECM are the integrins and a-dystroglycan (Figure I). Integrins are a large family of 
transmembrane proteins that mediate cell-matrix as well as cell-cell recognition and adhesion.
Both DGC and integrin complexes are localized in the sarcolemma and protrude into the 
ECM to protect the integrity of the sarcolemma and associated structures against physical 
damage during repeated rounds of contraction and relaxation. These complexes not only 
form a physical link between the cytoskeleton and the basal lamina, they are also instrumental 
in the mechanical force transmission and biochemical transmembrane signalling.2122 
Disruption of these complexes leads to muscular dystrophy.2023
a-Dystroglycan and defects of O-mannosyl-glycosylation
Dystroglycan is composed of tightly associated subunits a and p, which are encoded by a 
single gene (DAGI), and cleaved and glycosylated post-translationally. p-Dystroglycan spans 
the sarcolemma, which enables intracellular binding to dystrophin, which itself is connected 
to the actin cytoskeleton (Figure I). Extracellularly, p-dystroglycan binds to a-dystroglycan, 
which consists of a core protein (74 kD) that is heavily and variably glycosylated, resulting in 
forms with apparent molecular weights as high as 200 kDa. O-linked glycosylation is the 
most important contributor to this modification, which is important for many ligand-recep- 
tor interactions.24
Glycosylated a-dystroglycan in muscle binds to the ECM proteins laminin a2, biglycan, 
and perlecan (Figure I). The dystroglycan complex has an important receptor function and 
may participate in formation and maintenance of the basement membrane by promoting 
the polymerization of laminin on the cell surface.25
Mutations in the dystroglycan gene have not been described in humans; most likely, 
such mutations are lethal in an early stage. In mice, systemic knock-out models are lethal in 
an early embryonal stage; selective depletion of dystroglycan in mature muscle by chimeric 
expression or tissue specific knock-out mice causes a progressive myopathy with abnormal 
localization of basal lamina components laminin and collagen IV, and abnormalities of the 
neuromuscular junctions.25 However, defects in a-dystroglycan O-mannosyl glycosylation 
results in several forms of congenital muscular dystrophy (MDC) as well as limb-girdle 
muscular dystrophy (LGMD). The aberrant O-glycosylation is caused by mutations in proven 
or putative glycosyltransferase that participate in this process. These MDCs are therefore 
referred to as secondary dystroglycanopathies. Hypoglycosylation of dystroglycan impairs 
its ligand binding, which causes disruption of the link between the cytoskeleton and the 
ECM, probably contributing to the development of muscular dystrophy.24
38
So far, six genes have been identified to be involved in the O-mannosyl glycosylation of 
a-dystroglycan, mutations of which result in myopathies and abnormalities neuronal 
migration. These disorders manifest a spectrum that includes Muscle-eye-brain disease 
(MEB), Walker-Warburg syndrome (WWS), Fukuyama-type congenital muscular dystrophy 
(FCMD), congenital muscular dystrophy type 1C and 1D (MDC 1C and 1D), and limb girdle 
muscular dystrophy 2I, 2K, and 2M (LGMD 2I, 2K, and 2M).517 Since O-mannosyl glycosylation 
of a-dystroglycan also occurs in the central nervous system and in the eye, these myopathies 
are associated with brain and eye abnormalities, in particular with lissencephaly type II 
(cobblestone complex) and with pontocerebellar changes. Eye abnormalities include both 
anterior and posterior anomalies such as cataract, microcornea and microphthalmia, lens 
defects, retinal detachment and dysplasia, optic nerve and macula hypoplasia and atrophy. 
Although a-dystroglycan was also shown to be present in the epidermis in skin and produced 
by both keratinocytes and fibroblasts in vitro, neither dermal nor articular symptoms have 
been described in patients with a-dystroglycanopathies so far.26
Laminin a2 is associated with the dystrophin-glycoprotein complex. Whereas it is not a 
part of this complex, it is the major extracellular binding partner for a-dystroglycan thus 
helping to anchor the complex in the ECM. A secondary deficiency of laminin a2 occurs in 
some MDC syndromes associated with defective a-dystroglycan O-mannosyl glycosylation, 
including MDC1B, MEB disease, and Fukuyama MDC.27 Increasing insight in the molecular 
pathogenesis of the a-dystroglycanopathies has sparked some new therapeutic options in 
this group of disorders. Illustrative to this end is the putative human glycosyltransferase 
LARGE, which acts as a facilitator in the process of a-dystroglycan glycosylation. 
Overexpression of LARGE improves a-dystroglycan glycosylation in a mouse model deficient 
in LARGE, as well as in other a-dystroglycanopathy mouse models, thus opening perspectives 
for clinical intervention.28
Sarcoglycan and sarcoglycanopathies (LGMD 2C-F)
Sarcoglycans are N-glycosylated transmembrane proteins with a short intra-cellular domain, 
a single transmembrane region, and a large extra-cellular domain containing a group of 
conserved cysteine residues. Sarcoglycans thus form a membrane-spanning complex of 
glycoproteins, which is closely associated with the dystroglycan complex. Similar to 
dystroglycan, the sarcoglycan complex is located at the basal lamina (Figure 1). So far, six 
sarcoglycan proteins have been identified (a, |3, y, 5, e, and 9), ranging in size from 35-50 kDa. 
The major sarcoglycan complex in skeletal muscle is mainly composed of a, p, y, and 5 
sarcoglycan. The sarcoglycan complex is formed in the endoplasmic reticulum. It associates 
with the dystroglycan complex and sarcospan en route from the Golgi apparatus to the cell 
surface.29 Whereas the dystroglycan-complex is found in nearly all cell types, the a, p, y, 5 
sarcoglycan complex is primarily found in muscle.30
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In skeletal muscle, the sarcoglycan com plex has a num ber o f putative functions. Intra­
cellularly, the sarcoglycan com plex binds Y-filamin, w hich is a major muscle architectural 
protein located in the Z-line under the sarcolemma that binds actin. It is a com ponen t o f the 
chain b ind ing the sarcolemma to  the sarcomeric protein com plex and as such likely involved 
in signal transduction and force transmission. Extracellularly, the  sarcoglycan com plex binds 
to  biglycan and is associated w ith  a-dystroglycan (either d irectly or th rough biglycan).31 
Sarcospan probably contributes to  the stabilisation o f com ponents o f the dystroph in-g lyco- 
protein com plex as alpha dystroph in-glycopro tein  localization is lost in m utations o f the 
sarcoglycan com plex .20
M utations in genes encoding the sarcoglycans cause a num ber autosomal-recessive 
limb-girdle muscular dystrophies (sarcoglycanopathies; LGMD 2C-F): LGMD 2D (a- sarcoglycan), 
LGMD 2E (|3- sarcoglycan), LGMD 2C (Y-sarcoglycan), and LGMD 2F (5-sarcoglycan). Their 
clinical presentations range from  severe forms w ith  rapid onset and progression to  very mild 
forms that a llow  patients to  have a fairly normal lifespan and activ ity  levels. We refer to  a 
recent review for an extensive description o f the clinical characteristics.20 The sarcoglycan 
com plex is primarily expressed in muscle, and dermal or articular features have not been 
described. Secondary skeletal deform ities such as hyperlordosis and scoliosis can occur 
(Table 2).
a7/3l Integrln and congenital myopathy
Integrins are sarcolemma-spanning proteins o f w hich the extracellular dom ain extends into 
the ECM. Integrins contain large (a) and small (|3) subunits o f  120-170 kDa and 90-100 kDa in 
size, respectively (Figure l), and have b ind ing sites for d ivalent cations (Mg2+ and Ca2+), which 
are necessary for the ir adhesive function . There are many integrin isoforms, and many cells 
express m ultip le  isoforms on the ir surface. The expression o f a7 integrin (ITGA7) in myocytes 
is deve lopm enta lly regulated. In adult muscle, m ainly a7|31 integrin persists, w hich is 
concentrated in m yotendinous junctions bu t also present in neuromuscular junctions and 
along the sarcolemmal membrane. a7|31 Integrin provides resistance to  exercise-induced 
muscle dam age .32 Recent animal studies indicate com plem entary roles for the dystrophin 
and the dystrophin associated glycoprote in com plex and a7|31 integrin in maintain ing the 
functiona l in teg rity  o f  skeletal muscle.33 In m yotendinous junctions, a7|31 integrin organizes 
and maintains the connection between muscle and tendon and also functions as a laminin 
receptor.34 a7|31 Integrin is also expressed in the peripheral nervous system, where it probably 
functions as a Schwann cell receptor for laminin-2, provid ing a transm embrane linkage 
between the ECM and the cytoskeleton .35 Furthermore, a7|31 integrin plays an im portan t role 
in vascular deve lopm ent and in tegrity .36
Because o f the ir transm embrane structure and association w ith  other molecules, 
integrins mediate mechanical and functiona l con tinu ity  between the inside and the outside
40
o f the  cell, as well as transm embrane signalling. The cytoplasm ic dom ain o f integrin binds to 
cytoskeleton proteins like talin, vinculin, and a-actin in (which w ill no t be discussed in this 
review). Extracellularly, a7P1 integrin acts as a laminin receptor; it may interact w ith  laminin, 
collagen IV, and fibronectin , the  latter o f which links to  tenascin-X (TNX) (Figure 1). Integrin 
signalling is b id irectional. 'Inside-out' signals regulate integrin a ffin ity  fo r adhesive ligands, 
and ligand-dependent 'outside-in ' signals regulate cellular responses to  adhesion .34
Targeted deletion o f the a7P1 integrin gene leads to  a m ild fo rm  o f muscular dystrophy 
in m ice.37 Histological analysis o f integrin null skeletal muscle revealed typical symptoms o f a 
progressive muscular dystrophy starting soon after b irth in mice. It also shows impaired 
m yotendinous b ind ing due to  a decrease o f interdigitations, and the retraction o f 
myofilam ents from  the sarcolemmal m em brane .37 Subsequent studies revealed m utations o f 
the  a7 integrin gene in three patients w ith  congenita l m yopathy; one o f these patients was 
m entally retarded, and one o f  them  had a congenita l hip dislocation. No skin or o ther jo in t 
features were reported (Table 2).38 No additional patients have been reported since this initial 
report, suggesting tha t this is a very rare myopathy. Since integrins provide a major link 
between the cytoskeleton and the ECM, the genes encoding integrins may be candidate 
genes for other, as yet unclassified muscular dystrophies and myopathies.34
Laminin and congenital muscular dystrophy
Laminin is an om nipresent com ponen t o f developing and adult muscle basal lamina. Laminin 
is com posed o f three d is tinc t subunits (a-, |3-, and Y-chain; 400, 210, and 200 kDa, respectively), 
w hich o ligom erize to  form  a cruciform  protein (Figure 1). Five genes are known for the 
a-chain, three for the p-chain, and three for the Y-chain. Eleven d is tinct laminin isoforms are 
synthesized by a w ide  variety o f cells in a tissue-specific manner. The extrasynaptic basement 
m em brane o f adu lt muscle is rich in lam inin-2 (merosin), whereas the synaptic basement 
m em brane contains laminin-4, laminin-9, and laminin-11.
Laminins m odulate a variety o f cellular activities, including cell-cell recognition, d ifferen­
tiation, cell survival, and transmission o f force .39 Laminins interact w ith  a num ber o f ECM 
macromolecules such as nidogen, agrin, perlecan, and collagen IV. This lam in in-conta in ing 
ne tw ork is tig h tly  connected to  the sarcolemma through tw o  major transm embrane laminin 
receptors: the dystroph in-g lycoprote in  com plex and the integrins (Figure 1). Lam inin-a2 is 
also expressed in the central and peripheral nervous system, in sensory nerves, in skin, at the 
epiderm al/derm al junction , and around hair follicles.
Primary or secondary laminin a2 deficiency causes various forms o f congenita l muscular 
dystrophy (MDC 1A, 1B, and 1C), in which impaired anchoring o f muscle cells in the  ECM 
results in im paired m em brane stability and increased muscle fibre apoptosis .40 Histologically, 
this results in muscular dystrophy w ith  muscle fibre necrosis and regeneration, com bined 
w ith  endo- and perimysial fibrosis and inflam m ation. MDCs may be accompanied by mental
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Table  2 O verview o f the ECM molecules tha t are im plicated in myopathies or inherited
connective tissue disorders.
M o le c u le  T issue  d is t r ib u t io n  D isease  o r
m o u s e  m o d e l
Sarcolemma-associated ECM molecules (basal lam ina  o f  basement membrane)
a-D ystrog lycan  g lycosy la tion  muscle, skin, CNS MEB
WWS 
FCMD 
MDC 1C 
MDC 1D 
LGMD2I 
LGMD2K 
LGMD 2M
ß-D ystrog lycan muscle, skin, CNS M ouse m ode l: lethal
a-Sarcoglycan muscle LGMD 2D
ß-Sarcog lycan muscle LGMD 2E
y-Sarcoglycan muscle LGMD 2C
6-Sarcoglycan muscle LGMD 2F
a7ß l In tegrin muscle, PNS In tegrin  a7 de fic iency
Lam in in  a2 muscle, skin, CNS, PNS MDC 1A, 1B and 1C
C ollagen VI muscle, ep ith e liu m , cornea UCMD
Bethlem  m yopa thy
C ollagen XIII muscle M ouse m odel: m yopa thy
C ollagen XV muscle, vessels M ouse m ode l: m yopa thy
M atrix-em bedded ECM molecules (reticular lam ina  o f  basement m em brane and  more peripheral ECM)
C ollagen I th ro u g h o u t body, except cartilage O steogenesis im perfec ta
EDS arthrochalasia ty p e
C ollagen III muscle, skin, PNS vessels, GI EDS vascular typ e
C ollagen V th ro u g h o u t body, except cartilage EDS classical ty p e
C ollagen IX p red o m ina n tly  cartilage MED w ith  m yopathy
M ouse m odel: reduced muscle
Tenascin-C muscle, skin, CNS, GI streng th
Tenascin-X muscle, skin, PNS, te n d on , vessels EDS TN X-defic ient ty p e
Fibrillin-1 muscle, skin, bones, eye M arfan syndrom e
G lycosyla tion o f  fibu lin muscle, skin Cutis Laxa
Elastin muscle, skin Cutis Laxa
Perlecan muscle, bones SJS, SHS
In d ic a te d  a re  t h e  d is t r ib u t io n  a m o n g  v a r io u s  t is s u e s , a s s o c ia te d  d is e a s e  o r  a v a i la b le  m o u s e  m o d e ls ,  m a jo r  s y m p to m s ,  
a n d  g e n e  lo c u s . M o le c u le s  a re  s u b d iv id e d  as s a rc o le m m a -a s s o c ia te d  o r  m a t r ix - e m b e d d e d .  A b b r e v ia t io n s :  CNS: 
c e n t ra l n e rv o u s  s y s te m ; GI: g a s t r o in te s t in a l  s y s te m ; M , m u s c u la r  s y m p to m s ;  D, d e r m a l s y m p to m s ;  A , a r t ic u la r  
s y m p to m s ;  S, s k e le ta l s y m p to m s ;  + , p re s e n t;  -, a b s e n t  o r  n o t  r e p o r te d .
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Clinical and m olecular overlap betw een m yopathies and inherited connective  tissue diseases
Gene 
(gene 
locus) 
Location 
of sym
ptom
s
retardation (~6%), seizures (~30%), subclinical cardiac involvement, and neuronal m igration 
defects in a small p roportion  o f patients (Table 2). A lthough normal skin also expresses 
laminin a 2 in the basement m em brane at the  junc tion  o f the  dermis and epidermis, no 
dermal features have been reported in MDCs so far.
Mice knockout studies have shown that loss o f the laminin a2 chain can be partially 
compensated by forced increased expression o f a laminin a 1 chain transgene, which is normally 
not expressed in muscle.41 Most likely, laminin a1 chain in part ameliorates the developm ent o f 
laminin a 2 chain deficient muscular dystrophy through its binding sites for a7P1 integrin and 
a-dystroglycan, which partially restores anchoring o f muscle cells in the ECM.41
Matrix-embedded extracellular m atrix molecules and myopathies
Collagens are ubiquitous structural proteins responsible for m aintain ing the mechanical 
in teg rity  o f virtua lly all tissues, bu t d iffe rent isoforms have a tissue specific d istribu tion . In 
skeletal muscle, collagens are expressed principally by fibroblasts and by m yofibroblasts in 
the ECM. Collagen biosynthesis is a m ultistep process that is characterized by a large num ber 
o f  co- and post-translational m odifications, many o f them  unique to  collagens or collagen-like 
proteins. Currently, more than 20 d is tinc t collagen isoforms have been identified. They can 
be classified as either non-fibrillar (e.g. IV, VI, VIII, X, and XIII) or fibrillar (e.g. I, II, III, V, XI). Some 
non-fibrillar collagens are transm embrane proteins (e.g. collagen XIII), whereas others fo rm  
networks (e.g. collagen IV). Fibrillar collagens typ ica lly consist o f three po lypeptide  chains 
w ound  together to  form  triple-helical structures, w hich predom inantly occur in tissues that 
have to  resist shear, tensile stress, or pressure, such as muscle, bone, cartilage, and skin.1 
Table 3 presents an overview  o f the  various collagen types, the ir d istribu tion, function , and 
the related disorders.
Collagen VI, Bethlem myopathy and Ullrich congenital muscular dystrophy 
The major collagen o f the  basal lamina is type  IV collagen, whereas collagen type  VI occurs 
in both the basal lamina and the reticular lamina. It there forms a m icrofibrillar ne tw ork that 
likely interacts w ith  collagen I, collagen IV, and w ith  a variety o f proteoglycans such as 
biglycan and decorin (Figure 1).11 It consists o f  2 d ifferent 140-kD subunits (alpha-1 and 
alpha-2) and a 200-kD subunit (alpha-3), and forms 150 nm long fibrils (hence, it has been 
called 'short-chain' collagen) (Figure 1). Collagen VI fibrils fo rm  a m icrofibrillar network.
M utations in the gene encoding collagen VI (COL6A) affect collagen VI m icrofibril 
form ation, w hich results in a d isengagem ent o f collagen VI w ith  the basal lamina, leading to 
m yopathy .42 The exact mechanism and the downstream  effects o f collagen VI deficiency on 
muscle cells may involve the engagem ent o f m yofibre apoptosis, bu t are still subject o f 
research.43 Two genetically and clinically overlapping myopathies result from  collagen VI 
deficiency: Bethlem m yopathy and Ullrich congenita l muscular dystrophy (UCMD). These
44
collagen VI myopathies may be d ifferentiated by the age o f onset, severity o f muscle 
weakness, presence o f long finger flexion contractures at onset (Bethlem myopathy), distal 
hyperlaxity (UCMD), presence o f scoliosis, spinal rigidity, and respiratory failure (UCMD).
Bethlem m yopathy is a disorder characterized by slowly progressive axial and 
predom inantly proximal muscle weakness w ith  flexion contractures o f fingers and other 
jo ints. The disease presents w ith  variable onset (from  prenatal onset to  onset in mid 
adu lthood) and is usually on ly  slowly progressive. The m ode o f inheritance docum ented so 
far is autosomal dom inant, and m utations can a ffect any o f the  three COL6A genes. Muscle 
biopsy reveals normal o r m ild ly reduced expression o f collagen VI in the  endom ysium  o f 
m ost patients and loss o f connection  to  the basement membrane. Skin features may be 
present in some patients and include fo llicular hyperkeratosis and keloid form ation or 
"cigarette paper" scarring (Table 2).67
UCMD is a severe congenita l m yopathy includ ing progressive atrophy and weakness o f 
axial and appendicular muscles, coexisting w ith  progressive contractures as well as distal 
jo in t hyperlaxity. Symptoms are usually present at b irth  o r in early ch ildhood. Involvement o f 
the  diaphragm  can be prom inent, w ith  a varying degree o f respiratory failure. Muscle 
biopsies from  UCMD patients usually show a marked decrease or com ple te  absence o f 
collagen VI proximal to  the sarcolemma, bolstering the hypothesis tha t Ullrich disease results 
from  the loss o f signalling or mechanical anchoring o f the basal lamina to  the interstitium . 
UCMD is classically regarded as an autosomal recessive disease, bu t many cases have now 
been described w ith  de novo dom inan t m uta tions .42 Homozygous or com pound 
heterozygous null m utations in COL6A generally have a severe UCMD phenotype. In case o f 
alternative splicing, these m utations may occasionally present a m ilder Bethlem myopathy-like 
disease. Dom inant negative m utations may be as severe as the recessive null m uta tions .44
Since collagen VI d is tribu tion  is not lim ited to  muscle, extramuscular symptoms also 
occur. These include a striking jo in t hyperm obility, progressive contractures, and skin 
abnorm alities such as dry skin, p ro trud ing bulbs o f hair follicles, and abnorm al scar form ation 
(Table 2).745 The connective tissue features were already recognized in the initial descriptions 
by Ullrich, and referred to  in the nomenclature: 'congenital atonic sclerotic muscle 
dystrophy '.46 These features are rem iniscent o f  EDS, a ICTD tha t reveals clinical overlap w ith 
Bethlem m yopathy .10
Collagen XIII and mouse model
Type XIII collagen is a transm embrane protein found at many sites o f cell adhesion in various 
tissues. It plays an im portan t role in the em bedd ing  o f muscle fibres w ith in  the basal lamina. 
(Figure 1).47 It is also involved in a range o f in tegrin-m ediated adherens junctions including 
the m yotendinous junctions, costameres o f skeletal muscle, and the intercalated discs in the 
heart.48
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Table 3 O verview o f the most currently known collagen types, the ir d istribution, function, and the related disorders.
Type D is trib u tio n  /  fun ction D isorders
Fibrillar co llagen i
Fibrillar collaaens: M ost abu n d an t co llagen ty p e  o f  th e  hum an body; present in all tissues except 01
collagens th a t have the cartilage; m ajor co m p o n e n t o f  scar tissue, tendons, endom ys ium , and o f  epiphysis EDS, arthrochalasia typ e
a b ility  to  self assemble in to o f  bone.
fibrils II Hyaline cartilage; makes up  to  50% o f  all cartilage prote in . Stickler syndrom e ty p e  1
III M ajor co llagen o f  g ranu la tion  tissue; p roduced  by yo un g  fib rob lasts  before  ty p e  1 EDS, vascular ty p e
co llagen is synthesized; also found  in muscle, a rte ry  walls, intestines, and in uterus.
V Co-localizes w ith  ty p e  1 co llagen. EDS, classical typ e
XI M ino r co m p o n e n t o f  cartilage; co-loca lizes w ith  ty p e  II co llagen. Stickler syndrom e ty p e  II
and III
N on-fibrillar co llagen i
N etw ork fo rm ino  collaaens: IV Present in basal lam ina o f  eye lens, muscle, and skin, serves also as part o f  th e A lp o rt syndrom e
collagens th a t have the filtra tio n  system in capillaries and in g lo m e ru li in kidney.
a b ility  to  fo rm  a ne tw ork Vili Present in e ndo the lia l cells, vascular sm oo th  m uscle cells -
X Present in h yp e rtro p h ic  and m inera liz ing  cartilage. M etaphyseal chondroplasia
Association collaaens: VI Present in m ost in ters titia l tissue; interacts w ith  ty p e  1 and IV co llagen. UCMD and Beth lem  m yopa thy
collagens th a t have the VII Forms ancho ring  fibrils  in derm al and ep ide rm al jun c tio n s . Epiderm olysis bullosa
a b ility  to  associate w ith  fibrils IX Occurs in cartilage; associates w ith  ty p e  II co llagen du rin g  cartilage d eve lopm en t. M u ltip le  epiphyseal dysplasia
AR Stickler syndrom e
(Type IX, XII, XIV, XVI, XIX are
XII Interacts w ith  co llagen 1 fibrils, decorin , and g lycosam inoglycans; is th o u g h t to  act
FACIT's: Fibril Associated
as a crossbridge b e tw e e n  fibrils  and resist shear forces.
Collagens w ith  In te rrup ted  
Trinlp hplirpO XIV Occurs in so ft connec tive  tissues, and is associated w ith  m ature  co llagen fibrils.1 1 IU IC  1 IC IIL C jy
XIX Transient expression by d iffe re n tia tin g  m uscle cells.
-Pi-
C h a p te r 2
Transm em brane co llaaens XIII Is transm em brane  co llagen; in teracts w ith  in teg rin , fib ron e c tin , n idogen , and
perlecan.
XVII Is transm em brane  co llagen.
M u ltip lex ins  XV Has adhesion fu n c tio n  in skeletal and cardiac muscle.
XVIII Occurs p red o m ina n tly  in liver, lung, and kidney.
Clinical and m olecular overlap between m yopathies and inherited connective tissue diseases
Bullous P em phigoid  
Junctiona l ep iderm olysis 
bullosa
Various m alignancies
Studies in mice have shown tha t type  XIII collagen participates in the linkage between 
muscle fibre and basal lamina, a function  w hich is im paired by lack o f the  cytosolic and 
transm em brane domains o f this collagen. In w ild -type  muscle, type  XIII collagen was 
detected in the sarcolemma, whereas truncated protein was located in the adjacent ECM. 
A ffected skeletal muscles showed abnorm al myofibres w ith  a vague sarcolemma-ECM 
interphase along the muscle fibre and at the m yotendinous junctions, disorganized 
myofilaments, and streaming o f z-disks. The phenotype  was progressive and aggravated by 
exercise.47 No human disease has yet been associated w ith  collagen XIII deficiency.
Collagen XV and mouse model
Collagen type  XV and XVIII are structurally d ifferent from  o ther known collagen types and 
belong to  a subfam ily o f ECM proteins named m ultiplexins. A lthough these tw o  collagens 
are closely related and share similarities in tissue expression, the ir b io logical roles are 
essentially separate. Type XV collagen is a chondro itin  sulphate proteoglycan that belongs to 
the heterogeneous group o f non-fib ril-fo rm ing  collagens. It is predom inantly expressed in 
heart and in skeletal muscle and is probably involved in maintenance o f the  structural 
in teg rity  o f the ECM (Figure 1).49 Type XVIII collagen was identified as a heparan sulphate 
proteoglycan and interacts w ith  heparan sulfate, laminin, and perlecan .50 It plays an im portan t 
role in the regulation o f muscle deve lopm ent and regeneration .51
Col15A1-deficient m ice develop and reproduce normally, and are indistinguishable from  
the ir w ild  type  littermates. However, these knockout mice show progressive focal areas o f 
degeneration, regeneration, and variation in fibre size after 3 m onths o f age, and they are 
m ore vulnerable to  exercise-induced muscle in jury than contro ls .52 No human disease has 
yet been associated w ith  collagen XV deficiency.
Inherited connective tissue disorders: (re)new(ed) attention 
for myopathic features
ICTDs result from  defects in ECM molecules like collagens, fibrillin, elastin, and TNX. A lthough 
clinical symptoms are m ost p rom inent in skin, jo ints, and b lood vessels, muscle symptoms 
are increasingly acknow ledged, notably in Marfan syndrome, EDS, and cutis laxa.4-8-53-54
M atrix-em bedded extracellu lar m atrix  molecules and inherited connective 
tissue disorders
Collagen I and III, Osteogenesis imperfecta and Ehlers-Danlos syndrome
Collagen type  I and III are major com ponents o f muscle ECM tha t fo rm  fibrils o f similar
structure (300 nm, 67 nm fibrils). Type I collagen occurs th roughou t the  body, except in
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cartilage. It is the principal collagen o f the  dermis, fasciae, and tendons, and is a major 
com ponen t o f mature scar tissue. Type III collagen co-polymerizes w ith  type  I collagen and 
is a major com ponen t o f the  wall o f b lood vessels and o f ho llow  intestinal organs. Both types 
are present in epi- and peri-, as well as in endom ysium . Ultrastructurally, collagen I and III are 
predom inantly located at the reticular lamina and beyond (Figure 1).1
A defect in or deficiency o f collagen I causes osteogenesis im perfecta (OI), o f w hich four 
d is tinc t collagen I-related types are described .55 Besides b rittle  bones, the clinical character­
istics o f OI subtypes are variable and include muscle weakness, exercise intolerance, hearing 
loss, and fatigue (Table 2).5556 A lthough clinically well defined, the  pathophysio logy o f muscle 
weakness in OI has not been studied yet.
The arthrochalasia type  o f EDS (EDS type  VIIA and B) is also caused by m utations in the 
gene encoding collagen I. It is characterized by severe generalized jo in t hyperm ob ility  w ith  
recurrent subluxations, skin hyperextensibility, osteopenia, and muscle hypotonia (Table 2).53
Defects o f type  III collagen cause the vascular type  o f EDS (EDS type IV), which is 
characterized by ruptures o f arteries, ho llow  organs, tendons, and muscles, indicating a role of 
collagen III in muscle integrity .53 Muscle involvement consisting o f hypotonia, distal atrophy, 
muscle cramps and pain, and increased muscle ultrasound intensity have been described in a 
in a family w ith  the vascular type EDS and a mosaic for the COL3A1 m utation (Table 2).57
Collagen Vand Ehlers-Danlos syndrome
Collagen V is a m inor com ponen t o f muscle ECM. Collagen V co-polym erizes w ith  collagen 
type  I and as such is predom inantly located in the reticular lamina and beyond (Figure 1). 
Defects o f collagen V cause the classical type  o f EDS (EDS I /  II): m utations in the genes 
COL5A1 and COL5A2, (coding for a1(V) and a2(V) collagen chains) d isrupt the form ation o f 
heterotyp ic fibrils, resulting in abnorm al d iam eter and packing o f collagen fibrils .5358 Clinically, 
classical type  EDS is characterized by skin hyperextensibility, w idened atrophic scarring, both 
jo in t hyperm ob ility  (fingers, knees, elbows, trunk), and muscle hypotonia. Weak, hypotonic 
muscles w ith  deep tendon hyporeflexia are com m only reported. Fatigue is another frequent 
com pla in t,58 and severe muscle cramps, particularly at n igh t have been described (Table 2). 
As w ith  the other collagen disorders, muscular symptoms in the classical type  EDS are 
generally explained as a result o f increased extensibility o f tendons and avoidance o f exercise 
because o f jo in t hyperm obility. Furthermore, muscle fibres surrounded by defective collagen 
m igh t lose the ir parallel orientation upon contraction, thus decreasing mechanical in tegrity 
and resulting in muscle weakness.58 Finally, dysfunction  o f the Golgi tendon organ em bedded 
in the loose tendons may play a role in determ in ing muscle hypotonia, and thus contribute  
to  fa tigue and muscle weakness.58
Ch
ap
te
r 
2 
C
lin
ic
al
 a
nd
 
m
ol
ec
ul
ar
 
ov
er
la
p 
be
tw
ee
n 
m
yo
pa
th
ie
s 
an
d 
in
he
ri
te
d 
co
nn
ec
tiv
e 
tis
su
e 
di
se
as
es
Collagen IXand multiple epiphyseal dysplasia with m ild myopathy
Type IX collagen is a heterotrimer that belongs to the fibril-associated collagens with interrupted 
triple helices. It is predominantly found in cartilage, where it is probably involved in the organization 
and spacing o f type II collagen fibrils. It is a m inor com ponent o f muscle ECM. Ultrastructurally, it is 
located in the reticular lamina and in the more peripheral ECM (Figure 1).
M utations in the genes encoding tw o  o f the  three helices result in m ultip le  epiphyseal 
dysplasia (MED), a group o f autosomal dom inan t skeletal dysplasias characterized by 
early-onset osteoarthritis, a w addling  gait, and sometimes short stature (Table 2). MED w ith 
m inimal hip involvement, p redom inant knee involvement, and evidence for a m ild proximal 
m yopathy was reported as a result o f another m utation in COL9A3. Muscle biopsy revealed 
increased fibre diam eter variance in both type  I and II muscle fibres, representing myopathic 
changes .59
Tenascins and Ehlers-Danlos syndrome
Tenascins are very large glycoproteins w ith  m olecular weights ranging from  220 to  500 kDa. 
Vertebrates express four tenascins in the ir connective  tissues (tenascin-C, -R, -X, and -W). So 
far, tenascin-C and -X  were found to  be expressed in skeletal muscle.60 All tenascins have a 
similar structure, consisting o f a cysteine-rich N-term inal domain, fo llow ed by a series o f 
EGF-like repeats, m ultip le  fib ronectin  type-III repeats, and a C-terminal g lobu lar domain 
hom ologous to  fibrinogen. Their com plex dom ain structure allows tenascins to  interact w ith  
a variety o f ECM proteins, notably w ith  members o f the  integrin family.
Tenascin-C and mice m odel
In skeletal muscle, tenascin-C is found in the endom ysium  close to  the myotendinous 
jun c tio n  and in muscle spindles .60 Tenascin-C was found to  be upregulated in UCMD, 
suggesting that abnorm al expression o f proteoglycans and adhesion molecules may be 
involved in the pathogenesis o f the m yopathy in UCMD.61 Tenascin-C defic ient mice show 
reduced muscle streng th .62 
Tenascin-X and Ehlers-Danlos syndrome
TNX is present in the endo-, peri-, and epimysium. Its com plex structure enables m ultip le  
interactions w ith  other ECM (glyco)proteins, rendering TNX a crucial player in the organisation 
o f  the  skeletal muscle ECM. Ultrastructurally, it is predom inantly located in the reticular 
lamina and beyond (Figure 1).63 D isruption o f the  TNXB gene significantly decreases the 
expression o f type  VI collagen. Moreover, together w ith  o ther ECM molecules, TNX and type 
VI collagen are collectively involved in collagen fibrillogenesis in vitro and in vivo.64
Deficiency o f  TNX results in a phenotype similar to  the classical type  o f  EDS, bu t w ith  a 
recessive inheritance and lack o f skin hyperextensibility .6566 Clinical features resemble those 
seen in collagen VI m yopathies .10 Haploinsufficiency o f the TNX gene causes hyperm obility  
type  EDS in only a m inority  o f patients .67 Muscle weakness and distal contractures as seen in
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collagen VI m yopathies have been reported in TNX-deficient EDS.1068 Q uantitative muscle 
function  in TNX-deficient EDS patients proved severely reduced despite normal findings on 
e lectrom yography and muscle biopsy. M ost likely, alterations in the ECM m od ify  force 
transmission by the muscle connective  tissue and thus influence muscle function  in EDS.68
Fibrillin, fibulins, elastin, cutis laxa, and Marfan syndrome
Tissues that require elasticity in add ition  to  tensile strength have a netw ork o f elastic fibres 
in terwoven w ith  the collagen network. The netw ork o f elastic fibres in the ECM o f the  fascia 
gives muscle the ab ility  to  recoil after transient stretch .69 Elastin consists o f many soluble 
tropoelastin protein molecules, w hich are linked to  form  an insoluble, cross-linked array o f 
rubber-like fibres. M icrofibrillar molecules (fibrillin-1, fibrillin-2, fibulin-1, fibulin-4, and fibulin-5) 
con tribu te  to  the pro-elastin fibre assembly, structure, and fu n c tion .70 They are also associated 
w ith  collagen VI in tendons and are predom inantly located in the reticular lamina and in the 
more peripheral ECM.
Structural or functiona l defects o f the  elastic fibre system may cause cutis laxa syndrome. 
Cutis laxa syndrom e is a rare, genetically heterogeneous cond ition  presenting in the early 
m onths o f life w ith  loose and redundant skin folds, decreased elasticity o f the skin, and a 
variable spectrum  o f associated features, including generalized muscle weakness and 
hypotonia. Pathophysiological mechanisms in cutis laxa include fibu lin -4  and -5 mutations, 
elastin m utations, lysyl oxidase deficiency, and abnorm al glycosylation o f fibu lin  or o ther N- 
and O-linked glycoprote ins .5470
Fibrillin-1 m icrofibrils are d istributed th ro u g h o u t the muscle ECM and provide muscle 
w ith  low-range elasticity (Figure 1). M utations in the fibrillin-1 gene (FBN1) are associated w ith  
Marfan syndrom e .71 More than 1000 m utations have been identified and m ost o f them  are 
unique to an affected individual or family. Marfan considered muscle involvement integral to 
his syndrom e and initial reports m entioned muscle hypoplasia. However, over the years 
m yopathy disappeared from  the nosology and was no longer included in the diagnostic 
criteria .73 Only recently, muscle involvem ent in Marfan syndrom e has received renewed 
attention. Behan et al. reported a fam ily o f w hich members confirm ed to  the diagnostic 
criteria, and had additional muscle weakness associated w ith  respiratory failure. Muscle 
biopsy revealed defective fibrillin  d is tribu tion  in endom ysium , w ith  presence o f truncated 
forms o f fibrillin  in restriction m app ing .8 Furthermore, the m ajority o f individuals w ith  Marfan 
syndrom e lacks the ab ility  to  increase muscle mass in response to  g row th  and exercise. 
Patients w ith  early onset o f severe and rapidly progressing Marfan syndrome have profound 
muscle hypoplasia and hypotonia th ro u g h o u t life (Table 2).4A74 This is probably related to 
excess availability and signalling o f active transform ing g row th  factor |3 (TGF-|3), w hich is 
norm ally kept inactive by fibrillin  via TGF-p b ind ing to  the fibrillin  associated latent TGF-p 
b ind ing protein. Deficiency o f  fibrillin  thus results in an excess activ ity  o f TGF-p, w hich may
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impair satellite cell proliferation and differentiation. This probably contributes to the formation 
o f  fibrosis in response to  injury, inflamm ation, or disease.4 Recently, losartan, which 
antagonizes TGF- p, was found to  prevent aortic aneurysm and to  reverse muscle involvem ent 
in a mouse m odel o f  Marfan syndrom e .4
M utations in the fibrillin-2 gene (FBN2) cause the clinical syndrom e o f congenital 
contractural arachnodactyly (CCA), w hich shows phenotyp ic overlap w ith  Marfan syndrome 
and is also characterized by muscle hypotonia, which m ight be neurogenic in o rig in .75
Perlecan, Schwartz-Jampel syndrome and Dyssegmental Dysplasia
Perlecan is a m odular proteoglycan tha t is ub iquitously present in ECM and is one o f the 
largest single-chain polypeptides known to  date (470 kDa). The perlecan core protein is 
heavily glycosylated by numerous O-linked oligosaccharides and four heparan sulphate 
chains (fully glycosylated it can reach a m olecular w e igh t o f over 800 kDa). Perlecan plays an 
im portan t role at the neuromuscular junction , where it co-localizes w ith  the acetylcholine 
receptors in new ly fo rm ing  synapses and anchors acetylcholine esterase through its 
collagen-Q  ta il.76 Perlecan is involved in stabilization o f molecules w ith in  the extrasynaptic 
ECM, in g lom erular permeability, and in cell adhesion. Perlecan can d irectly interact w ith  a 
w ide  variety o f ECM molecules, including type  IV collagen, fibronectin , and laminin (Figure 1).
Mutations in the human perlecan gene (HSPG2) result in a spectrum  o f perlecan-related 
disorders, w ith  Schwartz-Jampel syndrome (SJS) at the moderate severe side and Silverman 
Handmaker syndrome (SHS) at the m ost extrem e end .77 These disorders are characterized by 
chondrodysplasia, bone dysplasia, congenital bow ing o f shortened femora and tibiae, and 
facial manifestations consisting o f a small mouth, micrognathia, blepharophimosis, and pursed 
lips. A recent study in perlecan-null mice demonstrated that clustering molecules, such as 
acetylcholine receptor and agrin, were present at the neuromuscular junction  but that 
acetylcholine esterase was com pletely absent, indicating that perlecan is a key molecule for 
localizing acetylcholine esterase at the synapse.78 Reduced amounts o f either truncated or 
normal perlecan molecules may result in reduced clustering o f acetylcholine esterase at the 
neurom uscularjunction in SJS, which w ould  likely cause a greater concentration ofacetylcholine. 
This w ould  stimulate acetylcholine receptor activity and thus cause myotonia (Table 2).78
Biglycan, decorin and mice models
Biglycan and decorin are small proteoglycans w ith  a h ighly hom ologous am ino acid 
sequence, d istinguished by the presence o f one (decorin) or tw o  (biglycan) chontro itin  or 
derm atan sulphate side chains. Numerous functions have been docum ented includ ing cell 
adhesion and signal transduction. Both biglycan and decorin have the ab ility  to  interact w ith  
collagens to  assemble supramolecular structures (biglycan w ith  type  I and VI collagen; 
decorin w ith  type  I, II, III, and VI collagen ).79 Biglycan also binds to  alpha- and gamma
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sarcoglycan. Decorin mediates the association o f TNX w ith  collagen fibrils and is mainly 
found in the ECM, whereas biglycan is localized more closely associated w ith  sarcoglycans 
near the sarcolemma.
Biglycan deficiency leads to  structural abnorm ality in collagen fibrils in bone, dermis, 
and tendon. Biglycan null mice have a reduced bone mass and an osteoporosis-like 
phenotype  w ith  g row th  failure and th inn ing  o f  the derm is bu t w ith o u t overt skin frag ility .80 
Decorin null mice also have structural abnorm alities o f  collagen fibrils and present w ith  lax 
skin o f markedly reduced tensile strength w ith  a th in dermis, similar to  that observed in the 
human EDS.80 Neither biglycan nor decorin gene m utations are known in human. However, 
the ir expression is notably altered in several muscular dystrophies. Variations in the transcript 
and protein levels o f these proteoglycans in DMD and MDC1A probably reflect the disruption 
o f ECM organization tha t occurs in these diseases, and the role o f  both molecules in the 
muscle response to  this dystrophic cell dam age .79 Furthermore, biglycan has an im portan t 
function  during muscle and connective tissue developm ent, and it may play a role in the 
pathogenesis o f collagen Vl-associated congenita l muscular dystrophies .81
Summarizing remarks
In conclusion, we have summarized some o f the present know ledge about ECM molecules 
present in muscle and o f the  diseases associated w ith  defects in these molecules, which 
include both myopathies and ICTDs. These disorders lead to  considerable muscle weakness 
in many cases and pose great differential diagnostic challenges. Future studies on patients 
and experim ental animal models may fu rthe r reveal the phenotyp ic  spectrum  and the 
pathogenic mechanism o f these disorders.
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Neuromuscular features 
of Ehlers-Danlos syndrome
A
Clinical evaluation of Ehlers-Danlos 
syndrome patients

CH
A
PT
ER 3
Initial clinical observations in 
Ehlers-Danlos syndrome
Report 1
Recurrent neuropathy associated with Ehlers-Danlos syndrome
Report 2
Myopathy and polyneuropathy in an adolescent with the kyphoscoliotic type 
of Ehlers-Danlos syndrome
Report 3
Ehlers-Danlos Syndrome due to tenascin-Xdeficiency: Muscle weakness and 
contractures support overlap with collagen VI myopathies
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Report 1: 
Recurrent neuropathy associated with 
Ehlers-Danlos syndrome
Adapted from:
Voerm ans NC, Drost G, van Kam pen A, Gabreëls-Festen AA, Lam m ens M, 
Hamel BC, Schalkw ijk J, van Engelen BG.
J Neurol 2006;253:670-1.
Abstract
Peripheral nervous system involvem ent in Ehlers-Danlos syndrom e has been reported only 
sporadically. We describe a patient w ith  the hyperm ob ility  type  o f Ehlers-Danlos syndrome 
w h o  sequentially suffered from  an axillary neuropathy, a brachial plexopathy, and a sciatic 
neuropathy. We shortly discuss the possible pathophysiological mechanisms involved.
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Introduction
The Ehlers-Danlos syndrom e (EDS) is a group o f  inherited connective tissue disorders (ICTDs) 
characterized by jo in t hyperm obility, skin hyperextensibility, and tissue frag ility  resulting in 
recurrent jo in t dislocations, vascular lesions, easy bruising, and excessive scarring .1 The 
hyperm ob ility  type  o f EDS is restricted to  m ild skin involvem ent and generalized jo in t 
hyperm obility. EDS is associated w ith  deficiency o f extracellular matrix (ECM) proteins such 
as collagen I, III and V and tenascin-X (TNX), bu t in the  hyperm ob ility  type  the protein 
deficiency is m ostly unknow n .1-3 A lthough initia lly described by Beighton in 1970,4 peripheral 
nervous system invo lvem ent in EDS has on ly  been reported sporadically.5-7 We here report a 
patient w ith  the hyperm ob ility  type  o f EDS w h o  subsequently experienced an axillary 
neuropathy, a brachial plexopathy, and a sciatic neuropathy.
Case report
A 30-year-old female w ith  the hyperm ob ility  type  o f  EDS (form er type  III) presented w ith  
acute onset o f paresis and sensory disturbances o f her lower le ft leg. The previous evening, 
she had fallen asleep w hile  s itting cross-legged. Sedation, w hich occurred as a side e ffect o f 
analgesics probably enabled her to  fall asleep in this seemingly awkward position. When she 
woke up after approxim ately four hours, she experienced weakness and numbness o f  her 
lower le ft leg. This had not recovered the o ther day when she was adm itted  to  the emergency 
room.
EDS was diagnosed at the age o f 20. She had suffered from  recurrent dislocations o f her 
righ t shoulder, w hich were in itia lly com plicated by an axillary neuropathy. Gradually, the 
dislocation became irreversible and was accompanied by increasing numbness and 
paresthesias in her w ho le  arm probably due to  stretching o f the brachial plexus. Both the 
axillary neuropathy and brachial p lexopathy were confirm ed by nerve conduction  studies 
and electrom yography. She underw ent a series o f  fixative operations o f her right shoulder. 
Nevertheless, due to  recurrent dislocations, post-operative infections, and a continual 
brachial p lexopathy she decided to  have her right arm am putated at the  age o f 27. Since 
then, she preferred sitting cross-legged to  increase her balance. Neuropathological studies 
o f the ulnar and radial nerve had then revealed no signs o f in fection nor m yxoid degeneration. 
The perineurium  and endoneurium  appeared normal. There was no more ultrastructural 
material available so tha t a still more refined investigation could not be perform ed. Her 
fam ily history was negative for EDS or Hereditary Neuropathy w ith  Liability to  Pressure 
Palsies. DNA analysis for 17p11.2 deletion was negative.
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Physical examination upon arrival at the em ergency room  revealed jo in t hyperm obility  
(Beighton score 7/9) and a sm ooth and velvety skin w ith o u t striae or hyperextensibility. Knee 
flexion (Medical Research Council (MRC) 4)8 and fo o t extension (MRC 2) were weak. Foot 
flexion and toe m ovem ents were absent. Sensory loss was present over the lateral lower leg 
and foot. Knee jerks were symmetrical; the  le ft ankle jerk was absent.
Two sequential EMG examinations, perform ed on day 2 and 3 weeks later showed signs 
o f  a previous le ft peroneal neuropathy, probably due to  her long-standing habit o f sitting 
cross-legged, and several findings that indicated a recent sciatic neuropathy in the same 
limb. These were: first absent and later delayed H-reflex latencies over the tibial nerve, normal 
findings in the gluteus medius muscle, and spontaneous activ ity  in the tibialis anterior 
muscle after tw o  weeks. She was discharged to  a rehabilitation clinic for physical therapy 
and was given a foot-ankle-orthesis. Muscle strength im proved gradually.
Discussion
The pathophysiological mechanism o f peripheral neuropathy in the hyperm ob ility  type  o f 
EDS appears evident; i.e. hyperm ob ility  o f jo in ts causes abnorm al stretching o f o r pressure on 
peripheral nerves, resulting in reversible neuropathy or p lexopathy .49 In addition, we 
suggested tha t increased vu lnerab ility  o f peripheral nerves themselves to  stretching or 
pressure due to  the genetic connective tissue defect in EDS m igh t also be involved. ECM 
proteins w hich are known to  be involved in EDS, such as collagen I, III, V and TNX, are 
d istribu ted th roughou t the  connective tissue o f peripheral nerves.61011 TNX or collagen 
defic ient perineurium  and endoneurium  m ight fail to  lim it excessive stretching o f  or pressure 
on nerves. This m ight cause secondary axonal or myelin damage and im paired peripheral 
nerve function . Clinicians and patients need to  be aware o f  this possible risk o f neuropathies 
in EDS, especially in the hyperm ob ility  type  o f EDS, in order to  prevent recurrent nerve 
injuries.
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Report 2: 
Myopathy and polyneuropathy in an 
adolescent with the kyphoscoliotic type 
of Ehlers-Danlos syndrome
Adapted from:
Voerm ans NC, Bonnem ann CG, Lam m ens M, van Engelen BG, Hamel BC. 
Am  J M ed G enet A 2009;149A:2311-6.
Abstract
Ehlers-Danlos syndrom e (EDS) is the  m ost prevalent inherited connective  tissue disorder. It is 
genetically and clinically heterogeneous and six major types are identified. The kyphoscoliotic 
type  o f EDS is characterized by generalized jo in t hyperm obility, severe muscle hypotonia at 
birth, progressive scoliosis, and ocular fragility.
We report a 16-year-old patient w ith  the kyphoscoliotic type  o f EDS w ith  generalized muscle 
weakness and hypotonia. Electromyography, muscle ultrasound, MRI, and muscle biopsy 
showed m yopathic changes, and nerve conduction  studies revealed a m ild axonal 
polyneuropathy. Taken together, these findings po in t to  considerable neuromuscular 
invo lvem ent in the kyphoscoliotic type  o f EDS beyond the neonatal period.
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Introduction
Ehlers-Danlos syndrom e (EDS) is one o f the m ost prevalent ICTDs. The syndrom e is divided 
in to  six major types, all o f w hich are characterized by sym ptom s due to  connective tissue 
weakness. Skin, jo in ts  and ligaments, b lood vessels, and eyes are predom inantly a ffected .19 
Former EDS type  VI, now  called the kyphoscoliotic type  o f EDS, is a rare, autosomal-recessive 
form  o f the disease presenting w ith  progressive kyphoscoliosis already present at birth, 
ocular manifestations, and neonatal muscle hypotonia (Table /). Therefore, this type  o f EDS 
should be considered in the differential diagnosis o f the  floppy  in fan t.912-14
In the  m ajority o f cases, the symptoms have been b iochem ically a ttribu ted  to  a 
deficiency o f lysyl hydroxylase 1 (LH/), a collagen m od ify ing  enzyme. This deficiency results 
in underhydroxylation o f collagen lysyl residues; hence, an abnorm al pattern o f lysyl 
pyridinolines and hydroxylysyl pyrid ino line crosslinks is excreted in the urine .1 Hom ozygosity 
or com pound  heterozygosity fo r m utan t PLOD allele(s) results in LH1 deficiency, and m utation 
analysis should be perform ed for m olecular confirm ation and to  allow  for prenatal diagnosis 
in subsequent pregnancies.15
We here report a patient w ith  the kyphoscoliotic type  o f EDS, in w hom  in the neonatal 
period a neuromuscular disorder was suspected. Electromyography and muscle biopsy then 
revealed no abnormalities. A t the age o f 12, the kyphoscoliotic type  o f EDS was diagnosed. 
At the age o f 16, generalized muscle weakness and hypotonia were present, and investigations 
revealed typical findings o f m yopathy and m ild axonal polyneuropathy, both o f w hich may 
have con tribu ted  to  muscle weakness.
Case report
The patient is the  first child o f first cousins from  the Netherlands. A neuromuscular disorder 
was considered initia lly because o f the  severe muscle hypotonia noted after birth; however, 
the  neuromuscular w ork-up at tha t time, including muscle biopsy and electrom yography, 
was normal (Figure /A). Nevo syndrom e was diagnosed at the  age o f 3 and the patient was 
reported by Hilderink and Brunner in 1995.16 In 2005, Giunta et al. reported this case again and 
concluded tha t Nevo syndrom e is allelic to  and clinically indistinguishable from  the 
kyphoscoliotic type  o f EDS (patient 7).17 M utation analysis o f PLOD/ showed a large 
hom ozygous deletion o f exon 17, fo r w hich both parents were heterozygous. Neuromuscular 
findings noted in the perinatal period, infancy, and ch ildhood are summarized in Table 2 and 
illustrated in Figure /A; fo r an extensive description we refer to  the previous reports on this 
pa tient.16-17
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Table  1 Diagnostic criteria o f the kyphoscoliotic type  EDS.1 The presence o f  three major 
criteria in an in fant is suggestive o f the  diagnosis, and laboratory and genetic 
testing is warranted.
M a jo r  c r i te r ia  M in o r  c r ite r ia  C o m m e n ts
Generalized jo in t
hype rm o b ility
Severe m uscle hypo ton ia  at
b irth
Scoliosis at b ir th  (progressive)
Scleral fra g ility  and rup tu re  o f 
th e  ocu la r g lobe
Tissue frag ility , inc lud ing  
a tro p h ic  scars 
Easy bruising 
Arterial rup tu re  
M arfano id  habitus 
M icrocornea
R adio log ica lly considerable 
osteopen ia
Family h istory, i.e., a ffec ted  sibs
M uscular hypo ton ia  can be 
very p ron o u nce d  and leads 
to  delayed gross m oto r 
d eve lo pm e n t
The p he n o typ e  is m ost o ften  
severe, fre q u en tly  resu lting  in 
loss o f  am bu la tion  in th e  2nd /  3 rd 
decade
There have been reports  o f  a less 
severe fo rm  o f  th e  cond ition , 
w ith  norm al a c tiv ity  o f  LH1 and 
norm al hydroxylysine co n te n t in 
th e  derm is
F igu re  1 Histological images o f the muscle biopsy o f the vastus lateralis muscle.
A: Rectus fem oris o pe n  m uscle b iopsy at age 2 m onths  revealed no abnorm alities. B: Rectus fem oris 
needle m uscle b iopsy  at age 16 years revealed fib rous and fa tty  tissue w ith  very fe w  rem ain ing  muscle 
fibres (arrow). H em atoxylin -P h lox in , Bar =  50 m icrom eter.
During puberty, the  patient noticed tha t muscle strength and exercise tolerance were less 
than that o f his peers, due to  w hich he had difficulties walking, running, and cycling. He 
frequently noted myalgia after m ild exercise; and walking distances was lim ited (< 500 m) 
due to  easy fatigability. At the  age o f 15, he had a rupture o f an aneurysm o f the left popliteal 
artery, after w hich a stent was placed. Neurological examination (at the  age o f 16) revealed
70
generalized muscle weakness. The pattern o f manual muscle testing scores (MRC scores) 
was confirm ed by results o f hand-held dynam om etry (data not shown). Muscle mass was 
reduced and m ild muscle hypotonia was still present (Figure 2). Deep tendon reflexes were
F igu re  2 Clinical features at the age o f 16.
A, B, and C: M axim al shou lder a b d u c tio n  w ith  m ild  scapular w in g in g  on  r ig h t side. E lbow  contrac tu re  
on  r igh t side. D: A tro p h ic  scarring on  knee.
A
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sym metrically depressed. Vibration sense was reduced in hands and feet bilaterally.18 Position 
sense o f fingers and toes was normal. Coordination tests o f arms were normal; tandem  gait 
was m ild ly impaired. Furthermore, he had a hyperextensible skin w ith  atrophic scars, a 
contracture o f  right e lbow; and hyperm ob ility  o f distal jo in ts  w ith  a Beighton hyperm obility  
score o f 4 /9  (a score o f > 5/9 indicates jo in t hypermobility)(Tab/e 2).1
Creatine kinase (CK) was m ild ly increased (344 U/l; N < 220 U/l). Nerve conduction  studies 
revealed low  sensory nerve action potential am plitudes and com pound  muscle action 
potentia l amplitudes, w ith  m ild ly reduced conduction  velocities in arms and legs, com patib le 
w ith  a m ild sensomotor axonal po lyneuropathy w ith  secondary slow ing o f conduction 
velocities (Tab/e 2). E lectromyography revealed small, polyphasic units in the biceps brachii, 
de lto id, and gluteus maximus muscles, reflecting myopathy. Laboratory investigations 
revealed no m etabolic or toxic cause o f polyneuropathy, and serum creatine kinase was 
m ild ly elevated (344 U/l; normal < 220 U/l). Muscle ultrasound revealed considerably 
increased echo intensity o f the flexor muscles o f the  forearm, o f the  quadriceps muscle, and 
o f  the anterior tibial muscle bilaterally. A trophy on muscle ultrasound was noted in most 
muscles exam ined .19 T l-w e igh ted  muscle MRI revealed m yopathic changes (increase o f fat 
tissue and atrophy) o f the erector spinae, gluteal, hamstrings, and calve muscles (Figure 3). 
Re-examination o f the  muscle biopsy perform ed at the age o f 2 m onths o f age revealed no 
abnorm alities (Figure !A). A second needle biopsy o f the right quadriceps muscle at the age 
o f  16 revealed fibrous and fa tty  tissue w ith  very few  atrophic muscle fibres (Figure !B).
F igu re  3 T1-weighted muscle muscle MRI.
A  and B: M yopa th ic  changes (increase o f  fa t tissue and a trophy) o f  th e  e rec to r spinae. C: M yopa th ic  
changes o f  th e  g lu tea l muscles. D: M yopa th ic  changes o f  th e  ham strings (unilateral arrows ind icate 
m yo pa th ic  changes).
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Table 2 Findings o f  physical exam ination and ancillary investigations.16'17
P erinata l /  N eo n a ta l period In fancy C h ildhood
Physical Reduced fetal m ovem ents Delayed m o to r d eve lo pm e n t Participates in all norm al schoo l activ ities except
e xam ina tion W eak c ry ing  and sucking (ro lling over at 13 m onths; sports
Severe genera lized hypo ton ia  w ith  facial w a lk ing  unsu p p o rted  at 22 m onths) No progression o f  kyphoscoliosis
weakness Gradual im p ro ve m en t o f  hypo ton ia
Severe th o ra co lu m ba r kyphoscoliosis M ild  facial weakness
M uscle a trophy, d is ta lly  m ost p ronounced
(D ifferentia l) N eurom uscular d isorder Nevo syndrom e K yp h o sco lio tic typ e  EDS
diagnosis M arfan syndrom e (age 3) (age 12)
Adolescence
Physical exam ination NCS EMG Muscle ultrasound Muscle MRI (Ti) Needle biopsy
Generalized m uscle weakness M ild  axonal sensom otor M yopathy: El MD Fatty in filtra tio n Fibrous and
(shoulder a b d u c tio n  and e lb o w p o lyn e u ro p a th y  w ith  m ild (Z) (Z) o f  e rector fa tty  tissue
flex ion  MRC 3; o th e r proxim al secondary re du c tio n  o f
Biceps brachii
spinae muscle w ith  very few
and d istal lim b  muscles and tru n k co n d u c tio n  velocities: 0.2 -5 .0 (abdom ina l level), a troph ic  muscle
m uscles MRC 4) Reduction  o f  co m p o u n d M o to r u n it ac tion Flexors in
4.6
g lu tea l maximus, fibres
Reduced m uscle mass and m uscle muscle ac tion  po tentia l potentia ls: forearm -3 .9 ham strings,
hypo ton ia a m p litu d e  and ve loc ity : - Small un its  (3-8 ms; Quadriceps 5.5 -7.1 gastrocnem ius,
Sym m etrica lly low  deep  te n d o n - M oto r: peroneal nerve (2.4 biceps brachii; g lu tea l A n te rio r tib ia l
2.6 2.6
and extensors in
reflexes mV, 32.6 m/s; p5 o f  norm al and d e lto id  muscle), w ith m uscle low er leg
Reduced v ib ra tio n  sense in hand values 11.2 mV;42.1 m /s ) polyphasia in biceps
and fee t b ila tera lly - Sensory: sural nerve brachii muscle
(measured w ith  Rydel Seiffer (1.6 mV;46.2 m/s; p5 o f Turns and am p litudes
tu n in g  fork: 3 and 2 respectively; norm al values 6.6 m V) analysis:
norm al values > 6.5 and > 4.5 m yopa th ic  in biceps
respectively, on  a scale o f  0 brachii
(absent) to  8 (m axim al)13
El: Echo intensity, expressed in Z-value; MD: muscle diameter, expressed in Z-value.19,20
Report 1, 2 & 3: In itia l clin ical observations in Ehlers-Danlos syndrom e
Discussion
In short, the  case presented here shows tha t considerable neuromuscular involvem ent may 
be present in the kyphoscoliotic type  EDS in adolescence. Remarkably, a neuromuscular 
disorder was considered in the neonatal period in this patient, bu t was then excluded by a 
muscle biopsy and electrom yography. The kyphoscoliotic type  o f EDS was diagnosed in 
ch ildhood. In adolescence, generalized muscle weakness and reduced vibration sense were 
present, and muscle ultrasound, muscle MRI, and electrom yography indicated considerable 
muscle involvement. Needle biopsy o f  the  right quadriceps muscle revealed alm ost only 
fibrous and fa tty  tissue w ith  very few  atrophic muscle fibres, w hich corresponds w ith  the 
abnorm alities found in the muscle ultrasound. Laboratory investigations revealed mild 
increase o f CK, ind icating lim ited muscle fibre necrosis. Furthermore, nerve conduction 
studies indicated a m ild axonal polyneuropathy w ith  m ild secondary slow ing o f conduction 
velocities. Both m yopathy and po lyneuropathy may con tribu te  to  muscle weakness in this 
patient.
In contrast to  these findings, muscle weakness is not included in the diagnostic criteria 
o f  the  kyphoscoliotic type  ofEDS (Table Í).91213 In addition, muscle weakness or polyneuropathy 
in this type  o f EDS has on ly  rarely been reported ;2122 Farag reported tw o  sibling w ith  the 
kyphoscoliotic type  EDS w ith  polyneuropathy and secondary muscle atrophy, w ith o u t 
fu rthe r specification o f its cause.22 Interesting though, loss o f am bulation in 2nd or 3rd decade 
is added as a com m ent to  the diagnostic criteria o f this type, bu t w ith o u t note or com m ent 
on w he ther muscle or peripheral nerve dysfunction  may con tribu te  to  this. This functional 
decline in adolescence corresponds to  the progression o f sym ptom s in the patient we 
described. It may suggest tha t neuromuscular features in the kyphoscoliotic type  o f EDS 
progresses w ith  aging. Furthermore, muscle weakness o r easy fa tigab ility  is likely to  remain 
unnoticed in patients w ho  avoid intense exercise to  prevent dermal, ocular or arterial 
damage, and w ho  are generally not referred to  a neuro(myo)logist after the neonatal period.
Presence o f m yopathy and polyneuropathy in this patient could have a d iffe rent genetic 
cause since the consanguineous parents m igh t carry another genetic defect affecting 
muscle and peripheral nerve structure and function. However, the  absence o f myopathic 
changes in the neonatal muscle biopsy makes the presence o f another m yopathy less likely. 
Alternatively, myopathy and polyneuropathy m ight also be associated w ith  the role o f LH1 in 
the ECM o f muscle and peripheral nerve. LH1 catalyzes the hydroxylation o f  lysine residues, 
m ainly bu t not exclusively in [X-Lys-Gly] triplets in collagen and proteins w ith  collagen-like 
sequences. The hydroxylysine residues form ed have tw o  im portan t functions: first, they are 
essential fo r the stability o f the intermolecular cross links that provide the collagen fibrils w ith 
the ir tensile strength and mechanical stability .23 Second, they serve as a ttachm ent sites for 
carbohydrate units, which have an im portant role in the regulation o f collagen fibril formation
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and m orpho logy and in the assembly o f type  IV collagen networks. This collagen crosslink 
form ation occurs in the ECM.23 Deficiency o f LH1 thus results in abnormal collagen 
m orpho logy and cross linking, w hich may influence muscle function. In analogy, abnormal 
com position  o f endo-, peri- and ep ineurium  may influence peripheral nerve function  in this 
type  o f  EDS, resulting in (poly)neuropathy .24 This case suggests that both muscle and 
peripheral nerve dysfunction may increase w ith  aging. However, the  exact mechanism in 
w hich this occurs is still unclear.
Our findings are supported by findings in LH1 knockout mice (Plodl-/-).23 These animals 
show considerable generalized muscle weakness and hypotonia after the neonatal period, 
causing gait abnormalities, and reduction o f spontaneous movements. These abnormalities 
are progressive w ith  age and are explained as a com bined result o f laxity or dislocation o f 
jo in ts  and muscle weakness. The muscle biopsy presented in this article reveals no signs o f 
myopathy; however, on ly  a long itudina l section is shown, w hich may fail to  reveal m ild 
m yopathic features.23
In summary, we have presented a 16-year-old patient w ith  the kyphoscoliotic type  o f 
EDS w ith  m ild generalized muscle weakness and reduced vibration sense. Ancillary 
investigations revealed typical signs o f  m yopathy and m ild axonal polyneuropathy. 
Remarkably, a neuromuscular disorder had been considered in the neonatal period due to 
hypotonia; however, e lectrom yography and muscle biopsy at tha t tim e revealed no signs o f 
myopathy. This case report may thus con tribu te  to  im proved recognition o f neuromuscular 
features in the kyphoscoliotic type  o f EDS beyond the neonatal period. Furthermore, it 
stresses the im portance o f  research on the role o f the  extracellular in muscle and peripheral 
nerve fu n c tion .25
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Report 3:
Ehlers-Danlos syndrome due to tenascin-X 
deficiency: Muscle weakness and contractures 
support overlap with collagen VI myopathies
Adapted from:
Voerm ans NC, Jenniskens GJ, Hamel BC, Schalkw ijk J, G u icheney P, van Engelen BG. 
Am  J M ed G enet A 2007;143A:2215-9.
Abstract
Kirschner et al. reported 5 patients w ith  Ullrich congenita l muscular dystrophy and clinical 
characteristics typical o f disorders o f  connective tissues such as Ehlers-Danlos syndrome 
(EDS). Electron m icroscopy o f skin biopsies revealed alterations in collagen fibril m orpho logy 
and an increase in extracellular material, similar to  findings in skin biopsies o f patients w ith 
EDS. The authors suggested that there is considerable clinical as well as m orphological 
overlap between Ullrich congenita l muscular dystrophy and inherited connective tissue 
disorders such as EDS.
We here report an EDS patient w ith  a reverse presentation. She was previously diagnosed 
w ith  tenascin-X (TNX) deficiency type  o f EDS and was referred to  the neurologist for muscle 
weakness. Physical exam ination revealed both jo in t hyperm obility, skin hyperextensibility, 
generalized muscle weakness, and distal contractures. Ancillary investigations showed 
normal CK and m yopathic features on e lectrom yography bu t not in the muscle biopsy. 
Qualitative evaluation o f collagen VI staining o f  the  muscle biopsy showed m ild ly reduced 
endomysial staining.
The com bination o f jo in t hyperm obility, generalized muscle weakness, and contractures is 
also characteristic o f collagen VI myopathies. Recent studies support the  functiona l links 
between collagen VI and TNX. This case provides additional support fo r the clinical and 
b iochem ical overlap between collagen VI-related myopathies and the TNX-deficient type  o f 
EDS.
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Introduction
In the ir article "Ullrich congenita l muscular dystrophy: connective tissue abnorm alities in the 
skin support overlap w ith  Ehlers-Danlos syndromes" Kirschner et al.26 reported 5 patients 
w ith  Ullrich congenita l muscular dystrophy (UCMD) and clinical characteristics typical o f 
ICTDs such as Ehlers-Danlos syndrome (EDS). Electron m icroscopy o f skin biopsies revealed 
alterations in collagen fibril m orpho logy and an increase in extracellular material, similar to  
findings in skin biopsies o f patients w ith  EDS. The authors suggested tha t there is considerable 
clinical as well as m orphological overlap between UCMD and ICTDs such as EDS.
Here, we confirm  the connection between myopathies and ICTDs from  the opposite 
perspective. Recently, we had the o p p o rtu n ity  to  investigate a patient w ith  autosomal 
recessive EDS due to  TNX deficiency w ith  a reverse presentation. She has previously been 
described as Patient 1 by Schalkwijk in 2001, and recently as Patient 1 by Voermans in 2007.227
This patient had been diagnosed w ith  classical type  o f  EDS at the age o f 27 and TNX 
deficiency was diagnosed at the  age o f  46. She presented the clinical features o f  EDS as well 
as generalized muscle weakness and distal contractures. The com bination  o f generalized 
muscle weakness and jo in t hyperm ob ility  is seen in UCMD, w hile  distal contractures typically 
occur in Bethlem Myopathy. Both UCMD and Bethlem m yopathy result from  defects in 
collagen VI, an ECM com ponen t tha t depends on TNX for proper function ing . We describe 
the clinical phenotype and the results o f ancillary investigations. Furthermore, we discuss 
some the results o f recent studies tha t support the functiona l links between collagen VI and 
TNX. We suggest tha t this case provides additional support fo r the  clinical and biochemical 
overlap between collagen VI-related myopathies and EDS related to  TNX deficiency.
Case report
A now 50-year-old wom an has suffered from  mild jo in t hypermobility, skin hyperextensibility, 
and easy bruising since childhood. She experienced recurrent dislocations o f  her right 
shoulder and had developed haematomas on the soles o f her feet after high jum p ing . She 
had never been good  at running. Classical type  o f EDS (type I/II according to  the classification 
at tha t time) was diagnosed at the age o f 27. The diagnosis was specified as TNX deficiency 
type  o f EDS at the age o f 46. Indeed, she had not presented atrophic scarring as is com m on 
in the classical type  o f EDS. Absence o f TNX protein in serum was confirm ed by ELISA. 
M utation analysis revealed a hom ozygous 2-bp deletion in exon 8 , w hich encodes the fourth 
fib ronectin  type-III repeat o f the  TNX protein. At tha t time, she was referred to  the neurologist 
w ith  weakness o f  her righ t hand and m ild generalized weakness o f arms and legs. A lthough 
m ild muscle weakness o f her arms had already been reported when she was originally
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diagnosed w ith  EDS at the age o f 27, muscle weakness had become sym ptom atic around 
the age o f 40 and has gradually increased since then. She was unable to  walk up stairs, her 
walking endurance was lim ited to  one hour, and she suffered from  reduced g ripp ing  force, 
predom inantly o f the  pincer grip.
A general physical exam ination at the  age o f  46 revealed generalized jo in t hyperm obility  
(Beighton score 5/9), bruises o f her fingers, bilateral pes planus, m olluscoid pseudotum ors on 
the lateral side o f her feet, and hyperextensibility o f her skin, w hich was sm ooth and velvety 
(Figure 4). She d id  not have atrophic scars. The neurological examination indicated generalized 
muscle hypotonia and generalized weakness o f  arm, leg, and neck flexor muscles (MRC 4). 
Muscle atrophy and weakness were m ost pronounced in her hands and lower arms (MRC 3), 
more on the right than on the left side. She had very m ild flexion contractures o f distal 
phalanges predom inantly o f the right hand. Tendon reflexes were sym metrically low.
CK was normal (88 U/l). Nerve conduction  studies revealed signs o f a m ild left carpal 
tunne l syndrome, bu t were otherw ise normal. Electromyography showed only mild 
non-specific changes w ith o u t clear signs o f  e ither a m yopathy or a neurogenic disorder. 
Needle biopsy o f the quadriceps muscle showed neither significant m yopathic changes nor 
signs o f  disuse. Guinea pig anti-hum an TNX antibodies were used to  stain TNX w ith in  muscle 
ECM. Visual inspection revealed absence o f TNX w ith in  muscle ECM.28 Mice anti-hum an 
collagen VI antibodies (Chemicon Millipore, Billerica, USA) were used to  stain collagen VI 
w ith in  muscle ECM. Visual inspection revealed decreased endomysial collagen VI staining 
(Figure 5).
This patient was investigated again at the  age o f 50. The severity o f the  contractures o f 
her fingers had gradually increased (Figure 6), for w hich she used an orthosis interm ittently. 
E lectromyography was repeated and revealed apparent m yopathic changes in the arm and 
hand muscles on both sides.
Discussion
In short, this patient shows clinical features that are characteristic o f the TNX-deficiency type  
o f  EDS includ ing jo in t hyperm obility, skin hyperextensibility, and easy bruising .2 The diagnosis 
was confirm ed by the absence o f TNX in serum and by m utation analysis. Starting at the  age 
o f  40, she gradually developed additional clinical symptoms tha t are frequently seen in 
collagen VI-related myopathies, includ ing generalized muscle weakness and contractures o f 
the  distal phalanges o f the hand.
TNX is an ECM-resident g lycoprotein w ith  a m ultidom ain  structure that consists o f 
an N-term inal region involved in o ligom erization, a series o f epidermal g row th  factor-like 
repeats, a number o f fibronectin-type III modules, and a C-terminal domain that is homologous
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F igure  4  Typical characteristics o f  TNX- 
d e fic ie n t EDS. A : Jo in t h ype rm ob ility . B and C: 
Skin h ype rex tens ib ility  (this shou ld  preferab ly 
tes ted  at th e  volar side o f  th e  forearm).
F igu re  5 Muscle b iopsy o f  th e  vastus lateralis 
m uscle (pe rfo rm ed  at th e  age o f  46) stained 
w ith  an ti-hum an  co llagen VI an tibod ies. Visual 
inspec tion  revealed decreased endom ysial 
co llagen VI s ta in ing. A: C ontro l subject.
B: TN X -defic ien t EDS patien t. Bar =  50 |jm ; 
o b je c tive  10x.
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Figure 6 Muscle atrophy and contractures.
A  and B: M uscle a trophy. C and D: Distal contractu res o f  th e  fo u rth  and fifth  proxim al and distal inter- 
phalangeal jo in ts.
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to  fibrinogen. Its com plex structure enables m ultip le  interactions w ith  o ther ECM (glyco) 
proteins, rendering TNX a crucial player in the organization o f  the ECM notably in skeletal 
muscle.29-31 Upon disruption o f the TNX gene, the expression o f type  VI collagen is significantly 
decreased .32 Moreover, TNX and type  VI collagen are collectively involved in collagen fib rillo - 
genesis in vitro and in vivo?3
In short, where Kirschner et al. observed EDS-like symptoms in UCMD patients, we report 
on collagen VI myopathy-like symptoms in an EDS patient. The observations in this patient 
and the results o f  previous studies on TNX and collagen VI interaction provide support fo r a 
clinical and biochem ical overlap between collagen VI-related myopathies and TNX-deficient 
type  EDS (Table 3). This overlap, w hich was already proposed by Kirschner et al., is o f 
conceptual interest and may in tim e have diagnostic and therapeutic consequences.26 
Further studies should elucidate w hether muscle symptoms are com m on in this and other 
types o f EDS.
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T a b le  3  Com parison o f  clinical and b iochem ical find ings in patients w ith  TNX-deficient typ e  o f  EDS, classical typ e  o f  EDS, hype rm o b ility  typ e  o f 
EDS, and U C M D / Bethlem  m yopathy.
TN X -d e fic ien t  
ty p e  EDS
Classical 
ty p e  EDS
H y p e rm o b ility  
ty p e  EDS U CM D  /  B eth lem  m yo pathy
Tendon/ske leton Jo in t h ype rm o b ility Join t h y p e rm o b ility G enera lized  jo in t  
h y p e rm o b ility , recurren t jo in t 
d is locations, ch ron ic  jo in t /  lim b 
pain
Distal jo in t h ype rm ob ility , 
contractures, Kyphoscoliosis, 
Torticollis, p ro m in e n t calcanei
Skin Elyperextensible and sm ooth , 
ve lve ty skin, m in im a l a troph ic
scars
Skin h y p erexten s ib ility , 
w id e n e d  a tro ph ic  scars,
sm ooth  ve lve ty  skin, m o lluscoid  
pseudo tum ors, subcutaneous 
spheroids
Skin in vo lv em e n t 
(h y p e rex te n s ib ility  an d /o r  
s m o oth , v e lv e ty  skin)
M inim a l a tro p h ic  scars, 
ve lve ty  skin, striae fo rm a tion , 
ke lo id  fo rm a tion , fo llicu la r 
hyperkeratosis
Muscle Generalized m uscle weakness, 
hypoton ia, d istal contractures
Elypotonia, delayed gross m o to r 
d eve lo pm e n t
M usculoskeletal pain M ild  to  severe weakness, 
respira tory failure
Vasculature Easy bruis ing Easy bruis ing Norm al N ot repo rted
O ther M anifestations o f  tissue 
e x te n s ib ility  and frag ility , surgical 
com plica tions, fa tigue
Inheritance Autosom al recessive A utosom al d om in a n t Autosom al d om in a n t A utosom al d o m in a n t or 
autosom al recessive
ECM m olecu le TNX ?, C ollagen V ?, TNX C ollagen VI
Gene (locus) TNXB (6p21.3) ?, COL5 (9g34) ?, TNXB (6p21.3) COL6A1, COL6A2 (21q22.3), 
COL6A3 (2q37)
EDS m ajor criteria according to  the  revised classification (Villefranche) are printed in bo ld .1 Characteristics o f  th e  TNX-deficient type  EDS are according to  Scha lkw ijke t a I.2 Zweers e t al. 
dem onstrated thatTNXB haplo insufficiency is associated w ith  the  hype rm ob ility  type  o f  EDS.3 UCMD/BM m yopathy characteristics were based upon th e  tab le  o f  Kirschner e t al.26
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Neuromuscular involvement in various types 
of Ehlers-Danlos syndrome
Adapted from:
Voerm ans NC, van A lfen N, Pillen S, Lam m ens M, Schalkw ijk J, Zw arts MJ, van Rooij IA, 
Hamel BC, van Engelen BG.
A nn Neurol. 2009;65:687-97.
Abstract
The Ehlers-Danlos Syndrome (EDS) is a clinically and genetically heterogeneous group o f 
inherited connective tissue disorders characterized by jo in t hyperm obility, skin hyperexten­
sibility, and tissue fragility. Muscle involvem ent is plausible based on recently discovered 
interactions between muscle and extracellular matrix molecules; however, muscle symptoms 
are only sporadically reported in case reports. Therefore, we designed a cross-sectional study 
to  find o u t w hether neuromuscular features are part o f  the EDS phenotype.
Standardized questionnaires, physical examination, laboratory investigations, nerve 
conduction  studies, e lectrom yography, muscle ultrasound, and muscle biopsy were 
perform ed in 40 EDS patients w ith  the vascular, classical, tenascin-X (TNX)-deficient type  
EDS, and hyperm ob ility  type  o f EDS due to  TNXB haploinsufficiency.
Muscle weakness, myalgia, and easy fa tigab ility  were reported by the m ajority o f patients. 
M ild to  moderate muscle weakness (85%) and m ild reduction o f  vibration sense (60%) were 
com m on. Nerve conduction  studies revealed axonal po lyneuropathy in five patients (13%). 
Needle electrom yography showed predom inantly m yopathic features in nine patients (26%), 
and a m ixed neurogenic-m yopathic pattern in m ost (60%). Muscle ultrasound revealed 
increased echo intensity (48%) and atrophy (50%). M ild m yopathic features were seen on 
muscle biopsy o f  five patients (28%). Overall, patients w ith  the hyperm ob ility  type  EDS due 
to  TNXB haploinsuffic iency were least affected.
M ild to  moderate neuromuscular involvem ent is com m on ly  present in various types o f EDS, 
w ith  a remarkable relation between residual TNX level and degree o f neuromuscular 
involvement, com patib le  w ith  a dose-effect relationship. The findings o f this study should 
increase awareness o f neuromuscular sym ptom s and signs in EDS patients and improve 
clinical care. It also points to  a possible role o f the extracellular matrix in muscle and peripheral 
nerve function.
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Introduction
The Ehlers-Danlos Syndrome (EDS) is a clinically and genetically heterogeneous group o f 
inherited connective tissue disorders (ICTDs) characterized by jo in t hypermobility, skin hyper­
extensibility, and tissue fragility. The revised classification o f EDS in six major types is based 
upon clinical and biochem ical features, and consists o f major and m inor diagnostic criteria 
(Table I;Figure I)} The hyperm ob ility  type  is the m ost com m on type  o f EDS, fo llow ed by the 
classical type. Together, these types account fo r approxim ately 90% o f all cases.2 The vascular 
type  is far less com m on, bu t associated w ith  deve lopm ent o f vascular dissections and 
aneurysms, which may cause severe neurological complications. The kyphoscoliotic, 
arthrochalasia, and dermatosparaxis types are rare, as are the various o ther forms. In 2001, a 
new  autosomal recessive type  o f EDS caused by deficiency o f tenascin-X (TNX) was 
iden tified .34 Subsequently, TNXB haplo-insuffic iency was found to  be associated w ith  the 
hyperm ob ility  type  o f EDS in a m inority  o f patients .56
Muscle involvem ent can be expected based on interactions between muscle and 
extracellular matrix (ECM) m olecules .7 Furthermore, muscle hypotonia and muscle rupture 
are part o f the diagnostic criteria o f EDS, and fatigue, musculoskeletal pain, and delayed gross 
m otor deve lopm ent are described as associated features (Table I).1 However, muscle 
sym ptom s such as muscle weakness and exercise intolerance are only sporadically reported 
in case reports. They are generally in terpreted to  result from  increased distensibility o f 
tendons, or from  exercise avoidance due to  jo in t hyperm ob ility .1'2'89 W ithin this frame o f 
reference, sym ptom s o f m ild muscle weakness m ight no t easily be detected as such. 
Furthermore, m ild muscle weakness can also manifest as fa tigue or com pensatory m usculo­
skeletal pain in non-affected muscles.1 Furthermore, patients w ith  EDS are generally not seen 
by a neurologist, and therefore m ild neuromuscular signs may also remain unnoticed.
Only tw o  previous studies have d irectly investigated neuromuscular involvem ent in EDS. 
In a study o f muscle function  in a patient w ith  classical type  EDS, muscle weakness and 
reduced jo in t proprioception were fo u nd .10 In a recent case study we dem onstrated muscle 
weakness in tw o  TNX-deficient EDS patients, w hich m ost likely resulted from  abnormal 
muscle ECM com position and impaired myofascial force transmission .11
To find ou t w hether neuromuscular features are in fact part o f EDS, we perform ed a 
cross-sectional observational study on the occurrence o f  neuromuscular sym ptom s in 
various EDS types. Patients w ith  the classical, the vascular, and the TNX-deficient type  EDS 
were included, since clinical criteria fo r these types are m ost stringent, and the diagnosis can 
often be confirm ed by biochemical or genetic analysis. To study the influence o f  residual 
TNX levels on neuromuscular involvement, we also included patients w ith  the hyperm obility  
type  o f EDS w ith  reduced TNX serum levels due to  TNXB haploinsufficiency .5
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F igu re  1 Clinical features o f EDS.
A  and B: Jo in t h yp e rm o b ility  o fh a nd s  in a pa tien t w ith  th e  TN X-defic ien t ty p e  EDS. C: Jo in t h ype rm o b ility  
o f  hands in a pa tien t w ith  th e  classical ty p e  EDS. D: A tro p h ic  scars in a pa tien t w ith  th e  classical typ e  
EDS. E: Skin h ype rex tens ib ility  in a pa tie n t w ith  th e  TN X -defic ien t ty p e  EDS. F, G and H: C ontractures o f 
th e  d istal phalanges o f  d ig itu m  IV and V o f  b o th  hands and a trophy o f  intrinsic hand muscles in a pa tien t 
w ith  th e  TN X -defic ien t ty p e  EDS, previously re po rted  by Voerm ans et al.12 I: Incom p le te  eye closure in a 
pa tie n t w ith  th e  vascular ty p e  EDS.
I
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Methods
Study population
A total o f 40 patients o f four w e ll-defined EDS types was included to  investigate w hether 
findings are related to  specific types o f EDS. We recruited ten patients o f each type. Patients 
w ith  the classical and vascular types were recruited am ong members o f the  Dutch EDS 
patient organization (ww w .ved.n l) w ith o u t know ledge o f the ir neuromuscular status. These 
patients all fu lfilled the clinical criteria .1 Results o f b iochem ical and genetic analysis which 
had been perform ed elsewhere were noted. The patients w ith  TNX-deficient type  EDS were 
referred to  us by the derm atology, human genetics or internal m edicine departm ents o f our 
hospital; these 10 patients represent all adu lt Dutch patients w ith  this type  o f EDS diagnosed 
so far, and derm atological, genetical, and biochem ical features o f six o f  them  have previously 
been described by Schalkwijk e t al.3 Measurement o f TNX in serum (n = 10) and m utation 
analysis o f TNXB (n = 6) had previously been perform ed, and the results o f these tests were 
no ted .35 Ten fam ily members w ith  reduced serum levels o f TNX due to  TNXB haplo- 
insufficiency and clinical features o f the  hyperm ob ility  type  EDS were recruited w ith o u t 
know ledge o f the ir neuromuscular status. Their derm atological and biochemical features 
were previously described by Zweers et al.5 For comparison, a num ber o f  healthy age and 
sex-matched controls, m ostly hospital employees and the ir fam ily members, were asked to 
fill o u t the  sym ptom s questionnaire. The study was perform ed in accordance w ith  the 
Helsinki criteria after approval by the local ethics com m ittee .27 Informed consent was 
obta ined from  all patients.
Clinical studies
Standardized questionnaires
All patients com ple ted a brief questionnaire focusing on medical history, muscle symptoms 
i.e. muscle weakness, muscle hypotonia, presence o f frequent or continuous myalgia, 
increased fa tigab ility  com pared to  peers, use o f a wheelchair, use o f walking aids, walking 
distance, and perform ing sports. In addition, patients and subjects were asked for occurrence 
o f paresthesias or numbness to  de tect en trapm ent neuropathies.
Standardized physical examination
The patients were all examined by one o f the authors using a standardized protocol. 
H yperm obility  was scored w ith  the Beighton score.28 Skin hyperextensibility was tested on 
the extensor side o f the forearm, and classified as normal or increased (> 4 cm ).1 Easy bruising 
was defined as presence o f spontaneous ecchymoses, w hich frequently recur in the same 
area and cause characteristic brownish d iscoloration .1 Cranial nerves were tested. Muscle 
strength was graded according to  the Medical Research Council (MRC) system .29 Thirteen
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Table  1 Various types o f Ehlers-Danlos syndrome. Diagnostic criteria and literature review 
on neuromuscular involvement.
D ia g n o s t ic  c r ite r ia
EDS type M ode o f  inheritance  
Biochem ical/ genetic defect
M a jo r criteria M inor criteria and  
associated
neurom uscular features
Classical typ e AD
Structura l defects  in the  
proa1(V) and proa2(V) chains 
o f  co llagen V e ncoded  by 
COL5AI in approx im ate ly  half 
o f  th e  patients
Skin hype rex tens ib ility  
W idened  a tro p h ic  scars 
(m anifesta tion  o f  tissue 
frag ility)
Jo in t h ype rm o b ility
M uscle hypoton ia  
Fatigue
H ype rm o b ility  AD /  AR 
ty p e  U nknow n
Reduced serum  level o f  TNX 
/  TNXB h ap lo -insu ffic iency  in 
fe w  patien ts  (< 5%)
Skin invo lvem en t 
(hype rextens ib ility  and /  or 
sm ooth , ve lve ty  skin) 
Generalized jo in t 
h ype rm o b ility
M usculoskeleta l pain
Vascular typ e AD
Structura l defects  in the  
p roa l(III) chain  o f  co llagen 
ty p e  III encoded  by COL3A1 
in a pp rox im ate ly  ha lf o f  the  
patients
Thin, trans lucen t skin 
A rterial /  intestina l /  uterine 
fra g ility  o r rupture  
Extensive bruis ing 
C haracteristic facial 
appearance
M uscle rup tu re
O the r types Various Various M uscle hypoton ia  
(in arthrochalasia typ e  
and kyphosco lio tic  
type)
Delayed gross m oto r 
d eve lo pm e n t 
(in kyphosco lio tic  
type)
TN X-defic ien t
typ e
AR
D efic iency o f  TNX, caused by 
m uta tions  in TNXB
Generalized jo in t
h ype rm o b ility
Skin hype rex tens ib ility
Easy bru is ing  w ith o u t a troph ic
scarring.
M o d e  o f  in h e r ita n c e ,  b io c h e m ic a l  a n d /o r  g e n e t ic  d e fe c t ,  d ia g n o s t ic  c r i te r ia ,  a n d  m u s c le  a n d  p e r ip h e r a l n e rv e  
in v o lv e m e n t  re p o r te d  in  l ite ra tu re .  (A D : a u to s o m a l d o m in a n t ;  AR; a u to s o m a l re c e s s iv e ). T h e  l i te r a tu r e  r e v ie w  w a s  
p e r fo r m e d  in  P u b m e d  w i t h  th e  f o l lo w in g  s e a rc h  te rm s : "E h le rs -D a n lo s  s y n d r o m e  /  EDS" a n d  "m u s c le  /  m y o p a th y "  o r 
" p e r ip h e r a l n e rv e  /  p o ly n e u r o p a th y " .  S u b s e q u e n t ly ,  w e  c h e c k e d  th e  re fe re n c e s  o f  th e s e  a r t ic le s  f o r  re le v a n t  o th e r  
a r t ic le s .
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Literature review
Peripheral nerve involvement Muscle involvement
P olyneuropa thy13 Muscle hypo ton ia  and hypoplasia9
Muscle weakness lc
Fatigue'
(Recurrent) n eu ro p a thy14-16 Muscle cram ps and m ya lg ia '17
Brachial p lexo p a thy18 Muscle cram ps, m yalgia, fin ge r flexor
Pressure neu ropathy  caused by arterial 
rup tu re 19
contrac tu res2c
(Axonal) po lyn e u ro p a th y21,22 Muscle cram ps8
HNPP23 M uscular d ys trophy24 
Muscle h ypo ton ia25,26 
Delayed m o to r d e ve lo p m e n t26
Muscle weakness1112
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proximal and distal lim b muscle groups bilaterally and tw o  trunk muscle groups were tested, 
which resulted in a m axim um  MRC sum score o f 140. Muscle strength was defined as m ildly 
reduced when the MRC sum score was 126 -  139 (mean MRC 4.5 - < 5); m oderately reduced 
in case o f a MRC sum score o f 112 - 125 (mean MRC 4 - < 4.5); and severely reduced w ith  a 
MRC sum score be low  112 (mean MRC < 4). To verify presence o f m ild muscle weakness, 
muscle force was also measured w ith  dynam om etry perform ed in five muscle groups 
bilaterally in standardized positions using a CIT hand held dynam om eter (www .citec.nu). 
The median o f three measurements o f each muscle group on both sides was calculated and 
compared w ith  the median and p5 value o f healthy controls previously reported .30 Muscle 
tone  o f the  biceps brachii and quadriceps muscles was evaluated bilaterally and semi- 
quantita tive ly in a sitting position (0 = hypotonia; 1 = norm otonia; muscle tone sum score 0
- 4), w ith  hypotonia defined as a sum score < 4. Coordination was tested bilaterally w ith  use 
o f  finger-nose-finger test and hee l-to -knee-to-toe test, and tandem  gait (0 = > 2 cm  deviation 
o r > 2 steps to  the side; 1 = < 2 cm deviation or < 2 steps to  the side; 2 = normal; coordination 
sum score 0-10). Reduced coord ination was defined as a sum score < 10. Testing o f sensation 
consisted o f assessment o f  vibration sense (w ith Rydell-Syffer tun ing  fork ),31 pain sense, and 
touch sense in legs and arms both proximally and distally; m ovem ent sense was tested in 
distal legs and arms (0 = absent; 1 = reduced, and 2 = normal). The Romberg test was scored 
as fo llow ing: not able to  stand w ith  eyes closed = 0; standing w ith  eyes closed < 60 seconds 
= 2; 60 seconds standing w ith  eyes closed = 4). The sensation and Romberg scores 
cum ulated in a sensation sum score o f 0 - 60, w ith  reduced sensation defined as a sum score 
< 60. Reflexes were evaluated bilaterally on a 3 -po in t scale (0 = absent; 1 = reduced; 2 = 
normal, w ith  a reflex sum score o f 0 -  16), w ith  hyporeflexia defined as a sum score < 16.
Functional measurements included the Vignos scale (measures lower extrem ity  function; 
1 = being able to  walk and c lim b stairs w ith o u t assistance; 10 = confined to  bed ),32 Brooke 
scale (measures upper extrem ity  function; 1 = patients being able to  fu lly abduct the ir arms; 
6 = no useful function  o f hands),33 Rivermead M ob ility  Index (measures the ab ility  to  move its 
ow n body; 0 = severely dependent on others fo r m obility ; 15 = norm al),34 and M odified 
Rankin Scale (measures recovery o f  m otor function  after stroke; 0 = normal; 5 = severe 
disability; 6 = dead ).3536
Ancillary investigations
Laboratory investigation
Creatine kinase (CK) was measured in the laboratory o f our centre (normal values: CK < 220 
U/l (males) and CK < 170 U/l (females)). In patients in w hom  a po lyneuropathy was detected, 
ancillary laboratory investigations were perform ed to  exclude an underlying cause o f 
po lyneuropathy according to  the Dutch national m ultid iscip linary protocol (vitamin B12, 
glucose, thyro id  function , calcium, phosphate, and liver function).
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Clinical neurophysiology
Electrophysiological examination was perform ed using standard techniques w ith  a Medelec 
Synergy EMG system (Viasys, Oxford Medical Instruments, Surrey, United Kingdom). Both 
nerve conduction  studies and needle e lectrom yography were perform ed according to 
standardized clinical protocols for the detection o f  a po lyneuropathy and myopathy. Findings 
were compared w ith  normal values from  a previously established database in our centre.
Nerve conduction studies
Nerve conduction  studies (NCS) included com pound muscle action potential (CMAP) 
am plitudes and nerve conduction  velocities (NCV) o f the peroneal and tibial nerves, sensory 
nerve action potential (SNAP) am plitude and NCV o f the sural nerve (if abnorm al bilateral 
measurements were performed), and H-reflexes o f the tibial nerves. In case o f (suspicion of) 
a polyneuropathy, NCV and CMAP o f the median nerve, and NCV and SNAP o f the radial 
nerve were also measured. Polyneuropathy was defined according to  the guidelines o f the 
American Association o f  Electrodiagnostic M edicine .37 We did not systematically screen for 
en trapm ent neuropathies.
Needle electromyography
Needle e lectrom yography was perform ed o f the  tibialis anterior, rectus femoris, biceps 
brachii, de lto id, and paraspinal L4-L5 muscles, all on the le ft side. Insertional activity, 
recru itm ent pattern on vo luntary contraction, and m otor un it action potential characteristics 
(amplitude, duration, num ber o f phases) were noted. M otor Unit Action Potential (MUAP) 
characteristics and recru itm ent pattern were defined as follows: 'p redom inantly m yopathic' 
(small (3 - 8 ms), polyphasic units w ith  m oderate to  normal recruitment); 'p redom inantly 
neurogenic' (large (> 12 ms) units w ith  poor to  moderate recruitment), or 'm ixed myopathic
- neurogenic', all in at least tw o  o f the  muscles tested. Turns and am plitudes measurements 
o f the rectus femoris and biceps brachii muscles were perform ed when m yopathic MUAPs 
were seen from  routine needle exam ination in these muscles.
Muscle Ultrasound
Muscle ultrasound examinations were performed bilaterally in five muscles (biceps brachii 
muscle, rectus femoris, and tibialis anterior muscles and extensors and flexors in forearm) using a 
standard technique as described previously.38,39 A broadband linear 5 - 17 MHz transducer (Philips 
IU22, The Netherlands) was used. All system-setting parameters were kept constant throughout 
the study (gain 70 dB, compression 55, no adjustments in time gain compensation or focus).
For echo-intensities (EI), a region o f interest was selected in each image using the lasso 
function. The criteria for selecting this region were inclusion o f as much o f the  muscle as 
possible w ith o u t surrounding fascia. Mean echo in tensity o f this region was then calculated
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w ith  a standard histogram function  (Adobe Photoshop; Adobe systems Inc., San Jose, 
California, USA) and expressed as a value between 0 (black) and 255 (white) as the ultrasound 
was created w ith  8 b it grey scale. Three consecutive measurements were taken o f every 
muscle and results were averaged.38 Muscle thickness was measured w ith  electronic callipers. 
Echo intensity and muscle thickness are d iffe rent fo r each muscle group, and depend on age 
and sex.3940 We used a database previously established in our centre to  calculate normal 
values for each muscle corrected for age and sex (unpublished data).3940 In order to  compare 
individual patients and muscles in this study, echo-intensity and muscle thickness were 
transform ed in to  Z-scores.3940 In effect, the Z-score reflects the num ber o f standard deviations 
a measure deviates from  normal, given a certain age and sex. Abnorm al EI was defined as 
one muscle w ith  Z-score > 2. For muscle atrophy, the same cu t-o ff value was used (Z-score < -2).
Muscle Biopsies
Muscle biopsy specimens were obtained from  the right vastus lateralis muscle. Frozen 
sections o f 10 ^m  were exam ined under a light m icroscope w ith  Hematoxylin-Phloxine, 
Periodic acid-Schiff, Sudan Black B, Trichrome-Gomori and enzyme histochemical staining 
(ATPase (pH 4.2, 4.6 and 10.3), succinic dehydrogenase, reduced n icotinam ide adenine d inu- 
c leotide-tetrazolium  reductase, cytochrom e C oxidase, acid phosphatase). Collagen VI 
staining was perform ed w ith  m onoclonal mice anti-hum an collagen VI antibodies 
(Chemicon, Millipore, Billerica, MA, USA). Additionally, we investigated six muscle samples (of 
one patient o f each type, and tw o  additional biopsies o f patients w ith  the classical type) w ith 
electron microscopy. For that purpose specimens were fixed in glutaraldehyde, postfixed in 
Osm ium  Tetroxide, em bedded in Epon and stained w ith  uranlyacetate and lead citrate. We 
used control specimens previously obtained from  patients w ith o u t clinical o r m orphological 
signs o f  myopathy. Muscle biopsy specimens were assessed by one investigator.
Statistics
The dem ograph ic and clinical data were recorded as variables in a SPSS database. Statistical 
analysis was perform ed using SPSS version 14.0 (SPSS Inc, Chicago, IL, USA). In add ition  to  the 
analysis o f the data o f all EDS patients, we perform ed subgroup analysis to  compare the 
various types o f EDS. A Chi-square or Fisher's exact test was used for d ichotom ous variables. 
W ith continuous variables, a Student's t-test was used in case o f a normal d istribution, and a 
M ann-W hitney-U test in case o f  a non-param etric d istribu tion. Correlation was calculated 
w ith  Pearson correlation coefficient. Statistical significance was defined as a p-value below  
0.05 (two-sided).
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Definition o f neuromuscular involvement
Neuromuscular involvem ent was defined as consistent abnormal findings on questionnaires 
or physical exam ination or both, supported by abnorm al results o f  appropria te ancillary 
investigations.
Results
Study population
A total o f 40 patients from  27 families was included in this study: 10 non-related classical type 
EDS patients (eight female; median age 36; age range 27-63), 10 non-related vascular type 
patients (seven female; median age 33; age range 14 - 41), 10 TNX-deficient type  patients 
(seven female; median age 42; age range 20 - 60), and 10 hyperm ob ility  type  due to  TNXB 
haplo-insuffic iency (nine female; median age 30; age range 23 - 62); the  latter tw o  groups 
be longing to  seven families.
The diagnosis was based on the diagnostic criteria in all vascular and classical type  EDS 
patients .13 Biochemical analysis was previously perform ed in five patients w ith  the classical 
type  EDS and revealed reduced am ount o f collagen V in tw o  patients. All patients w ith  the 
vascular type  EDS had reduced expression o f collagen III. This diagnosis was genetically 
confirm ed in three vascular type  patients: the  m utations found in COL3A1 were: 3512 G>A (n 
= 1); 545 G>C (n = 1); and 370 G>T (n = 1). M utation analysis was not perform ed in the other 
seven vascular type  EDS patients. The clinical features o f all TNX-deficient type  EDS patients 
were similar to  those previously described .34 TNX in serum was < 0.1 ng /m l (n = 10), and 
m utation analysis perform ed in six patients revealed the fo llow ing  m utations in TNXB: 
hom ozygous 2 bp deletion in exon 8 [AA56063] del (n = 2); hom ozygous 30 kB deletion (n = 
1); heterozygous 30 kB deletion and second TNX m utation not found (n = 3) (data previously 
published by Schalkwijk et al, 2001).3 Four o f the  first-grade fam ily m embers o f the 
TNX-deficient type  EDS patients had been diagnosed w ith  hyperm ob ility  type  EDS; the 
o ther six subjects had not been diagnosed w ith  the hyperm ob ility  type  so far, bu t d id  reveal 
one o r more o f  the clinical features o f the hyperm ob ility  type  o f EDS.15 TNX in serum was 
found to  be half o f  the  normal value in all subjects (range 46 -  68% o f normal) (n = 10).5 
M utation analysis had revealed TNXB haploinsufficiency in nine o f them: heterozygous 2 bp 
insertion in exon 3 [GT44906] ins (n = 6; all relatives o f the index patient); heterozygous for 30 
kB deletion (n = 1); heterozygous 2 bp deletion in exon 8 [AA56063] del (n = 2). In one patient, 
no m utation  was found (daughter o f the patient in w hom  the second TNXB m utation was 
not found) (data previously published by Zweers e t al, 2003).5
Twenty healthy subjects filled o u t the symptoms questionnaire (14 female; median age 
35; age range 22 - 64).
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Clinical studies
Standardized questionnaires
All patients com ple ted the questionnaires. Seven EDS patients reported a previous 
neurological disease, m ost frequently am ong the patients w ith  the vascular type  o f EDS: 
carotid-cavernous fistula, migraine, brachial p lexopathy due to  subclavian artery aneurysm, 
subarachnoidal haemorrhage, and young stroke. In tw o  o f them , the neurological event was 
the initial sym ptom  o f the vascular type  o f EDS. Furthermore, tw o  patients w ith  the classical 
type  o f  EDS reported scoliosis w ith  lum bar stenosis and carpal tunnel syndrom e respectively, 
and one patient w ith  the TNX-deficient type  reported carpal tunnel syndrome. No other 
com plaints suggestive for en trapm ent neuropathies were reported.
Results o f questionnaires are listed in Table 2. Overall, patients w ith  the classical type 
reported m ost complaints on the neuromuscular questionnaire.
Standardized physical examination
Physical examination was perform ed in all patients and revealed typ ica l EDS features (joint 
hyperm obility, skin hyperextensibility, and easy bruising) as described in the clinical criteria 
(Figure /).U5 One vascular type  EDS patient had m ild facial weakness and incom plete eye 
closure (Figure /), w ith o u t clinical signs o f myasthenia gravis or myotonia. Another vascular 
type  EDS patient had a partial le ft ocu lom oto r paresis after surgical correction o f a left 
caroticocavernous fistula. One patient w ith  the TNX-deficient type  EDS had generalized 
muscle weakness, contractures o f  the  distal phalanges o f d ig its IV and V o f both hands, and 
atrophy o f intrinsic hand muscles (Figure /)(previously reported by Voermans et al).1112
Results o f physical examination are listed in Table3. M ild to  moderate muscle weakness 
(mean MRC 4 - 5) was found in all types o f EDS. Muscle weakness tended to  be more 
p rom inen t in proximal lim b muscles and axial muscles: knee flexion, hip flexion, neck and 
trunk flexion, and hip extension (mean MRC < 4.4); whereas all o ther muscles tested had a 
mean MRC o f > 4.4 (data not shown). MRC sumscore was not correlated statistically 
significantly w ith  age (r = - 0.17; n.s.). Results o f dynam om etry corroborated the findings o f 
manual muscle testing: the  median force o f all 5 muscles tested bilaterally (measured in 
Newton) o f all EDS patients was be low  or at the  p5 o f the normal values (data not shown).
Hypotonia was present in 43% o f the EDS patients (n = 17/40), and coord ination was 
reduced in 18% (n = 7/40). Sensory testing was abnorm al in 60% o f the patients (n = 24/40); 
this predom inantly consisted o f m ild reduction o f vibration sense in legs. Functional 
assessment showed m ild im pairm ent in the vascular, classic, and TNX-deficient type  o f  EDS, 
bu t not in patients w ith  the hyperm ob ility  type  EDS due to  TNXB haploinsufficiency.
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Table  2 Results o f questionnaires. Num ber (%) o f  EDS patients and controls w ho  report various neuromuscular symptoms, and p-value o f difference 
in frequency o f reported symptoms between EDS patients and controls.
Vase 
n =  10
Clas 
n =  10
TNXd  
n =  10
TNXh  
n =  10
D ifferences  b e tw e e n  
EDS types  
P -value (#)
EDS to ta l 
n =  4 0
C ontrols  
n =  20
D iffe rences  
patien ts -con tro ls  
P -value (#)
M uscle weakness 6 9 9 2 0.005 clas -  TNXh 
TN X d-T N X h
26 65% 0 < 0.001
M uscle hypoton ia 2 8 5 2 0.023 clas -  vase 
clas -  TNXh
17 43% 0 0.001
M yalgia (continuously  o r fre q u en tly  a fte r exercise) 6 10 9 4 0.011 clas -  TNXh 29 73% 2 10% < 0.001
Easy fa tig a b ility  (com pared to  peers) 6 9 7 2 0.005 clas -  TNXh 24 60% 0 < 0.001
(In te rm itten t) paresthesias in arms and /  o r legs 4 6 3 0 0.011 clas -  TNXh 13 33% 1 5% 0.018
W alking d istance < 5 km 5 9 6 2 0.005 clas -  TNXh 22 55% 1 5% 0.001
(In te rm itten t) use o f  w hee lcha ir I 2 0 0 n.s. 3 8% 0 n.s.
Use o f  w a lk ing  aids 2 5 4 0 n.s. 11 28% 0 < 0.001
Perform ing sports (at least once a week) 5 5 5 5 n.s. 20 50% 14 70% n.s.
Vase: vascular typ e  EDS; Clas: classical typ e  EDS; TNXd: TNX-deficient type  EDS;TNXh: hype rm ob ility  type  EDS due to  TNXB haploinsufficiency. (#) Chi-square test; n.s. no statistically 
significant differences.
C hapte r 4 Neurom uscular in vo lvem ent in various types o f Ehlers-Danlos syndrom e
Ancillary investigations
Results of ancillary investigations are listed in Table 3.
Laboratory investigations
Creatine kinase was normal in most patients and was not correlated statistically significantly 
with age (r = -0.13; n.s.). Ancillary laboratory investigations revealed no metabolic 
abnormalities in patients with a polyneuropathy (data not shown). Screening for vasculitis as 
a cause of the polyneuropathy was not performed in these patients since systemic signs of 
vasculitis were absent.
Clinical neurophysiology
Nerve conduction studies were performed in 39 patients, and needle electromyography in 
35 patients.
Nerve conduction studies
Nerve conduction studies were abnormal in 38% of the patients (n = 15/39), fulfilling the criteria 
of a sensorimotor axonal polyneuropathy in 13% (n = 5/39). Low CMAP amplitudes in the legs 
with normal sensory conduction were found in 21% of the patients (n = 8/39), predominantly 
in patients with myopathic MUAPs and a myopathic recruitment pattern on electromyography 
(see below). This might suggest that CMAP amplitudes were low secondary to myopathy.
Needle electromyography
Needle electromyography was abnormal in 91% of all EDS patients (n = 32/35), and no 
statistically significant differences existed between the EDS types. The recruitment pattern 
and MUAP characteristics were predominantly myopathic in 26% of the patients (n = 9/35), 
predominantly neurogenic in two patients with the TNX-deficient type with a polyneuropathy, 
and a mixed pattern was encountered in 60% of all EDS patients (n = 21/35). Complex 
repetitive discharges were detected in one muscle in two patients; no other signs of 
spontaneous activity were found.
Muscle Ultrasound
Muscle ultrasound was performed in all patients and showed increased echo intensities in 
48% (n = 19/40) and atrophy in 50% of the patients (n = 20/40). Increased echo intensity was 
most pronounced in the flexors and extensors in the forearm and in the tibialis anterior 
muscle, and atrophy was most pronounced in the quadriceps muscle. In one patient with the 
vascular type EDS, an area of increased signal intensity with a diameter of 1 cm in the right 
quadriceps was observed, probably reflecting a previous haemorrhage which might have 
been due to local muscle rupture.
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Table 3 Results of physical examination and ancillary investigations. Results of testing of 
muscle force, muscle tone, coordination, sensation and reflexes: the mean MRC 
sum score, and the number of patients with abnormal test results are shown. 
Results of ancillary investigations: the median creatine kinase level with range; 
the number of patients in which nerve conduction, electromyography, muscle 
ultrasound, and muscle biopsy was performed (bold), and the number of patients 
in which the test results were abnormal are shown.
Vasc Clas TNXd TN Xh EDS D iffe ren ces betw een
total EDS types
P-value
Physical examination n = 10 n = 10 n = 10 n = 10 n = 40
Mean MRC sum score 128.9 124.8 127.6 135.8 127 0.002 clas - TNXh (§)
(0-140) (SD) (11.4) (8.3) (9.2) (3.2) (13.8) 0.021 TN Xd- TNXh
Normal muscle strength 2 0 2 2 6 n.s. (*)
Mild muscle weakness 5 5 4 8 22 n.s. (*)
Moderate muscle 2 4 4 0 10 n.s. (*)
weakness
Severe muscle weakness 1 1 0 0 2 n.s. (*)
Hypotonia 2 7 7 1 17 0.020 clas - TNXh (*)
TN Xd- TNXh
Reduced coordination 1 3 3 0 7 n.s. (*)
Reduced sensation 6 7 6 5 24 n.s. (*)
Hyporeflexia 1 3 6 0 10 0.011 TNXd -TNXh (*)
Vignos (1-10) 1.9 2.0 1.5 1.0 1.6 0.032 clas - TNXh (§)
Brooke (1-6) 1.0 1.2 1.1 1.0 1.1 n.s. (§)
Rivermead (0-15) 13.1 12.5 14.5 15.0 13.8 0.002 clas - TNXh (§)
Modified Rankin scale (0-6) 1.7 2.0 1.3 0.2 1.1 0.006 vasc - TNXh (§)
0.002 clas - TNXh
< 0.001 TN Xd- TNXh
Laboratory investigations n = 8 n = 9 n = 10 n = 6 n = 33
Median creatine kinase 130 119 107 97 118 n.s. (±)
(U/l) (47-681) (40-169) (50-287) (57-223) (40-681)
(range)
Number of patients with 2 0 1 1 4 n.s. (*)
increased CK
Nerve conduction studies n = 9 n = 10 n = 10 n = 10 n = 39
Abnormal 4 2 8 1 15 0.023 vasc - TNXd (*)
0.006 TN X d - TNXh
Axonal sensomotor 1 0 4 0 5 n.s. (*)
polyneuropathy
103
C
ha
p
te
r 
4 
N
eu
ro
m
us
cu
la
r 
in
vo
lv
em
en
t 
in 
va
rio
us
 
ty
pe
s 
of 
Eh
le
rs
-D
an
lo
s 
sy
nd
ro
m
e
T a b le  3 Continued.
Low CMAP amplitudes 2 1 4 1 8 n.s. (*)
in legs
Entrapment neuropathy :
CTS 1 1 1 0 2 n.s. (*)
Peroneal entrapment 1 1 n.s. (*)
Electromyography n = 9 n = 10 n = 7 n = 9 n = 35
Abnormal 8 9 7 8 32 n.s. (*)
MUAP characteristics and
recruitment pattern:
Predominantly 3 1 1 4 9 n.s. (*)
myopathic
Predominantly 0 0 2 0 2 n.s. (*)
neurogenic
Mixed myopathic - 5 8 4 4 21 n.s. (*)
neurogenic
Myopathic pattern in T/A
Rectus femoris 4/5 3/7 0/5 3/9 10/26
Biceps brachii 6/9 3/8 2/6 2/8 13/31
Muscle ultrasound n = 10 n = 10 n = 10 n = 10 n = 40
Increased echo intensity 6 7 4 2 19 n.s (*)
Reduced muscle diameter 6 5 6 3 20 n.s (*)
Muscle biopsy n = 3 n = 8 n = 5 n = 3 n = 18
Mild myopathic features 2 1 1 1 5 n.s. (*)
V asc : v a scu la r  ty p e  EDS; C las: c la ss ic a l ty p e  EDS; T N X d : T N X -d e fic ie n t ty p e  EDS; T N X h : h yp e rm o b ility  ty p e  EDS d u e  tc  
TNXB h a p lo in su ff ic ie n cy . 1 In th e  p a tien t w h o  a lso  had lo w  C M A Ps in legs . (§) S tu d en t's  t-test; (*) F isher's e x a c t  test; (±) 
M an n -W h itn ey-U  test; n.s. no sta t is t ica lly  s ig n if ica n t d iffe ren ces . A  C h i-sq u a re  o r F isher's e x a c t  te s t w a s  u sed  for 
d ic h o to m o u s  v a r ia b le s . W ith  c o n tin u o u s  v a r ia b le s , a S tu d en t's  t-test w a s  u sed  in ca se  o f a no rm a l d is tr ib u t io n , and  a 
M an n -W h itn ey-U  te st in c a se  o f a n o n -p a ra m e tr ic  d is tr ib u t io n .
Muscle Biopsies
Needle muscle biopsy was performed in 18 patients and wound healing was normal in all. 
Findings of histological analysis of muscle biopsies were slightly abnormal in 28% of the 
patients (n = 5/18), found at least once in every EDS type. These included increased variation 
of fibre diameter, sporadic isolated atrophic fibres, a mild increase of internal nuclei (Figure 2), 
or the presence of some lobulated fibres. In one patient one ragged red fibre was seen 
(female 50 years), and in another case few COX-negative fibres were found (male, 37 years), 
but this might also be present in healthy subjects. Necrotic fibres, and signs of fibrosis or fibre
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Figure 2 Mild myopathic changes in the muscle biopsy (lateral vastus muscle) of a hyper­
mobility type EDS patient due to TNXB haploinsufficiency.
Mildly increased variation in fibre diameter and increase of central nuclei (5%)(arrow). Bar = 100 |jm .
type grouping were absent. Histochemical and enzymehistochemical staining showed no 
signs of congenital myopathy or dystrophy. Collagen VI staining was present in both endo- 
and perimysium, and the distribution pattern and intensity of staining did not differ from 
control sections. No vascular abnormalities, such as perivascular infiltrations, perivascular 
fibrosis or abnormal vessel calibres were present.
We investigated six muscle samples (of one patient of each type, and two additional biopsies 
of patients of the classical type) with electron microscopy (EM). Overall, qualitative evaluation 
of the EM images showed relatively low connective tissue density; however, this varied 
between the histological location within the biopsy specimen (endomysium between 
individual muscle fibres; endomysium between muscle fibre and capillaries; perimysium at 
the septa). Furthermore, in the biopsy of a patient with the classical type EDS, short collagen 
fragments were seen at the sarcolemma (Figure 3). This finding was confirmed in the biopsies 
of a second and third patient with the classical type EDS.
A summary of the findings of clinical and ancillary investigations is presented in Table 4; this 
reflects a variable degree of neuromuscular involvement in the vascular, classical, and 
TNX-deficient EDS types, and to a lesser extent in patients with the hypermobility type EDS 
due to TNXB haploinsufficiency.
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Figure 3 Electron microscopy of the biopsy of a classical type EDS patient (A) and a control 
subject (B).
A lower density of collagen fibrils in the ECM between muscle fibres (long arrow) and between muscle 
fibres and capillaries (C) (short arrow) in the biopsy of the classical type EDS patient (A) than in a control 
biopsy (B). Furthermore, collagen fibrils are more often short in the biopsy of the classical type EDS 
patient (A) than in a control biopsy (B). Bar = 1 jm .
Table 4 Summary of findings: Neuromuscular involvement in EDS.
Vasc Clas TNXd TNXh
Questionnaires 
Neuromuscular complaints + +++ ++ +/-
Physical examination 
Reduced sensation + + + +/-
Muscle weakness + + + +/-
Functional impairment + + + -
Clinical neurophysiological studies 
Polyneuropathy (NCS) + ++
Abnormal MUAPs (myopathic or mixed ++ + + +
myopathic-neurogenic (EMG))
Muscle ultrasound 
Increased echo intensity + + + +/-
Muscle biopsy 
Myopathic changes + +/- +/- +/-
- : n on e ; +/- : m ild  in p art o f p a tien ts ; + : m ild ; ++  : m o d e ra te ; + + +  : seve re . V asc : v a scu la r  ty p e  EDS; C las: c la ss ica l ty p e  
EDS; TN X d : T N X -d e fic ie n t ty p e  EDS; T N X h : h y p e rm o b ility  ty p e  EDS d u e  to TNXB h ap lo in su ff ic ie n cy .
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Discussion
This cross-sectional observational study demonstrates mild to moderate neuromuscular 
involvement in a large proportion of EDS patients. To our knowledge, this is the first 
systematic study on neuromuscular involvement in various well defined EDS types. This 
involvement consisted of an axonal sensorimotor polyneuropathy predominantly in the 
TNX-deficient type, whereas patients of all types had either mixed myopathic-neurogenic or 
myopathic features on electromyography. However, the muscle biopsy revealed only mild 
changes. Furthermore, complete absence of TNX (TNX-deficient type EDS) was associated 
with more severe neuromuscular symptoms than reduction of TNX serum levels 
(hypermobility type EDS due to TNXB haploinsufficiency). An inverse relation between 
residual TNX levels and degree of neuromuscular involvement was suggested by the 
differences between these two EDS types.
The results of this study confirm the findings of previous case reports and animal studies 
on neuromuscular symptoms in EDS.9-111315'20-24'26'41-44 In addition, muscle hypotonia, muscle 
rupture, fatigue, and musculoskeletal pain are included in the diagnostic criteria of EDS.1 It is 
therefore remarkable that neuromuscular function in EDS has not been systematically 
studied before.
The discrepancy between moderate neuromuscular symptoms and only mild structural 
abnormalities on muscle biopsy may be related to non-neuromuscular problems in EDS: 
musculoskeletal pain, increased fatigability, and mild impairment may be due to articular and 
skeletal problems in EDS. Nevertheless, presence of myopathy and polyneuropathy points to 
an additional alternative explanation: abnormal composition of muscle ECM may play a role 
in the pathophysiology of muscular features.711 Similarly, an altered peripheral nerve ECM 
may play a role in the pathophysiology of polyneuropathy in EDS.16
The findings of this study indeed support the hypothesis of a pathophysiological role of 
muscle and peripheral nerve ECM in neuromuscular features in EDS. First, the qualitative 
variation in the neuromuscular phenotype among the various EDS types may reflect the 
tissue specific distribution of the involved molecules. Collagen III (vascular type) and TNX 
(TNX-deficient type and hypermobility type with TNXB haploinsufficiency) are widely 
distributed in the ECM of both peripheral nerve and muscle, whereas collagen V (classical 
type) is only a minor component of peripheral nerve ECM.4546 This may explain peripheral 
nerve and muscle involvement in the vascular and TNX-deficient types, but absence of 
peripheral nerve dysfunction in the classical type of EDS.45 Second, the inverse relation 
between residual TNX levels and degree of neuromuscular involvement may indicate a 
dose-effect relation both in muscle ECM (epimysium, perimysium, endomysium) and in 
peripheral nerve ECM (epineurium, perineurium, epineurium).16 Third, reduction of density of 
collagen fibrils in the ECM of muscle on electron microscopy indicate that the composition
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of the ECM is altered, which may indirectly support the pathophysiological role of the ECM 
in muscle function.
Abnormalities in muscle ECM composition may influence muscle function by altering 
myofascial force transmission.71147 This biomechanical theory proposes that in addition to 
myotendinous force transmission, force can be transmitted from muscle fibres onto the 
connective tissue within muscle and between adjacent muscle and compartments. This 
concept may help to understand why muscle strength is reduced in EDS, whereas muscle 
histology reveals only mild abnormalities, and CK is not elevated.47
Another possible explanation of muscle weakness due to ECM abnormalities may be 
related to mitochondrial dysfunction and increased apoptosis. This was recently detected in 
the collagen 6 myopathies Ullrich congenital muscular dystrophy and Bethlem myopathy. 
These two myopathies are also caused by ECM defects and show a remarkable overlap of 
dermal and articular features with EDS.1248-50 These findings illustrate how a genetic defect 
primary affecting the ECM influences cellular function.51 Whether a similar pathophysiological 
mechanism is indeed involved in EDS needs to be investigated. Reduction of collagen VI 
mRNA expression in fibroblasts of Tnxb knockout mice may point in this direction.52
In conclusion, this study demonstrates neuromuscular features as part of EDS by showing 
mild to moderate neuromuscular involvement in four subtypes of EDS, with a dose-effect 
relation of residual TNX levels and degree of neuromuscular involvement. The results of this 
study further suggest that neuromuscular involvement in EDS is a direct effect of the ECM 
defect within muscle and peripheral nerve. This is in contrast with the widespread explanation 
of fatigue and musculoskeletal pain in EDS, i.e. that avoidance of exercise due to fear of 
dislocations and increased extensibility of tendons lead to muscle weakness and fatigue.2
Results of this study may contribute to increased recognition of neuromuscular features 
in various types of EDS, which is important for diagnosis and therapy. Results of this study 
also point to a biomechanical role of the ECM in muscle and peripheral nerve function, 
which has to be studied in further detail.11,53
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5
Fatigue is a frequent and clinically relevant 
problem in Ehlers-Danlos Syndrome
Adapted from:
Voermans NC, Knoop J, van de Kamp N, Hamel BC, Bleijenberg G, van Engelen BG. 
Semin Arthritis Rheum. 2010;40:267-74.
Abstract
Ehlers-Danlos Syndrome (EDS) is a clinically and genetically heterogeneous group of 
inherited connective tissue disorders characterized by joint hypermobility, skin hyperexten­
sibility, and tissue fragility. Fatigue and musculoskeletal pain are associated features, but have 
never been studied systematically.
We used a multidimensional assessment method to measure fatigue, its clinical relevance, 
and possible determinants. A questionnaire study was performed among 273 EDS patients. 
The following dimensions were assessed: fatigue severity, functional impairment in daily life, 
physical activity, psychological distress, sleep disturbances, concentration problems, social 
functioning, self efficacy concerning fatigue, causal attribution of fatigue, pain, and disease 
related factors.
More than three quarter of EDS patients suffer from severe fatigue. Patients who are severely 
fatigued are more impaired than non-severely fatigued patients and report a higher level of 
psychological distress. The five possible determinants involved in fatigue are sleep 
disturbances, concentration problems, social functioning, self efficacy concerning fatigue, 
and pain severity.
This is the first study on fatigue and its possible determinants in EDS and shows that fatigue 
is a frequent and clinically significant problem in EDS. The five possible determinants of 
fatigue could form a starting point for the development of an effective cognitive behavioural 
intervention for fatigue in EDS.
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Introduction
The Ehlers-Danlos Syndrome (EDS) is a clinically and genetically heterogeneous group of 
inherited connective tissue disorders caused by mutations in genes encoding various types 
of collagen or collagen modifying enzymes.1-3 The hypermobility type is the most common 
type of EDS, followed by the classical type.4 Diagnostic criteria include joint hypermobility, 
skin hyperextensibility, and tissue fragility resulting in easy bruising and abnormal scarring.1 
Chronic joint/limb pain is one of the minor diagnostic criteria in the hypermobility type, and 
fatigue is acknowledged as an associated feature in the classic type.1 Both symptoms 
generally receive little medical attention, although patients' reports suggest that these 
symptoms contribute significantly to the burden of disease in EDS.5
Fatigue can be defined as an overwhelming sense of tiredness, lack of energy, and 
feeling of exhaustion, and is not the same as muscle weakness.67 Fatigue is a common 
symptom in various chronic diseases, and was found to be a major determinant of disability 
which significantly influences the quality of life.7-12 The frequency of fatigue in EDS, its clinical 
relevance, and its associations with possible determinants have not yet been investigated 
together. We therefore performed an extensive questionnaire study on fatigue in EDS and 
used a multidimensional assessment method to measure fatigue, its clinical relevance and 
possible determinants in EDS. Questionnaire studies, due to their relatively unbiased and 
potential broad-ranged character, may shed light on the patients' perspective of fatigue and 
pain in EDS. This method has been used in several other chronic disorders and may identify 
possible determinants of fatigue in EDS, which can serve as a starting point for effective 
behavioural interventions.613
Methods
Patients
A cross sectional design was used to assess fatigue in patients with EDS. We asked 500 
members of the Dutch patient organization of EDS (VED: www.ved.nl) to participate, and 19 
additional patients were recruited from the outpatient departments of the Radboud 
University Nijmegen Medical Centre; these latter patients were also included in a clinical 
study on neuromuscular features in EDS.14 The intention of the study was described as 'to 
learn more about various complaints in Ehlers-Danlos syndrome' to prevent a selection bias 
for fatigued patients. Written information on this purpose was provided to all patients, and 
all patients gave informed consent. 327 Questionnaires were returned (63% response rate). 
The study was approved by the local ethics committee.
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Assessment
All patients were sent a booklet with: 1) various questions on EDS type; clinical features of 
EDS;1 presence of muscle symptoms;14 previous surgery and comorbidity; use of medication 
(based on a questionnaire assessing volumes of medical consumption in the previous six 
months);15 three most important complaints in order of priority; and 2) seven validated 
questionnaires (see below).
Fatigue severity
The Checklist Individual Strength (CIS) measures four aspects of fatigue. We used the 
subscales fatigue severity (eight items, score range from 8 to 56) and concentration problems 
(five items, score range from 5 to 35).6 High scores indicate more severe problems in the 
domain that is measured. A CIS-fatigue score of 35 or more was used to identify severe 
fatigue; this score is higher than the mean plus two standard deviations of a healthy control 
group.6-16
Dimensions o f Fatigue
The multidimensional assessment method measures the following dimensions of fatigue: 
functional impairment in daily life, level of physical activity; psychological distress; sleep 
disturbances; concentration problems; social functioning and social support; self-efficacy 
concerning fatigue; causal attribution of fatigue; pain; and disease related factors.
Functional impairment in daily life
The Sickness Impact Profile (SIP) is aimed at measuring changes of conduct in everyday 
activities due to sickness.1317-19 For functional impairment, we used the subscales household 
management, work, and recreation and pastimes. Higher scores on a subscale indicates 
more disabilities in this domain. Physical disabilities were measured with the physical 
functioning subscale of the ShortForm-36 (SF36).20 Scores range from 0 (maximum physical 
limitations) to 100 (optimal physical functioning).21 Additionally, we included the number of 
weekly worked hours (paid and unpaid) as measures of functional ability. Unpaid work was 
defined as study, household duties, and volunteer work.
Physical activity
The level of physical activity was measured with the subscales mobility and ambulation of 
the SIP.
Psychological distress
The Beck Depression Inventory (BDI-pc) was used to measure clinical depression, which was 
defined as a score of > 4 (on a scale of 0 to 21),22 Psychological distress was measured with 
the sumscore o f the subscales anxiety and depression of the Symptom Check List (SCL-90).23 
Higher scores indicate a higher level of psychological distress.
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Sleep disturbances
Sleep disturbances were measured with the sleep/rest scale of the SIP (reflecting disturbance 
of the normal wake and sleep pattern) and the sleep subscale of the SCL (reflecting quality 
of nocturnal sleep). Higher scores indicate more sleep disturbances. To differentiate between 
daytime and nighttime sleeping problems, we split the SIP sleep and rest subscale in items 
focusing on daytime sleeping, and the item focusing on nighttime sleep disturbances. 
Furthermore, we asked for the duration of night time and daytime sleep (hrs), and the 
occurrence of good quality of nighttime sleep (%).
Concentration problems
Perceived concentration problems were measured with the concentration subscale of the 
CIS. Furthermore, we used the alertness behaviour subscale of the SIP. Higher scores indicate 
more concentration problems.
Social functioning
Social functioning and social support was measured with the social interaction subscale of 
the SIP and the social functioning subscale of SF36. Higher scores indicate more impairment. 
Self efficacy concerning fatigue
Self efficacy, a sense of control over fatigue symptoms, was measured with the Self Efficacy 
Scale (SES). The SES consisted of seven questions that measured sense of control with respect 
to fatigue. The total score ranges from 7 to 28, and a higher score reflects a higher sense of 
control.24
Causal attribution of fatigue
Patients were asked for their causal attribution of fatigue with the following options: EDS 
itself, too many activities, not enough leisure time, sleep disturbances, personal reasons, 
worrying thoughts, depressive thoughts, and a positive family history of fatigue. Patients 
could choose one or more attributions.
Pain
The visual analogous scale (VAS) scores for the current and the most severe pain (subscale of 
the McGill Pain Questionnaire) were filled in.25 Pain was further assessed by the following 
three questions of the McGill Questionnaire: whether pain occurred (yes or no); whether it 
occurs at least 12 hours each day (% yes); and whether analgesics are used (% yes). 
Furthermore, we asked whether myalgia was present (% yes).
Disease related factors
Disease related factors questioned were hypermobility, dislocations, skin hyperextensibility, 
and easy bruising.1 We added questions on muscle hypotonia, myalgia, and muscle weakness 
since we recently showed considerable neuromuscular involvement in various types of 
EDS.14
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Im pact o f  fatigue and im pact o f  pain
The pain subscale of the SF36 was used to assess the impact of pain; it measures the 
magnitude of pain and its resulting self-reported functional limitations due to pain. Scores 
range from 0 to 100 (0 = no pain and no impairments due to pain; 100 = maximal pain and 
maximal impairment due to pain). We used the same items and scores again, replacing the 
word pain by fatigue, to be able to compare the impact of fatigue (magnitude of fatigue and 
self-reported functional limitations due to fatigue) with the impact of pain.
Statistics
SPSS for Windows (version 16.0) was used to carry out data analysis, and we used descriptive 
statistics to depict the sample. We defined two groups of patients: severely fatigued patients 
(CIS fatigue > 35) versus non-severely fatigued patients (CIS fatigue < 35).616 We tested the 
differences in scores on the various measures between the non-severely and severely 
fatigued patients with a Chi-square or Fisher's exact test (dichotomous variables), Student's 
t-test (variables at least interval level), or a Mann-Whitney-U test (ordinal variables). 
Correlations were calculated with the Pearson coefficient (r). Probability (P) values smaller 
than 0.05 were regarded as statistically significant. For each dimension, we selected the 
measure with the strongest and statistical significant correlation with the CIS-fatigue score 
for subsequent multiple linear regression analysis, in which we determined the contribution 
of various measures to the level of fatigue (backward method; p in = 0.01; p out = 0.05). 
The measures that resulted from this regression analysis were considered to be possible 
determinants of fatigue.
Results
Excluded were patients who were younger than 16 years (n = 16), patients in whom EDS had 
not been diagnosed (n = 30), and patients who had filled out the CIS fatigue severity scale 
incompletely (n = 8). Hence, 273 patients were included; in 53 of them the specific type of 
EDS was not (yet) known although EDS was diagnosed by a medical specialist; in all other 
patients the EDS type was classified according to the diagnostic criteria.1 Demographic 
characteristics of the patients are summarized in Table 1.
Three m ost important symptoms
264 patients completed the questionnaire on most important complaints. The mean number 
of self-reported complaints was 5.6 (SD 2.5), and 204 patients reported at least four 
complaints. Musculoskeletal pain, hypermobility/dislocations, and fatigue were most 
frequently reported spontaneously: 99% of the patients reported musculoskeletal pain as
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Table 1 Demographics of Ehlers-Danlos syndrome (EDS) patients. Distinction between 
non-severely and severely fatigued patients.
EDS type Num ber M ean age Fem ale EDS Non- EDS S ta t.s ig n .1 of
of
patien ts
(range) (%  o f type) severe ly  
fa tig ued  
(%  o f type)
Severe ly  
fa tig ued  
(%  o f type)
d iffe rence  (P)
Classical 45 43.1 (16-68) 35 (78) 14 (31) 31 (69) 0.032 clas - hyper
Hypermobility 162 38.8 (16-74) 152 (94) 26 (16) 136 (84)
Vascular 11 33.6 (19-61) 9 (82) 5 (45) 6 (55)
Kyphoscoliotic 2 21.0 (16-26) 0 (0) 2 (100) 0 (0)
Other / Type 
unknown
53 46.2 (19-89) 48 (91) 15 (28) 38 (72)
Total 273 40.7 (16-89) 244 (89) 62 (23) 211 (77)
1 F isher's e x a c t  te s t . c las : c la ss ica l typ e ; h yp er: h yp e rm o b ility  typ e .
one of their three most important complaints; 63% hypermobility/dislocations; and 57% 
fatigue. In contrast, dermal features (skin hyperextensibility, easy bruising, abnormal scar 
formation) were far less often reported, although they are part of the diagnostic criteria.1
Fatigue severity and dimensions
The mean CIS fatigue score was 41.7 (SD 11.3). The majority of patients (77%) was severely 
fatigued (CIS fatigue > 35). Severe fatigue was more common in the hypermobility type than 
in the classic type (P = 0.032)(Table 1). Age, sex, and level of education did not differ between 
severely and non-severely fatigued patients. Table 2 shows the differences between 
non-severely and severely fatigued patients on the various dimensions. In all dimensions, 
being severely fatigued was associated with more problems or limitations.
Previous surgery, comorbidity, and use of medication
Previous surgery of any kind was reported by 247 patients (90%). The patients who were 
operated before had a higher CIS fatigue score than those who were not (mean (SD): 42.4 
(11.0) vs. 34.5 (11.9); P = 0.001). 117 (43%) Patients reported any kind of comorbidity, and this 
group had a higher mean CIS fatigue score than the patients without self-reported 
co-morbidity (mean (SD): 43.9 (9.3) vs. 40.0 (12.4); P = 0.003). Among the patients with 
comorbidity, anaemia was mentioned by three patients, and hypothyroidism by two. 
Analgesics with possible sedative (side-) effects were used by 62 patients, and these patients
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Table 2 Differences between non-severely and severely fatigued patients on ten
dimensions, each of which is assessed by one or more measures (left columns). 
Correlation of each of these measures with the CIS fatigue score is given in the 
right columns. The measure with the highest correlation coefficient of each 
dimension is highlighted. These measures were used in the multiple regression 
analysis (Table 4).
EDS
N on-severe ly
fatigued
mean 
(SD) /  %
EDS
Severe ly
fatigued
mean 
(SD) /  %
S ign .
te stin g 1
P
Pearson co rre lation  
(un less o th erw h ise  
specified )
Correlation Stat.sign. of 
coefficient correlation 
r a
1) Functional impairment in daily life
SF36 physical functioning 61 (27) 37.1 (23) < 0.001 -0.498 0.000
SIP work problems 96 (145) 198 (163) < 0.001 0.343 0.000
SIP household management 119 (131) 195 (116) < 0.001 0.341 0.000
SIP recreation and pastime 58 (63) 123 (76.4) < 0.001 0.403 0.000
Weekly worked hours (paid) 14 (19) 5 (14) 0.001 - 0.332 0.000
Weekly worked hours (unpaid) 8 (17) 7 (19) n.s. - 0.022 n.s.
2) Physical activity
SIP mobility 39 (68) 94 (114) < 0.001 0.344 0.000
SIP ambulation 83 (102.0) 156 (120) < 0.001 0.319 0.000
3) Psychological distress
% BDI PC > 4 3 20 0.0102 0.337 0.000
SCL psychological distress 33 (7.3) 42 (16) < 0.001 0.420 0.000
4) Sleep disturbances
SIP sleep and rest Daytime 30 (34) 68 (59) < 0.001 0.409 0.000
sleep
SIP sleep and rest Nighttime 11 (24) 31 (31) < 0.001 0.338 0.000
sleep
SIP sleep and rest 42 (44) 100 (70) < 0.001 0.478 0.000
SCL sleep disturbances 4 (2) 7 (3) < 0.001 0.462 0.000
Duration nighttime sleep (hrs) 8 (1) 7 (2) n.s. - 0.078 n.s.
Duration daytime sleep (hrs) 0.3 (0.7) 0.9 (1) < 0.001 0.264 0.000
% Good quality of nighttime 61 32 < 0.0012 - 0.2904 0.000
sleep
5) Concentration problems
CIS concentration 11 (7) 16 (9) < 0.001 0.359 0.000
SIP alertness behaviour 62 (80) 153(158) < 0.001 0.357 0.000
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Ta b le  2 Continued.
6) Social functioning and social support 
SIP social interaction 82 (116) 190 (180) < 0.001 0.404 0.000
SF36 social functioning 80 (21) 54 (23) < 0.001 - 0.557 0.000
7) Self-efficacy concerning fatigue
SES28 21 (4) 18 (4) < 0.001 - 0.403 0.000
8) Causal attribution o f fatigue
% Ehlers-Danlos syndrome 82 94 0.0103 0.1864 0.003
% Too many activities 27 13 0.0122 - 0.1554 0.012
% Not enough leisure time 6 6 n.s.3 - 0.0594 n.s.
% Sleep disturbances 19 37 0.0132 0.2324 0.000
% Personal reasons 2 7 n.s.3 0.0014 n.s
% Worrying thoughts 17 19 n.s2 0.0594 n.s.
% Depressive thoughts 6 10 n.s.3 0.1194 n.s.
% Family history of fatigue 6 4 n.s.3 - 0.030 n.s.
9) Pain
% Occurrence of pain 69 96 0.0012 0.3874 0.000
% Daily pain duration > 12 20 54 0.0012 0.2104 0.002
hours
% Use of analgesics 56 86 0.0012 0.1804 0.000
% Occurrence o f frequent or 65 87 < 0.001 0.3804 0.000
continuous myalgia
Current pain: VAS 4 (3) 5 (2) 0.002 0.373 0.000
Most severe pain: VAS 5 (4) 8 (2) 0.001 0.540 0.000
10) Disease related factors
% Hypermobility 91 95 n.s.3 0.1044 n.s.
% Dislocations 76 78 n.s.2 0.0494 n.s.
% Skin hyperextensibility 57 48 n.s.2 - 0.0804 n.s.
% Easy bruising 89 83 n.s.2 - 0.0644 n.s.
% Muscle weakness 61 80 0.00392 0.1674 0.006
% Muscle hypotonia 43 56 n.s.2 0.2094 0.001
1 In d e p e n d e n t t-test u n le ss o th e rw ise  s p e c if ie d . 2 C h i-S q u a re  tes t. 3 F isher's E xac t test. 4 S p ea rm ans 's  rho;
n o n -p a ra m e tr ic  co rre la tio n . SD = stan d ard  d e v ia t io n .
had a higher CIS fatigue than those not using these medications (46.7 (SD 7.9) vs. 40.1 (SD 
11.8); P < 0.001). Antidepressive drugs with possible sedative (side-)effects were used by 38 
patients, and the CIS fatigue did not differ significantly in both groups (44.1 (SD 10.5) vs. 41.7 
(SD 11.0); P = 0.24). Use of benzodiazepines was reported by 39 patients, and these patients 
had a higher CIS fatigue than those not using (46.5 (SD 9.4) vs. 40.8 (SD 11.4); P = 0.003). Use of
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beta-blockers was reported by 6 patients, and the CIS fatigue did not differ from the patients 
not using them (39.2 (SD 6.6) vs. 41.8 (SD 11.4); P = 0.59). Table3 summarizes the (categories of) 
diagnoses reported as co-morbidity and the self-reported medication with possible sedative 
(side-)effects.
Table 3 Self-reported co-morbidity and use of medications with possible sedative 
(side-)effects.
Self-reported  (category) o f co-m orb id ity Num ber o f EDS 
patien ts
Anaemia 3
Hypothyroidism 2
Hypertension 11
Diabetes mellitus 2
Other internal diseases 21
Osteoarthritis 5
Other reumatological diseases 25
Chronic obstructive pulmonary disease / Bronchial asthma 22
Migraine / other headaches 4
Other neurological diseases 5
Depression 2
Burnout 3
Other psychiatric diseases 8
Allergy 14
Dermatological diseases 6
Gynaecological diseases 5
Ophthalmological diseases 4
Cardiac disease 6
Self-reported  use o f  m ed ication  w ith  po ssib le  sed ative  (side-)e ffects
One or more analgesics with sedative (side-) effects 62
Tramadol 14
Opiates / other opiate agonists 39
Codeine 22
Antiepileptic drugs 3
Baclofen 2
One or more antidepressive drugs w ith possible sedative (side-)effects 38
One or more benzodiazepines 39
One or more beta-blockers 6
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Regression analysis
The measures with the highest correlation coefficient for each dimensions were selected to 
be included in the multiple regression analysis; these measures are highlighted in Table 2. 
Regression analysis with CIS fatigue as dependent variable resulted in a model with five 
possible determinants: disturbances in sleep and wake pattern (SIP sleep and rest), 
concentration problems (CIS concentration), social functioning (SF36 social functioning), self 
efficacy concerning fatigue (SES28), and pain (most severe pain: VAS). Together, these 
possible determinants predicted 38% of the fatigue severity (Table 4).
Table 4 Multiple regression analysis of possible determinants of fatigue. Results of multiple 
linear regression analysis, in which we determined the contribution of one 
measure of each dimension to the level of fatigue. This analysis resulted in a 
model with five possible determinants, which are highlighted in the table below. 
This model predicted 38% of the fatigue severity score of the CIS.
Ind ep en d en t va r iab le s  D ep end ent va riab le
CIS fatigue
Dimension Possible determinant beta Stat.sign. P
1) Functional impairment in daily life
2) Physical activity
3) Psychological distress
SF36 physical functioning 
SIP mobility
SCL negative affectivity
4) Sleep disturbances SIP sleep and rest 0.136 0.028
5) Concentration problems CIS concentration 0.148 0.007
6) Social functioning and social support SF36 social functioning - 0.229 < 0.001
7) Self efficacy concerning fatigue SES28 - 0.240 < 0.001
8) Causal attribution of fatigue Sleep disturbances
9) Pain Most severe pain: VAS 0.220 < 0.001
10) Disease related factors Muscle hypotonia
B a ckw a rd ; p in = 0.01; p o u t = 0 .05; A d ju sted  R2 = 0 .382 .
Impact o f fatigue and impact o f pain
Pain severity (most severe pain (VAS)) was higher in the severely fatigued than in non-severely 
fatigued patients (P = 0.001). In contrast, fatigue had more frequently a larger impact on daily 
functioning than pain (P < 0.001): in 40% of the EDS patients fatigue had a larger impact than 
pain (SF36 fatigue > SF36 pain); for 34% of the patients the impact of pain was equivalent to 
that due to fatigue (SF36 pain = SF36 fatigue); and 26% reported a larger impact of pain 
symptoms than of fatigue (SF36 fatigue < SF36 pain).
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Discussion
This is the first in-depth questionnaire study on fatigue in EDS, showing that fatigue is a 
frequent and clinically relevant problem in EDS: 77% of EDS patients suffer from severe 
fatigue; and patients who are severely fatigued are more impaired and report a higher 
level of psychological distress. Patients with the hypermobility type EDS are most often 
severely fatigued. Furthermore, severe fatigue in EDS is related to sleep disturbances, 
concentration problems, social functioning, self efficacy concerning fatigue, and pain.
The prevalence of 77% severe fatigue and the mean CIS fatigue score of 41.7 is high in 
comparison with the general population. In a Dutch study on chronic fatigue in disease-free 
breast cancer patients, a control group of 78 healthy females (mean age 48.1 (SD 6.2) years) 
was used. The mean CIS fatigue in this group was 19.4 (SD 11.0), and 11% of the women had 
a CIS fatigue of 35 or more.12 Another study reported a mean CIS fatigue of 17.3 (SD 10.1) in a 
group of 53 healthy Dutch controls with predominantly female subjects.26 The prevalence of 
severe fatigue in this EDS population was also high in comparison with rheumatoid arthritis, 
another chronic disorder with extensive articular involvement and high prevalence of pain. A 
recent study among 150 rheumatoid arthritis patients reported a mean CIS fatigue of 34.2 
(SD 10.2), with 52% of the patients being severely fatigued.11
Many EDS patients in this study reported previous surgery and one or more disorder as 
comorbidity. Patients with previous surgery or comorbidity had a higher mean CIS fatigue 
score than those without, although in both groups this was above 35. However, anemia and 
hypothyroidism, disorders known to cause fatigue, were very rare. Furthermore, the 
prevalence of medication use with possible sedative (side-)effects is high in this population. 
The mean CIS fatigue score in the patients using analgesics with possible sedative side 
effects or benzodiazepines was higher than in the other EDS patients. Most likely, use of 
this medication contributes to the high prevalence of severe fatigue in this population. 
The limitation of these data is that it is based on self-reports, and this may not be very 
accurate. Furthermore, it is difficult to evaluate the individual contribution of these factors 
to fatigue, since they are probably interrelated, and dependent on the severity of EDS.
We found that pain is another common and clinically relevant symptom in EDS, which 
is in line with the results of a previous study on pain in EDS.27 In fact, pain was more often 
spontaneously reported than fatigue, whereas fatigue had a larger impact than pain on 
daily functioning. Hence, our study shows that both pain and fatigue contribute to the 
burden of disease in EDS. Therefore, fatigue and pain should preferably be evaluated 
collectively and addressed simultaneously in symptomatic treatment. Pain and fatigue are 
mentioned as associated features in the diagnostic criteria,1 but generally receive little 
attention in medical practice and literature. The finding that these symptoms are very 
often spontaneously reported as most important complaint, that they are severe, and
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have a large impact emphasize the importance of questionnaire studies.
We identified five possible determinants of fatigue in EDS: sleep disturbances, 
concentration problems, social functioning, self efficacy concerning fatigue, and pain. Since 
we used cross sectional data, we were only able to show that these factors are possible 
determinants. However, a strong association of these possible determinants with severe 
fatigue is suggested by this study. More precisely, sleep disturbances,28 low self-efficacy 
concerning fatigue, and pain most likely contribute to persistence of severe fatigue. Sleep 
problems in EDS were previously found to consist predominantly of difficulties initiating and 
maintaining sleep.29 We added the finding that a significant number of patient rest and sleep 
during the day, which was associated with fatigue severity. Concentration problems may 
rather be a result of fatigue, whereas social impairment might be either a perpetuating factor 
or a consequence of fatigue.1230 A follow-up study would allow to analyze whether these 
possible determinants are cause or consequence of fatigue.
A limitation of this study is the ascertainment bias introduced by addressing members of 
a patients support group, and only using the questionnaires which were returned. Both 
patients who are not severely impacted by the disease and busy with their work and family 
and patients who are severely affected with major impairment might not get involved in a 
patient support group and tend not to complete questionnaires. However, recruitment of 
consecutive EDS patients at an outpatients department is complicated, since the care for EDS 
patients is multidisciplinary, and most hospitals do not have a specialized EDS centre. 
Furthermore, we were unable to perform a non-responders analysis, since the patient 
support group took care of the mailing of the questionnaires and did not send us the names 
and addresses of their members for privacy reasons.
The results of our study can serve as a starting point for symptomatic treatment 
approaches. A cognitive behavioural intervention focusing on pain, sleep disturbances, the 
reaction of others to the symptoms and self efficacy concerning fatigue could help to reduce 
fatigue and fatigue related disabilities. Positive results of this approach can be expected from 
recent findings in other chronic diseases with high frequency of severe fatigue.31-33 
Furthermore, medical interventions should address pain and evaluate medication use, and 
irregular sleeping patterns should be analyzed for treatable causes.
In short, this is the first in-depth questionnaire study on fatigue in EDS, showing that 
fatigue is a frequent and clinically relevant problem in EDS.
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Pain in Ehlers-Danlos syndrome is 
common, severe, and associated with 
fatigue and functional impairment
Adapted from:
Voermans NC, Knoop J. Bleijenberg G, van Engelen BG.
J Pain Symptom Manage. 2010;40:370-8.
Abstract
The Ehlers-Danlos Syndrome (EDS) is a clinically and genetically heterogeneous group of 
inherited connective tissue disorders characterized by joint hypermobility, skin hyperexten­
sibility, and tissue fragility. Musculoskeletal pain is mentioned in the diagnostic criteria and 
described as early in onset, chronic, and debilitating. However, systematic research on pain 
in EDS is scarce. Therefore, we investigated prevalence and impact of pain and associated 
features in a large group of EDS patients.
We performed a study among members of the Dutch EDS patient organization (n = 273), and 
included the McGill Pain Questionnaire to investigate various aspects of pain, the Sickness 
Impact Profile to study functional impairment, the Symptom Check List subscale sleep to 
evaluate sleep disturbances, and the Checklist Individual Strength subscale fatigue to 
determine fatigue severity.
The results of this study show that 1) chronic pain in EDS is highly prevalent and associated 
with regular use of analgesics; 2) pain is more prevalent and more severe in the hypermobility 
type than in the classical type; 3) pain severity is correlated with hypermobility, dislocations, 
and previous surgery; 4) pain is correlated with low nocturnal sleep quality; and 5) pain 
contributes to functional impairment in daily life, independently of the level of fatigue.
From this large cohort of EDS patients, we conclude that pain is common and severe in EDS. 
Pain is related to hypermobility, dislocations, and previous surgery and associated with 
moderate to severe impairment in daily functioning. Therefore, treatment of pain should be 
a prominent aspect of the symptomatic management of EDS.
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Introduction
The Ehlers-Danlos Syndrome (EDS) is a clinically and genetically heterogeneous group of 
inherited connective tissue disorders, caused by mutations in genes encoding various types 
of collagen or collagen modifying enzymes (collagen I, III, V, tenascin-X (TNX) or lysyl 
hydroxylase-1). The collagen in connective tissue increases its elasticity and thus helps tissues 
to resist deformation. In the skin, muscles, ligaments, blood vessels, and visceral organs 
collagen plays a very significant role. Reduced elasticity secondary to abnormal collagen in 
EDS results in joint hypermobility, skin hyperextensibility, tissue fragility, and possibly to 
ruptures of visceral organs and blood vessels.
The revised classification of EDS in six major types is based upon clinical and biochemical 
features.1 The hypermobility type is the most common type, followed by the classical type; 
together these types account for 90% of cases.2 The vascular, kyphoscoliotic, arthrochalasia, 
and dermatosparaxis types are rare, as is the TNX-deficient type which has been described 
more recently.34 Musculoskeletal pain is mentioned in the diagnostic criteria of the 
hypermobility type and described as early in onset, chronic, and possibly debilitating.15 This 
latter aspect is clearly illustrated by a recent patients' report of pain in EDS.6
Systematic research on pain in EDS is restricted to a questionnaire study on 51 patients, 
which showed that moderate to severe pain is common in EDS. Pain was often chronic and 
multifocal and suggested to have several causes; secondary to frequent dislocations, 
resulting from repeated soft tissue injury, or related to multiple operations with peripheral 
nerve injury.5 This multifactorial basis was assumed to cause a variable course of pain in EDS: 
pain related to repeated soft tissue injury or multiple operations with peripheral nerve injury 
was thought to cause a constant level of pain, whereas hypermobility and dislocations may 
lead to additional peaks of pain.5 Differences between EDS types could not be tested due to 
the small sample size.5 Other studies on general symptoms in EDS also reported high 
prevalence of pain, but did not focus on specific pain characteristics.7-10
Pain was found to be a prominent symptom in our questionnaire study on fatigue in EDS 
(90%),11 and myalgia was frequently reported in our study on neuromuscular features in EDS 
(73%).12 Furthermore, the previous study on pain in EDS was restricted in size and focus.5 
Therefore, we investigated prevalence, characteristics, and impact of pain in a large group of 
EDS patients. Our aims were: 1) to determine pain prevalence, pain characteristics, and use of 
analgesics (to replicate the findings of previous studies); 2) to investigate whether differences 
in pain prevalence and impact of pain occur between the two most common types of EDS 
(hypermobility and classic type); 3) to explore the relation between pain and disease-related 
factors. Since sleep disturbances are common in EDS,13 we also wanted to 4) investigate the 
relation of pain with sleep disturbances. Finally, we meant to 5) assess the contribution of 
pain to functional impairment in daily life. Since previous research has shown that pain and
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fatigue are associated,14 we controlled for the contribution of fatigue when determining the 
relationship between pain and level of disabilities. This study may thus contribute to a better 
recognition and understanding of pain in EDS, which is a necessary starting point for 
treatment protocols for pain in EDS.
Methods
Patients
We used a cross sectional design to assess fatigue and pain in patients with EDS. In total, 519 
patients were asked to participate (500 questionnaires were sent to members of the Dutch 
patient organization of EDS (VED: www.ved.nl), and 19 patients were recruited from the 
outpatient departments of internal medicine, dermatology, and human genetics of the 
Radboud University Nijmegen Medical Centre). These 19 patients were also included in our 
clinical study on neuromuscular features in EDS.12 Three hundred twenty-seven questionnaires 
were returned (63% response rate). Questionnaires were provided on paper, patients were 
asked to fill them out by themselves, and return them by mail. We excluded patients who 
were younger than 16 years, patients in whom EDS had not (yet) been diagnosed, and 
patients who had filled out the CIS questionnaire incompletely.
Written information about the purpose of the study was provided, and all patients gave 
informed consent. To prevent a selection bias for patients the purpose of the study was 
described as 'to learn more about various complaints in Ehlers-Danlos syndrome'. The study 
was approved by the local ethics committee.
Assessment o f pain
Prevalence o f pain, pain characteristics, and use o f  analgesics
We used the McGill Pain Questionnaire because it provides qualitative and quantitative data 
on various aspects of pain in a standardized way.15 The first question concerns the occurrence 
of pain. If no pain is reported, the subsequent questions on this questionnaire do not have to 
be filled out, and patients are referred to the next questionnaire in the booklet. Therefore, 
only the patients that reported having pain were included for the subsequent subgroup 
analyses of pain severity, pain characteristics, use of analgesics, differences between two EDS 
types, relation of pain with disease-related factors and sleep disturbances, and impact of 
pain (See: Flow chart in Figure I). For the multiple regression analysis, we used all 273 patients 
(See: Flow chart in Figure I and paragraph on Statistics below).
The subsequent questions of the McGill pain Questionnaire focus on pain severity, 
changes of pain over time, and specific characteristics of the pain. The pain severity is scored 
as current pain, most severe pain, and least severe pain, measured with the visual analogous
132
scale (VAS): a score of 0 indicates no pain, and a 100 indicates unbearable pain. Pain at the 
day of filling out the questionnaire is scored as none -  mild -  moderate -  severe. Pain 
characteristics are assessed with use of a list of adjectives reflecting pain quality and intensity, 
of which patients have to select the most appropriate ones. Use of analgesics is qualitatively 
assessed with the McGill questionnaire. Additionally, we used the items on a health care use 
questionnaire that assessed doses of (non)prescribed medication to screen whether patients 
exceeded the maximally allowed doses.16
In our study on neuromuscular features in EDS, muscle weakness and myalgia were 
frequently reported by EDS patients (65% and 73% respectively).12 Therefore, we also asked a 
question on myalgia, how often this occurred, and which parts of the body were involved.
Figure 1 Flow chart of the inclusion and exclusion of EDS patients in this study.
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The relation o f  pain with disease-related factors
We asked patients about the previous or current presence (yes or no) of joint hypermobility, 
dislocations, dermal features (velvety skin; hyperextensible skin; easy bruising; presence of varices; 
thin, translucent skin; molluscoid pseudotumors; impaired wound healing; scars that are thin, 
wide and discoloured and / or have an atrophic appearance; and presence of striae), muscle 
weakness, and about previously performed operations (with explanations of medical terms).
The relation o f  pain with sleep disturbances
The McGill questionnaire includes items on waking up during the night due to pain, and on 
the duration of being awake at night. Sleeping problems were further measured with the 
sleep subscale of the Symptom Check List (SCL-90). This scale consists of three items that 
focus on the quality of sleep (difficulty falling asleep, early awakening, and sleep disturbances 
during the night) which must be rated on a 5-point scale.17 A total score is obtained by 
adding the item scores, scores can range from 3 (not bothered by sleep problems) to 15 (high 
level of distress because of sleep problems).
Contribution o f  pain and fatigue to functional impairment in daily life
We used the McGill Pain questionnaire items on functional limitations due to pain. These 
functional consequences of the pain are scored in the following order: none -  mild -  
moderate -  severe, and concern limitations in daily activities, both work and leisure activities, 
appetite, and lack of energy. Physical disabilities were measured with the physical functioning 
subscale of the ShortForm-36 (SF36).18 Scores range from 0 (maximum physical limitations) to 
100 (optimal physical functioning).19 Additionally, the Sickness Impact Profile (SIP) was used to 
assess functional disability. The SIP is a standardized list of statements aimed at measuring 
changes of conduct in everyday activities due to sickness. We used eight SIP categories: 
sleep and rest, home management, ambulation, social interaction, mobility, alertness 
behaviour, work, and recreation and pastimes. Higher scores mean more functional 
disability.20-23 We used the SIP sum score to assess the level of overall disabilities.19
The Checklist Individual Strength (CIS) subscale fatigue severity consists of eight items. 
Each item was scored on a seven point Likert scale (scores range from 8 to 56). High scores 
indicated high levels of fatigue. The CIS has good reliability and validity.24
Statistics
Data analysis was carried out using SPSS for Windows (version 16.0). Descriptive statistics 
were used to describe the sample. For the analyses of pain characteristics and impact of pain, 
only patients that reported having pain on the first question of McGill pain questionnaire 
were included. Differences in prevalence and severity of pain between the classical and 
hypermobility types were tested with the independent t-test for continuous variables and
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with a Chi-square or Fisher's exact test for dichotomous variables. Correlations were 
calculated with the Pearson coefficient or Spearman's coefficient. Multiple regression analysis 
was performed (enter method; p in = 0.05; p out = 0.1); with functional impairment (SIP sum 
score) as dependent variable. For this analysis, we used the data of all patients, and designated 
'no pain' as a VAS score of 0 (See Flow chart in Figure 1). Pain severity (VAS of most severe pain; 
VAS of current pain) and fatigue (CIS fatigue) were defined as predictors. In all analyses 
probability (P) values smaller than 0.05 were regarded as statistically significant.
Results
Patients
In total, 327 questionnaires were returned. Excluded were patients who were younger than 
16 years (n = 16), patients in whom EDS had not (yet) been diagnosed (n = 30), and patients 
who had incompletely filled out the CIS questionnaire (n = 8). Hence, 273 patients were 
included. The mean age of EDS patients was 41 years (range 16 - 89), and 89% of the patients 
was female. Highest level of education was in 16% of patients low (primary school, low 
vocational school); middle in 47% (high school, middle vocational school), and high (higher 
vocational school, university) in 37%. EDS was diagnosed by a medical specialist in all 
patients. In 53 o f them (91% female), the specific type of EDS was not (yet) known; in all other 
patients the EDS type was diagnosed based upon clinical features, and partly supported by 
biochemical or genetic analysis: 45 EDS patients of the classical type (78% female); 162 of the 
hypermobility type (94% female), 11 of the vascular type (82% female), and two of the 
kyphoscoliotic type (0% female).1 No differences were found in age or gender between the 
various EDS types or between patients with or without classification. Overall, 237 patients 
(87%) had undergone surgery at least once; this included various orthopaedic operations (all 
types) and vascular surgery after ruptured aneurysm or abdominal surgery after ruptured 
intestines (vascular type).
Assessment o f pain
Prevalence o f  pain, pain characteristics, and use o f  analgesics
Of the 273 patients included, 246 reported having pain (90%) on the first question of the 
McGill questionnaire (Table 1; highlighted row). Female patients reported pain more frequently 
than male patients: 92% vs. 74% (P = 0.001), and patients with the hypermobility type EDS 
reported pain more frequently than those with the classical and vascular type (98% vs. 76% 
and 55% respectively (P < 0.001); Table 1). The findings presented below are the result of the 
subgroup analyses of these patients with pain (n = 246), while for the multiple regression 
analysis data of all patients were used (n = 273)(Figure 1).
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Table 1 Pain severity in the three most common EDS types (n = 246). VAS scores of current, least severe, and most severe pain and use of analgesics 
of patients with the three most common types of EDS, and differences of pain severity between these types.
EDS type Total Classical Hyper
mobility
Vascular Kypho
scoliotic
Not known Differences 
between types1 
P-value
Total number of patients 273 45 162 11 2 53 n.s.
Prevalence of pain: number of patients 246 34 159 6 1 46 < 0.001 clas < hyper
(%  of patients of that type) (90) (76) (98) (55) (50) (87) < 0.001 hyper > vase
Joint hypermobility 230 26 157 4 1 42 n.s.
Dislocations 193 17 137 2 0 37 n.s.
Dermal features 236 34 149 6 1 46 n.s.
Muscle weakness 196 27 125 3 0 41 n.s.
Previous operations 228 33 146 5 1 43 n.s.
Current pain: 48.0 39.2 49.1 21.2 0.016 clas > vase
mean VAS score (SD) (22.4) (25.4) (21.0) (12.0) 0.001 hyper > vase
Least severe pain: 21.5 19.6 21.6 6.3 0.018 hyper > vase
mean VAS score (SD) (16.3) (17.3) (15.5) (6.3)
Most severe pain: 82.5 76.0 85.3 67.7 0.014 clas < hyper
mean VAS score (SD) (17.4) (19.5) (13.5) (30.9)
Use of analgesics: 216 27 145 4 n.s.
number of patients (88) (82) (91) (67)
(%  of patients of that type)
Fisher exact test, n.s.: not significant. not tested, clas: classical type EDS; hyper: hypermobility type EDS; vase: vascular type EDS.
Reported pain severity (VAS of current pain, least severe pain, and most severe pain) is 
presented in Table 1. Overall, patients with the hypermobility type had the highest VAS scores 
for current pain, least severe pain, and most severe pain (Table 1). Pain was most frequently 
localized in neck, shoulders, hips, and forearms, and legs (> 40% of all patients), which might 
reflect a pattern of musculoskeletal pain (Figure 2). In contrast, headache or abdominal pain 
was reported infrequently. This was supported by the response to the question of presence 
of myalgia: frequent or continuous myalgia was reported by 87% of patients with pain. It did 
not occur in a specific distribution; approximately 60% of patients reported myalgia in arms, 
legs, and /  or trunk.
The majority of patients reported chronic pain (i.e. lasted longer than one year; 92%); 
gradual increase of pain (84%); and an equal severity of pain (64%). Frequently used adjectives 
(reported by > 40% of the patients) to characterize the pain were: cutting, nagging, tiring, 
troublesome, and sickening. Pain severity changed over time, but remained continuously 
present to some degree in most patients (85%). The majority of patients suffered pain the day 
before filling out the questionnaire (95%). In 90% of them pain occurred more than 4 hours, and 
72% of them had to rest due to pain the previous day. Of the patients resting, 38% rested for at 
least 4 hours that day. The majority of patients (89%) suffered from pain at the day of filling out 
the questionnaire, and in 53% of the patients this pain severity was moderate to severe.
One or more analgesics were used by 89% of the EDS patients with pain; paracetamol 
was used by 59%; paracetamol with codeine by 21%; acetylsalicylic acid by 4%, other 
non-steroid anti inflammatory drugs by 67%, tramadol by 23%, and anti-neuropathic drugs 
by 11% of the patients (Table 2). Reported doses did not exceed the maximally allowed 
prescriptions.
The relation o f  pain with disease-related factors
Joint hypermobility was reported by 230 of the 246 patients with pain. Dislocations occurred 
in 193 patients, dermal features were reported by 236 patients with pain. Previous surgery 
was reported by 227 of these patients, and muscle weakness by 196 (Table 1).
Most severe pain (VAS) was significantly correlated with previous surgery (0.213; P < 0.01), 
hypermobility (0.175; P < 0.001), and dislocations (0.183; P < 0.001). Current pain (VAS) was 
significantly correlated with dislocations (0.153; P < 0.05). Neither most severe pain nor 
current pain (VAS) was significantly correlated with dermal features or muscle weakness.
The relation o f  pain with sleep disturbances
Half of the patients with pain (n = 246) was awake during the night due to pain (50%); and of 
these patients, 93% was awake at least two hours. The mean SCL sleep subscale score was 6.7 
(SD 3.3; range 3 - 15). Pain severity was significantly correlated with SCL subscale score sleep 
(r = 0.31; P < 0.001 for most severe pain, and r = 0.29; P < 0.001 for current pain P < 0.001).
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Table 2 Use of analgesics in EDS patients reporting pain (n = 246). Use of analgesics in EDS 
patients reporting pain; several patients used more than one analgesic.
Drug %  O f pa tien ts  w ith  pa in  (n=246) 
using ana lg esics
Paracetamol
Paracetamol 59
Paracetamol w ith codeine 21
Non-steroidal anti-inflammatory drugs
Acetylsalicylic acid 4
Ibuprofen 31
Naproxen 14
Diclofenac 16
Opiates
Tramadol 23
Neuropathic pain drugs
Amitriptyline 7
Carbamazepine 1
Gabapentin 3
Other
Various 33
Contribution o f  pain symptoms to the functional impairment in daily life 
Based on the results of the McGill Questionnaire, eighty-seven percent of the patients with 
pain (n = 246) was impaired in performing their daily activities, and in 55% of them this 
consisted of moderate to severe impairment. Appetite was reduced in 32% of patients. 
Furthermore, patients had moderate to severe impairment due to pain based on the SF-36: 
mean SF-36 sub score pain was 42.4 (range 0 - 100; SD 20.2). Pain severity was significantly 
correlated with the total SIP score (r = 0.45; p < 0.001 for most severe pain, and r = 0.43 
(P < 0.001) for current pain). The mean total SIP score was 1157 (SD 660; range 0 - 2865) 
reflecting severe impairment in daily functioning.
Multiple regression analysis of data of all patients (n = 273) resulted in a model in which 
pain severity (most severe pain (VAS)) and fatigue severity predicted 31% of functional 
impairment (Table 3). The predictive value of the model with current pain rather than most 
severe pain as independent variable had a similar predictive value (28%; data not shown).
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F ig u re  2 Distribution pattern o f pain in EDS patients.
Pain occurred in at least 40% (grey) and respectively 50% (black) of EDS patients. Pain was most 
frequently localized in neck, shoulders, hips, and forearms, and legs, which might reflect a pattern of 
musculoskeletal pain.
Table 3 Results of multiple regression analysis of pain and fatigue with functional
impairment as dependent variables (n = 273). Regression analysis with functional 
impairment as dependent variable, and pain and fatigue as independent variables.
D ep end ent va r iab le : Fu n ction a l im p a irm ent (SIP sum  score)
Independent variables beta P
1) Pain Most severe pain (VAS) 0.241 < 0.001
2) Fatigue CIS fatigue 0.392 < 0.001
Enter; p in = 0 .05 ; p o u t = 0.1; a d ju sted  R2 = 0 .309 .
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Discussion
This study in a large group of EDS patients shows that 1) chronic pain is highly prevalent in 
EDS and is associated with regular use of analgesics; 2) pain is more prevalent and more 
severe in patients with the hypermobility type than in those with the classical type and 
vascular type; 3) pain severity is related to hypermobility, dislocations, and previous 
operations, but not to other disease related factors; 4) pain is related to sleep disturbances; 
and 5) pain is related to functional impairment in daily life, independently of the level of 
fatigue.
Previous studies also reported high prevalence of pain in EDS, but were limited in size 
and scope.578 Results of our study confirm the high prevalence of pain and add the finding 
that pain is most common and most severe in patients with the hypermobility type of EDS. 
Furthermore, this study shows that myalgia is reported by the majority of patients, and that 
pain is predominantly localized in neck, shoulders, hips, and legs, but not in head or 
abdomen. Most severe pain is correlated to hypermobility, dislocations, and previous surgery. 
Together, these findings may indicate that pain in EDS has a compound origin: a constant 
level of pain may originate in the musculoskeletal system1 and additional peaks of severe 
pain may be related to recurrent (sub)luxations and/or dislocations, as suggested by Sacheti.5
The results of this study further show that pain severity in EDS is related to sleep 
disturbances. Pain has previously been reported as one of the causes of low sleep quality in 
EDS, causing difficulties in initiating and maintaining sleep.13 Also in other chronic diseases, 
pain severity was found to be related to sleep disturbances. However, recent data seem more 
consistent with poor sleep leading to an increasing pain severity than pain predicting poor 
sleep.25 Furthermore, pain severity in EDS was found to be independently related to 
functional impairment. This relationship between pain severity and disability has also been 
found in other populations with chronic pain, e.g. in patients with chronic lower back pain or 
fibromyalgia.25
This study has not focused on the psychological variables which are known to influence 
pain, such as catastrophizing of pain and fear of exercise-related pain.14 These and other 
factors should be addressed in future studies on pain in EDS, since they may be a starting 
point for treatment of chronic pain in EDS.26 27 Based on experience with chronic pain in other 
diseases, cognitive behavioural interventions in EDS might reduce pain and pain related 
disability.26 In addition, symptomatic treatment of pain in EDS can be directed at prevention 
of dislocations and optimizing medical treatment of pain. Patients' report of severe pain in 
EDS stress the importance of development of multidisciplinary treatment protocols.6
A possible limitation of our study is the selection bias occurring with recruitment of 
members of the Dutch EDS Foundation. The previous questionnaire study on 51 patients, 
which showed that moderate to severe pain is common in EDS, also relied on members of a
140
national EDS foundation.5 Patients who are most severely affected might be more likely to 
join a patient support group. EDS patients with only mild symptoms might not even be 
diagnosed and not seek medical attention. This selection bias has to be taken into account 
when interpreting the results of this study.
These limitations notwithstanding, our findings suggest that pain is a very common and 
severe symptom in this group of EDS patients. It is related to dislocations, sleep disturbances, 
and moderate to severe impairment in daily functioning. Therefore, treatment of pain should 
be a prominent aspect of clinical management of EDS and multidisciplinary protocols should 
be developed.
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Neuromuscular features 
of Ehlers-Danlos syndrome
B
Quantitative muscle function measurements 
of tenascin-X-deficient Ehlers-Danlos syndrome 
patients and tenascin-XB knockout mice
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Reduced quantitative muscle function in 
tenascin-X-deficient Ehlers-Danlos patients
Adapted from:
Voermans NC, Altenburg TM, Hamel BC, de Haan A, van Engelen BG. 
Neuromuscul Disord. 2007;8:597-602.
Abstract
The Ehlers-Danlos Syndrome (EDS) is a heterogeneous group of inherited connective tissue 
disorders. Skeletal muscle features belong to the clinical criteria of EDS and are generally 
interpreted to result from increased tendon distensibility or exercise avoidance. However, 
muscle function in EDS has hardly been investigated as such.
We performed a pilot study consisting of clinical investigations, electromyography, muscle 
ultrasound, muscle biopsy, and quantitative muscle function tests on two EDS patients with 
deficiency of tenascin-X. Quantitative muscle function proved severely reduced despite 
normal findings on electromyography and muscle biopsy. These findings dispute the 
interpretation of increased tendon distensibility. We hypothesize that alterations in the 
extracellular matrix modify myofascial force transmission and thus influence muscle function 
in EDS.
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Introduction
The Ehlers-Danlos Syndrome (EDS) is a clinically and genetically heterogeneous group of 
inherited connective tissue disorders (ICTDs) characterized by articular hypermobility, skin 
hyperextensibility and tissue fragility.1 Mutations in type V collagen can explain part of classical 
type EDS cases.1 A clinically distinct, recessive form results from tenascin-X (TNX) deficiency.2 
The hypermobility type of EDS has been associated with TNXB gene haploinsufficiency.3
The diagnostic criteria of EDS include muscle hypotonia, and muscle symptoms have 
been reported.14-7 Muscle symptoms are generally interpreted to result from increased 
distensibility of tendons or from exercise avoidance due to joint hypermobility and pain.7 
However, muscle function in EDS has hardly been investigated as such. We therefore 
performed a pilot study with two EDS patients comprising clinical investigations, electro­
myography, muscle ultrasound, muscle biopsy, and quantitative muscle function tests.
Methods
Patient selection
We selected two female EDS patients: one with TNX deficiency and absence of TNX in serum, 
with a clinical presentation resembling the classical type of EDS. She has been previously 
been described by Schalkwijk et al. in 2001 (Patient 1)2 and by us in 20078 (3rd Report in Chapter 
3); and one with hypermobility type of EDS with reduced TNX levels in serum probably due 
to TNXB gene haploinsufficiency.3 Mutation analysis of TNXB in patient 1 revealed a 
homozygous 2-bp deletion in exon 8 that encodes the fourth fibronectin type III repeat. 
Analysis of the mutations described by Schalkwijk et al. in patient 2 revealed no abnormalities.2
Clinical studies
Muscle ultrasound
Muscle ultrasound of the quadriceps muscle was performed using standard techniques as 
previously described.9 Results were compared with normal values acquired in healthy adults 
in the same centre.10
Electromyography
Electrophysiological examination was performed using standard techniques with a Medelec 
Synergy EMG system (Oxford Medical Instruments, Surrey, United Kingdom).
Muscle biopsy
Muscle biopsy specimens were obtained from the right vastus lateralis muscle in both
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patients. Frozen sections of 10 ^m were examined using standard enzyme histochemical 
and immune histochemical techniques. Guinea pig anti-human TNX antibodies were used to 
stain TNX within muscle ECM.2
Quantitative muscle function testing and analysis
In a single experimental session the patients' neuromuscular function of the quadriceps muscle 
was investigated as reported previously.11 They were asked to perform and sustain a maximal 
voluntary contraction during approximately three seconds. Next, a 10 Hz contraction was 
elicited with seven stimulation pulses and a fused tetanic contraction was evoked with 150 Hz 
stimulation for one second. Isometric knee extension torque was measured at 90-degree knee 
flexion with the subjects seated on a custom-built rigid chair. Torque was measured with a 
force transducer fixed to the shin. During each voluntary contraction the subjects were 
vigorously verbally encouraged, and visual feedback allowed them to achieve maximal 
performance. Torque signals were digitized (1000 Hz) and stored on disc for immediate and 
off-line analysis with custom Matlab software packages. From the signals, maximal rates of 
torque generation and relaxation were calculated, as well as the time between the stimulus 
and initial torque rise. Results were compared with previously published normal values.1213
Results
Patient 1
A 46-year-old woman with TNX-deficient type of EDS presented with weakness of her right 
hand and mild generalized weakness of arms and legs, which had started insidiously four 
years prior to testing. She had suffered from recurrent dislocations of her right shoulder, was 
unable to walk up stairs and had difficulties swallowing. Her walking endurance was limited 
to one hour and she had difficulties keeping her balance on uneven ground. A general 
physical examination revealed hypermobility, bruises on her fingers, bilateral pes planus, and 
hyperextensibility of her skin, which was smooth and velvety. The results of the neurological 
examination included mild dysphagia, generalized muscle hypotonia, mild weakness of the 
neck flexor muscles and the arms and legs, both proximally and distally, with the most 
pronounced weakness in the muscles of her right hand. There was muscle atrophy of her 
right lower arm and hand. Tendon reflexes were symmetrically low (Table 1).
Nerve conduction studies were normal and electromyography showed mild aspecific 
changes, without clear signs of either a myopathy or neurogenic disorder. Muscle ultrasound 
of the quadriceps muscle revealed no atrophy. Muscle biopsy of the quadriceps muscle 
showed no significant myopathic changes. Staining with antibodies against TNX revealed 
absence of TNX within muscle ECM (Figure 1). Quantitative muscle function testing (Table 2)
150
revealed a low maximal knee extension torque at voluntary contraction. During voluntary 
effort, maximal performance was only achieved after practice and with verbal encouragement. 
Torques were most steady with visual feedback (Figure 2). The torque variation with 10 Hz 
stimulation looked normal. However, the twitch torque was relatively high. The interval 
between stimulation and initial torque production, as well as the relaxation pattern were 
normal. Torque generation at 150 Hz appeared faster than normal (Figure 3).
Figure 1 Muscle biopsies stained with anti-human TNX antibodies: qualitative evaluation 
of staining. Bar = 50 ^m.
A: The biopsy of a control subject: normal TNX staining. B: The biopsy of patient 1: absence o f TNX. 
C : The biopsy of patient 2: reduced staining of TNX.
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Patient 2
A 22-year-old woman with EDS of the hypermobility type with reduced TNX serum levels 
had suffered from muscle hypotonia since infancy. Her gross motor development had been 
delayed and she had never been proficient at sports. Her family history was positive for EDS 
of the hypermobility type. She had received two corrective surgeries for her congenital hip 
dysplasia but still experienced difficulty walking, which is why she had been using a 
wheelchair for the preceding three years. She played wheelchair tennis twice a week for 30 
minutes. She reported experiencing gradual, progressive muscle weakness, which was more 
pronounced in her legs than in her arms, and occasional muscle cramps in her calves.
The general physical examination revealed hypermobility and mild scoliosis. There was 
no hyperextensibility of the skin but scars were broad, striae were present on abdomen and 
hips, and the skin was smooth and velvety. Neurological examination revealed a mild paresis 
of the right proximal arm muscles and of both legs with generalized hypotonia. Muscle 
atrophy was pronounced in her right arm and right anterior tibial muscle, but absent in her 
quadriceps muscles. She was confined to a wheelchair and was only able to remain upright 
without support for a short period. Tendon reflexes were symmetrically low (Table /).
Table 1 Results of physical examination.
P atien t 1 P atien t 2
Beighton score 5/9 5/9
Skin features bruises on fingers; broad scars;
hyperextensibility; striae on abdomen and hips;
smooth, velvety skin no hyperextensibility;
smooth, velvety skin
Muscle tone generalized hypotonia generalized hypotonia
Muscle atrophy none atrophy of right arm muscles and 
of right anterior tibial muscle
Deep tendon reflexes symmetrically low symmetrically low
Sensation normal normal
Muscle strength (MRC) Right Left Right Left
Neck flexors 4 4
Biceps brachii 4 4 4 5
Flexion wrist 4 4 5 5
Deep flexors of fingers 3 4 5 5
Iliopsoas 4 4 3 4
Quadriceps 5 5 4 4
Anterior tibial 4 4 3 4
M RC: M ed ica l Research  C o u n c il,14
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Results of nerve conduction studies, electromyography and muscle ultrasound were 
normal. A needle biopsy of the quadriceps muscle showed no significant myopathic 
changes. Staining with antibodies against TNX revealed reduced presence of TNX within 
muscle ECM (Figure 1). The torque characteristics of this patient were very similar to those of 
patient 1 (see Table 2 and Figure 2): a low maximal torque, a relatively high twitch torque, a 
normal interval between stimulation and initial torque production, a normal relaxation, and 
relatively fast torque generation. Again, maximal performance during voluntary effort was 
only achieved after practice and visual feedback enhanced steadiness of the torque.
Table 2 Results of ancillary investigations.
P atien t 1 Patien t 2 N orm al va lues
Clinical test
Electromyography Mild aspecific changes: Normal
some small, polyphasic units
Muscle ultrasound of the Normal Normal
quadriceps muscle
Needle biopsy of the No significant myopathic No significant myopathic
quadriceps muscle changes changes
Type I fibres: 60% 24% 35 - 50%
Percentage and 46 - 92 |jm 46 - 63 jm 40 - 84 |jm
diameter
Type II fibres: 40% 76% 50 - 65%
Percentage and 50 - 83 jm 46 -  63 jm 40 - 84 jm
diameter
Quantitative muscle function testing
Maximal knee extension 87 74 125 ± 23
torque at voluntary (n = 8)13
contraction (Nm)
Torque variation with normal normal
10 Hz stimulation
Twitch torque 26% of tetanic torque 27% of tetanic torque 19 ± 2% of tetanic
torque (n = 8)13
Interval between normal normal
stimulation and initial
torque production
Relaxation pattern normal normal
Rate of torque generation 1.60% 1.72% 1.43 ± 0.02%
at 150 Hz (%Tmax/ms) (n = 8)13
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Figure 2 Torque production over time during repeated maximal voluntary attempts with 
visual feedback and verbal encouragement, showing torque increases after serial 
attempts with visual feedback.
A: For patient 1 the first, second and fifth attempt are depicted in the black, dark grey and light grey 
curves, respectively. B : For patient 2 the torque productions of the first, third and sixth attempt are 
shown in the thick, medium and thin light grey curves, respectively.
A
Patient 1
Time (ms)
B
Patient 2
Time (ms)
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Figure 3 Torque production as a result of 10 Hz stimulation for patient 1, patient 2 and a
healthy subject, showing reduced torque production, but normal torque variation.
T im e (ms)
Discussion
The main finding of our study is that quantitative muscle function proved severely reduced 
in the two EDS patients, despite normal findings on electromyography and muscle biopsy. 
Our data are compatible with the one case study that addressed muscle function in the 
classical type of EDS in which generalized mild to moderate weakness was observed.15
It is unlikely that enhanced tendon compliance due to increased tendon distensibility 
can account for the observed muscle weakness in this study. First, increased tendon 
compliance would have increased the interval between stimulation and initial torque 
production and would have affected the relaxation rate (this is mostly pronounced at short 
muscle length), which were both normal in both patients. Second, it would have slowed 
torque generation whereas in these patients it was accelerated. Furthermore, increased 
compliance is assumed to decrease efficiency of contraction, forcing muscle cells to operate 
at a relatively shortened length, which would result in lower twitch torques. Yet, both patients 
displayed relatively high twitch torques. Thus, although TNX is expressed in tendon sheaths, 
changes in myotendinous force transmission cannot explain the present results.
Furthermore, disuse cannot fully account for the results of this study, since torque 
generation would then be relatively faster, and relative twitch torques would be higher than 
in control subjects. Our results did not show this. First, the findings in both patients were very
155
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similar, whereas patient 1 was normally ambulant. Second, physical examination, muscle 
ultrasound, and biopsy revealed no signs of atrophy in the quadriceps muscle in either of the 
patients. Fibre size diameter was within the normal range in both patients, but slightly higher 
in patient 1 than in patient 2. This difference might correspond to the somewhat higher 
maximal knee extension torque at voluntary contraction in patient 1, and reflects the limited 
contribution of disuse to muscle weakness in patient 2 .
Alternatively, since TNX is expressed in muscle ECM in animal models,16-19 absence or 
reduction of TNX in the ECM of muscle may influence muscle function in these EDS patients. 
Hence, rather than in its adjacent structures (tendons and joints), the cause of muscle 
weakness in EDS may be located in the ECM of muscle itself. The ECM of skeletal muscles is 
located between muscle fibres (endomysium), surrounds fascicles (perimysium), and covers 
the whole muscle (epimysium). It shapes the muscle and gives the contractile cells 
cohesiveness and elasticity, and has additional functions at the neuromuscular and 
myotendinous junctions. TNX indeed plays a central role in the organization of muscle ECM 
through interaction with various ECM components, such as collagen I, III, V, XII and XIV, 
Consequently, TNX might be important for the compliance of connective tissues.16
Previous studies on the role of the muscle ECM in muscle function have lead to the 
concept of myofascial force transmission. It is generally assumed that muscle force is 
transmitted via the myotendinous junction to the tendon and further onto the bone. 
However, in addition to myotendinous force transmission, up to 40% of muscle force can be 
transmitted from muscle fibres onto the endomysium and from there to peri- and epimysium, 
and extra muscular connective tissue.20 This so-called myofascial force transmission might be 
influenced by altered tensile characteristics of muscle ECM as in EDS. Hence, absence or 
reduced presence of TNX in muscle ECM in these patients, as shown in Figure 1, may point to 
a relation between reduced myofascial force transmission and muscle weakness in EDS. The 
exact mode in which the TNX-deficient ECM affects muscle function has neither been 
investigated in this study nor in previous studies. However, it is conceivable that TNX 
deficiency reduces the stiffness of epimuscular myofascial pathways and thus causes a 
pathological reduction of the force transmitted this way. This would change the required 
muscular coordination drastically and interfere with mechanical interaction between 
antagonistic muscles.21
In conclusion, quantitative muscle function proved severely reduced in the two EDS 
patients, despite normal findings on electromyography and muscle biopsy. These finding 
dispute the common interpretation of increased tendon distensibility, and support the 
hypothesis that alterations in the ECM influence muscle function in EDS.
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Mild muscular features in tenascin-XB 
knockout mice, a model of Ehlers-Danlos 
syndrome
Adapted from:
Voermans NC, Verrijp K, Eshuis L, Balemans MCM, Egging DF, Sterrenburg E, 
van Rooij IALM, van der Laak JAWM, Schalkwijk J, van der Maarel SM, Lammens M, 
van Engelen BG.
Connect Tissue Res 2011 Mar 15 [Epub ahead of print]
Abstract
Tenascin-X (TNX) is an extracellular matrix glycoprotein whose absence in humans leads to a 
recessive form of Ehlers-Danlos Syndrome (EDS), a group of inherited connective tissue 
disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. A 
mouse model of the TNX-deficient type EDS has been used to characterize the dermatological, 
orthopaedic, and obstetrical features. The growing insight in the clinical overlap between 
myopathies and inherited connective tissue disorders asks for a study of the muscular char­
acteristics of inherited connective tissue diseases. Therefore, this study aims to define the 
muscular phenotype of Tnxb knockout mice.
We performed a comprehensive study on the muscular phenotype of these Tnxb knockout 
mice, consisting of standardized clinical assessment, muscle histology, and gene expression 
profiling of muscle tissue. Furthermore, peripheral nerve composition was studied by 
histology and electronmicroscopy.
The main findings are presence of mild muscle weakness, mild myopathic features on 
histology, and functional upregulation of genes encoding proteins involved in extracellular 
matrix degradation and synthesis. Additionally, sciatic nerve samples showed mildly reduced 
collagen fibril density of endoneurium.
The muscular phenotype of Tnxb knockout mice consists of mild muscle weakness with 
histological signs of myopathy and of increased turnover of the extracellular matrix in muscle. 
Furthermore, mildly reduced diameter of myelinated fibres and reduction of collagen fibril 
density of endoneurium may correspond with polyneuropathy in TNX-deficient EDS patients. 
This comprehensive assessment can serve as a starting point for further investigations on 
neuromuscular function in Tnxb knockout mice.
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Introduction
Tenascin-X (TNX) is an extracellular matrix (ECM) glycoprotein, the absence of which in 
humans leads to a recessive form of Ehlers-Danlos Syndrome (EDS), a group of related 
inherited connective tissue disorders.12 TNX-deficient type EDS has a phenotype similar to 
the classic type EDS with hypermobile joints, hyperextensible skin, and easy bruising, but 
without atrophic scarring and with an autosomal recessive inheritance pattern.13 Haploin- 
sufficiency of Tenascin-XB (TNXB) is associated with joint hypermobility in females.4
Tnxb knockout (KO) mice have been used for detailed study of the dermatological 
phenotype and to increase insight in the dermatological features of TNX-deficient type EDS.5-8 
Additionally, articular and obstetrical aspects were investigated, the results of which showed 
that this mouse model only partly reflects the multisystem involvement of TNX-deficient type 
of EDS in human.910 Protein expression studies in Tnxb KO mice tissue have further suggested 
a role of TNX in developing and adult muscles; TNX was found to be abundantly expressed in 
various tissues during embryonic development, among which are perimysium of skeletal 
muscle and tendons.1112 In adulthood, TNX is predominantly expressed in skeletal and cardiac 
muscle. Therefore, TNX was initially referred to as 'the muscle tenascin'.12 In addition, in both 
patients and mice, abnormalities of elastic fibres were observed in skin.13 TNX was indeed 
found to be highly expressed in the peripheral nervous system, more specifically in 
perineurium and endoneurium .1415 However, myelin sheath thickness, axonal size, and 
ultrastructure of the sciatic nerve of Tnxb KO mice were reported to be normal.15 Hence, it was 
suggested that TNX has only a subtle function in peripheral nerve macromolecular organization.15
The growing insight in the clinical overlap of myopathies and inherited connective tissue 
disorders such as collagen VI myopathies, EDS, and Marfan syndrome16-18 calls for a study of 
the muscular phenotype of inherited connective tissue disorders. In the initial dermatological 
study, Tnxb KO mice were reported to have no perinatal abnormalities, exhibit normal 
growth, and develop progressive skin hyperextensibility, similarly as in EDS patients.5 
Therefore, Tnxb KO mice probably offer a suitable animal model to study the muscular 
phenotype of TNX-deficient EDS in more detail. Despite the abovementioned histological 
findings, the muscular phenotype of Tnxb KO mice has not been investigated in detail so far.
This study aims to assess the muscular phenotype of Tnxb KO mice in a broad approach, 
consisting of standardized clinical assessment, muscle histology, gene expression profiling 
on muscle tissue, and peripheral nerve histology and electronmicroscopy. Such detailed 
observation will enable a comprehensive assessment of the muscular phenotype of Tnxb KO 
mice, which may be a good starting point for further investigations on the influence of 
alterations of the ECM on muscle and peripheral nerve function. Additionally, it may increase 
insight in the neuromuscular symptoms in TNX-deficient EDS patients and strengthen the 
connection between the ECM and neuromuscular features.19
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Materials and methods
Mice
Tnxb KO mice were obtained from Bristow et al.3 These mice have a heterogeneous genetic 
background. Therefore, mice backcrossed to a C57/BL6 background, as described previously59 
were used in these studies. Briefly; -/- offspring from heterozygous parents was obtained by 
the backcrossing of Tnxb KO mice with six generations of C57/BL6 mice. Wild-type (WT) C57/ 
BL6 mice were used as controls. Long term motor activity assessment was performed in 
eight female Tnxb KO mice and eight female WT mice, both at six and 16 months. For 
functional strength measurements, eight female Tnxb KO mice and eight female WT mice 
were tested at the age of three, six, and 16 months. Body weight was measured at 16 months 
of age. Muscle biopsies of the quadriceps muscles for histochemical studies were obtained 
in six male Tnxb KO and WT mice of eight months of age. Gene expression studies were 
performed on biopsies of the quadriceps muscle of the same male Tnxb KO and WT mice of 
eight months of age. Since we detected the presence of axonal sensomotor polyneuropathy 
in TNX-deficient EDS patients,20 we made a histological and electronmicroscopic analysis of 
the sciatic nerve of one Tnxb KO and one WT mouse of 16 months of age, both females. The 
experimental design was approved by the animal use committee of Radboud University 
Nijmegen Medical Centre.
Long term m otor activity assessment
Straightforward observation of motor behaviour of Tnxb KO mice and WT mice revealed no 
differences.5 We therefore assessed long term motor activity in a home cage-like environment 
('Phenotyper') as previously reported.2122 Tnxb KO and WT mice (n = 8 in each group; female; 
6 and 16 months) were randomly placed in 16 cages with versatile video-based observation 
system for one week (Noldus PhenoTyper, Wageningen, The Netherlands). We used the 
mobility detection parameter of the Ethovision video tracking software (Noldus; immobility 
threshold setting of 20% and strong mobility threshold of 60%) to measure the level of 
activity. This was expressed as mean hourly distance moved (cm) at six and 16 months of age. 
Additionally, we measured the mean duration of immobility (s), total duration of mobility (s), 
and total duration of strong mobility (s) per hour at 16 months of age. Data were recorded 
digitally and quantified automatically as previously described.2122
Functional muscle strength measurement
Functional muscle strength was tested with use of a paw-fall-through test and hang-time 
test.23 Mice (n = 8 in each group; female; 3, 6, and 16 months) were placed on a 60 x 40 cm 
piece of 1.5-cm mesh hardware cloth, approximately 35 cm above their cage filled with 
sawdust. During a 1-minute observation period, the number of times individual limbs fell
162
through the wire was counted (number of paw-fall-through events in 1 min: 'PFT 1min'). The 
network was then inverted and the time for the mouse to fall off was recorded during a 
maximum of two minutes before being placed back into its cage (hangtime duration: 'HT 
dur' (ms)).
Quadriceps muscle samples
At 8 months of age 6 male Tnxb KO mice and 6 male WT littermates were sacrificed by cervical 
dislocation. The quadriceps femoris muscle samples were obtained bilaterally immediately 
after death. The material was snap-frozen in chilled isopentane at - 140 °C. Sections of 10 ^m 
underwent Hematoxylin-Phloxine staining and were examined under a light microscope. Of 
each mouse, both left and right sections were studied. Presence of fibrosis was evaluated 
qualitatively. The number of cells with internal nuclei was measured by evaluating a minimal 
of 300 fibres of each biopsy, and calculating the percentage of cells with internal nuclei. Up 
to 3 to 5% of cells with internal nuclei can be considered normal. A higher percentage of 
internal nuclei is indicative for myopathy. Fibre diameters were measured in both WT and 
Tnxb KO mice using KS400 image analysis software (Zeiss GMBH, Germany). An interactive 
digital region growing procedure with possibility for interactive correction was applied to 
recognize individual muscle fibres. Subsequently, the software calculated the diameter of 
each muscle fibre automatically. Diameters were converted from pixels to micrometers.24
Subsequently, immunohistochemical staining with antibodies to collagen I, III, V, VI, TNX, 
elastin, and laminin a2 was performed. Collagen I, III, and V were selected since they are 
known to be deficient in the classic or vascular type EDS, collagen VI since it is deficient in 
two myopathies (Ullrich congenital muscular dystrophy and Bethlem myopathy) with clinical 
features overlapping those of EDS,25 and elastin since it is involved in cutis laxa, another 
inherited connective tissue disorder with muscle weakness. Laminin a2 antibodies were 
included as a control staining. The following antibodies were used: polyclonal goat 
anti-collagen I antibodies (2 ^g/ml), polyclonal goat anti-collagen III antibodies (2 ^g/ml), 
polyclonal goat anti-collagen V antibodies (Southern Biotech, USA) (2 ^g/ml), monoclonal 
mouse anti human collagen VI antibodies (Chemicon international, California, USA), 
polyclonal goat anti-rat elastin antibodies (Elastin Products Company, USA), and polyclonal 
rabbit anti-laminin a2 antibodies (DAKO Cytomation, Denmark) (2 ^g/ml), and polyclonal 
rabbit anti-TNX antibodies.9 Frozen sections were fixed in ice-cold acetone for 10 minutes, 
dried and incubated with the primary antibody diluted in PBS containing 1 % BSA overnight 
at 4 degrees. After washing with PBS, the bound antibodies were detected with a biotinylated 
secondary antibody (Vector, Burlingame, CA). After using the Vectastain Elite ABC kit the 
sections were coloured with AEC Chromogen (ScyTek labatories, USA). Sections were 
counterstained with Hematoxylin. Staining of these proteins in endomysium and perimysium 
was individually scored by two investigators and graded in five semi-quantitative categories:
163
C
ha
p
te
r 
8 
M
ild
 
m
us
cu
la
r 
fe
at
ur
es
 
in 
te
na
sc
in
-X
B 
kn
oc
ko
ut
 
m
ic
e,
 a 
m
od
el
 o
f 
Eh
le
rs
-D
an
lo
s 
sy
nd
ro
m
e
0 = absence; 1 = limited staining; 2 = moderate staining; 3 = considerable staining; 4 = strong 
staining. Subsequently, consensus was reached in case of unequal scores. The scores were 
averaged to reach an overall score for KO and WT mice based upon these individual semi­
quantitative scores.
Gene expression profiling
Total RNA was isolated from quadriceps muscle of WT and Tnxb KO mice (8 months o f age) as 
described.26 cRNA was prepared by linear amplification and concurrent incorporation of 
biotin-UTP with the TotalPrep RNA amplification kit from Ambion, USA. Quantity and quality 
of the cRNA was checked with the Bioanalyzer lab-on-a-chip. 1.5 mg Of cRNA from each 
sample was hybridized to the Illumina Mouse Sentrix-6 BeadChip. Arrays were normalized 
and analyzed with Rosetta Resolver.
Sciatic nerve sample
The sciatic nerve was obtained bilaterally immediately after death (n = 1 in each group; 
female; 16 months). The proximal part of the nerve was snap-frozen in chilled isopentane at
- 140 °C, and the distal end was fixated in 2% Glutaraldehyd in 0.1M Na-cacodylate, postfixed 
in 1% K-hexacyanoferrat(II).3H20 in 1% Osmium Tetroxide - stained with 4% uranylacetate for 
30 min. and lead citrate for 10 min. For each mouse, images of ten representative electron 
microscopic fields of view were recorded using a JEM-1200EX II (Jeol Europe B.V., The 
Netherlands) microscope at low magnification setting (1.2k -  1.5k). Image acquisition was 
performed using digital imaging plate technology for TEM via the Dibis Micron Vario (Ditabis, 
Pforzheim, Germany). This system uses reusable image plates which are exposed in the TEM 
identical to classical photo negatives. Plates were read out digitally in a separate system (read 
out pixel size 17.5 x 17.5 ^m2). Resulting images (size 4910 x 4340 pixels) were stored as 
uncompressed tiff files. An image of a carbon replica specimen (2160 lines/mm line replica; 
EMS, Hatfield, UK) was recorded prior to acquisition of images for each mouse. Images were 
analyzed using KS400 image analysis software (Zeiss GMBH, Germany). This software uses an 
adaptive digital region growing algorithm to automatically recognize individual myelinated 
axons. The inner and outer diameter of each myelinated axon was measured as described 
previously for the muscle fibres; this implies measurement of the minor axis of the ellipse as 
the diameter.24
Statistics
The behavioral data (long term motor assessment and function muscle strength 
measurement) were recorded in a SPSS database (SPSS version 16.0, SPSS Inc, Chicago, IL, 
USA). Statistical analyses were performed using a Student's t-test for normally distributed 
continuous variables and a Mann-Whitney U test for skewed continuous variables.
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Differences in density of staining of the muscle biopsies with the various antibodies 
were calculated with the Mann-Whitney-U test. For the analysis of muscle fibre diameters, 
histograms were produced. The 5th and 95th percentiles of muscle fibre diameter in WT 
mice were calculated. Subsequently, the percentage of fibres below this 5th and exceeding 
the 95th percentiles were determined for each mouse biopsy. Percentages in Tnxb KO mice 
were compared with WT mice (Mann-Whitney U-test).
Histograms of myelinated fibre diameters were produced. Significance of observed 
differences between distributions were calculated using the non-parametric two-sample 
Kolmogorov-Smirnov test and the Mann-Whitney U test (central tendency). To find 
differentially expressed genes ANOVA analyses were performed on the gene expression data 
in Rosetta Resolver v4 (P < 0.001, Bonferroni correction). Differentially expressed genes were 
exported and, functional annotation was determined using WebGestalt software.27 A 
hypergeometric test was performed with the whole gene list as a reference (P < 0.01) to find 
functional groups that were overrepresented in this gene list. Biosemantic analysis was 
performed using Anni 2.0 to find other disorders in which similar genes were shown to be 
involved in the disease mechanism as in the Tnxb KO mice.28
Results
Long term m otor activity assessment
As expected, long term assessment of motor activity showed the longest distance moved 
during the first night and day, and an obvious day-night rhythm for all parameters. Although 
the Tnxb KO mice tended to move more at nighttime, no statistically significant differences 
between de WT and Tnxb KO mice in hourly walking distance, duration of immobility, 
duration of mobility, or duration of strong mobility were found at six or 16 months of age 
(Figure 1).
Functional muscle strength measurement
Tnxb KO mice showed statistically significantly more paw-fall-through events than the WT 
mice at three, six, and sixteen months of age. Furthermore, hang-time duration was shorter 
in Tnxb KO mice than in WT mice at all ages; but these differences were not statistically 
significant (Table 1).
Observation during these tests showed that four of the eight Tnxb KO mice at 16 months 
of age hardly moved spontaneously during both trials of the paw-fall-through test. They only 
slowly moved around in a square of approximately 5 x 5 cm, whereas the WT and other Tnxb 
KO mice moved around the whole mesh hardware cloth (60 x 40 cm). These four KO mice 
had less than four paw-fall-through events in both trials. Hence, this lack of spontaneous
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Figure 1 Results of long term assessment of motor activity showed no statistically
significant differences between the wildtype (WT) and tenascin-XB knockout 
(Tnxb KO; KO) mice in hourly walking distance, duration of immobility, duration of 
mobility, or duration of strong mobility at six or 16 months of age. No statistical 
significant differences between Tnxb KO en WT mice were found.
A and B: Graphic representation o f hourly distance moved at six and 16 months o f age (in cm), w ith 
standard errors indicated w ith  error bars. C, D, and E: Graphic representation o f hourly duration o f 
immobility, mobility, and strong m obility at 16 months o f age (in sec), w ith  standard errors indicated 
w ith  error bars.
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Figure 1 Continued.
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movement on the screen in Tnxb KO mice might have negatively influenced the results of the 
paw-fall-through test. Furthermore, results of the hang-time test might have been negatively 
influenced by the heavier weight of WT mice: at 16 months of age the mean weight was 30.3 
g (SD 4.8) in WT mice and 23.1 g (SD 1.5) in the Tnxb KO mice (P = 0.03). The two WT mice with 
a weight > 32 g indeed had a hang-time duration < 120 seconds.
Table 1 Results of hang-time and paw-fall-through test.
Tnxb KO mice showed statistically significantly more paw-fall-through events than 
the WT mice at three, six, and sixteen months of age. Hang-time duration was 
shorter in Tnxb KO mice than in WT mice at all ages; but these differences were not 
statistically significant.
3 m onths 6 m onths 16 m onths
Num ber WT Tnxb KO WT vs KO WT Tnxb KO WT vs KO WT mice Tnxb KO WT vs KO
o f events / mice mice P-value mice mice P-value n=8 mice P-value
duration n=8 n=8 n=8 n=8 n=8
PFT 1 min: 2.3 4.1 0.004# 2.3 3.3 0.041# 3.9 5.1 0.045#
mean (1.2) (1.0) (0.7) (1.0) (1.1) (1.3)
(SD)
HT dur (ms): 120 59 n.s.* 120 93 n.s.* 120 93 n.s.*
median (75-120) (30-120) (51-120) (24-120) (42-120) (34-120)
(range)
#: S tu d en t's  t-te s t. *: M a n n -W h itn e y -U  test. PFT 1 m in: n u m b e r o f  p a w - fa ll- th ro u g h  even ts  in 1 m in. HT dur: 
hang - h a n g tim e  d u ra t io n . n.s.: n o t s ta tis tic a lly  s ig n ifica n t.
Quadriceps muscle samples
Histological analysis of quadriceps muscle biopsies of the Tnxb KO mice revealed myopathic 
changes consisting of increase of fibre size variation and increase of internal nuclei (Figure 2A). 
The number of muscle cells with internal nuclei was higher in Tnxb KO mice than in WT mice 
(mean percentage of muscle cells with internal nuclei: 0.76 vs. 5.5; P < 0.001)(Figure 2B). 
Furthermore, Mann-Witney U test in fibre size diameter revealed that the percentage of 
muscle fibres in the Tnxb KO biopsies with a diameter below the p5 of WT mice did not differ 
from the percentage in WT mice, and that the percentage of muscle fibres with a diameter 
above p95 of WT mice was higher in Tnxb KO mice than in WT mice (P = 0.012)(Figure2C).
For each antibody the sections showed a consistent pattern of staining intensity. 
Staining of the collagens I, III, and V, elastin, and laminin a2 did not differ between the two 
groups. Staining of collagen VI was less in Tnxb KO mice than in WT mice for perimysial 
staining (P = 0.003); and endomysial collagen VI staining tended to be less (P = 0.051). The
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sections of the Tnxb KO mice stained negatively for the TNX-antibody as expected, whereas 
the WT group showed TNX staining of endo- and perimysium. In general, endomysial 
staining was less than perimysial staining for collagen I, III, V, and VI in both groups, and for 
TNX in the WT mice. In contrast, laminin a2 staining was more pronounced in the endomysium 
than in the perimysium (semi-quantitative data: Table 2), compatible with the transmembrane 
localization of the two major laminin a 2 receptors: the dystrophin-glycoprotein complex and 
integrins (Staining with anti TNX and anti laminin a2 antibodies: Figure 3; Staining with 
antibodies against collagens I, III, and V, VI, elastin, laminin a2, and TNX: Supplemental figure 1 
in original online publication).29
Table 2 Semi-quantitative evaluation of immunohistochemical staining of ECM molecules 
in muscle.
Immunohistochemical staining of the collagens, laminin, and elastin did not 
differ between the two groups, except collagen VI staining of the perimysium.
The sections of the Tnxb KO mice stained negative for the TNX-antibody as 
expected, whereas the WT group showed TNX staining of endo- and perimysium. 
Endomysial staining was generally less than perimysial staining for collagen I, III,
V, VI, and elastin in both groups, and for TNX in the WT mice. In contrast, laminin 
staining was more pronounced in the endomysium than in the perimysium.
Collagen I Collagen III Collagen V Collagen VI Laminin Elastin Tenascin-X
E P E P E P E P E P E P E P
WT overall 
score
0.9 2.6 1.6 2.8 2.0 2.6 2.2 3.3 2.6 2.0 0.8 2.4 0.8 1.7
Tnxb KO 
overall score
1.0 2.7 1.8 2.9 2.3 2.6 1.6 2.3 2.5 2.2 0.7 2.2 0 0
Differences 
in staining *
n.s. n.s. n.s. n.s. n.s. n.s. n.s 0.003 n.s. n.s. n.s. n.s. P < P < 
0.001 0.001
M ean score o f  d e n s ity  o f  s ta in in g , based u p o n  s e m i-q u a n tita t iv e  e v a lu a tio n : 0 =  absence ; 1 =  lim ite d  s ta in in g ; 
2 =  m o d e ra te  s ta in in g ; 3 =  co n s id e ra b le  s ta in in g ; 4  =  s tro n g  s ta in in g ; E =  e n d o m y s iu m ; P =  p e r im ys iu m .
*: M a n n -W h itn e y -U  test. n.s.: n o t s ta tis tica lly  s ig n ifica n t.
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Figure 2 Histological analysis of quadriceps muscle biopsies of the Tnxb KO mice revealed 
myopathic changes consisting of increase of fibre size variation and increase of 
internal nuclei (n = 6 in both groups; of each mouse muscle biopsies were taken 
bilaterally).
A: HE staining o f biopsy o f one o f the Tnxb KO mice (male, eight months), showing myopathic features 
consisting o f increased number o f internal nuclei and increased variance o f fibre diameter. Bar = 0.05 
mm = 50 |jm . Normally, nuclei in muscle cells are located peripherally and immediately below the 
sarcolemma. Internal nuclei are nuclei that are located anywhere else: the arrow points to  one o f the 
internal nuclei. This is a selection o f an area in which these myopathic features were most pronounced 
(lower image). In comparison, a normal biopsy o f a WT mouse (male, eight months) is presented above. 
B: Percentage o f muscle cells w ith  internal nuclei in WT and Tnxb KO mice. The outliers are indicated as 
* and °. The Mann-Whitney U Test was used to  test the differences, which showed that internal nuclei 
were more frequent in Tnxb KO mice (P < 0.001). C: Mann-Witney U test in fibre size diameter revealed 
that the percentage o f muscle fibres in the Tnxb KO biopsies w ith  a diameter below the p5 o f WT mice 
did not differ from the percentage in WT mice, and that the percentage o f muscle fibres w ith  a diameter 
above p95 o f WT mice was higher in Tnxb KO mice than in WT mice (P = 0.012).The vertical lines indicate 
the 5th en 95th percentiles o f the diameters in WT mice.
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Figure 3 Staining with anti-TNX and anti-laminin a2 antibodies in WT and Tnxb KO mice 
(male, eight months).
Absence o f TNX staining in the Tnxb KO mice and equal staining o f laminin a2 TNX endomysial 
staining was less pronounced than perimysial staining for TNX in the WT mice, and laminin a2 
staining was more pronounced in the endomysium than in the perimysium in both WT and Tnxb 
KO mice. Bar = 0.1 mm = 100 jm .
anti-TNX antibodies anti-laminin antibodies
Gene expression profiling
The muscle function of Tnxb KO mice was further studied with genome-wide transcriptome 
analysis. Total RNA was isolated from quadriceps muscle of 8 months old WT (n = 6) and Tnxb 
KO mice (n = 6) and hybridized to Illumina Mouse Sentrix-6 BeadChips. ANOVA statistical 
analysis of the microarray data revealed 266 genes differentially expressed (P < 0.001, 
Bonferroni corrected). Of these 74 were downregulated and 192 were upregulated. 
(Supplemental table 1 in original online publication).29 Annotation of the genes with the 
Webgestalt software enabled the different genes to be classified according to function 
(Supplemental table 2 in original online publication).29 Table 3 shows a summary of the 
functional groups which are overrepresented in the list of differentially expressed genes in 
Tnxb KO mice (Cellular components: lysosome, ECM, and cell surface / Molecular function: 
carbohydrate binding, peptidase activity, and structural molecule activity. / Biological 
process: inflammatory response, proteolysis and vascular development). Striking is that the
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genes in these functional groups are mainly upregulated. The increased expression of matrix 
metalloproteinases (MMPs) was reported before in skin of Tnxb KO mice30 and is also observed 
in the muscles (MMP2, MMP3). The biosemantic analysis showed a list of muscular disorders 
in which similar genes were shown to be involved in the disease mechanism as in the Tnxb 
KO mice. These neuromuscular disorders are amyotrophic lateral sclerosis, nemaline 
myopathy, multiminicore myopathy, Charcot-Marie Tooth disease, Duchenne muscular 
dystrophy, and spinal muscular atrophy.
Table 3 Summary of the functional groups which are overrepresented in the list of 
differentially expressed genes in TNX KO mice.
Functiona l g ro u p  overrep resented N um ber o f 
genes
P-value
Cellular com ponent
Lysosome 10 6.72 E-06
Extracellular matrix 15 5.19 E-05
Cell surface 7 2.93 E-03
M olecular function
Carbohydrate binding 17 5.96 E-08
Peptidase activity 20 1.42 E-04
Structural molecule activity 14 8.75 E-03
Biological process
Inflammatory response 15 2.83 E-08
Proteolysis 24 6.83 E-06
Vascular development 8 1.80 E-03
Sciatic nerve sample
Electronmicroscopy of the sciatic nerve revealed many areas with lower density of the 
connective tissue fibrils in the endoneurium of Tnxb KO mouse in comparison with the WT 
mouse (qualitative evaluation; Figure 4A). Furthermore, a few signs of degeneration and 
regeneration were seen in the sciatic nerve of the Tnxb KO mouse. Histometry of the 
myelinated fibres of the sciatic nerve showed smaller inner and outer diameters in the Tnxb 
KO mouse (Outer diameters: Figure4B). In addition, results of the two-sample Kolmogorov- 
Smirnov test and Mann-Whitney U test showed that the diameter distributions and central 
tendencies differed significantly between the Tnxb KO mouse and the WT mouse for both 
inner and outer diameter (Table 4).
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Table 4 Diameter of myelinated fibres of sciatic nerve in TNX KO and WT mice.
Results of the two-sample Kolmogorov-Smirnov test and Mann-Whitney U test 
showed that the diameter distributions and central tendency differed significantly 
between the TNX KO mouse and the WT mouse for both inner and outer diameter.
D iam e te r o f  m ye lina ted  fib res
Myelinated fibres 
in WT mouse 
(n=320)
Myelinated fibres 
in TNX KO mouse 
(n=377)
Distribution  
shape difference*
Central 
tendency#
Inner diameter 2.3 (1.5-3.6) 2.1 (1.3-3.1) P = 0.01 P = 0.02
(median (p25 - 75) in |jm)
Outer diameter 4.2 (2.8-5.8) 3.8 (2.4-5.3) P = 0.02 P = 0.005
(median (p25 - 75) in jm )
*: T w o -s a m p le  K o lm o g o ro v -S m irn o v  test. #: M a n n -W h itn e y  U -test.
Discussion
The main findings of this study on the muscular phenotype of Tnxb KO mice are normal long 
term spontaneous locomotor activity, presence of mild functional muscle weakness, mild 
myopathic features on histology, and functional upregulation of genes encoding proteins 
involved in degradation and synthesis of the ECM in muscle. Additionally, the sciatic nerve 
specimen showed mildly reduced collagen fibril density of endoneurium between these 
fibres. Together, these findings point to mild changes in muscle function and composition, 
and possibly to altered endoneurium composition in Tnxb KO mice. Furthermore, the results 
of gene expression profiling suggest a possible pathophysiological role of TNX deficiency in 
myopathy in EDS. We will shortly discuss these findings below.
Tnxb KO mice performed less at the paw-fall-through test, whereas differences in 
performance on the hang-time test were not statistically significant. These differences may 
have been influenced by the higher weight and longer distances moved in WT mice; a 
higher weight may predispose to shorter hang-time duration, and the mice that move most 
on the mesh are at risk for more paw-fall-through events. If we had corrected for these 
parameters, differences between Tnxb KO en WT mice might have been larger. What causes 
this higher weight in WT mice at 16 months of age has not been investigated further; it might 
be due to increase of fat, muscle tissue, or body size, or due to water retention or differences 
in bone mass. Osteoporosis and osteopenia are reported in EDS,2 and it has been suggested 
that changes found in skin collagen also occur in bone collagen.31 Furthermore, the Tnxb KO 
mice tended to move slightly more during the long term spontaneous locomotor activity
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Figure 4 Electronmicroscopy of the sciatic nerve in a Tnxb KO mouse revealed zones 
with lower density of the connective tissue fibrils, signs of degeneration and 
regeneration of myelinated fibres, and smaller inner and outer diameters of 
myelinated fibres.
A: Electronmicroscopy o f the sciatic nerve revealed zones w ith  lower density o f the connective tissue 
fibrils in Tnxb KO mice (lower image) in comparison w ith  the WT mice (upper image). The enlarged box 
in both images magnifies the lower density o f connective tissue fibrils in Tnxb KO mice. Furthermore, 
more signs o f degeneration (asterisk) and regeneration were seen in the Tnxb KO biopsy. Bar = 1 |jm. 
The inner diameter (ID) and outer diameter (OD) o f the myelinated fibres have been indicated. 
B: Histogram o f outer diameter o f myelinated fibres shows a mild shift to  the smaller diameters in the 
Tnxb KO mouse. Diameters on x-axis represent the outer diameter o f myelinated axons, and the density 
on the y-axis represents the frequency o f the axons o f a specific diameter, normalized for the surface 
measured.
A
WT
mouse
Tnxb KO 
mouse
B
□  WT □  Tnxb KO
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task, but these differences were not statistically significant. Most likely, muscle strength is 
only mildly reduced in Tnxb KO mice, and this reduction does not interfere with spontaneous 
walking of mice held captive.
Histological analysis of the muscle biopsies revealed mild to moderate myopathic 
features in the majority of mice; this was confirmed by quantitative analysis of percentage of 
cells with internal nuclei and of variation of fibre size diameter. This was more pronounced 
than the myopathic features detected in muscle biopsies of TNX-deficient EDS patients.20 
This might be related to relatively old age of these mice (8 months for mice is late adulthood). 
The presence of even more pronounced myopathic features we detected in very old Tnxb KO 
mice (22 months; data not shown) supports this. A progression of myopathic features with 
ageing is also observed in other myopathies and muscular dystrophies.3233 Furthermore, no 
differences in collagen I, III, V, elastin, and laminin a2 staining were found, but perimysial 
collagen VI staining was less in Tnxb KO mice. This is compatible with previous findings of 
Minamitani et al.3435 and our previous observation in a patient with TNX-deficient type EDS.18
The results of gene expression profiling a significant upregulation of genes encoding 
structural ECM components as well as genes involved in synthesis and degradation of the 
ECM. This probably results from altered interstitial fibroblast function in muscle, which have 
been shown to contribute significantly to the deposition of the ECM in skeletal muscle.36 
These genes are, according to the available literature, also differentially expressed in various 
other myopathies such as nemaline myopathy (TPM2),37 and multiminicore myopathy 
(SEPN/).38 TNX deficiency in perimysium, and to a lesser extent in endomysium may play a 
role in the development of myopathic features and functional muscle weakness in Tnxb KO 
mice.
The sciatic nerve histology and electromicroscopy revealed mildly reduced diameter of 
myelinated fibres and reduction of collagen fibril density of endoneurium between these 
fibres. This might correspond with the presence of mild axonal polyneuropathy in 
TNX-deficient EDS patients.20 Clearly, this observation requires further investigation in a larger 
number of mice. Our findings are in contrast which the results of Matsumoto et al.,15 who 
showed that the thickness of myelin sheaths and the size of the individual axons in these 
mice appeared normal, and that the ultrastructure of the sciatic nerves of Tnxb KO mice were 
similar to those of WT mice. However, quantization of the number and size of sciatic nerve 
axons from wild-type and Tnxb KO mice in this study did show a trend toward smaller axons 
in Tnxb KO mice.15 The larger differences between Tnxb KO and WT mice in our study might 
be related to the older age of mice.
Tenascin-C (TNC), another member of the tenascin family is predominantly expressed in 
tendons and ligaments, peripheral and central nervous system, and the ECM of tumour 
stroma.39-41 TNC modulates adhesion of cells to fibronectin and can be classified as an 
adhesion modulating ECM protein. Reduced muscle strength in Tnc KO mice has been
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described, consisting of reduced grip strength and lower latency to fall on the wire hanging 
test.42 Another comparison can be made with lysyl hydroxylase-1 KO mice, a mice model of 
the kyphoscoliotic type of EDS.43 These mice show difficulty in locomotion, most likely due 
to laxity or dislocation of the joints, enhanced by general weakness of the muscles.43 
Neuromuscular function could also be studied in more detail in this mice model.
The results of this current animal study strengthen our recent finding of mild to moderate 
neuromuscular involvement in patients with various types of EDS.20 This consisted of axonal 
sensorimotor polyneuropathy in the TNX-deficient type and mixed myopathic-neurogenic 
or myopathic features on electromyography in all patients. Hence, with their mild muscular 
features, the Tnxb KO mice form a good fit to the mild neuromuscular phenotype in EDS 
patients.
Our study has several limitations. First, the use of animals of an advanced age raises 
doubt whether the abnormalities are of pathological or of biological interest. Furthermore, 
use of animals of different age and different gender for various investigations may complicate 
the interpretation of the results. However, due to its explorative design, these results could 
serve as a starting point for further physiological studies on muscle function in Tnxb KO mice.
To summarize, the muscular phenotype of Tnxb KO mice consists of mild muscle 
weakness with histological signs of myopathy and of increased turnover of the ECM in 
muscle. Furthermore, mildly reduced diameter of myelinated fibres and reduction of collagen 
fibril density of endoneurium may correspond with polyneuropathy in TNX-deficient EDS 
patients. Together, these results strengthen the clinical overlap of myopathies and inherited 
connective tissue disorders caused by ECM defects.18-25-44'45 They thus support the concept 
that a normal composition of the ECM is important for adequate functioning of muscle and 
maybe also of peripheral nerve. Furthermore, the results show that this mouse model can be 
used for further investigations on the influence of TNX deficiency on muscle and peripheral 
nerve function. Quantitative muscle function testing of isolated muscles and muscle groups 
will enable direct measurement of the influence of the ECM alterations on muscle function .46 
Eventually, this may lead to studies on treatment approaches such as training or pharmaco­
logical interventions, similarly as in a mouse model of collagen VI myopathies.47
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Muscle characteristics and altered myofascial 
force transmission in tenascin-X deficient mice, 
a mouse model of Ehlers-Danlos syndrome
Adapted from:
Huijing PA, Voermans NC, Baan GC, Busé TE, van Engelen BG, de Haan A.
J Appl Physiol. 2010;109:986-95.
Abstract
The Ehlers-Danlos syndrome (EDS) is a group of inherited connective tissue disorders caused 
by defects in collagens or tenascin-X (TNX). Muscle involvement can be expected based on 
interactions between muscle and extracellular matrix molecules; however, muscle function 
has not yet been investigated quantitatively. This study aims to investigate effects of TNX 
deficiency on muscular characteristics in Tnxb knockout (KO) mice, a mouse model of EDS. 
This study focused on both intra- and intermuscular aspects of muscle force. Intramuscular 
aspects were studied during isometric contractions of isolated (maximally dissected) 
muscles, when the muscle-tendon complex length is fixed. In this situation, the actual active 
length of the muscle fibres is dependent on the properties of the series elastic components, 
consisting of the network of endo-, peri-, and epimysium, and of the tendon. Study of the 
intermuscular aspects of muscle force (in minimally dissected muscles) has proved to be an 
effective method to investigate myofascial force transmission.
At lower muscle lengths maximally dissected medial gastrocnemius muscle-tendon complex 
of Tnxb KO mice showed lower active force, lower maximal rate of relaxation, and longer time 
delay between first stimulation pulse and initial force rise, supporting the hypothesis that 
relatively more slack needs to be taken up as well as more elastic length changes occurs. In 
addition, study of the minimally dissected lower leg muscles shows that TNX deficiency 
strongly affects the mechanical interaction between antagonistic as well as synergistic 
muscles. This is consistent with the concept of altered myofascial force transmission due to 
increased compliance o f myofascial components.
Altered properties of the force transmission pathways of muscle (being either part of the 
myotendinous or myofascial pathways) due to TNX deficiency directly affect muscle function 
in Tnxb KO mice. In parallel, such effects are likely to contribute to muscle weakness 
experienced by patients with EDS.
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Introduction
The Ehlers-Danlos syndrome (EDS) is a group of inherited connective tissue disorders caused 
by defects in metabolism of fibrillar collagens. It presents with joint hypermobility, skin hy­
perextensibility, abnormal scar formation, easy bruising, and tissue fragility.12 EDS is caused 
by mutations in the genes encoding collagen I, III and V, and tenascin-X (TNX), molecules 
which are known to be abundantly expressed in the extracellular matrix (ECM).1-3
Primary muscle involvement in EDS can be expected based on interactions between 
muscle and these ECM molecules.4 In a recent case study we indeed demonstrated reduced 
muscle function in two EDS patients, which could not be attributed to increased tendon 
compliance or disuse.5 Subsequently, we found considerable clinical muscle weakness in 
patients with various types of EDS accompanied by mild histological myopathic changes.6
This study aims to investigate the effects of TNX deficiency on muscular characteristics in 
Tnxb knockout (KO) mice, a mouse model of EDS. Various intra- and intermuscular aspects of 
muscle force may be affected by TNX deficiency. Intramuscular aspects can be studied during 
isometric contractions of isolated muscles. During an isometric contraction the muscle-tendon 
complex length is fixed, but the actual active length of the muscle fibres is dependent on the 
properties of the series elastic components, consisting of the network of endo-, peri-, and 
epimysium, as well as of tendon. Similarly, these properties affect the rate of length change of 
the fibres during the initial phase of force generation, and hence influence the rate of force 
building up. These intramuscular aspects of muscle force may be affected by TNX deficiency 
via altered visco- elastic properties of the connective tissue within muscle and tendon.
Study of the intermuscular aspects of muscle force has proved to be an effective method 
to investigate myofascial force transmission.7 This concept is based on the ability of muscle 
to transmit forces between muscle fibres and connective tissue within muscle (endo- and 
perimysium) and between individual muscles and connective tissue between muscles 
(epimysium, fascia, septum, neurovascular tract). As a result, morphologically defined 
muscles are not independent actuators, but are capable of mechanical interaction via their 
connective tissue structures.8-10 As such, force exerted at the origin of a muscle within its 
natural context of connective tissue is not necessary equal to the force exerted at its insertion, 
since additional loads initiated in neighbouring muscles act on the muscle. Hence, the 
difference in forces measured at the muscle's origin and insertion is an unequivocal indication 
for net epimuscular myofascial force transmission.9 Furthermore, as epimuscular myofascial 
force transmission is mediated by surrounding connective tissues, the fraction of force 
transmitted myofascially has been found to depend on muscle length and its position 
relative to its surrounding structures.11
In view of the above, we hypothesize that TNX deficiency affects not only intramuscular 
aspects of muscle force via altered visco-elastic properties of the connective tissues; it also
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reduces the stiffness of myofascial pathways, causing pathological changes in force 
transmitted this way. The current study therefore aims to investigate directly the effect of 
TNX deficiency on muscle characteristics in a mouse model of TNX-deficient type EDS.12 To 
do so, this study combines measurement of both intramuscular and tendon aspects (i.e. 
force characteristics of the maximally dissected medial gastrocnemius muscle tested in 
isolation; series A) and intermuscular aspects (i.e. force characteristics of the triceps surae 
muscle and anterior crural muscles without major dissection to detect changes in mechanical 
interaction between these muscle groups; series B). Contractile responses from Tnxb KO mice 
will be compared with those from wild-type (WT) mice.
Material and methods
The experimental design was approved by the Ethics Committee for Animal Experimentation 
of the Vrije Universiteit Amsterdam.
Tenascin-XB knockout mice
Tnxb KO mice were obtained as previously reported by inactivating murine Tnxb.1213 The 5' 
end of the gene was targeted, thus replacing the first five coding exons with lacZ and a 
neomycin resistance cassette. Correct targeting of Tnxb was confirmed by Southern blotting 
and, as expected, Tnxb KO mice lacked both TNX mRNA and protein.12 Experiments were 
performed on two groups of Tnxb KO mice that had been crossed back with six generations 
of C57BL/6N mice.
Series A: Eight female Tnxb KO mice (mean body mass of 39.3 g., SE = 0.6 g.) and seven female 
WT C57BL/6 (WT; mean body mass of 41.6 g., SE = 1.5 g.) mice were tested (age 12 - 14 months). 
Series B: Six female Tnxb KO mice (mean body mass of 30.2 g., SE = 0.91 g.) and six female WT 
C57BL/6 (WT) mice were used as a control (mean body mass 31.2 g., SE = 2.49 g.) (age 12 - 14 
months).
All mice were deeply anaesthetized by administration (i.p. 0,1 ml /10g g body mass) of a 
solution of fentanyl citrate (0,079 mg/ml) and fluonizole (2.5mg/ml) (Hypnorm®) and 
midazolam (1.25 g/ml)(Dormicum®). Additional doses of were given as necessary ( 0.05 ml or 
0.10 ml, i.p.). During surgery and data collection, animals were placed on a heated water pad 
of approximately 37 °C to prevent hypothermia.
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Table 1 Biom echanical concepts in this study.
C oncept A b b re v ia tio n
(unit)
D escrip tion
Optim um  length
(mm)
The muscle's length at which the length o f the muscle's 
sarcomeres are, on average, on the plateau o f the length-force 
curve; this represents the length at which actin and myosin have 
a maximal overlap.
Active slack length Active slack length is the lowest muscle length at which active 
force approaches zero. At any length be low  that length the 
active muscle is slack. Below active slack length even a fully 
active muscle does not exert force on its outside world, and 
the distance between its proximal and distal end may not 
adequately reflect its true length due to  buckling o f tissues.
Muscle slack(ness) A characteristic o f the series elastic com ponents o f muscle; it 
reflects the necessity to  stretch the series elastic components 
minimally before they can transmit forces; this is referred to 
when it is mentioned that a muscle needs tim e to  take up 
slackness before shortening once contraction has started.
Passive force Fmp
(mN)
The force required to  stretch a relaxed muscle to  a given length.
Active muscle force Fma
(mN)
Total force minus passive force; this estimates the com ponent o f 
force that is related to  the attachment o f cross bridges.
Normalized active 
force
%Fma Active force at a given length as a percentage o f active force at 
optim um  length (£o).
Total force Fmt
(mN)
The final force that a muscle attains follow ing stimulation. This 
force includes the passive force that existed prior to  stimulation 
and the com ponent o f force that is generated in response to 
the stimulus.
Optim um  force Fo
(mN)
Maximal active muscle force (at l o ) in a length-force curve.
Active peak force peakFma
(mN)
Maximal active muscle force in a force-time curve for each 
given length; these peak forces at a certain length are plotted 
in the length-force curve. The active peak force at £o equals the 
optim um  force.
Normalized maximal 
rate o f relaxation
%MRR 
(m N/ms)
Maximal rate o f relaxation as a percentage o f the rate o f relaxation 
after the first contraction (in isometric fatigue protocol); after 
stimulation w ith  150 Hz (in frequency-force measurements); or 
after contraction at ¿o (in length-force measurements).
Normalized maximal 
rate o f force rise
%MRFR Maximal rate o f force rise as a percentage o f the rate o f force rise 
after the first contraction (in isometric fatigue protocol); after 
stimulation w ith  400 Hz (in frequency-force measurements); or 
after contraction at ¿o (in length-force measurements) (mN/ms).
Maximal power 
production
(mW) Highest power (muscle force x velocity) obtained from the fitted 
power - velocity curve.
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Surgical procedures
Dissection o f  sciatic nerve
The sciatic nerve was dissected free from surrounding tissues and severed as proximally as 
possible. Subsequently, all of its branches except the branch to the medial gastrocnemius 
(seriesA) or the common peroneal and tibial nerves (series B) were cut. To be able to clamp the 
femur, small insertions were made in the musculature located anteriorly and posteriorly of 
the femur, and a metal clamp was inserted and tightened.
Dissection o f  muscles
Series A: Maximally dissected medial gastrocnemius muscle
The medial gastrocnemius muscle (GM) was fully dissected from the surrounding tissue, with 
the exception of blood supply and innervating nerve.
Series B: Anterior crural and Triceps surae muscles
For this segment of the experiments, dissection of the lower leg was minimized to free the 
distal tendons of target muscles. Only limited fasciotomy was performed distally to expose 
the distal tendons of the tibialis anterior muscle (TA), extensor hallucis longus muscle (EHL) 
and extensor digitorum longus muscle (EDL), and to sever the retinaculae (i.e. the transverse 
crural ligament and crural cruciate ligament). Otherwise the connective tissue at the muscle 
bellies and tendons was left intact. The distal tendons of EDL were tied together (Ethilon 
surgical suture) and severed distally of the knot. Also, the distal tendons of TA and EHL were 
tied (polyester yarn) and severed from their insertions. Below, this complex will be referred to 
as TA+EHL complex. A small piece of the epicondylus lateralis comprising the origin of the 
EDL muscle was cut from the femur. Similarly, a small piece of bone was cut, comprising the 
insertion of the triceps surae muscle (TS) via the Achilles tendon on the calcaneus bone. All 
tendons described were tied to kevlar threads (4% elongation at a break load of 800 N), that 
were in turn attached to rods for later connection to a force transducer. In the reference 
position (corresponding to a knee angle of 100° and ankle angle of 180° plantar flexion), the 
original position of the proximal tendon of EDL on the epicondylus lateralis of the femur was 
marked by placing corresponding markers on the proximal EDL tendon and lateral collateral 
ligament. The foot was firmly attached to a plastic foot plate (Figure 1A and 1B).
Experimental set-up, conditions, and treatm ent o f data
Series A: Maximally dissected medial gastrocnemius muscle
The distal tendon of the GM (length ~ 4mm) was connected to a force transducer of an 
isovelocity measuring system .14 The attachment of the proximal tendon was left intact. The 
femur was fixed to the measuring system. Length changes of the GM tendon complex were 
induced with a computer-controlled servomotor connected to a lever on which the force
186
transducer was mounted. Contractions were induced by electrical stimulation using a 
constant current stimulator. Electrical pulses (width 50 s^) were applied to the sciatic nerve 
with a constant current (1 mA), being high enough to fully activate all muscle fibres. The 
muscle temperature was maintained at 34 -  36 °C with a water-saturated airflow around the 
muscle, which at the same time kept the muscle moistened.14 Force and length signals were 
digitized (1 - 5 kHz) and stored on disc. At the end of the experiment, the medial gastrocnemius 
muscles were excised and weighed. Thereafter, the mice were humanely killed with an 
overdose of anaesthesia.
Muscle optimum length was first estimated using a few twitch contractions (one per 
minute). (Tetanic) optimum length (£o) was subsequently determined using only 3 -  4 tetanic 
contractions (stimulation frequency 150 Hz, duration 150 ms). About 10 min later, the 
following series of contractions started. Duration of a single pulse in all experiments was 50 s^. 
Length-Force protocol
Muscles were stimulated isometrically in random order at various lengths (steps of 0.5 mm) 
between i o-4  and o^+2 mm for 150 ms with a stimulation frequency of 150 Hz with >2 min 
rest intervals to prevent fatigue.
Stimulation frequency
Contractions were performed at £o using the following stimulation frequencies 25, 50, 75, 100, 
250 and 400 Hz and pulse duration of 50 s^ with durations long enough to allow the muscles 
to reach their peak force at each particular frequency. Between the contractions there was 
at least 2 min rest.
Force-Velocity protocol
Contractions were performed during which the muscles were allowed to shorten at different 
constant velocities (at random; 0, 20, 30, 40, 50, 75, and 100 mm/s). Just before the start of the 
contraction, the muscle was (passively) stretched to 0.5 mm over i 0. During the initial part of 
the contraction, the length of the muscle was kept constant until the (increasing) force had 
reached the level that was estimated to be the force that could be sustained during the 
shortening at the imposed velocity. In this way, the measured force was constant when the 
muscle passed £o during shortening.15
Hence, the velocity of the length change of the muscle tendon complex is also the 
velocity of shortening of the muscle fibres, since no length change occurs in the series elastic 
elements at constant force. The stimulation frequency used was 400 Hz, except for 
contractions with shortening velocities of 0 and 20 mm/s, where 200 Hz was used. These 
frequencies were high enough to obtain maximal forces at all shortening velocities. After 
each contraction, there was at least 2 min rest.
Fatigability protocol
A series of 20 repeated isometric contractions was induced at £o (duration 150 ms, one 
contraction every 500 ms, and stimulation frequency 150 Hz).
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Data management
From the isometric force traces the following parameters were calculated: Active peak force 
(peak Fma; mN) was taken as the highest force minus the passive force. The maximal rates for 
force rise (%MRFR) and relaxation (%MRR in mN/ms) were taken as the maxima and minima 
of the differentiated force signal at the beginning and end of the contraction, respectively. 
The above data were normalized for the data obtained 1) at £o to study the influence of 
length, 2) at a stimulation frequency of 250 Hz (for Fma) and 400Hz (for MRFR and MRR) to 
study the influence of stimulation frequency and 3) to the first contraction of the series to 
study the fatigability and all data are presented as percentage. The time (ms) between the 
first stimulation pulse and the increase of force above 2% of the maximal force was 
determined as time needed to take up the slack of the muscle. For the shortening 
contractions, the force was obtained when the muscle passed £o. Power was calculated by 
multiplying the force by the imposed velocity (mW). For each muscle maximal power was 
obtained from the fitted curve through the power-velocity data points.
Series B: Anterior crural and Triceps surae muscles
The animal was mounted in the experimental set-up, at a knee angle of approximately 110 °, 
(measured post-experimentally in images to be equal to mean ± SE 111.8 ° ± 1.4 ° and 111.8 ± 
5.1 ° for the Tnxb KO and WT group respectively). The foot, attached to a plastic plate, was 
attached to a rigid frame with the ankle in extreme plantar flexion to create room for free 
passage of the distal tendons of EDL and TA+EHL at the ankle. The distal tendons of TA+EHL 
and EDL as well as the proximal EDL tendon were connected to force transducers 
(ME-MeBsysteme GmbH, Germany, compliance of 0.025 mm/N) mounted on single-axis 
micro-positioners. Also the kevlar thread attached to TS distal tendons was attached to a 
force transducer. The sciatic nerve was placed on a pair of silver electrodes and prevented 
from dehydration by covering it with paper tissue saturated with isotonic saline and a thin 
piece of latex.
Ambient temperature (22 ± 0.5 °C) and air humidity (70 ± 2%) were kept constant by a 
computer-controlled air-conditioning system (Holland Heating, Waalwijk, the Netherlands). 
Muscle and tendon tissue was further prevented from dehydration by regular irrigation with 
isotonic saline. Before acquiring length-force data, EDL was preconditioned by isometric 
contractions at alternating high (£o) and low ( l o - 3) lengths, until active forces at low length 
were reproducible (i.e. effects of previous activity at high length are minimized).16 The 
proximal EDL tendon was set at a position 1 mm distal of the marker position on the femur 
(i.e. shorter muscle). Throughout the experiment, the proximal tendon of EDL was kept at this 
position. The EDL distal tendon was set at 1 mm below its optimum length and kept at that 
position during the experiment. Also for TS, as well as TA+EHL temporary estimates of 
optimum force (i.e. the highest active force measured as a function of length) and optimum
188
Figure 1 Experimental set-up of the experiments.
A: Experimental set-up o f series A: Maximally dissected medial gastrocnemius (GM):
The sciatic nerve was dissected free from surrounding tissues and severed as proximally as possible. 
Subsequently, all o f its branches except the branch to  the GM were cut. To be able to  clamp the femur, 
small insertions were made in the musculature located anteriorly and posteriorly o f the femur, and a 
metal clamp was inserted and tightened. Subsequently, the GM was fully dissected from the surrounding 
tissue, w ith  the exception o f the blood supply and the innervating nerve.
B: Experimental set-up o f series B: Minimally dissected Anterior crural and Triceps surae muscles: a 
lim ited fasciotomy was performed distally to  expose the distal tendons o f the tibialis anterior muscle 
(TA), extensor hallucis longus muscle (EHL) and extensor d igitorum  longus muscle (EDL), and to  severe 
the retinaculae. The distal tendons o f EDL were tied together and severed distally o f the knot. Also, the 
distal tendons o f TA and EHL were tied. (TA+EHL complex), severed from their insertions and attached 
to  the force transducer. Also the proximal EDL tendon was attached to  a force transducer. The lines o f 
pull o f EDL, TA+EHL and TS muscles were aligned w ith  the line o f pull o f their respective force 
transducers. The sciatic nerve was placed on a pair o f silver electrodes was to  activate the muscles o f 
the lower leg.
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B
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length (the length of occurrence of the highest active force) were estimated. These values 
were used only during the execution of the experiment.
Length-force protocol
During measurement of TS length-force characteristics, muscle-tendon complex length of 
TA+EHL complex was kept relatively short (i.e. on the ascending limb of its length force 
curve). Initially this length corresponded to an active force of approximately 1/3 of optimum 
force (1/3 Fmao). Similarly, for measurement of the TA+EHL length-force characteristics, TS 
muscle-tendon complex length was not changed and kept at a length initially corresponding 
to an active force of approximately 1/3 of optimum force. Therefore, if no myofascial muscular 
interaction would occur one would expect TA+EHL and TS muscle forces respectively to 
remain constant during measurements of length-force characteristics of its antagonistic 
muscle group.
Prior to excitation of the sciatic nerve, all muscles were brought passively to the desired 
lengths by moving the distal positioners (Muscle to be manipulated; stepwise per 0.5 mm; 
other muscles at length corresponding to that yielding an active force of approximately 1/3 
of optimum force.) The imposed length change was read from the micromanipulator to the 
nearest 0.1 mm. Post-experimentally changes in muscle-tendon complex length are 
expressed as deviation from optimum length. All muscles were activated simultaneously by 
supramaximal stimulation of the sciatic nerve with a constant current (< 3 mA) and a 
stimulation frequency of 100 Hz (pulse width 0.5 ms). Two twitches were evoked, followed by 
a tetanic contraction of 300 ms. For a typical example of force data collected see Figure 2. 
Timing of stimulation and analog-to-digital (A/D) conversion of force data (12-bit A/D 
converter, sampling frequency 1000 Hz) was controlled by a special purpose microcomputer. 
After each tetanic contraction, the muscles were allowed to recover near active slack length 
for 2 minutes. Passive isometric force was measured prior to the tetanic contraction and total 
force was measured at a point during the final quarter of the tetanic force plateau.
Treatment of data
Passive muscle force (Fmp), as a function of muscle tendon complex length, was fitted with 
an exponential curve using a least-squares criterion:
y = exp (ax + b) + C,
where y represents passive muscle force, x represents muscle-tendon complex length and a, 
b and C are fitting constants. Active muscle force (Fma) was estimated by subtracting from 
total force (Fm) actually measured the passive force (Fmp) for the appropriate muscle length, 
calculated using the fitted exponential function. Active length-force data thus obtained 
were then least square fitted applying a stepwise polynomial regression procedure (see 
section on statistics):
y = b0 + b1x + b2x2 + .... bnxn ,
190
where y represents active muscle force, x represents active muscle length and b0 through bn 
are fitting constants. For TS, as well as TA+EHL, optimum length of the muscle-tendon 
complex (4 ) to be used in further analysis was defined, for each individual muscle, as the 
muscle length at which the fitted active force curve showed a maximum. TS and TA+EHL 
distal active slack lengths were estimated by selecting data at lower muscle lengths (Fma < 
0.3 x Fmao) and extrapolated using the fitted curve;
y = exp (b0 x + b1) + b2 , 
where y represents muscle active force, x represents active muscle force length and b0 
through b2 are fitting constants.
Similar polynomial fitting procedures were applied for forces exerted in the active and 
passive states by EDL at its proximal and distal tendons, as well as TS and TA+EHL distal forces 
in the case where they were not lengthened. For EDL, the differences in passive and active 
force exerted at the distal and proximal tendon (AFmp EDL(Fdist - Fprox) and AFma EDL(Fdist
- Fprox) respectively) were calculated by subtracting proximal from distal force as determined 
from the polynomials. For all forces studied and with use of the selected polynomials, mean 
and standard errors of active and passive muscle force were calculated. This was done so for 
given deviations from respective optimum lengths of muscles that had been changed in 
muscle - tendon complex length to measure it length-force characteristics.
Statistics
Series A: Maximally dissected medial gastrocnemius muscle
Possible differences in GM maximal isometric force, muscle mass and peak power between the 
Tnxb KO and the WT group were determined using the Student t-test. A repeated-measures 
analysis of variance was used to determine the differences in the effects of stimulation 
frequency, length and fatigue between the groups. The significance level was set at 0.05.
Series B: Anterior crural and Triceps surae muscles
For curve fitting of TS and TA+EHL active length-force data, the procedure starts with a first 
order polynomial and the power was increased up to the sixth order, as long as this yields a 
significant improvement of the statistical description of the length-active force data, as 
determined by one-way analysis of variance (ANOVA).17 Bivariate analyses of variance (SPSS 
version 14.0) were used to test for significance of main effects of muscle -  tendon complex 
length (repeated measurements) of both TS and TA+EHL, of the presence of TNX deficiency, 
and of their interaction. This was done for: 1) TS active and passive length force characteris­
tics; 2) TA+EHL active and passive length force characteristics; 3) distally exerted EDL active 
and passive forces; 4) proximally exerted EDL active and passive forces; and on 5) active and 
passive EDL proximo-distal EDL force differences. Additionally, for lengthening of TS, analyses 
of variance were used to determine effects of TS length: 6) on active and passive force
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Figure 2 A typical example of raw force data collected as a function of time.
Force at exerted at its distal tendon by the triceps surae com plex (TS). Force exerted at the tied distal 
tendons o f m. tibialis anterior and m. extensor hallucis longus (TA+EHL). Forces exerted by m. extensor 
d igitorum  longus at its proximal tendon (EDL prox) and at its tied distal tendons (EDL dist). Note 
differences between these tw o  force tracings that indicate epimuscular myofascial force transmission 
between EDL and its surroundings. For TS and TA+EHL forces refer to  left y-axis (drawn in black) and for 
EDL force to  the right y-axis (drawn in grey). All muscles were activated maximally w ith  all m otor units 
recruited. Approximate tim ing o f stimulation is provided on the line inserted just above the x-axis.
0.5 
0.4
0 .3  
0.2
0.1 
0.0
0 2 4 6 8 10 12 
time (s)
exerted distally by TA+EHL while kept at unchanged relatively short muscle tendon complex 
length; and for lengthening of TA+EHL; and 7) on active and passive force exerted distally by 
TS, while kept unchanged relatively short muscle tendon complex length. In addition, t-tests 
were used to test for differences in distal active slack length of TS and TA+EHL.
Results
Series A: M axim ally dissected m edial gastrocnemius muscle
GM Muscle length
Maximal forces were not different between WT (1.74 ± 0.38 N) and Tnxb KO mice (1.47 ± 0.36 
N). Actual GM muscle belly length (excluding distal tendon length) measured at optimum
192
length was not different between the groups (12.85 ± 5.12 mm vs. 13.14 ± 0.69 mm for Tnxb 
KO and WT, respectively). Only at low lengths normalized active isometric force (%Fma) was 
significantly lower in Tnxb KO mice compared to WT mice (at £o-  4, £o-  3.5, and £o-  3; 
P = 0.030, P = 0.026, and P = 0.032 respectively) (Figure3A). At these low muscle lengths, the 
relaxation was slower in Tnxb KO mice as indicated by a significantly lower maximal rate of 
relaxation (%MRR) (at £o- 4, £o-  3.5, and £o-  3; P = 0.026, P = 0.022, and P = 0.038 respectively) 
(Figure3B). Note that although these differences seem small, the relative effects are substantial. 
Force and relaxation rate in Tnxb KO mice were ~ 65% of WT at £o - 3mm and ~ 46% at £o - 
3.5mm. Furthermore, the delay between the first stimulus pulse and the increase of force 
above 2% of the maximal active force (2%Fact) was significantly longer in Tnxb KO mice at 
short length ( £o- 4 and £o-  3.5; P = 0.025 and P = 0.026 respectively)(Figure 3C), indicating 
that relatively more slack is needed to be taken up at shorter lengths in Tnxb KO mice.
GM stimulation frequency
There were no significant differences between Tnxb KO mice and WT mice in isometric peak 
forces, normalized maximal rates of force rise, and normalized maximal rates of relaxation at 
any stimulation frequency applied at £o or at £o-  3.5 (data not shown).
GM Shortening velocity
No significant differences in force-velocity characteristics and maximal power production 
were found between Tnxb KO (18.2 ± 4.3 mW) and WT mice (20.9 ± 6.3 mW).
GM Isometric fatigue
The fatigue protocol lead to a similar reduction in force in Tnxb KO mice and WT mice (73.2 ± 
4.0% and 70.4 ± 5.1% respectively). There were no significant different changes in the maximal 
rate of force rise and maximal rate of relaxation between Tnxb KO mice and WT mice during 
the series of repeated isometric contractions.
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Figure 3 Effects of changes in muscle length on isometric force, maximal rate of relaxation 
and delay between stimulation and force increase in WT and Tnxb KO mice (Tnxb 
-KO).
Muscle length is expressed as deviation from optim um  length (^o). A: Normalized active isometric force 
is significantly lower at low lengths (¿o-  4 mm, ¿o-  3.5 mm, and ¿o-  3 mm) in Tnxb KO mice compared 
to  WT mice. B: Significantly lower maximal rate o f relaxation at these low  muscle lengths (¿o-  4, i o-  
3.5, and i o-  3 mm) C: Significantly longer delay between the first stimulus pulse and the increase o f 
force above 2% o f the maximal active force in Tnxb KO mice at short length ( i o-  4 mm and i o-  3.5 mm).
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Figure 4  Effect o f changes in m. triceps surae length on forces exerted by antagonistic
m uscles kept at constant length.
A: Active force (Fma) exerted by the m. tibialis anterior-m.extensor hallucis longus complex (TA+EHL) 
w ith  changing lengths o f TS: Normalized active TA+EHL force decreased substantially (by max. 80% o f 
initial force) as a function o f increasing TS length. The effect o f TNX deficiency is to  limit this TS length 
dependent decrease in normalized active force to  levels not exceeding 33% o f initial force. B: Proximal 
EDL active force (Fma prox) exerted by m. extensor d igitorum  longus (EDL) w ith  changing lengths o f TS: 
Proximal active force increases (max. increase > 0.1 N) as a function o f increasing TS length. This effect is 
still present but less pronounced in Tnxb KO mice. C: Distal active force (Fma dist) exerted by EDL with 
changing lengths o f TS: Distal EDL active force decreases as a function o f increasing TS length. This 
effect is still present but less pronounced in Tnxb KO mice. Al(m+t) is the symbol used to  indicate change 
o f muscle tendon com plex length expressed w ith  respect to  optim um  length.
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Series B: Anterior crural and triceps surae muscle forces
Effects o f  TS length change on forces exerted by antagonistic muscles a t constant length
(a) Effects on TA+EHL
ANOVA showed significant effects of TS length on active forces exerted by antagonistic 
muscles, while the length this complex (TA+EHL) was kept unchanged and relatively short. 
Normalized active force decreased substantially (by max. 80% of initial force) as a function of 
increasing TS length (Figure4A). ANOVA also indicated significant effects of TNX deficiency, 
but no significant interaction could be shown. The effect of TNX deficiency is to limit this TS 
length dependent decrease in active force to levels not exceeding 33% of initial force.
(b) Effects on EDL 
Proximal force
ANOVA showed significant main effects (i.e. TS length, TNX deficiency) on EDL proximal 
active force, as well as significant interaction. Note that proximal active force increases (max. 
increase > 0.1 N) as a function of increasing TS length. These effects are still present but less 
pronounced in Tnxb KO mice (Figure4B).
Distal force
ANOVA showed significant effect of TS length on EDL distal active force, as well as significant 
interaction of effects of TS length and TNX deficiency. Note that distal active force decreases 
as a function of increasing TS length (Figure 4C).
Proximo-distal EDL total force differences
This difference in force exerted in the proximal and distal tendons of EDL is indicative of net 
epimuscular myofascial force transmission between EDL and other muscular or non-muscular 
tissues. A positive difference (distal force exceeding proximal force), indicates that a net load 
is exerted on EDL in proximal direction. The force corresponding to this load is integrated 
into the force exerted in the distal tendon (see schematics inserted into Figure 5). For negative 
proximo-distal forces differences the reverse is the case. ANOVA showed significant effects of 
TS length on the EDL total proximo-distal force difference, as well as significant interaction of 
effects of TS length and TNX deficiency. Therefore, it is concluded that both TS length and 
TNX deficiency affect myofascial force transmission within the mouse lower leg (Figure 5A). 
At very low lengths (i.e. for TS £o < -4) a proximal load is exerted on EDL in both WT and Tnxb 
KO mice. The pattern of change of this difference varies substantially between WT and Tnxb 
KO mice: with increasing TS length in WT mice, the EDL force difference decreases rapidly to 
change sign (i.e. load direction, at approximately TS £o < -4) and this distally directed load 
increases substantially with further increasing TS length. For Tnxb KO mice, the proximo-distal 
EDL force difference deceases gradually (to DF = 0 at high TS length), thus not changing 
direction at all. It is concluded that TNX deficiency significantly affects myofascial force 
transmission, not only in the magnitude of the net myofascial load on EDL, but also with 
regard to the direction of loading (Figure 5). Comparison with Figure 4B and C shows that this
196
effect of the TNX deficiency is mediated predominantly by preventing a high increase in 
proximal EDL force at higher TS lengths.
F igure 5 Changes in proximo-distal extensor digitorum longus (EDL) force differences with 
changes in length of antagonistic or synergistic muscles.
A: Effect o f changing triceps surae (TS) muscle-tendon com plex length. B: Effects ofm .tibialis anterior-m. 
extensor hallucis longus com plex (TA+EHL) length. Al(m+t) is the symbol used to  indicate change of 
muscle tendon complex length expressed w ith  respect to  optim um  length. The EDL proximo-distal 
total force difference is plotted. Note that any such difference is indicative o f net myofascial force 
transmission between EDL and surrounding muscular and /  or non-muscular tissues. For WT mice, note 
that w ith  increasing TS length, as well as TA+EHL length, this EDL proximo-distal force difference 
decreases rapidly to  zero to  change sign (i.e. loading direction), between £ o - 3.5 < l < £ o - 4. At higher 
lengths this distally directed load increases substantially w ith  further increasing lengths for WT mice.
In contrast, for Tnxb KO mice (TNX-KO), this proximo-distal EDL force difference only deceases gradually 
(to a value o f AF = 0 at highest TS lengths, indicating no net myofascial force transmission). Note that this 
means that for Tnxb KO mice myofascial loading direction o f EDL is not changed at all over the whole 
length range studied. The inserts illustrate schematically the direction o f the net myofascial loads on 
EDL, where P and D indicate proximal and distal directions, respectively.
A
-5 -4 -3 -2 -1 0
^(m+t) Triceps Surae (mm)
B
Fmt EDL (Fdist-Fprox) (N)
0.08 .
-5 -4 -3 -2 -1 0
/’(m+t) TA+EHL (mm)
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Effects o f  TA+EHL length change on forces exerted by antagonistic muscles a t constant length
(a) Effects on TS
ANOVA showed significant main effects (TA+EHL length, TNX deficiency) on active forces 
exerted by antagonistic TS, while the length of this muscle was kept at unchanged and 
relatively short, as well as significant interaction between effects of length and TNX 
deficiency. Normalized active force decreased substantially (by max. 40% of initial force) as a 
function of increasing TA+EHL length (Figure 6A). The effect of TNX deficiency is to limit the 
length dependent decrease in TS active force to levels not exceeding 7.4 % of initial force.
(b) Effects on EDL 
Proximal force
ANOVA showed significant main effects (of TS length and TNX deficiency) on EDL proximal 
active force, but no interaction. Note that, at low lengths, proximal active force increases 
(max. increase > 0.1 N, TA+EHL = -1 mm at ) as a function of increasing TA+EHL length, but 
remains at similar values for higher TA+EHL lengths. This effect is still present in Tnxb KO mice, 
but occurs at lower force levels (Figure 6B): the curve is shifted downward.
Distal force
ANOVA showed significant effects of TA+EHL length on EDL distal active force, as well as 
significant interaction of effects of TS length and TNX deficiency. Note that distal active force 
decreases as a function of increasing TA+EHL length (Figure6C) in both WT mice and Tnxb KO 
mice. However, such decrease in active force is much smaller in Tnxb KO mice.
Proximo-distal EDL total force differences
ANOVA showed significant main effects on the EDL total proximo-distal force difference, as 
well as significant interaction of effects of TS length and TNX deficiency. Therefore, it is 
concluded that TA+EHL length and TNX deficiency affect myofascial force transmission 
within the mouse lower leg. Similar as for TS length change, the pattern of effects of TA+EHL 
length changes show the following: At low lengths, the force difference is always positive for 
both WT and Tnxb KO mice indicating that a net load is exerted on EDL from proximal 
direction. In both cases this load decreases to very low values with increasing TA+EHL 
lengths. However for WT mice (Figure5B), this occurs after minor TA+EHL length increase (= 
0.6 mm) after which the direction of loading is reversed and increases progressively with 
further length increases. For Tnxb KO mice the proximally directed net myofascial load 
decreases much more gradually to levels approaching zero at high TA+EHL lengths, i.e. the 
reversal of loading direction is absent.
(c) TS and TA+EHL length-force characteristics
ANOVA showed a significant main effect (i.e. for factor length) for both TS (Figure 7A) and TA+EHL 
(Figure 7B) active, as well as passive length -force curves. However, despite non-overlapping curves, 
any possible effects of TNX deficiency, as well as its interaction with length could not be shown to 
be significant (ANOVA) for either muscle due to a relatively high individual variation of force values.
198
Figure 6 Effects o f changes in m.tibialis anterior - m .extensor hallucis longus com plex
length on forces exerted by antagonistic m uscles kept at constant length.
A: Force exerted by m. triceps surae (TS) w ith  changing lengths o f m. tibialis anterior m. extensor hallucis 
longus com plex (TA+EHL). Normalized active force (Fma) decreased substantially (by max. 40% o f initial 
force) as a function o f increasing TA+EHL length. The effect o f TNX deficiency is to  lim it this length 
dependent decrease in TS active force to  levels not exceeding 7.4 % o f initial force. B: Proximal force 
exerted by m. extensor d igitorum  longus (EDL) w ith  changing lengths o f TA+EHL. Proximal active force 
(Fma prox) increases as a function o f increasing TA+THL length at low lengths, but remains at similar 
values for higher TA+EHL lengths. This effect is still present in Tnxb KO (TNX-KO) mice, but occurs at 
lower force levels: the curve is shifted downward. C: Distal force exerted by (EDL) w ith  changing lengths 
o f TA+EHL. Distal active force (Fma dist) decreases as a function o f increasing TA+EHL length in both 
w ild type (WT) mice and Tnxb KO mice. However, such decrease in active force is much smaller in Tnxb 
KO mice. A£(m+t) is the symbol used to  indicate change o f muscle tendon com plex length expressed 
w ith  respect to  optim um  length.
A
B
C
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Figure 7 Triceps surae (TS) and m.tibialis anterior--m.extensor hallucis longus complex 
(TA+EHL) length-force characteristics.
A: TS active and passive length-force curves for Tnxb KO mice (TNX-KO) and for the WT mice. B: TA+EHL 
active and passive length-force curves for TNX knockout mice (TNX-KO) and for the WT mice. Note that 
no significant differences could be proved for these curves between Tnxb KO mice and WT mice. 
h i  (m+t) is the symbol used to  indicate change o f muscle tendon complex length expressed with 
respect to  optim um  length.
A
B
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Discussion
The results of this study show that altered properties of any series elastic component of 
muscle due to TNX deficiency directly affect muscular characteristics. More specifically, 
study of the intramuscular aspects (Series A) points to changes in the series elastic component 
within the (maximally dissected) muscle-tendon complex and study of muscle within its 
connective tissue context showing altered mechanical interaction between muscles (Series B) 
points at altered compliance of connective tissues located outside the individual muscles.
Mechanical interaction between antagonistic and synergistic muscles due to myofascial 
force transmission has been described in the last few years.518-20 Altered intra- and epimuscular 
myofascial force transmission may drastically affect muscular coordination required for 
physiological movements. Main findings are summarized below.
Series A. Intramuscular changes: increased muscle compliance
At optimum length ( i o) several properties of dissected GM are unchanged in Tnxb KO mice 
compared to WT mice: 1) maximal isometric force and maximal power production; 2) 
stimulation frequency-force relationship; and 3) fatigability during a series of repeated 
isometric contractions. In contrast, at low lengths ( i o-  4, i o-  3.5, and i o-  3), some GM 
properties were affected significantly in Tnxb KO mice: 4) active force exerted at lower lengths 
was lower; 5) the maximal rate of relaxation was lower; 6) the time delay between first 
stimulation pulse and the time of attainment of 2% of maximal active force was longer in 
Tnxb KO mice. This last finding is not directly related to our hypothesis, but indicates that 
relatively more slack must be taken up at lower lengths in Tnxb KO mice. The other findings 
are related to the higher series elastic compliance present in the disease, which causes more 
shortening to be imposed on the muscle fibres in Tnxb KO mice at the onset of contraction 
at low lengths. Vice versa, more lengthening is imposed on the muscle fibre at the onset of 
relaxation at low lengths. These findings are in accordance with the results of our previous 
pilot study in two TNX-deficient EDS patients, which were only tested at long length.5
Series B. Intermuscular effects: reduced myofascial interaction between 
synergistics and antagonistic muscles
TNX deficiency strongly affects the mechanical interaction between muscles, which reflects 
the reduction of epimuscular myofascial force transmission (i.e. transmission directly 
between muscle belly and its surrounding tissues). The decrease in normalized distal active 
force in their agonistic muscle (TA+EHL and TS respectively) with increasing length of the 
antagonistic muscle (TS and TA+EHL respectively) in normal mice results from myofascial 
force transmission between these muscle groups. The effect of TNX deficiency is to limit this 
antagonist-length dependent decrease in active force, which is compatible with the
201
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hypothesis of increased compliance of tissues surrounding the individual muscles. Second, 
the difference in force exerted at proximal and distal tendons of EDL is indicative of net 
epimuscular myofascial force transmission between EDL and other muscular or non-muscular 
tissues.
This difference also proved to be a function of the antagonistic or synergistic 
muscle-tendon complex length (TS and TA+EHL respectively) and was affected by TNX 
deficiency. The deficiency significantly affects net epimuscular myofascial force transmission, 
not only in the magnitude of the net myofascial load on EDL, but also with regard to the 
direction of loading. Whereas in WT mice the direction changes rapidly from proximal to 
distal to distal loading of EDL with increasing TS length, such change of direction does not 
occur in Tnxb KO mice. In other words, in comparable experimental conditions Tnxb KO 
muscles act more independently than healthy muscles. It seems inevitable that such altered 
function will require altered patterns of muscular coordination to allow effective movement.
The structure that is most likely responsible for a proximal load is the neurovascular tract 
(i.e. the connective tissues reinforcing blood vessels and nerves outside of the muscle).19 This 
load and loading direction is thought to be present permanently (unless the muscle is 
lengthened proximally,20 note that this is only possible in polyarticular muscles). The similarity 
of proximal loads on EDL (see Figure4 at low lengths for TA+EHL and TS) is hypothesized to 
indicate that the compliance of the neurovascular tract to this muscle is not affected in a 
major way by the TNX deficiency. This would agree with the clinical observation that EDS 
patients with TNX deficiency, in contrast to other types of EDS, do not suffer from major 
damage to blood vessels and nerves. In healthy animals, as the synergistic or antagonistic 
muscles are lengthened, a distally directed myofascial load on EDL is enhanced and 
compensates for proximally directed load at slightly higher lengths (change of net loading 
direction) and becomes dominant (net distally directed load) at even higher lengths. In 
contrast, for Tnxb KO mice enhanced compliance of collagenous tissues connecting EDL to 
synergistic or antagonistic muscles necessitates much higher length changes of these 
muscles to even attain equilibrium between the opposing myofascial loads on EDL at very 
high lengths, let alone attaining a change in direction of loading.
Conclusion
Taken together, these findings indicate that the series elastic components of the 
muscle-tendon complex located within and between muscles is changed in Tnxb KO mice. 
As such, these findings support the hypothesis formulated previously that TNX deficiency 
reduces the stiffness of myofascial pathways and thus causes a pathological reduction of the 
force transmitted this way.5 This study and previous animal experiments have shown that 
myofascial force transmission occurs between antagonistic muscles, which points to the 
high interdependence of muscles and their role in higher levels of motor organization.1920
202
Whether and to what extent reduced myofascial force transmission changes the muscular 
coordination and interferes with mechanical interaction between antagonists muscles in 
TNX-deficient EDS patients needs to be studied in detail.
In addition, the results of the present study constitute a new type of evidence supporting 
the concept of myofascial force transmission: altered ECM elastic properties affect quantity 
and quality of myofascial force transmission. So far, evidence of myofascial force transmission 
was based upon use of physiological animal models, or on experiments in human patients 
suffering from spastic paresis.19
Altered myofascial force transmission in Tnxb KO mice is likely to be related to TNX 
deficiency. TNX is abundantly expressed in various tissues during embryonic development, 
among which are tendons and perimysium of skeletal muscle.2122 In adulthood, TNX is 
predominantly expressed in connective tissue of skeletal and cardiac muscle.22 TNX is 
involved in collagen deposition and maturation,223 and several studies suggest that TNX acts 
as a bridge between collagen fibrils and as such may be important for the compliance of 
connective tissues.24 Firstly, TNX is located between collagen fibrils organized in bundles25 
and the interfibrillar distance is increased in skin of TNX-deficient patients. Furthermore, TNX 
was found to assemble into disulfide-linked oligomers, of which trimers are the predominant 
form. This disulfide-linked trimer structure of TNX is a property that is probably important for 
bridging.24 TNX interacts with types I, III and V fibrillar collagen molecules and with decorin, 
and binds to the fibril-associated types XII and XIV collagens.2426 Finally, the FNIII domains of 
TNX may be important for elastic properties of the molecule.24
In short, altered muscular function in Tnxb KO mice is partially explained by changes of 
series elastic components of the muscle-tendon complex, which results in altered intra- and 
epimuscular myofascial force transmission. We hypothesize that this direct effect of altered 
ECM composition contributes to muscle weakness in EDS patients, in addition to mild 
myopathic effects of the disease on muscular histology.
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Influence of tenascin-X deficiency on 
muscular properties of the thigh muscles: 
a quantitative study in Ehlers-Danlos 
syndrome patients
Adapted from:
Gerrits KH, Voermans NC, de Haan A, van Engelen BG.
Submitted.
Abstract
The Ehlers-Danlos syndrome (EDS) is a clinically and genetically heterogeneous group of 
inherited connective tissue disorders characterized by joint hypermobility, skin hyperexten­
sibility, and tissue fragility. Muscle involvement in EDS can be expected based on interactions 
between muscle and ECM molecules (such as collagen I, III, V, and tenascin-x (TNX)). A recent 
study in Tnxb knockout mice showed reduced quantitative muscle function due to an 
increased compliance of the series elastic component. This calls for confirmation in 
TNX-deficient EDS patients.
We therefore performed quantitative muscle function measurements at different joint 
angles and evaluated voluntary activation capacity in seven TNX-deficient EDS patients.
The main findings were that: 1) TNX-deficient EDS patients exhibited reduced maximal 
voluntary torque of the knee-extensors across all joint angles tested (at 30 °, 60 °, and 90 ° 
knee flexion), while no differences were found on MVTs of knee flexors; 2) the normalized 
maximal rate of torque development did not differ between the groups, but the time to 
reach this normalized maximal rate of torque development was delayed in TNX-deficient 
patients, especially at 30 °; 3) normalized torques (normalized to the highest torque at 60 °) 
were not different between EDS patients and controls at 30 ° and tended to be higher in EDS 
patients at 90 °; and 4) EDS patients exhibited reduced voluntary activation capacity, 
particularly at low muscle length as compared to controls. Importantly, these results could 
not be explained by a difference in level of physical activity.
In short, isometric voluntary peak torque is reduced in TNX-deficient patients, due to an 
increased compliance of the series elastic component of muscle tissue and to a failure to 
maximally voluntary activate the muscles.
208
Introduction
The Ehlers-Danlos syndrome (EDS) is a clinically and genetically heterogeneous group of 
inherited connective tissue disorders (ICTDs) characterized by joint hypermobility, skin 
hyperextensibility, and tissue fragility.1 Mutations in type I and V collagen can explain part of 
the classical type EDS cases, and the vascular type is caused by mutations in the gene 
encoding collagen III. A clinically distinct recessive form results from deficiency of tenascin-X 
(TNX), another extracellular matrix molecule (ECM) that is expressed in muscle.23
Muscle involvement in EDS can be expected based on interactions between muscle and 
ECM molecules known to be deficient in EDS, such as collagen I, III, V, and TNX.4 In fact, 
muscle hypotonia and muscle rupture are diagnostic criteria of EDS, and fatigue, musculo­
skeletal pain, and delayed gross motor development are described as associated features in 
these criteria.1 However, muscle symptoms in EDS have long been interpreted to result from 
exercise avoidance due to joint hypermobility and instability,5 and reports on neuromuscular 
function in EDS have been sparse until recently.6-9
Inspired by a number of EDS patients at our outpatients department and the interactions 
mentioned above, we performed a systematic observational study on neuromuscular 
features in TNX-deficient and other types of EDS (n = 40). The results showed muscle 
weakness in most patients (85%), with signs of mild myopathy and / or axonal polyneuropathy.10 
Overall, patients with the hypermobility type EDS caused by TNXB haploinsufficiency (with 
reduced TNX serum levels) were less affected than the TNX-deficient EDS patients (with 
complete absence of TNX). This pointed to a relation between residual TNX level and degree 
of neuromuscular involvement, compatible with a dose-effect relation. The interaction 
between ECM molecules involved in EDS (collagen I, III, V, and TNX) and the transsarcolem- 
mal molecules,4 the finding of reduced collagen fibril density in muscle of TNX-deficient EDS 
patients,10 and the dose-effect relation described above10 suggest that the ECM defect in EDS 
influences muscle function.
The results of our pilot study on quantitative muscle function in EDS patients were 
indeed compatible with the hypothesis of a role of the ECM in muscle function .11 This study 
in two TNX-deficient EDS patients measured knee extension torques at relatively long muscle 
length (90° knee flexion; longer than optimum muscle length). It showed reduced maximal 
torques at voluntary contraction, normal torque variation with 10 Hz stimulation, relatively 
high twitch torques compared to tetanic torques at 150 Hz stimulation, and a normal delay 
between electrical stimulation and torque generation. Physical examination, muscle 
ultrasound, and muscle biopsy had revealed no signs of atrophy. Hence, the findings could 
not be attributed to reduced physical activity or muscle atrophy. Further, it seemed unlikely 
that the reduced muscle function resulted from increased tendon compliance. This would 
have reduced torque generation, have lowered the twitch torques, have increased the delay
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between stimulation and torque generation, and have delayed relaxation. On the other 
hand, muscle function was studied at a relatively long muscle length (i.e. 90 ° knee-flexion), 
which may have masked the effects of increased tendon compliance. We therefore 
hypothesized that quantitative muscle function in EDS was lowered due to a reduction of 
myofascial force transmission secondary to the ECM defect.11
Our subsequent quantitative muscle function study in Tnxb knockout (KO) mice indeed 
showed differences only at low muscle lengths (optimum length - 4, - 3.5, - 3 mm). The 
normalized active isometric force was lower; the delay between stimulus and attainment of 
2% of maximal active force (i.e. the electromechanical delay) was longer; and the relaxation 
rate was reduced. These parameters were all normal at optimum length and above. This 
pointed to changes in the series elastic component within the maximally dissected GM 
muscle-tendon complex, which implies the ECM network of both endo- and perimysium 
within the muscle and the myotendinous pathway.12
These experiments at short muscle length added two important findings to the results 
of the pilot study in EDS patients described above. First, the altered muscle properties at 
short muscle length pointed to an increased compliance of the series elastic component, 
whereas in the pilot study with measurements at relatively long muscle length (90° knee 
flexion) no such observations were made. Changes of series elastic components would 
indeed be expected to manifest first at short muscle length, since more slack has to be taken 
up at the onset of contraction before the series elastic component can transmit forces. 
Second, normalized active isometric force after electrical stimulation in Tnxb KO mice was 
normal at optimum length and above, whereas maximal torque at voluntary contraction in 
TNX-deficient EDS patients was reduced at relatively long muscle length. This difference 
raised the question whether reduced voluntary activation capacity contributes to muscle 
weakness in EDS patients, as we previously reported in neuromuscular diseases (fascioscapu- 
lohumoral dystrophy, mytonic dystrophy, hereditary motor sensory neuropathy).13
These findings call for confirmation in TNX-deficient EDS patients, with an experimental 
protocol including quantitative muscle function measurements at different joint angles and 
evaluation of voluntary activation capacity. Therefore, the purpose of the present study was 
to test the hypotheses that 1) isometric peak torque (of maximal voluntary contraction); that 
2) rate of torque development (of triplet torque) of knee extensor muscles of TNX-deficient 
patients is lower compared to control subjects; and that 3) this is more pronounced at low 
knee flexion (i.e. relatively short muscle length) compared to high knee flexion (i.e. relatively 
long muscle length). Furthermore we tested 4) whether voluntary activation capacity is 
reduced in TNX-deficient patients and whether this also depends on knee joint angle. Finally, 
we evaluated current physical activity of patients and control subjects to exclude that the 
findings of this study could be influenced by differences in physical activity.
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Methods
Subjects
We invited all ten TNX-deficient EDS who had previously participated in our clinical study on 
neuromuscular features in EDS.10 All were willing to participate; but three patients were 
excluded: one due to pregnancy; one due to admittance to the ICU at the time of the study; 
and one since she could not tolerate the electrical stimulation during the study. The age- and 
sex matched controls consisted of three friends of the patients; and the other two were 
recruited among the university staff.
Median age of the seven patients included was 42 years (SD 16), and four of them were 
female; median age of the controls was 43 years (SD 16). TNX-deficient EDS was diagnosed by 
a medical specialist in all patients, based on clinical features described by Schalkwijk et al. 
and confirmed by complete absence of TNX in serum .3 TNXB mutation analysis was performed 
in four patients; revealing a heterozygous 30 kB deletion in two patients, in whom the second 
TNX mutation had not found, and a homozygous 2 bp deletion (exon 8) in two other patients. 
These four patients were previously reported by Schalkwijk et al.(Patient 1 and her sister; 
patient 2 and her brother).3 The study was approved by the medical ethical committee of the 
Radboud University Nijmegen medical centre.
Experimental design
All measurements were performed on one day at the Research Institute MOVE.
All subjects were asked to refrain from strenuous exercise for 48 h prior to the experiments. 
To be able to control for level of physical activity, we used the International Physical Activity 
Questionnaire (IPAQ; see below). To assess maximal voluntary torque (MVT), voluntary activation 
capacity, and rate of torque rise of the right thigh muscles, subjects performed isometric 
voluntary (both knee-extensors and -flexors) as well as electrically elicited (knee-extensors 
only) contractions at 30 °, 60 ° and 90 ° knee flexion (0 ° corresponds with full extension). Before 
experiments started subjects were familiarized with the test procedures such as electrical 
stimulation. Furthermore, subjects were trained to perform a maximal voluntary contraction of 
approximately 3 - 5 s duration. Knee extension and flexion torques were measured with the 
subjects seated on a custom-built computer-controlled lower limb dynamometer. The lower 
leg was connected to the lever arm of the dynamometer with the hip flexed at approximately 
60 ° and the knee flexed at different angles. Padded straps around the pelvis and upper body 
minimized undesired movements of the hip during the measurements. Furthermore, care was 
taken that the axis of the lever arm was always aligned with the axis of the knee joint (lateral 
femur condyl). Knee extension and flexion torques (0.001 Nm resolution) were measured at the 
motor axis and are therefore independent of the length of the lever arm. Torque signals were 
digitized (1000 Hz) and stored on disc for immediate and off-line analysis.
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Assessment o f physical activity
To evaluate current physical activity, all subjects were asked to fill in the long form of the 
IPAQ.14 This written questionnaire assesses physical activity undertaken across a 
comprehensive set of domains including: leisure time physical activity, domestic and 
gardening (yard) activities, work-related physical activity, and transport-related physical 
activity. The items in the questionnaire are structured to provide separate scores on these 
domains. The total score is expressed as MET minutes per weeks (METs are multiples of the 
resting metabolic state, and a MET minute is computed by multiplying the MET score of an 
activity by the minutes it is performed). This requires recording of duration (in minutes) and 
frequency (days per week) of walking, moderate-intensity- and vigorous-intensity activities. 
The following values were used for analysis of the IPAQ data: walking 3.3 METs; moderate 
physical activity 4.0 METs, and vigorous physical activity 8.0 METs. Using these values, scores 
were calculated for each domain. The sum of activities in the four domains represents the 
total weekly physical activity for each subject (MET -  minutes/week scores). Based on these 
calculations, three categorical scores were arbitrarily defined: low (< 600 METs per week), 
moderate (600 - 3000 METs per week), and high (> 3000 METs per week).(Online available 
guidelines of the IPAQ: http://www.ipaq.ki.se/scoring.pdf).
Torque measurements
Numbers in brackets correspond with the aims in the introduction.
M aximal voluntary torque a t various muscle lengths (1;3)
Similar procedures were followed at each of the three knee angles tested (30 °, 60 °, and 90 ° 
of knee flexion). We always started at 60 ° because pilot experiments have shown that the 
electrical current needed to evoke maximal contractions (see below) was highest at this 
position. The other two angles were randomly assigned. First, subjects were asked to perform 
two to four maximal voluntary knee extensions and flexions, each separated by 2 min rest. 
The highest torque produced during these attempts was defined as MVT. During each 
voluntary effort subjects received substantial verbal encouragement and visual feed-back to 
achieve maximal performance. To minimize the total number of maximal contractions, 
possibly leading to muscle fatigue, an extra attempt was made only if the last attempt was > 
10% higher than the previous. MVTs were normalized to the MVT at 60 ° knee flexion (nMVT).
M aximal triplet torque and voluntary activation capacity (4)
A modified super-imposed stimulation technique was used to estimate the voluntary 
activation capacity (i.e. the degree of maximal voluntary activation) during each attempt. 
Self-adhesive surface electrodes (8 x 13cm, Schwa-Medico B.V., Nieuw Leusden, the 
Netherlands) were placed over the medial distal part and the lateral proximal part of the 
quadriceps muscle. A constant current electrical stimulator (model DS7A, Digitimer Ltd,
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Hertfordshire, UK) imposed a brief train of 3 electrical pulses (triplet) at 300 Hz (pulse width: 
0.2 ms) on the relaxed quadriceps muscle. Subsequently, the same triplet was imposed on 
top of the plateau phase of the maximal voluntary contraction. The stimulation current for 
the triplets was set at supra-maximal intensity to improve the signal-noise ratio. Most 
subjects could tolerate these stimulations, most likely due to the short duration of the 
stimulation. The maximal triplet torque was used as an estimate of torque capacity 
independent of the degree of voluntary activation. The voluntary activation capacity during 
a maximal voluntary contraction was estimated calculating the 'voluntary activation index' 
with the equation:
Voluntary activation index (%) = 1 -
Superimposed trip le t torque
Control trip le t torque
where the superimposed triplet torque is the extra torque produced by the triplet on top of 
the maximal voluntary contraction and the control triplet torque is the torque produced by 
the same triplet imposed on the relaxed muscle. To estimate the maximal torque capacity 
(MTC; voluntary torque which would have been possible when voluntary activation was 
maximal) the MVT was corrected with the voluntary activation index of the knee-extensor 
muscles.
Rate o f  torque development (2)
From the torque differential of the supramaximal triplet stimulation we calculated the 
maximal rate of torque development (MRTD) which was then normalized to the peak torque 
of that particular triplet (normalized MRTD = nMRTD). The time to MRTD (tMRTD) was defined 
as the time from start of stimulation to the moment at which MRTD was reached.
D ata analysis and statistics
Off-line analysis of torque recordings was performed with applications using custom Matlab 
software packages. To examine differences in the MVT, triplet torque, voluntary activation 
index, MTC, MRTD and tMRTD with varying joint angle between patients and control 
subjects, repeated- measures factorial analyses of variance (ANOVAs) were performed and 
the interaction between group and angle was examined. Post hoc simple (subject group) 
and repeated (angle) contrast analysis was used to study differences between repeated 
measures. All data are presented as mean ± SD unless otherwise indicated, and levels of 
significance were set at P < 0.05.
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Table 1 Biom echanical concepts in this study.
Term d e fin it io n A b b rev ia tion
(unit)
D escrip tion
Metabolic equivalent MET METs are multiples o f the resting metabolic state, and a MET 
minute is com puted by m ultip lying the MET score o f an 
activity by the minutes it is performed.
Maximal voluntary MVT Torque measured at maximal voluntary contraction.
torque (N.m)
Normalized MVT nMVT MVT normalized to  the highest torque at 60 ° knee flexion.
Voluntary activation VA The degree o f maximal activation during voluntary
capacity en (%) contraction; this is measured w ith  the voluntary activation
voluntary activation index (with the maximal torque capacity and the
index superimposed trip le t torque as its variable).
Maximal torque MTC The torque reached after maximal trip le t stimulation; this is
capacity (N.m) considered to  be independent o f the degree o f voluntary 
activation.
Maximal rate of MRTD maximal rate w ith  which the torque increases after electrical
torque development (N.m/ms) stimulation (supramaximal trip le t stimulation).
Normalized MRTD nMRTD MRTD normalized to  the peak torque o f that particular 
triplet.
Time to  reach MRTD tMRTD The tim e from start o f stimulation to  the m om ent at which
(ms) MRTD is reached.
Results
Assessment o f pysical activity
All healthy subjects and all but one patient were classified as ” highly active" with a sum score 
of > 3000 METmin per week. One patient had a sum score of 1559 and was classified as 
moderately active. The mean sum score was 7988 for the healthy subjects and 8789 for the 
TNX-deficient EDS patients. Table2 shows the weekly MET minutes in the various domains. 
TNX-deficient EDS patients tended to be physically more active at work, whereas healthy 
controls were more active in leisure time activities. Differences between the two groups 
were not statistically significant.
Torque measurements
M aximal voluntary torque a t various muscle lengths (1;3)
All subjects were able to perform maximal voluntary contractions and achieved the highest 
torque output within a few attempts, with no further increase on subsequent trials.
For the knee-extensors across all angles measured, patients showed significantly lower 
absolute MVTs compared to controls (P = 0.018): 69 ± 19 Nm versus 128 ± 3 5 Nm at 30 °, 115
214
Table 2 The weekly MET minutes in the various domains of TNX-deficient EDS patients and 
healthy controls. Weekly MET minutes (minutes per week * intensity).
H ea lthy  sub jects TN X -defic ien t EDS pa tien ts
E E E E
crc
z:
E
*c
E
*xrc aLT.
crc
z:
E
*c
E
*xrc aLT.
Work 2777 0 10008 4193 4784 0 10080 4373
Transportation 1408 900 2754 775 1167 0 2772 1026
Gardening and domestic
chores
1428 90 5160 2114 1781 0 3645 1383
Leisure time 2375 636 4068 1595 1055 0 2076 713
Total physical activity 7988 5571 13212 3021 8789 1559 15405 5020
± 34Nm versus 207 ± 55 Nm at 60 °, and 106 ± 43 Nm versus 155 ± 66 Nm at 90 °, respectively 
For the knee flexors no such differences were observed (P = 0.113) (Figure 1A and B).
In addition, across groups the torque produced was dependent on knee-flexion angle, P 
= 0.000 (Figure 1C and D). However, the relationship between torque and joint angle of the 
knee-extensors but in patients tended to be slightly different than that observed in control 
(P = 0.069). In patients, the reduction of knee-extensor torque from 60 ° to 90 ° tended to be 
less compared to that observed in controls (P = 0.077). The relationship between torque and 
joint angle of the knee flexors was not different. (P = 0.525).
M aximal triplet torque and degree o f voluntary activation capacity (4)
In contrast with the results for MVT, absolute triplet torque of the knee-extensors was not 
significantly lower in EDS patients than in controls (P = 0.487): 47 ± 20 Nm versus 51 ± 18 Nm 
at 30 °, 62 ± 20 Nm versus 70 ± 21 Nm at 60 °, and 51 ± 20 Nm versus 63 ± 24 Nm at 90 °, 
respectively. Furthermore, the triplet torque was dependent on knee- flexion angle across 
groups (Figure 2) and this torque-angle relation was not significantly different between 
patients and controls (P = 0.453).
There were substantial and significant differences between groups with respect to the 
degree of maximal voluntary activation (i.e. voluntary activation capacity measured with the 
voluntary activation index) of the knee-extensor muscles (Figure 3). The control subjects 
showed high voluntary activation indices across all angles tested, with voluntary activation 
indices > 90%. Patients were, however, much less capable of reaching these high values, and
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scored significantly less compared to controls (P = 0.001). In addition, across groups the 
voluntary activation index was dependent on knee-flexion angle (P = 0.000) showing a 
reduced voluntary activation index with lower knee-flexion (i.e. towards knee-extension). 
This angle dependency differed between groups (P = 0.026), such that this reduction in 
voluntary activation index at lower knee was more pronounced in the patients.
Rate o f  torque development (2)
Results of normalized maximal rate of torque development (nMRTD) as well as the time to 
reach nMRTD (tMRTD) are presented in Figure 4. There were no significant differences 
between the groups (P=0.842) regarding the nMRTD (Figure4A), nor was there any effect of 
angle (P = 0.258). In contrast, tMRTD was significantly delayed in the EDS patients (P = 0.005, 
Figure4B). In addition, across groups there was a significant effect of knee-flexion angle (P = 
0.007), which was different between patients and controls (P = 0.042). In EDS patients, tMRTD 
gradually increased with lower knee-flexion, with the longest values at 30 ° (P = 0.010). In 
contrast, differences between angles seemed less in controls who showed the longest 
tMRTD at 60 ° (P = 0.016).
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Figure 1 (Normalized) maximal voluntary torques (MVT) produced at different knee-
flexion angles of knee-extensor (A and C) and knee-flexor (B and D) muscle in 
patients with EDS (black bars) and healthy control subjects (grey bars).
A: Knee extensors: maximal voluntary torques. B: Knee flexors: maximal voluntary torques. Error bars 
reflect SD.
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Figure 1 Continued.
C: Knee extensors: normalized maximal voluntary torques. D: Knee flexors: maximal voluntary torques. 
Error bars reflect SD.
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Figure 2 Normalized triplet torque of the knee-extensors.
The absolute trip le t torque (TRIP torque) o f the knee-extensors was not significantly lower in EDS 
patients than in controls (data n o t shown). Furthermore, the trip let torque was dependent on knee- 
flexion angle across groups (normalized TRIP torque; Figure 2) and this torque-angle relation was not 
significantly different between patients and controls (P = 0.453). Error bars reflect SD.
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Figure 3 Voluntary activation capacity of knee-extensor muscles.
There were substantial and significant differences between groups w ith  respect to  the voluntary 
activation capacity (measured as the voluntary activation index (VA%)) o f the knee-extensor muscles: 
the control subjects showed high voluntary activation indices across all angles tested, w ith  voluntary 
activation indices > 90%. Patients were, however, much less capable o f reaching these high values, 
and scored significantly less compared to  controls (P = 0.001). In addition, across groups the voluntary 
activation index was dependent on knee-flexion angle (P = 0.000) showing a reduced voluntary 
activation index w ith  lower knee-flexion (i.e. towards knee-extension). Error bars reflect SD.
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Figure 4 Results of the normalized maximal rate of torque development (nMRTD) as well 
as the time to reach nMRTD (tMRTD).
A: There were no significant differences between the groups (P = 0.842) regarding the nMRTD, nor was 
there any effect o f angle (P = 0.258) B: The tMRTD was significantly delayed in the EDS patients (P = 0.005). 
In addition, across groups there was a significant effect o f knee-flexion angle (P = 0.007), which was 
different between patients and controls (P = 0.042). In EDS patients, tMRTD gradually increased w ith 
lower knee-flexion, w ith  the longest values at 30 ° (P = 0.010). In contrast, differences between angles 
seemed less in controls w ho showed the longest tMRTD at 60 ° (P = 0.016). Error bars reflect SD.
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Discussion
Background
Our current study was inspired by the combined findings of a pilot study in TNX-deficient EDS 
patients11 and the experiments in Tnxb KO mice.12 In the animal model, altered muscle contractile 
properties were observed only at short muscle length with lower normalized active isometric 
force, a longer electromechanical delay, and a reduced relaxation rate. These results indicated 
an increased compliance of the series elastic component. However, the results of the pilot 
study on quantitative muscle function in TNX-deficient EDS patients had not confirmed this 
observation. This might be due to the fact that the measurements in TNX-deficient EDS patients 
were performed at relatively long muscle length, at which possible adaptations in the series 
elastic component may not have been detectable. Further, the observation in the pilot study 
that patients showed reduced voluntary torque also at relatively long muscle length may point 
to a reduction of the maximal voluntary activation capacity in EDS patients.
This present study was therefore designed to assess the influence of TNX deficiency on 
muscle function in more detail in EDS patients. Further, we aimed to investigate the degree 
ofmaximal voluntary activation. We therefore investigated muscle function of knee-extensors 
and -flexors in EDS patients at different muscle lengths.
The main findings of the study were that: 1) TNX-deficient EDS patients exhibited 
reduced MVT of the knee-extensors across all joint angles tested (at 30 °, 60 °, and 90 ° knee 
flexion), while no differences were found on MVTs of knee flexors; 2) the normalized maximal 
rate of torque development (nMRTD) did not differ between the groups, but the time to 
reach nMRTD was delayed in TNX-deficient patients, especially at 30°; 3) normalized torques 
(normalized to the highest torque at 60 °) were not different between EDS patients and 
controls at 30 ° and tended to be higher in EDS patients at 90 °; and 4) EDS patients exhibited 
reduced voluntary activation capacity, particularly at low muscle length as compared to 
controls. Importantly, these results could not be explained by a difference in level of physical 
activity. We will discuss these findings below (the numbers in brackets correspond with the 
aims in the introduction).
M axim al voluntary torque production (1)
The muscle weakness observed in the present study (substantial MVT reduction primarily of 
the knee-extensors) confirms the results of our previous pilot experiment11 and of our clinical 
study.10 First, the two TNX-deficient patients in the pilot study showed significant torque 
reduction of the knee-extensor muscles at 90 ° knee flexion. Second, the clinical study 
showed muscle weakness measured by dynamometry in the majority of EDS patients (in 
88% of patients the muscle force of the knee extensors measured with dynamometry was 
below or at the p5 of the normal values).1015
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Muscle weakness in EDS has long been suggested to result from reduced physical 
activities due to exercise avoidance.1,5 To control for differences in physical activity, we 
assessed the level of physical activity by a standardized questionnaire (IPAQ). We observed 
even somewhat (but not statistically significantly) higher average levels of physical activities 
compared to the control subjects. Based on the results of the present study it seems, 
therefore, unlikely that reduced physical activity would be responsible for the deteriorated 
muscle function of the EDS patients. Furthermore, only one of the seven EDS patients 
included in the present study showed signs of muscle atrophy (assessed with ultrasound 
measurements during previous experiments).10 Therefore it is unlikely that muscle atrophy 
fully accounts for the muscle weakness observed. Instead, this would suggest that TNX 
deficiency directly influences muscle function.
Influence o f knee-flexion angle on m axim al voluntary torque production and 
rate o f torque development (2,3)
To obtain a more definite understanding of (the degree of) muscle weakness, we assessed 
muscle function across a range of joint angles at which the muscle is active during 
physiological movements. At short muscle length, more slack has to be taken up at the onset 
of contraction before the series elastic component can transmit forces. Therefore, effects of 
changes in the series elastic component on torque production will most likely predominate 
at short muscle length. Hence, assessment of muscle function at relatively short muscle 
length, in addition to optimum and relatively long muscle length can help to determine 
whether and to what extent possible changes in the series-elastic component affect muscle 
function.
Normalized active isometric force in Tnxb KO mice was indeed reduced only at short 
muscle length.12 This points to increased compliance of the series elastic component of the 
muscle-tendon complex. Interestingly, and perhaps surprisingly, no reduction in the 
normalized torque of EDS patients at 30 ° knee flexion was observed. Furthermore at relatively 
longer muscle length (i.e. 90 ° knee-flexion) normalized torques even tended to be higher in 
the patients compared with the controls. So, the results of the torque angle-relation do not 
support the hypothesis of increased compliance of the series-elastic component. In contrast, 
the observed increase in tMRTD in the TNX-deficient EDS patients does clearly support this 
hypothesis.
These seemingly conflicting results might have several explanations. First, it is well 
known that the applied length change of the thigh muscles is relatively low by changing the 
joint angle of the knee16 Nevertheless, torque-angle relations have been studied extensively 
in human knee-extensors and are frequently used as an indirect measure of length-tension 
relations of these muscles.1718 However, the extent of these length changes in vivo are likely to 
be considerably less compared to those applied when studying the length- tension
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relationship of a maximally dissected muscle in situ. Moreover, if the compliance of the series 
elastic component of the muscle-tendon complex is indeed increased, the muscle length 
changes in the EDS patients may even be even less. This is due to the fact that most of the 
changes in the muscle-tendon complex would be accounted for by length changes of the 
myotendinous pathway. It may therefore be possible that the range of muscle-length 
studied in the present study (30 -  60 -  90 ° knee flexion) is simply too narrow to provide 
evidence for an altered length-tension relationship.
Further, the torque-angle relation in EDS patients differed from that in control subjects 
with an increased normalized torque at 90 ° knee-flexion. This relatively higher torque at 
higher knee-flexion (i.e. longer muscle length) might be indicative for a shift of the 
torque-angle relation towards longer muscle length. In this case, the MVT at 60 ° knee-flexion 
would be below the optimum torque (i.e. the maximum of the torque-angle curve). 
Consequently, the torque at 30 ° knee-flexion would have been related to a lower than 
optimum torque. This would lead to an overestimation of the normalized torque at 30 °, 
thereby explaining the absence of reduced normalized torque at low muscle length. 
However, we only studied muscle function at three different joint angles, which seems 
insufficient to provide conclusive evidence for the hypothesized shift in the relationship.
Triplet torques and voluntary activation capacity (2,4)
In contrast with the results for reduced MVT we found no differences in the maximal triplet 
torques. This suggests that the intrinsic torque generation, independent of voluntary control, 
is not affected by TNX-deficient EDS patients. In addition, the normalized triplet-angle 
relations were not different between patients and controls. This finding does not support the 
above suggested shift in torque- angle relation. However, it should be noted that an increase 
in the series elastic component could mask possible changes in the torque angle relation. 
This is especially the case when torques are produced at lower than maximal possible levels. 
Although triplets were imposed at maximal current intensity, the absolute torque level is still 
only about half of the maximal possible torques at maximal tetanic torque production.
In the pilot experiment in two TNX-deficient EDS patients,11 apart from the reduced MVT 
at 90 °, no signs of an increased series elastic compliance were observed; torque variation 
with 10 Hz stimulation was relatively normal, we observed relatively high twitch torques 
compared to tetanic torques at 150 Hz stimulation, and found a normal delay between 
electrical stimulation and torque generation. It seems that the use of high knee-flexion angle 
(and thus possibly relatively long muscle length) in that particular study has masked possible 
effects of increased series elastic compliance.
Finally, the present study clearly showed an impaired capacity of maximal voluntary 
activation in the EDS patients. This seems somewhat surprising since EDS is not considered 
to affect central nervous system functioning. A number of studies have shown reduced
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voluntary activation capacity in various central nervous system disorders,19-21 various 
neuromuscular disorders (fascioscapulohumoral dystrophy, mytonic dystrophy, hereditary 
motor sensory neuropathy), and chronic fatigue syndrome.1322 In fact, fascioscapulohumoral 
dystrophy is not considered to affect the central nervous system either. The authors 
suggested that loss of central activation capacity might not only be interpreted negatively. It 
may also be seen as a positive adaptation which protects the affected muscle against further 
damage.23 Furthermore, reduction of physical activity, which is known to affect the voluntary 
activation capacity24 cannot explain our observations.
The reduced voluntary activation capacity seems to explain an important part of the 
torque loss observed during maximal voluntary contractions. However, the extreme loss of 
voluntary activation capacity with lower knee-flexion, may be partly due to underestimation 
of voluntary activation capacity. An increase in the compliance of the series elastic 
component would affect the height of the triplet torque. That is, when compliance is 
increased, more slack has to be taken up before the series elastic component can transmit 
forces. This would result in lower 'resting' maximal triplet torques, but not 'superimposed' 
triplet torques as the latter is imposed on top of an already activated muscle. Since the 
voluntary activation capacity is calculated by expressing the superimposed triplet relative to 
the resting triplet, this would lead to an underestimated voluntary activation capacity. 
Having that in mind, still voluntary activation is also reduced at relatively long muscle length, 
when the influence of the series elastic component should be negligible. We presently have 
no explanation for this observation and this may require further investigation.
Final conclusion
The results of the present study show that isometric voluntary peak torque is reduced in 
TNX-deficient patients. An important part of the observed muscle weakness seems to be 
explained by failure to maximally voluntary activate the muscles. In addition, the series 
elastic component of muscle tissue is increased based upon the increased electromechani­
cal delay between stimulus and torque development and the noticeably reduced voluntary 
activation capacity at low knee-flexion. However, such possible increased compliance 
seemed not to result in obvious torque reduction at low knee-flexion angle, although 
measurements of full torque-angel relations may be required to provide conclusive evidence. 
These findings confirm our observation of mild to moderate neuromuscular involvement in 
various types of EDS syndrome.10 The finding of reduced voluntary activation capacity points 
to a central activation failure, which has been described in various neuromuscular disorders 
and central fatigue syndrome.1322 This calls for further research on central and peripheral 
fatigue in EDS, results of which explain the high prevalence of severe fatigue among EDS 
patients.25
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Neuromuscular features 
of Marfan syndrome
Clinical evaluation of 
Marfan syndrome patients
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Neuromuscular features in Marfan syndrome
Adapted from
Voermans N, Timmermans J, van Alfen N, Pillen S, op den Akker J, Lammens M, Zwarts MJ, 
van Rooij IA, Hamel BC, van Engelen BG.
Clin Genet. 2009;76:25-37.
Abstract
Marfan syndrome is a clinically and allelic heterogeneous, inherited connective tissue 
disorder w ith  infrequently reported neuromuscular features. This study is the first to  delineate 
these symptoms in a non-selected population.
Neuromuscular involvement was evaluated in ten Marfan patients through a standardized 
questionnaire, physical examination, nerve conduction study, needle electromyography, 
muscle ultrasound, laboratory investigation, and muscle biopsy. Existing neuroimages were 
screened for dural ectasia and spinal meningeal cysts. Twenty healthy controls w ith similar 
age distribution completed the questionnaire.
Various neuromuscular symptoms indeed occurred more frequently in the patients. Four 
older patients reported muscle weakness, five patients a m ild-to-moderate reduction o f 
vibration sense, and all older patients mentioned mild functional impairments. Nerve 
conduction studies showed axonal polyneuropathy in four and electromyography 
myopathic and neurogenic changes in all patients. Increased echo intensity and atrophy on 
muscle ultrasound was found in more than half o f the patients. Muscle biopsies obtained in 
tw o  patients showed myopathic changes in the older, female patient. Lumbosacral dural 
ectasia in combination w ith one or more lumbosacral spinal meningeal cysts was confirmed 
in seven patients, w ith  one patient showing an additional thoracolumbar kyphoscoliosis. 
The majority o f Marfan patients displayed neuromuscular symptoms characterized as 
myopathy or polyneuropathy or both, and signs o f lumbosacral radiculopathy, w ith 
symptoms being most pronounced in the older patients. A lthough meriting corroboration, 
these findings indicate a need to further the awareness o f neuromuscular involvement in this 
population.
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Introduction
Marfan syndrome is an inherited connective tissue disorder characterized by a varying 
pattern o f organ involvement including the cardiovascular and pulmonary systems, eyes, 
skeleton, skin, and dura. At least 90% o f all Marfan patients fulfilling the clinical diagnostic 
criteria show a mutation in the fibrillin-1 gene (FBN1) on chromosome 15, w ith  27% o f the 
mutations being spontaneous.1 Many symptoms do not present until puberty or later, and 
severe complications rarely develop before adulthood. In 1972, before the availability o f 
elective open-heart surgery, Marfan patients tended to die from  acute aortic dissection or 
rupture and had an average life expectancy o f 32 (± 16) years. In 1993 the average life 
expectancy had been extended to 41 (± 18) years through management by expert centres.2 
W ith increasing life expectancy, the life-threatening cardiovascular involvement shifted to 
more chronic ocular, orthopaedic, and, possibly, neuromuscular complications.3-7
Although Marfan himself considered muscle involvement integral to his syndrome, 
neuromuscular features have since received little notice.8 Muscle hypoplasia and myopathy 
were repeatedly reported, but, over the years, myopathy disappeared from the nosology and 
was no longer included in the diagnostic criteria.9 Only recently has muscle involvement in 
Marfan syndrome received renewed attention, probably due to the increasing insight into the 
role o f extracellular matrix molecules in muscle pathophysiology.1011 Investigating a family with 
Marfan syndrome and muscle weakness associated with respiratory failure, Behan et al. found 
that muscle biopsies showed fibrillin to  be truncated and abnormally distributed in the endo- 
and perimysium .12 A study o f young female Marfan patients reported reduced quadriceps 
strength that could not fully be explained by a decrease in lean leg mass, major cardiovascular 
disease, or use o f selective p-blockers.13 This suggested qualitative skeletal-muscle alterations 
related to fibrillin abnormalities in the connective tissue o f muscles.13 In most Marfan patients 
growth and exercise does not lead to an increase in muscle mass, while patients w ith an early 
onset, severe, and rapidly progressive type have profound muscle hypoplasia and hypotonia.13,14 
The muscular features are probably related to fibrillin deficiency, which causes excess availability 
and signalling o f transforming growth factor p, leading to impaired muscle-cell development 
and response to injury or inflammation.1415
In addition to  muscle involvement, radiculopathy caused by lumbosacral dural ectasia 
w ith  spinal meningeal cysts may contribute to  weakness and atrophy in Marfan syndrome.16 
Dural ectasia is probably caused by a weakening o f the connective tissue o f the dural sac due 
to  fibrillin-1 deficiency and its severity seems to be related to  age.16 Symptoms that may occur 
are postural headaches, leg pain, abdominal pain, and low back pain.17 Hydrostatic pressure, 
transmitted pulsation o f the cerebrospinal fluid, and weakened dura may contribute to  a 
gradual increase o f the size o f the spinal meningeal cysts, which, in turn, may cause 
lumbosacral root compression.16-21
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To investigate whether and to which extent neuromuscular features occur in Marfan 
patients, and to  determ ine whether they are related to age, we conducted a cross-sectional, 
observational study in ten non-selected, younger and middle-aged Marfan patients. We 
applied diagnostic procedures conventionally used in the work-up o f neuromuscular 
diseases. To our knowledge, this is the first study to do so.
Methods
Study population
W ithout knowledge o f their neuromuscular status, we invited 12 consecutive patients 
visiting our Marfan outpatient clinic to  participate in our study. Two patients declined 
participation because they considered the study too tim e consuming. The 10 consenting 
patients (4 women; median age 40; age range 27 - 65) all fulfilled the diagnostic criteria o f 
Marfan syndrome at that tim e (Ghent nosology, 1996).49 Mutation o f the fibrillin-1 gene 
(FBN1) was confirmed by DHPLC in nine patients, which is in agreement w ith  the rate of 
mutation detection reported in the literature.1
To allow us to  compare the self-reported neuromuscular symptoms o f the Marfan group 
w ith those o f the general population, we used the scores o f 20 healthy controls (mostly 
hospital staff) w ho  had completed the relevant questionnaire in an earlier study into 
neuromuscular involvement in Ehlers-Danlos syndrome.22 The control group had a similar 
age distribution (median age 35; age range 22-64) but did contain proportionally but not 
significantly more female patients (n = 14).
The study was performed in accordance w ith the Helsinki criteria after approval by the 
local ethics committee. All participating patients gave their w ritten informed consent prior 
to  their participation.
Clinical studies
Standardized questionnaire
All patients and controls completed a brief, standardized questionnaire assessing muscle 
weakness, muscle hypotonia, frequent or continuous myalgia, and relative fatigability 
(compared to healthy age peers), while wheelchair use, use o f walking aids, walking distance 
(with aids; < or 5 km), and engagement in sports (none or at least once weekly) were also 
charted. Other neurological symptoms and previous neurological diagnoses were noted if 
present.
Standardized physical examination
The patients were all examined by the same neurologist follow ing a standardized protocol.
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The clinical hallmarks o f Marfan syndrome were noted, cranial nerves tested, and muscle 
mass qualitatively evaluated (normal vs. reduced) based upon the clinical experience o f the 
investigator. The muscle strength o f tw o  trunk-muscle groups and 13 proximal and distal 
limb-muscle groups were tested manually and graded according to the Medical Research 
Council system (MRC score range 0 - 5 per muscle), resulting in a maximum MRC sum score 
o f 140.23 To verify the manual findings, muscle force was bilaterally quantified (in Newton) 
using a hand-held dynamometer (www.citec.nu) in five muscle groups, i.e., during shoulder 
abduction, elbow flexion and extension, a three-point grip, and knee extension, all performed 
in standardized positions. Per muscle group three measurements were taken and the mean 
force across measurements calculated, while for each patient the number o f muscles in 
which this force was below the P5 value found in normal populations was noted .24 The 
median force values for the male and female patients were then compared w ith  the P5 and 
P50 values o f the norm population. Coordination was tested bilaterally by use o f a finger- 
nose-finger, a heel-to-knee-to-toe, and a tandem gait test. Sensation was examined by 
assessing vibration (with Rydell-Syffer tuning fork),25 pain, and touch sense in the legs and 
arms, both proximally and distally; movement sense was tested in the distal legs and arms on 
a 3-point scale (0 = absent; 1 = reduced, and 2 = normal). Reflexes were evaluated bilaterally 
using the same scale (total score: 0 -  16), w ith  scores < 16 indicating hyporeflexia. Functional 
measurements included the Vignos scale (assessing lower extrem ity functions w ith  1 
signifying the ability to  walk and climb stairs w itho u t assistance and 10 being confined to 
bed),26 Brooke's scale (measuring upper-extremity functions; 1 = being able to  fully abduct 
one's arms; 6 = no useful function o f hands),27 the Rivermead M obility Index (evaluating 
disability related to  bodily mobility; m inim um  score = 0; maximum score = 15 w ith higher 
scores reflecting better mobility), and the Modified Rankin Scale (gauging the degree of 
disability or dependence in daily activities; m inim um  score = 0; maximum score = 6, w ith 
higher scores reflecting more impairment).28-30
Ancillary investigations
Nerve conduction studies
By electrically stimulating peripheral nerves, nerve conduction studies (NCS) measure the 
conduction o f m otor and sensory nerves and together w ith  needle electromyography (EMG; 
see below) the technique helps determ ine the presence o f polyneuropathy and 
radiculopathy. M otor NCS in terms o f distal m otor latency, compound muscle-action 
potential (CMAP) amplitudes, and nerve conduction velocities (NCVs) were performed o f the 
left peroneal nerve to the extensor digitorum brevis and anterior tibial muscles, the tibial 
nerve to the abductor hallucis muscles, and the median nerve to the abductor pollicis brevis 
muscle. Sensory NCS recording sensory-nerve action-potential (SNAP) amplitudes and NCVs 
were done o f both sural nerves. H-reflexes o f both tibial nerves to  the m. soleus were
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recorded. In case o f a suspected polyneuropathy, NCS were supplemented w ith the ulnar 
nerve to the m. abductor digiti m inim i and the superficial radial sensory nerve. The data of 
the clinical neurophysiological studies (i.e., our NCS and needle EMGs) were compared with 
the results in our database obtained in healthy controls. Polyneuropathy was defined in 
accordance w ith the guidelines o f the American Association o f Electrodiagnostic Medicine.31
Needle electromyography
By capturing the electrical potentials spontaneously generated by muscle cells at rest and 
during contraction, needle EMG allows the differentiation o f neurogenic and myopathic 
diseases. We tested the anterior tibial, rectus femoris, biceps brachii, deltoid, and paraspinal 
L4 - L5 muscles, all on the left side. M otor unit action potentials (MUAPs) w ith  a duration o f 3
- 8 ms, polyphasic units, and normal-to-fast recruitment w ith  low  (< 1 mV) amplitudes on 
maximal contraction were classified as ‘myogenic', while those w ith  a 8 - 12 ms duration, an 
interference pattern, normal recruitment, and an amplitude o f 1 - 2 mV on maximal 
contraction) were considered ‘normal'. MUAPs lasting in excess o f 12 ms, having a poor-to- 
moderate recruitment w ith  high amplitudes (> 2 mV) on maximal contraction were defined 
as ‘neurogenic'. Occurrence o f myopathic and neurogenic units in arm and leg muscles was 
noted. To quantify suspected neurogenic or myopathic MUAPs, turns and amplitude analysis 
o f the rectus femoris and biceps brachii muscle were performed when the routine needle 
examinations were suggestive o f myopathic m otor units.32 The results o f the clinical neuro­
physiological studies were reviewed by tw o  neurologists.
Muscle ultrasound
Muscle ultrasound non-invasively visualizes muscle atrophy (reduced diameter) and 
intramuscular fibrosis and fa tty  infiltration (increased echo intensity), both o f which occur in 
various neuromuscular disorders.33 Examinations were performed bilaterally in five muscles 
(biceps brachii muscle, extensors and flexors in forearm, quadriceps femoris and anterior 
tibial muscle) using a standard technique previously described.3435 The mean muscle-echo 
intensities (i.e., the mean grey values o f the muscles) were determined using a computer-as­
sisted grey-scale analysis w ith  256 grey levels.34 In the quadriceps femoris muscle, the rectus 
femoris was chosen for quantitative analysis o f the echo intensity, as in severe neuromuscular 
disorders the outline o f the vastus intermedius muscle can be difficult to  define. Muscle 
thickness was measured w ith electronic callipers.
Echo intensity and muscle thickness are different for each muscle group and depend on 
age and sex.3536 Normal values for each muscle corrected for these variables were calculated 
w ith use o f a previously established database.36 To allow comparison o f individual patients 
and muscles, the echo-intensity and muscle-thickness data were transformed into Z-scores, 
which reflect the number o f standard deviations a measure deviates from normal, given a
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certain age and sex.35,36 Echo intensity was defined as abnormal when at least one muscle 
had a Z-score > 2, which cut-o ff value (Z-score o f diameter < -2) was also used for muscle 
atrophy. The muscle-ultrasound readings and analyses were reviewed by one o f our team's 
physicians Below, we will report cases w ith an increased echo intensity and atrophy, and 
detail the number o f muscles in which both parameters were abnormal (Z-scores o f echo 
intensity > 2 and Z-scores o f diameter < -2) as well as their mean Z-scores.
Lumbosacral imaging
Because our NCS and EMGs uncovered lumbosacral radiculopathy, an experienced 
radiologist reviewed the existing MRI and CT studies (previously performed as screening for 
aortic dilatation) and looked for dural ectasia and spinal meningeal cysts at lumbosacral 
level.
Laboratory investigation
Creatine kinase (CK) was measured as a marker o f muscular dystrophy (normal values: CK < 
220 U/l (men) and CK < 170 U/l (women)). If the NCS and EMGs showed signs ofpolyneuropathy, 
laboratory tests were performed to exclude common causes o f polyneuropathy (i.e., 
diabetes, thyroid dysfunction, diabetes, liver dysfunction, and vitamin B1 or B12 deficiency).
Muscle biopsies
Needle biopsy specimens were obtained from  the right lateral vastus muscle in tw o  patients 
that did not use oral anticoagulation and had given their informed consent for the procedure. 
Frozen sections o f 10 ^m were examined by the neuropathologist under a light microscope 
w ith Hematoxylin-Phloxine (HE), Periodic acid-Schiff, Sudan Black B, Trichrome-Gomori and 
enzyme histochemical staining (ATPase at pH 4.2, 4.6 and 10.3), succinic dehydrogenase, 
reduced nicotinamide adenine dinucleotide-tetrazolium reductase, cytochrome C oxidase, 
and acid phosphatise (NADH).
Definition o f neuromuscular involvement
When a patient's outcomes on the questionnaire and/or physical examination were 
consistently abnormal and supported by abnormal results o f relevant ancillary investigations, 
none o f which could be explained by other common causes, we took this to  be indicative of 
neuromuscular involvement.
Statistics
Statistical analysis was performed using SPSS version 14.0 (SPSS Inc, Chicago, IL, USA). Because 
o f the small sample size, Fisher's exact test was used w ith  dichotomous variables. Statistical 
significance was set at P < 0.05. A Pearson correlation coefficient was calculated to  detect
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correlations between age and muscle strength (MRC sum score) and impairment (Modified 
Rankin Scale, Brooke's scale, Vignos scale, and Rivermead M obility Index), and the presence 
o f neurogenic units at the lumbosacral level on electromyography. Subsequently, linear 
regression analyses were performed to quantify the relationships between age and the 
above-mentioned outcomes.
Results
Study population
Table 1 lists the characteristics o f the study population.
Clinical studies
The results for the standardized questionnaire, physical examinations, and ancillary 
investigations are summarized in Tables 2A, 2B, and 3.
Standardized questionnaires
The patients' neurological history revealed tension-type headache, migraine, temporal-lobe 
epilepsy, benign cramp-fasciculation syndrome, and cerebral abscesses follow ing infectious 
endocarditis. Six patients used oral anticoagulants and nine a p-blocker.
Relative to  their healthy peers, the patients more often reported muscle weakness (n = 4), 
muscle hypotonia (n = 2), myalgia (n = 9), easy fatigability (n = 8), and walking distance < 5 
km (due to pain and muscle weakness; n = 4) and they also tended to engage less in sports. 
One patient used a walking stick (F65), and one knee braces and a rolling walker (F58). Overall, 
the proportion o f neuromuscular complaints was larger in the older patients. One patient 
reported previous lower back pain radiating to both legs (M32) and three older patients 
reduced sensation in the legs and a feeling o f insecurity when walking (F58, M59, and F65). 
One older patient (F58) reported faecal and urinary retention requiring in term ittent bladder 
catheterisation and manual removal o f faeces. No complaints o f (nocturnal) respiratory 
failure were reported.
Standardized physical examination
Various typical, clinical hallmarks o f Marfan syndrome were observed in all patients, i.e., 
positive wrist and thum b signs due to  arachnodactyly, long arms w ith elbow contractures, 
jo in t hypermobility, increased arm span-to-height ratios, high-arched palate, (kypho)scoliosis, 
pectus carinatum or excavatum, and ectopia lentis. Ptosis was observed in tw o  patients, one 
o f w hom  also showed drooping o f both lower eyelids (Figure 1). No other cranial nerve 
abnormalities were found. The four oldest patients had m ild-to-moderate muscle weakness
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Table  1 The genetic test results, histories, and m edication use for all ten Marfan patients.
Sex and FBN1 m utation Medical history Neurological history Medication
age (tested with DHPLC)
M 27 Missense mutation exon 26 (3302A>G; Y1101C) Endocarditis lenta; ascending aorta 
dilatation: Bentall procedure (at age 
12); mitral valve prolaps: prothesis
sotalol, oral anticoagulation
M 28.1 Base insertion (frame shift mutation) exon 23 VSD defect, surgically corrected; aortic Temporal lobe epilepsy; carbamazepine, metoprolol,
(2851 insG) root dilatation: Bentall procedure 
(at age 12)
migraine oral anticoagulation
M 28.2 Base substitution in n itro46 (IVS46+5G>A) resulting Lens luxation; ascending aorta metoprolol,
in skipping o f exon o f FBN mRNA dilatation and aortic insufficiency: 
Bentall procedure (at age 14)
oral anticoagulation
M 32 Missense mutation exon 63 (7916A>G ;Y2639C) Lens luxation; mitral prolaps and 
insufficiency both surgically corrected 
(at age 31)
metoprolol, lisinopril
F 33 Missense mutation exon 56 (6883T>C; C2295R) Inguinal hernia; hormonal growth 
inhibition; mitral valve prolaps; 
scoliosis: brace
metoprolol
M 46 Although DHPLC analysis did not reveal a mutation, Inguinal hernia; pectus carinatum; Hypophysis adenoma; metoprolol, simvastatin,
this patient did fulfil the diagnostic criteria lens luxation; retinal detachment; tension-type headache carbasalaatcaldum, thyrax,
(meeting major criteria for skeletal, ocular, and aortic root and ascending aorta cabergoline
cardiovascular systems, and dura) dilatation, both surgically corrected 
(at age 42); testis carcinoma
F 55 Missense mutation exon 59 (7364G>A; C2445Y) Aortic dissection: Bentall procedure Benign cramp-fasciculation metoprolol, oral
(at age 43); endocarditis after dental syndrome; cerebral anticoagulation, oral
treatment abscesses anticoagulation
F 58 Missense mutation exon 6 (640G>C; G214R) Lens luxation; thoracolumbar 
kyphoscoliosis: spondylodesis 
Th10-L2; mild dilatation o f aortic root; 
mitral valve prolaps
Lumbar root compression 
w ith paresis and sensation 
disturbances
tim optol
M 59 Missense mutation in exon 55(6827G>A; C2276Y) Aortic dissection; Bentall procedure 
(at age 55) lens luxation
Tension-type headache atenolol, carbasalaatcaldum, 
oral anticoagulation
F 65 Genomic deletion exon 50 - 63 Ascending aorta dilatation and aorta 
insufficiency: Bentall procedure (at 
age 47); descending aorta dissection, 
surgically corrected
propanolol, simvastatin, 
oral anticoagulation
DHPLC: Denaturing high performance liquid chromatography. FBN-7: Fibrillin-1 gene.
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240 Table 2A Self-report outcomes for the patients and the healthy controls and patients' results for the physical examination.
The numbers (percentages) o f the patients and healthy controls reporting the symptom are indicated w ith the significance levels 
reflecting the between-group differences in the frequency o f the subjective symptoms; + indicates the actual patients reporting and/ 
or showing the symptoms upon examination and their mean scores per test/scale are listed. Absence o f subjective symptoms or normal 
results on physical examination are specified as
Marfan Healthy Patients M 27 M28.1 M 28.2 M 32 F 33 M 46 F 55 F 58 M 59 F 65
patients controls vs. healthy
(n=10) (n=20) controls
P-value(#)
Standardized questionnaire
Muscle weakness 4 0 P = 0.008 - - - - - - + + + +
Muscle hypotonia 2 0 n.s. - - - - - - + + - -
Myalgia 9 (90%) 2 (10%) P < 0.001 - + + + + + + + + +
(freguent or continuous)
Easy fatigability 8 (80%) 0 P < 0.001 + + + - - + + + + +
(relative to  healthy age peers)
Walking distance < 5 km 4 (40%) 1 (5%) P = 0.031 - - - - - + - + + +
Use o f walking aids 2 (20%) 0 n.s. - - - - - - - + - +
Wheelchair use 1 (10%) 0 n.s. - - - - - - - + - -
Engagement in sports 4 (40%) 14 (70%) n.s. + + + +
(at least once a week)
Physical exam ination
Mean MRC sum score (SD) (0-140) 133 (13.2) 140 140 140 140 140 140 131 101 138 118
Number o f muscles w ith reduced strength on 4 0 1 0 2 2 7 2 4 7
dynamometry
Reduced muscle mass 4 + - - - - + - - + +
Reduced coordination 4 - - - - - + - + + +
(coordination sum score (6) (4) (6) (4)
range 0-10)
Reduced sensation 5 
(sensation sum score 
range 0-60)
Hyporeflexia 3 
(Total reflex score range 0-16)
Mean Vignos score (1-10) 2.1
Mean Brooke score (1-6) 1.1
Mean Rivermead score (0-15) 13.6
Mean Modified Rankin scale (0-6) 1.4
n.s.: no s ta tis tic a lly  s ig n ific a n t b e t w e e n -g ro u p  d iffe re n c e . (#): Fis
1 1 1 
1 1 1
15 15 15
0 0 2
■'s e xac t tes t. MRC: M e d ica l Research C ounc il.
- - + + + + +
(46) (58) (56) (53) (56)
- - + - + - +
(14) (8) (12)
1 1 2 2 6 3 3
1 1 1 1 1 1 2
15 15 15 14 7 13 12
0 0 2 2 4 1 3
Table 2B Dynamometry results o f the group o f Marfan patients.
The 2nd and 5th columns list the sex-related median muscle forces (P50) for the five muscle as measured w ith a hand-held dynam ometry 
for the patients and the 3rd, 4th, 6th and 7th columns the sex-related P5 and P50 values for the healthy controls.
Marfan patients (n=6)
Men
Healthy controls24 Marfan patients (n=4)
Women
Healthy controls24
P50 force (N) 
(range)
P5 force (N) P50 force (N) P50 force (N) 
(range)
P5 force (N) P50 force (N)
Shoulder abduction 131 (109-163) 111 160 78 (25 -140) 75 105
Elbow flexion 183(66-240) 216 >250 122 (86 -149) 146 190
Elbow extension 131 (106-151) 115 156 90 (72 - 121) 80 105
Three point grip 122 (66 - 135) 94 125 71 (45 - 93) 65 86
Knee extension 205 (143 - 238) > 160 > 160 120 (72 - 147) > 160 > 160
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Figure 1 Various observations in three Marfan patients.
A: Generalized muscle hypoplasia in a 27-year-old male Marfan patient who also showed kyphoscoliosis, 
pectus carinatum, elbow contractures, and arachnodactyly. B: Bilateral ptosis in a 28-year-old male 
Marfan patient, w ith bilateral drooping o f the lower eyelids showing the whites o f the eyes between the 
eyelid and the iris. C: Asymmetric atrophy and dystrophic changes in the right lower and upper leg o f a 
58-year-old female Marfan patient.
(MRC sum scores < 140). The dynam om etry results corroborated the findings obtained in the 
manual tests: all patients w ith  reduced MRC sum scores had at least tw o  muscles w ith  force 
values below the normal P5 (Table2A). Furthermore, the median force during elbow flexion 
in the men and during shoulder abduction, elbow flexion, and knee extension in the women 
was below or near the normal P5 value (Table 2B). Muscle weakness correlated w ith  age 
(r = - 0,67; P = 0.04), w ith a 5.8 decrease o f the MRC sum score every 10 years (P = 0.04). Muscle 
mass was reduced in four patients, w ith  the tw o  male patients reporting that it had overall 
been poor since childhood (i.e., generalized muscle hypoplasia; M27, M46). The tw o  female 
patients stated that the muscle mass in their legs had gradually diminished in the past few 
years (i.e., muscle atrophy; F58, F65; also see Figure /). Coordination was reduced in four and 
sensation in five (mostly involving mild reductions in vibration sense in the legs and/or arms).
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Hyporeflexia occurred in three patients and consisted o f reduced ankle-jerk reflexes (M46, 
F65) and absent knee-jerk and ankle-jerk reflexes (F59), which findings are consistent w ith  the 
occurrence o f polyneuropathy and radiculopathy in these patients.
The functional assessment revealed mild impairments in the older patients (M46, M59, 
F55, F58, and F65): w ith a mean score o f 2.1/10 the Vignos lower-extrem ity score was increased 
in half o f the patients. Brooke's upper-extremity score was abnormal in one patient (mean 
score: 1.1/6). The Rivermead M obility Index was reduced in four patients yielding a mean 
index o f 13.6/15. The Modified Rankin Scale showed abnormal scores in six patients (mean 
score: 1.4/6), all indicating mild disability. Impairments gradually increased w ith  age, w ith all 
outcomes except the Brooke scores showing significant correlations: Vignos r = 0.76; P = 0.01 
w ith a 0.8-point increase each decade (P = 0.01); Rivermead M obility Index r = - 0.66; P = 0.04 
w ith a 1.1-point decrease (P = 0.04), and the Modified Rankin Scale r = 0.73; P = 0.02 w ith a 
0.7-point increase (P = 0.02).
Ancillary investigations
Nerve conduction data
NCS results were abnormal in five patients. In four patients findings were compatible w ith  an 
axonal sensorimotor polyneuropathy, o f w hom  three, as well as another patient, additionally 
showed signs o f a lumbosacral radiculopathy (CMAP reduction > SNAP reduction; increased 
H-reflex latency), w ith involvement o f the L5 level in all four, and also L3-L4 level in tw o 
patients.
Electromyographic readings
The needle EMGs were abnormal in all patients, revealing a mixed pattern w ith  small and 
enlarged MUAPs. The younger patients overall had myopathic MUAPs in both arms and legs, 
pointing to myopathy. The older patients predominantly had neurogenic MUAPs mainly in 
their legs and paravertebral muscles, indicating lumbosacral radiculopathy, compatible w ith 
the NCS findings. The presence o f neurogenic units in the EMGs o f the lumbosacral muscles 
correlated w ith age (r = 0.70; P = 0.03), showing an increase o f 12% over 10 years (P = 0.03). A 
mild myopathic shift was seen in the turns and amplitude analysis o f the rectus femoris 
muscle in tw o  o f the seven patients tested and in the biceps brachii muscle in 3/9, outcomes 
that are indicative o f myopathy.
Myopathic units typically have short durations and small amplitudes accompanied by 
polyphasia. In case o f denervation due to  axonal polyneuropathy or radiculopathy w ith 
subsequent reinnervation, the units become larger (lasting longer at higher amplitudes) and 
these superimposed neurogenic changes may mask any myopathic changes, which may 
explain why in the older patients myogenic features were no longer found.
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Table 3 Results o f the ancillary investigations.
The second column lists the number o f patients in which mentioned tests revealed abnormal results, the number o f muscles in which 
increased echo intensity and reduced muscle diameter was found, and the mean Z-score o f echo intensity and muscle diameter for each 
patient. In the other colum ns'+' indicates the patients showing abnormal test results. Normal results are specified as
Patient M 27 M 28.1 M 28.2 M 32 F 33 M 46 F 55 F 58 M 59 F 65
(n=10)
Laboratory investigations
Median creatine kinase (U/l) 100 217 225 124 99 71 63 70 126 70 100
(range) (63 - 225)
Nerve conduction
Abnormal 5 - - - + - + - + + +
Axonal polyneuropathy 4 - - - - - + - + + +
Signs o f radiculopathy 4 - - - + - + - + - +
(at least one lumbosacral level)
Electromyography
Abnormal 10 + + + + + + + + + +
Mixed pattern o f small and enlarged MUAPs:
myogenic = neurogenic 2 - + - - - + - - - -
myogenic > neurogenic 5 + - + + + - + - - -
myogenic < neurogenic 3 - - - - - - - + + +
Mild myopathic pattern in T/A o f rectus femoris 2 (n = 7) + - - n.p. - - + n.p. n.p. -
Mild myopathic pattern in T/A o f biceps brachii 3 (n = 9) + + - - n.p. - + - - -
Muscle ultrasound
Increased Echo intensity 6 + - - - + + + + +
Number o f muscles w ith increased echo intensity (0 -10) 1 0  0 0 0 6 1 3  1 1
Mean Z-score o f echo intensity 0.8 0.0 1.1 0.5 0.8 1.9 0.6 1.6 0.9 1.1
Muscle atrophy 8 + - + - + + + + + +
Number o f muscles w ith muscle atrophy (0 - 10) 6 0 1 0 1 7 2 3 2 1
Mean Z-score o f muscle diameter -3.4 0.0 -0.5 0.0 - 1.2 -2.1 - 1.1 -0.6 -0.8 -0.8
Muscle biopsy (n =  2)
Myopathic features 1 n.p. n.p. n.p. - n.p. n.p. n.p. + n.p. n.p.
MR! (screening for aortic dilatation)
Presence o f dural ectasia 7 + + + - - + + + - +
Presence o f meningeal spinal cysts 8 + + + - + * + + + - +
CMAP: C o m p o u n d  m usc le  a c tio n  p o te n tia ls . SNAP: S ensory n erve  a c tio n p o te n tia l MUAP: M o to r u n it  a c tio n p o te n tia l. CRD: Co m p le x  re p e tit iv e  d ischarges. T/A: Turns arid  a m p litu d e
analysis. *: Indicates the presence o f a single dural cyst at the left thoracolumbal spine but not at the lumbosacral level, n.p.: Not performed.
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Ultrasound findings
Muscle ultrasound data were obtained in all 10 patients and showed increased echo 
intensities in six. The elevations were most pronounced in the tibial anterior muscles and in 
the forearm extensors and flexors (data not shown). Eight patients showed muscle atrophy, 
which was most pronounced in the forearm extensor and the quadriceps muscles (data not 
shown).
Lumbosacral imaging data
For nine patients recent MRI scans were available, w ith  additional CT scans (both conducted 
to  screen for aortic dilatation) for three o f these patients; for one patient only a CT scan had 
been performed. For one patient lumbosacral MRI images from a previous examination 
because o f weakness and atrophy in her legs were also available (F58).
Lumbosacral dural ectasia in combination w ith one or more lumbosacral spinal 
meningeal cysts was confirmed in seven patients, w ith  one patient showing an additional 
thoracolumbar kyphoscoliosis (F58). One o f the three patients w itho u t lumbosacral dural 
ectasia had a left thoracolumbar cyst but no lumbosacral cysts (F33), and the tw o  other 
patients had neither lumbosacral dural ectasia nor cysts. Because the MRI scans were 
originally optimized for routine aortic-diameter monitoring only, the quality o f the images 
showing the structures in the lumbosacral region was suboptimal, thus preventing a detailed 
evaluation o f the relationship between meningeal spinal cysts and radices.
Laboratory test results
Creatine kinase was normal in nine patients and borderline in one. In the four patients w ith  a 
polyneuropathy the results o f the ancillary lab tests were normal (data not shown).
Muscle biopsies
Enzymehistochemical staining excluded the presence o f common congenital myopathies or 
dystrophies in the muscle biopsies o f both patients tested, and there were no signs of 
inflammation. The biopsy o f one patient (M32) was normal while the other patient's specimen 
(F58) revealed myopathic features, which consisted o f a mild increase o f muscle-fibre calibre 
variation and scattered lobulated fibres (Figure 2). The lobular or trabecular pattern o f the 
oxidative enzyme reaction in these lobulated fibres reflects an abnormal distribution o f the 
intermyofibrillar mitochondria, possibly caused by a malfunctioning putative anchoring 
mechanism. Lobulated fibres can occur as a nonspecific alteration o f muscle fibres in many 
diverse, often longstanding, myopathies such as facioscapulohumeral muscular dystrophy, 
limb-girdle muscular dystrophies, and hypothyroidism .37
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Figure 2 Muscle biopsy o f the left quadriceps muscle o f a 58-year-old female Marfan 
patient revealing myopathic features.
A: Increased variation in the muscle fibre diameter (HE). B: Several lobulated fibres are visible in the 
centre o f the picture (NADH). Bar = 50 micrometer.
Discussion
Our comprehensive investigations demonstrated neuromuscular involvement in the 
majority o f the ten clinically and genetically proven Marfan patients we tested, albeit to  a 
variable degree. Symptoms included m ild-to-moderate myopathy and polyneuropathy and 
occasional signs o f lumbosacral radiculopathy. The deficits were most pronounced in the 
older patients, w ith muscle force, functional impairment, and neurogenic units on electro­
myography increasing w ith  age. Our findings underscore the need to  inform  medical 
practitioners that the range o f complications that can occur in patients w ith Marfan 
syndrome extends from  cardiovascular, ocular, and orthopaedic symptoms to neuromuscular 
involvement and lumbosacral radiculopathy.
Previous cardiovascular complications (endocarditis, mitral-valve prolaps, and aortic 
root/ascending aorta dilatation) and the medication used (P-blocker) may have contributed 
to  the fatigue reported by our Marfan patients and may hence be common in all patients. 
Furthermore, simvastatin can cause myalgia w ith signs o f myopathy and increases the risk of 
polyneuropathy.38 However, results o f previous studies suggest that cardiovascular disease 
and side effects o f medication cannot fully explain the muscle weakness in Marfan patients.713 
Likewise, results from  our study suggest that Marfan syndrome is directly associated with 
moderate-to-m ild myopathy and/or polyneuropathy, while the presence o f spinal meningeal 
cysts was related to  lumbosacral radiculopathy.
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Myopathy in Marfan syndrome m ight be linked to  abnormal fibrillin in muscle connective 
tissue (endo-, peri- and epimysium ),1239 which results in abnormal muscle-cell development 
and reactions to  injury or inflam m ation .1415 Abnormalities in muscle connective tissue further 
influence force transmission between muscle cells and their environment, thus also 
contributing to muscle weakness.4041
In addition to  a myopathy, four patients had an axonal polyneuropathy. Although 
fibrillin-1 and fibrillin-2 have been found in the connective tissue sheaths o f peripheral 
nerves,4243 peripheral neuropathy in Marfan syndrome has only been reported once.44 
Abnormal packing o f peripheral nerves due to fibrillin deficiency may increase the 
susceptibility to  pressure or stretch, as in other inherited connective tissue disorders.45 To 
establish whether fibrillin abnormalities also affect axonal functioning, clinical, electrophysi- 
ological, and histological examinations are warranted in larger cohorts o f Marfan patients.
In most o f the older patients physical examination and nerve conduction studies as well 
as electromyography uncovered signs o f lumbosacral radiculopathy. This co-occurred w ith 
dural ectasia and spinal meningeal cysts. However, due to the limited resolution of 
lumbosacral structures, we were unable to  determ ine the exact nature o f the structural 
relationship between meningeal spinal cysts and radices based on the scans we had at our 
disposal, which requires targeted MRI imaging o f the lumbosacral spine as well as a larger 
patient sample. Nevertheless, co-occurrence o f clinical and electrophysiologically confirmed 
signs o f radicular dysfunction and dural ectasia w ith  meningeal cysts suggests a partial 
causal association between the tw o  irregularities, which assumption is supported by 
previous reports.19
Our findings o f neuromuscular involvement in Marfan syndrome confirm the results of 
recent questionnaire studies on muscle function in Marfan syndrome in relation to  ageing,71213 
and the findings reported in a mouse model o f Marfan syndrome.14 In analogy, we recently 
demonstrated that neuromuscular features also frequently occur in another inherited 
connective tissue disorder, i.e., Ehlers-Danlos syndrome.2241 A further comparison can be 
made w ith Ullrich congenital muscular dystrophy and Bethlem myopathy, both o f which are 
caused by collagen VI deficiency.4647
The small number o f patients tested in this study is a lim itation. It was our aim to perform 
an observational and in-depth investigation to  confirm the findings o f questionnaire studies, 
but this design came w ith some restrictions. Our findings and conclusions evidently warrant 
corroboration in larger samples and designs that would also allow correlations between age, 
the extent o f the cardiovascular and neuromuscular involvement and the dural ectasia to  be 
further delineated.
In short, the majority o f Marfan patients examined in this study showed neuromuscular 
involvement, primarily consisting o f myopathy and polyneuropathy, w ith  some signs of 
(poly)radiculopathy. Overall, the symptoms were most pronounced in the older patients.
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These results call for further research in larger groups, and, if confirmed, should lead to 
increased attention to  neuromuscular symptoms and lumbosacral radiculopathy, especially 
since the life expectancy o f patients w ith  Marfan syndrome has increased.
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Chapter 11 Neuromuscular features in Marfan syndrome
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Radicular dysfunction due to 
spinal deformities in Marfan syndrome 
at older age: three case reports
Adapted from
Voermans NC, Hosman AJ, van Alfen N, Bartels RH, de Kleuver M, op den Akker JW, 
van Engelen BG.
Eur J Med Genet. 2010;53:35-9.
Abstract
Marfan syndrome is an inherited connective tissue disorder due to  mutations in fibrillin-1. 
It presents w ith cardiovascular, ocular, skeletal, pulmonary and dural signs and symptoms. 
Some o f the symptoms o f later onset are those associated w ith scoliosis and dural ectasia. 
This is the enlargement o f the neural canal especially in the lower lumbar and sacral region 
and occurs in over 90% o f Marfan patients.
We here report three patients w ith  lumbar and/or sacral radiculopathy due to (kypho) 
scoliosis and dural ectasia w ith  spinal meningeal cysts. The pain, muscle weakness, muscle 
atrophy, and sensory disturbances illustrate the severe neurological complications which 
may occur in Marfan syndrome, especially at later age. Awareness o f these complications and 
development o f management protocols is essential since life expectancy o f Marfan patients 
has increased. Marfan syndrome m ight gradually become recognized as an inherited 
connective tissue disorder w ith  potentially severe neurological complications during ageing.
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Introduction
Marfan syndrome is an autosomal dom inant inherited disorder o f the connective tissue with 
an estimated prevalence o f 1 in 5000. Phenotypic expression is variable and mutations in 
fibrillin-1 on chromosome 15 are detected in 66 - 91°% o f cases, o f which 27% are de novo.1 
Clinical presentation includes cardiovascular, ocular, skeletal, dermal, pulmonary, and dural 
signs and symptoms. Many symptoms present during puberty or later and severe 
complications (e.g. severe scoliosis and pectus excavatum, spontaneous pneumothorax, 
retinal detachment or sight-threatening glaucoma resulting from  a dislocated lens) rarely 
develop before adulthood. W ith the availability o f elective cardiac surgery and management 
by expert centres, the mean life expectancy o f Marfan patients has increased from  32 years 
in 1972 to  41 years in 1993, and probably even much further since then .2-9
This increased life expectancy may be accompanied by increase o f spinal and 
neurological complications. Some o f the symptoms o f later onset are those associated with 
scoliosis and dural ectasia.10 Scoliosis affects around 60% o f Marfan patients and may rapidly 
progress during growth spurts, leading to marked deformity, back pain, and restricted 
ventilation .411 Dural ectasia is the enlargement o f the neural canal especially in the lower 
lumbar and sacral region, which occurs in over 90% o f Marfan patients,12 and less frequently 
in Ehlers-Danlos syndrome or neurofibromatosis type I.1314 It is probably caused by ongoing 
hydrostatic pressure and transmitted pulsation o f cerebrospinal fluid, which progressively 
dilates the dural sac since the elastin composition o f the dura mater is altered due to  fibrillin 
deficiency.512 It can present as thinning o f the cortex o f the vertebral bodies, pedicles, and 
laminae o f the vertebrae, as widening o f the neural foraminae, or as an anterior (sacral) 
meningocele.10 The diameter o f dural ectasia seems to be related to  age, and dural ectasia 
can be present for a long tim e w ithou t producing any noticeable symptoms.1215 Symptoms 
can include leg pain, abdominal pain, lower back pain, or postural headaches.11 When the 
dilated part o f the dura protrudes through the neural foramina, arachnoid cysts may develop 
either outside or inside the dura, which are respectively referred to  as extradural cysts: type I
-  II and intradural cysts: type III).1216-18 Since classification based on imaging studies is difficult, 
these arachnoid cysts m ight better be described as spinal meningeal cysts. They have been 
associated w ith additional neurological symptoms, including sphincter disturbance and 
radicular compression w ith neurological deficits, especially in the elder patients.4-5-11-12-16-16-19-22 
Studies on treatm ent o f symptomatic dural ectasia w ith or w itho u t spinal meningeal cysts 
are not available.
We here report three patients w ith  lumbar or sacral radiculopathy due to (kypho)scoliosis 
and dural ectasia w ith  spinal meningeal cysts. The pain, muscle weakness, muscle atrophy, 
and sensory disturbances illustrate the severe neurological complications which may occur 
in Marfan syndrome, especially at a later age.
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Case reports
The patients were referred to  the neuromuscular outpatients department by the cardiologist 
at the multidisciplinary outpatients department for Marfan patients in one o f the three 
specialized Marfan centres in the Netherlands Marfan syndrome was diagnosed based on 
the clinical diagnostic criteria14 and confirmed by FBN/ mutation analysis in all three patients. 
Patient 2 has previously been reported in our systematic study on neuromuscular features in 
ten Marfan syndrome patients (F59).15
Patient 1
This 64-year year-old male patient suffered from severe pain for four years, radiating from his 
lower back to his left upper leg during walking or standing upright. Lower back pain had been 
present for longer, but was never as severe. The current pain had a burning character w ith a 
Visual Analogous Score o f 9/10 when upright, completely disappearing after lying down. Pain 
severity had gradually increased and the pain also radiated to  his right leg since one year. He 
was severely limited in his daily activities since he could not stand or walk longer than ten 
minutes because o f the severe pain. He had also noticed numbness o f the ventral and medial 
side o f his lower leg. Erections had disappeared ten years ago, and the patient suffered from 
urinary hesitation, which was ameliorated by tamsulosin. Defecation was normal. Transdermal 
opiod patches and gabapentin had only resulted in partial pain reduction.
Physical examination showed typical signs o f Marfan syndrome, w ith mild weakness o f hip 
flexion and o f the ankle dorsiflexors bilaterally (Medical Research Council (MRC) 4).23 Vibration 
sense was reduced in both feet, and pain and touch sensation were reduced in dermatomes L2
- L4 on the left. Knee reflexes were normal, and ankle jerks were absent bilaterally.
Nerve conduction studies revealed an axonal polyneuropathy, w ith neurogenic changes 
in the tibialis anterior muscle on needle EMG examination. Neurogenic changes were also 
found in both rectus femoris muscles, w ith denervation in the L4 paraspinal muscles on both 
sides, indicating bilateral L4 radiculopathy. Neurogenic changes o f an older date were also 
observed in the gastrocnemius muscle on the left side (right side not tested), compatible with 
previous S1 radiculopathy or axonal polyneuropathy. Sagittal MRI imaging o f the lumbosacral 
spine revealed a kyphosis o f segments L3 - L5, w ith extensive degenerative changes (irregular 
superior and inferior endplates, osteophytes, bulging discs). The body o f L3 was mildly laterally 
displaced to the left in relation to the body o f L4, in combination w ith a right sided discus 
protrusion at this level. These findings resulted in bilateral narrowing o f the foramina. Radices S1 
were compressed along their course due to  large bilateral sacral dural ectasia (Figure /).
Neurosurgical intervention was not considered beneficial due to  high risk o f dural tears. 
A selective locoregional anaesthetic block o f the left L4 nerve root resulted in mild reduction 
o f the radiating pain.
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Figure  1 Patient 1: T2 weighted MRI at the age o f 64 years.
A: Sagittal MRI images o f the lumbosacral spine revealed an kyphosis o f segments L3 - L5, w ith extensive 
degenerative changes (irregular superior and inferior endplates, osteophytes, bulging o f discs), dural 
ectasia and extensive sacral spinal meningeal cysts. B: Transversal MRI images: the right S1 root is 
compressed by large spinal meningeal cysts and no longer completely surrounded by fat.
Patient 2
A 58-year female patient suffered from progressive scoliosis, for which a thoracolumbar 
spondylodesis (anterior fusion and anterior single rod instrumentation Th9 - L2 through a left 
sided thoraco-abdominal approach) was performed at the age o f 33 years. At the age o f 49, 
she reported symptoms o f spinal stenosis. She developed a paresis o f the right ankle and toe 
dorsiflexors, for which an orthesis was prescribed. Three years later she experienced 
numbness o f the left foo t and ankle. At the age o f 56 years weakness o f her right foot 
increased, and the quadriceps and hamstring muscles also became weak. She started using 
knee braces. One year later, paresis o f the gluteus muscles occurred, which further impaired 
walking. W ith help o f a walking aid she could walk a maximum o f 2 km, needing several 
pauses. Gradually she developed urine retention and constipation for which she started 
in term ittent bladder catheterization and had to remove faeces manually.
Physical examination at the age o f 51 years revealed typical signs o f Marfan syndrome, 
including severe kyphoscoliosis o f the thoracolumbar spine after surgical correction.
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Figure 2 Patient 2: T2 weighted MRI at the age o f 58 years: dural ectasia and extensive 
spinal meningeal cysts at the level o f L5 - 1.
A: Transverse MRI images showed a close relationship o f the radices S1 and S2 w ith the dural ectasia and 
spinal meningeal cysts. Sagittal MRI images further showed a severe thoracolumbar kyphoscoliosis, 
along which the spinal cord, (epi)conus and cauda were extended. No signs o f root compression were 
found at these levels (not shown). B: Transverse MRI images: the posterior surface o f the L2 body 
revealed a large bony defect partially surrounding the conus and seemingly stretching it. Just above 
that level, susceptibility artefacts due to  a ferromagnetic metal implant were observed.
Strength, sensation, and reflexes o f her arms, hands, and left leg were normal, but a mild 
paresis o f her right leg MRC grade 4.5 was found. Examination at the age o f 58 years showed 
progressive weakness o f her right more than left leg and foot (MRC scores: Right: distally 0; 
hip flexion 3, hip extension 0; hip adduction 4, hip abduction 1, knee extension 3; Left: distally 
3, proximally 4). Deep tendon reflexes were reduced in the left leg and absent on the right, 
and vibration sense was reduced in both feet. Muscle atrophy was most pronounced in her 
right leg, and she had bilateral claw feet (left more than right).
Nerve conduction studies indicated an axonal polyneuropathy. Repeated needle elec­
tromyography revealed denervation in several leg muscles (rectus femoris, tibialis anterior, 
and gastrocnemius bilaterally; right extensor hallucis longus and right gluteus medius), with 
marked progression o f neurogenic changes over the course o f seven years. These findings 
were compatible w ith  a progressive radiculopathy at multiple lumbosacral levels. Sagittal 
MRI revealed dural ectasia and extensive spinal meningeal cysts at the sacral level. Transverse 
imaging showed a close relationship o f the radices S1 and S2 w ith  the spinal meningeal 
cysts. Furthermore, sagittal imaging showed severe thoracolumbar kyphoscoliosis, w ith  an 
elongated aspect o f the spinal cord, (epi)conus and cauda at these levels. Furthermore, the 
body o f L2 showed a large bony defect o f the posterior surface, partially surrounding the 
conus. The conus seemed to be stretched ou t at this level (Figure 2).
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The patient participated in a clinical rehabilitation program to increase physical condition 
and to lim it impairments. This program consisted of: pelvic floor therapy to improve control o f 
defecation; training with a hand bike to improve outdoor mobility; provision o f new orthopaedic 
shoes; physical therapy including hydrotherapy, focusing on walking and improvement of 
muscle strength and cardiorespiratory fitness; occupational therapy for adaptive equipment 
recommendations and usage training, and environmental adaptation including provision of 
equipment; and psychological assessment and counselling. Based on reduction o f her 
impairments and on the general satisfaction o f this patient, this program was successful. 
Operative intervention including multiple osteotomies o f the lumbar spine and instrumenta­
tion over a long segment was considered but not performed since its outcome was deemed 
too unpredictable in relation to the possible complications o f the procedure.
Patient 3
This 51-year old male patient suffered from a ruptured aneurysm o f the abdominal aorta at 
the age o f 49 years, which resulted in spinal cord ischemia w ith paraparesis, impotence and 
urinary retention for which he performed in term ittent bladder catheterization. He had 
gradually regained m obility after rehabilitation, but in spite o f the improvement o f muscle 
strength and m obility he experienced progressive pain, radiating from  his lower back to 
both legs and the sacral dermatomes. At rest the pain consisted o f a cold burning sensation 
exacerbated by touch. Walking o f short distances (20 m -  100 m) caused a feeling o f stiffness 
in his lower legs that would gradually turn in to  severe pain. If he continued walking he 
would fall because o f muscle weakness and pain.
Physical examination showed typical signs o f Marfan syndrome. Muscle strength was 
normal in his arms and reduced in the legs (MRC scores: proximally 4; distally 2-3). Sensation 
was reduced below the 12th thoracic dermatome. Pain sense and vibration sense were absent 
in his feet. Touch o f the sacral region was very painful locally. A lthough the knee jerks were 
increased, his ankle jerks were absent bilaterally.
Nerve conduction studies showed an axonal polyneuropathy. Needle electromyogra­
phy showed neurogenic changes in the extensor hallucis, tibialis anterior, and gluteus 
medius muscles on the left, and o f the gastrocnemius and gluteus maximus on the right, 
w ith  signs o f reinnervation in the right gluteus maximus. Findings were compatible w ith  an 
additional longer lasting radiculopathy o f the L5 - S2 levels on the left and S1 - S2 levels on 
the right. No EMG abnormalities were found in the hands. T2 weighted MRI studies o f the 
thoracic, lumbar and sacral spine showed thoracic scoliosis, an anterolisthesis o f L5 - S1, and 
lumbosacral dural ectasia and spinal meningeal cysts w ith  severe scalloping o f the posterior 
surface o f S1 and S2, suggestive o f longer lasting compression by the dural ectasia. Both S1 
roots were in close contact w ith the dural ectasia and spinal meningeal cysts. No signs of 
syringomyely were seen (Figure 3).
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Neurosurgical intervention was again not considered beneficial due to the multifactorial 
origin o f the pain and the high risk o f perioperative dural tears.
F igure 3 Patient 3: T2 weighted MRI at the age o f 51 years.
A: Sagittal MRI images o f the thoracic, lumbar and sacral spine showed an anterolisthesis o f L5 - S1, 
thoracic scoliosis, and lumbosacral dural ectasia and spinal meningeal cysts w ith severe scalloping of 
the posterior cortex S1 and S2. B: Transverse MRI images: Both S1 roots are in close contact w ith the 
dural ectasia and bilateral spinal meningeal cysts.
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Discussion
We here report three genetically confirmed older Marfan patients w ith pain in the lower 
back and legs and neurological impairment due to progressive radiculopathy at multiple 
lumbosacral levels. In all patients symptoms occurred predominantly while standing upright 
or walking, which suggests a role o f the hydrostatic pressure o f the cerebrospinal fluid w ithin 
the dural ectasia and/or meningeal cyst in the progression o f radicular compression. A 
concomitant axonal polyneuropathy was detected in all patients, which concurs w ith our 
previous findings in ten Marfan patients.15 The previous spinal cord ischemia has probably 
contributed to the severity o f neurological features in patient 3. Imaging studies revealed 
(kypho)scoliosis, anterolisthesis, degenerative changes, and sacral root compression by dural 
ectasia w ith  spinal meningeal cysts in all three patients. Surgical options were considered 
limited due to the high risk o f occurrence o f dural tears and osseous complications.
Neurological impairment secondary to  spinal abnormalities in Marfan syndrome has 
occasionally been reported. Hoshino reported a Marfan patient w ith  dysesthesia of 
dermatome S2 and sacral pain due to  S2 root compression by an arachnoid mass.16 
Furthermore, a 25-year old man w ith a two-year history o f worsening distal sensory and 
m otor deficits o f the lower limbs due to  a large intraspinal arachnoidal cyst was reported by 
Lazzaro.19 A study by Foran et al. showed that dural ectasia is often accompanied by leg pain 
and sensory deficits in the legs, but this was based on questionnaires and did not include 
clinical or imaging data.24
Dural ectasia w ith or w itho u t spinal meningeal cysts may cause symptoms through a 
variety o f mechanisms,24 including direct pressure on the periosteum and erosion o f bony 
elements o f the lumbosacral spine,2526 distortion or traction on neural roots,27 structural 
thinn ing and weakening o f the sacrum leading to micro-fractures or instability, direct 
pressure on abdominal organs by anterior meningocele, shifts in cerebrospinal fluid volume, 
or increased pressure w ith in focal cysts.28-30 In the three patients reported here, both osseous 
deformities and dural ectasia w ith spinal meningeal cysts are likely to  have contributed to 
the radicular dysfunction. An increased vulnerability o f the peripheral and central nervous 
system to mechanical stress by dural ectasia m ight predispose to  these symptoms in Marfan 
syndrome, similarly as in other inherited connective tissue disorders.31 Awareness o f these 
complications and development o f management protocols is essential since life expectancy 
o f Marfan patients has increased.7 Marfan syndrome m ight become better recognized as an 
inherited connective tissue disorder w ith  potentially severe neurological complications, also 
at older age.15
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Summary and outlook
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Summary, general discussion, 
and directions for further research
The last part o f this thesis summarizes the results o f our clinical and experimental studies; 
it discusses these findings in the context o f other studies and it explores the future research 
possibilities.
Summary
This thesis is the result o f the first systematic study on neuromuscular involvement in tw o  
inherited connective tissue disorders (ICTDs), Ehlers-Danlos syndrome (EDS) and Marfan 
syndrome, and on its underlying pathophysiological mechanism. Neuromuscular symptoms 
such as muscle weakness, exercise intolerance, easy fatigability, and muscle cramps had only 
sporadically been reported, and were generally understood to be secondary to  reduced 
physical activity (Table I in Chapter4).1
Part I: Introduction and outline
Part I presented a general introduction (Chapter I) and a literature review focussing on the 
molecular and clinical overlap o f ICTDs and myopathies (Chapter 2).
Chapter I: General Introduction and outline
Our clinical interest in the neuromuscular features in EDS and Marfan syndrome was raised 
by the encounter w ith  these patients w ho were referred for evaluation o f a suspected 
neuromuscular disorder. They suffered from  muscle weakness, fatigue or exercise intolerance, 
and pain. Ancillary investigations excluded a concomitant neuromuscular disorder. 
Furthermore, the extracellular matrix (ECM) molecules which are deficient in EDS and Marfan 
syndrome (collagen I, III, and V, tenascin, fibrillin) are distributed in the dense connective 
tissue network w ith in muscle and peripheral nerve.
The finding that Bethlem myopathy and Ullrich Congenital Muscular Dystrophy (UCMD) 
are caused by mutations in the gene encoding collagen VI has further increased our attention 
on neuromuscular features in EDS and Marfan syndrome.2 Apparently, a primary change in 
the ECM which surrounds muscle cells significantly influences muscle function. In addition, 
patients w ith collagen VI myopathies display hypermobility and skin changes in addition to 
muscle weakness.34 This points to  a clinical overlap o f these collagen VI myopathies w ith  the 
ICTDs.
The encounter w ith  EDS and Marfan patients w ith  neuromuscular symptoms and the 
discovery o f collagen VI myopathies also raised our scientific interest into the physiological 
mechanisms in which alterations o f the muscle ECM influence muscle function. This interest 
has further grown w ith current investigations on myofascial force transmission. This concept 
assumes that the connective tissue w ith in and between the muscles plays a role in 
transmission o f force generated by the myocytes.5
The goal o f this study was twofold: 1) to  explore the occurrence o f neuromuscular 
symptoms in EDS and Marfan syndrome; and 2) to  elucidate the role o f the ECM in muscle 
function. Therefore, we defined the follow ing aims (numbering corresponds w ith the parts 
o f the outline):
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(I) to  present an overview o f the clinical and molecular overlap o f ICTDs and myopathies;
(IIA) to  study the occurrence and nature o f neuromuscular features in EDS;
(IIB) to  investigate the pathophysiological mechanisms o f muscle weakness in EDS in order 
to  explore the role o f the ECM in muscle function, and;
(III) to  examine the occurrence o f neuromuscular features in Marfan syndrome, to  find out 
w hether the findings in part IIA are specific for EDS or can also be found in other ICTDs.
The main findings are summarized.
Chapter 2: Literature review
In Chapter 2 we presented a literature review on the molecular and clinical overlap o f ICTDs 
and myopathies.6 Various ICTDs are associated w ith mild to  moderate neuromuscular 
involvement in addition to  the well known dermal, vascular, or articular symptoms. These 
disorders are caused by defects o f matrix-embedded ECM molecules that are also present in 
the connective tissue w ith in muscle (collagens I, III, V, IX, lysylhydroxylase, tenascin, fibrillin, 
fibulin, elastin, and perlecan) and interact directly or indirectly w ith  the trans-membrane 
protein complexes o f muscle cells (dystroglycan, integrins, sarcoglycans). Neuromuscular 
features o f ICTDs have so far only sporadically been reported, but can be expected based 
upon these interactions.
In parallel, a number o f myopathies (e.g. congenital muscular dystrophy 1A, 1B or 1C, and 
Bethlem myopathy) are caused by defects in either sarcolemma-related ECM molecules 
(a-dystroglycan, sarcoglycan, integrin, and laminin) or matrix-embedded ECM molecules 
(collagens VI, XIII, and XV). These molecules all interact w ith  other molecules in the ECM 
network. Clinical characteristics o f some o f these myopathies imply skin and jo in t features 
that are characteristic o f ICTDs.
By focusing on the structure, function, and interaction o f these ECM molecules, this 
review pointed to the collective molecular background o f these disorders. The clinicians and 
researchers dealing w ith  (patients w ith) these myopathies and ICTDs should be aware o f this 
clinical and molecular overlap. Only a multi-disciplinary approach will allow full recognition 
o f the wide variety o f symptoms present in this clinical spectrum o f ECM defects. Furthermore, 
jo in t hypermobility should be recognized as a distinctive feature in the differential diagnosis 
o f myopathies, and as such be o f value for all neuromuscular physicians.7 Hence, this review 
explored the field o f research o f the subsequent studies and offered a rationale for them.
Part II: Neuromuscular features o f Ehlers-Danlos syndrome 
Part IIA: Clinical evaluation o f Ehlers-Danlos syndrome patients
The molecular and clinical overlap o f ICTDs and myopathies called for a study on the occurrence 
o f neuromuscular features in ICTDs. In part IIA, the results o f these case reports and systematic 
studies on neuromuscular symptoms, fatigue, and pain in EDS were presented.
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Chapter 3: Initial clinical observations in Ehlers-Danlos syndrome
In Chapter 3, we reported three remarkable EDS cases w ith various neuromuscular features. 
The first report describes a 30-year-old female hypermobility type EDS patient w ith various 
compression neuropathies: she subsequently suffered from axillary neuropathy, brachial 
plexopathy, peroneal neuropathy, and sciatic neuropathy.8 The latter had occurred after 
having sit cross-legged for several hours. These compression neuropathies were all confirmed 
by nerve conduction studies and electromyography, and genetic analysis had excluded a 
hereditary neuropathy w ith liability to  pressure palsies. Peripheral neuropathy in the 
hypermobility type o f EDS may be due to hypermobility o f jo ints which causes an abnormal 
stretching o f or pressure on peripheral nerves, resulting in a neuropathy or plexopathy. In 
addition, increased vulnerability o f peripheral nerves to stretching or pressure due to the 
genetic ECM defect m ight be involved. Clinicians and patients should be alert for this 
possible risk o f neuropathies in EDS in order to  prevent recurrent nerve injuries w ith 
subsequent impairments.8
After that, we reported the neuromuscular features o f an adolescent patient w ith the 
kyphoscoliotic type o f EDS due to a homozygous deletion o f PLODI (lysine hydroxylase 
1;1p36.3-p36.2).910 Muscle hypotonia and weakness had so far only been recognized in 
neonates w ith this EDS type, but not later in life. At the age o f 16, this patient displayed both 
proximal and distal muscle weakness and hypotonia. Ancillary investigations revealed signs 
o f myopathy and mild axonal polyneuropathy, both o f which may have contributed to 
muscle weakness. This case report may thus improve recognition o f neuromuscular features 
in the kyphoscoliotic type o f EDS beyond the neonatal period, which has to be taken into 
account into rehabilitation programs for these patients.10
The third case is a 50-year-old TNX-deficient type EDS patient, w ho presented w ith 
moderate proximal and severe distal muscle weakness, and generalized jo in t hypermobility 
w ith  atrophy and contractures in her hands.11 Because o f muscle weakness, she had been 
referred to  our outpatients department several years before, even prior to  EDS was diagnosed. 
Muscle biopsy had not revealed any myopathic changes initially, and a second biopsy at the 
age o f 50 did neither. The combination o f muscle weakness, hypermobility, and contractures 
also occurs in collagen VI myopathies.4 Collagen VI is an ECM component that depends on 
TNX for proper functioning. The muscle biopsy in this patient indeed showed mildly reduced 
collagen VI staining.11
Chapter 4: Systematic clinical observational study on neuromuscular features in Ehlers-Danlos 
syndrome
The variety o f these case reports contributed to  the design o f the systematic observational 
study on neuromuscular features in EDS described in Chapter4. Standardized neuromuscular 
questionnaires, physical examination, nerve conduction studies, electromyography, muscle
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ultrasound, and muscle biopsy were performed in 40 EDS patients w ith  the vascular, classic, 
TNX-deficient, and hypermobility type o f EDS caused by TNXB haploinsufficiency.12
Muscle weakness, myalgia, and easy fatigability were reported by the majority o f patients 
(respectively 65%, 73%, and 60%). M ild-to-moderate muscle weakness and reduction o f 
vibration sense were common (85% and 60% respectively). Nerve conduction studies 
demonstrated axonal polyneuropathy in five patients (13%) in absence o f a metabolic cause 
o f polyneuropathy. Needle electromyography revealed predominantly myopathic features 
in 23%, and a mixed neurogenic-myopathic pattern in 53% o f the patients. Muscle ultrasound 
showed increased echo-intensity and atrophy in approximately one half o f the patients (50% 
and 48% respectively). Mild myopathic features were seen in muscle biopsies o f five patients 
(28%). Furthermore, qualitative evaluation o f electron microscopic images revealed a lower 
density o f collagen fibrils in the endomysium and perimysium in all EDS types; and collagen 
fibrils were more often short in the biopsies o f the classical type EDS. Overall, patients with 
the hypermobility type EDS caused by TNXB haploinsufficiency were least affected, which 
points to  a remarkable relation between residual TNX level and degree o f neuromuscular 
involvement. This dose-effect relation points to  a role o f the ECM in muscle and peripheral 
nerve function in these patients.12
Chapter 5 and 6: Questionnaire study on fatigue and pain in Ehlers-Danlos syndrome 
In order to  further assess the prevalence o f fatigue and pain in EDS, and the impact o f EDS on 
daily life, we performed a written questionnaire study among 273 members o f the Dutch 
Ehlers-Danlos patient organization (Chapter 5)1314
More than three quarter o f EDS patients (77%) suffered from  severe fatigue.14 Patients 
w ho were severely fatigued were more impaired than non-severely fatigued patients and 
reported a higher level o f psychological distress. The five possible determinants involved in 
fatigue were sleep disturbances, concentration problems, social functioning, self efficacy 
concerning fatigue, and pain severity. These determinants could form  a starting point for the 
development o f an effective cognitive behavioural intervention for fatigue in EDS.14
Since pain severity was one o f the determinants o f fatigue, we subsequently analyzed 
various aspects o f pain and their relation w ith functional impairment and sleep disturbances 
(Chapter 6).13 The results showed that chronic pain in EDS is highly prevalent (90%) and 
associated w ith  regular use o f analgesics. Moreover, pain was more prevalent and more 
severe in the hypermobility type than in the classical type, and pain severity in EDS was 
correlated w ith hypermobility, dislocations, previous surgery, and w ith low nocturnal sleep 
quality. Pain was also found to  contribute to  functional impairment in daily life, independently 
o f the level o f fatigue. Therefore, treatm ent o f pain should be a prominent aspect of 
symptomatic management o f EDS as well.13
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Part IIB: Quantitative muscle function measurements o f tenascin-X-deficient 
Ehlers-Danlos syndrome patients and tenascin-XB knockout mice
The studies described in Part IIB focused on the pathophysiological mechanisms o f muscle 
weakness in EDS and were performed both TNX-deficient EDS patients and on Tnxb knockout 
(KO) mice. We refer to  Box 3 and Table I in Chapter 9 for a description o f these quantitative 
muscle force measurements and concepts. Table I in this chapter summarizes and combines 
the findings o f these studies.
Chapter 7: Pilot study on quantitative muscle function in two tenascin-X-deficient Ehlers-Danlos 
syndrome patients
We started w ith a pilot study on quantitative muscle function in tw o  TNX-deficient EDS 
patients and measured knee extension torques at relatively long muscle length (knee flexion 
90°) (Chapter 7).16 The results showed reduced maximal torques at voluntary contraction, 
relatively high tw itch torques, a normal delay between stimulation and torque generation, 
increased rate o f torque rise, and normal relaxation.
These findings could not be attributed to reduced physical activity or muscle atrophy 
alone since physical examination, muscle ultrasound, and muscle biopsy showed no signs of 
atrophy; and the findings in both patients were very similar, although one o f them  used a 
wheelchair.16 Changes in myotendinous force transmission due to enhanced tendon 
compliance could not explain the findings either. This latter would have reduced torque 
generation, have lowered the tw itch torques, have increased the delay between stimulation 
and torque generation, and have delayed relaxation. In contrast, we hypothesized that TNX 
deficiency reduces the stiffness o f (intra- and extramuscular) myofascial pathways, and thus 
causes a pathological reduction o f the force transmitted this way (myofascial force 
transmission).16 This would, in its turn, change the required muscle coordination drastically, 
and interfere w ith  mechanical interaction between antagonistic muscles in physiological 
movements.16
Chapter 8: Standardized neuromuscular assessment o f tenascin-XB knockout mice 
We subsequently performed a quantitative muscle strength study on Tnxb KO mice (Chapter 
9).17 This was preceded by a study on the neuromuscular phenotype o f these Tnxb KO mice 
in order to  better characterize the phenotype o f these mice (Chapter 8).18 This study consisted 
o f standardized functional assessment (hangtime and paw-fall-through test, and long-term 
spontaneous m otor activity assessment and quantification), muscle histology, and RNA 
expression profiling o f muscle tissue. In addition, peripheral nerve composition was studied 
by histology and electronmicroscopy.
The results showed presence o f mild muscle weakness w ithou t reduction o f long-term 
spontaneous m otor activity, and mild myopathic features in the muscle biopsies. The results
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BOX 3 Quantitative muscle assessment.
Quantitative muscle assessment implies various ways to  quantitatively measure muscle force. We will 
shortly describe the concepts and methods used.
Torque
Series elastic 
component
Compliance
Slack
Voluntary
activation
capacity
Myofascial
force
transmission
The moment o f force; this is the tendency o f a force to  rotate an object around an axis. 
The magnitude o f torque depends on three quantities: (1) the force applied; (2) the 
length o f the lever arm connecting the axis to the point o f force application; and (3) 
the angle between the two.
The series elastic component o f muscle consists o f the ECM w ith in muscle and the 
tendons attached to  the muscle. When the musculotendinous unit is activated the 
SEC acts as a spring or coil and is lengthened while the muscle fibres shorten. As SEC 
lengthens, elastic energy is stored. If the active musculotendinous unit shortens after 
an isometric force generation phase, the stored energy is released, allowing the SEC to 
contribute to  total work production. During relaxation the muscle connective tissue 
and tendons return to their unstretched configuration.
Compliance in muscle physiology is a measure o f the tendency o f the series elastic 
component in muscle and tendon to  resist recoil toward its original dimensions upon 
removal o f a distending or compressing force. It is the reciprocal o f "elastance"
Looseness or lack o f tension; this is a characteristic o f the SEC compounds o f muscle; it 
reflects the necessity to  stretch the SEC before force can be built up and be transmitted.
The capacity o f a subject to  voluntarily activate one's muscles in comparison w ith the 
activation reached after maximal activation (e.g. w ith electrical stimuation). It reflects 
the percentage o f maximal torque generation capacity that can be generated by 
voluntarily contraction.
The ability o f muscle to  transmit forces between muscle fibres and connective tissue 
w ith in muscle (endomysium and perimysium) and between individual muscles and 
connective tissue between muscles (epimysium, fascia, septum, neurovascular tract)
Skin phenotype o f Tnxb knockout (KO) mice: A: six-month-old W T (black) and Tnxb KO (grey) 
littermates were anesthetized and held by the skin o f their back. The hyperextensible skin o f the Tnxb 
KO mouse is apparent. B: when awake mice were again held by the skin o f the back: the W T mouse 
(black) struggled but could not turn; the Tnxb KO mouse (grey) turned, climbed his own skin and bit 
the investigator. Reproduced w ith permission o f NPG.15
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BOX 3 Continued.
C: Functional strength measure­
ment w ith use o f the paw-fall- 
through test: during a 1-minute 
observation period, the number 
o f times individual limbs fell 
through the wire were counted.
D: Long term motor assessment 
in a home cage-like environment; 
the box on top o f the plastic 
cage contains the camera and 
computer. The mouse is sitting in 
the left back corner (white arrow). 
Both experiments are described 
in Chapter 8.
E: Experimental set-up o f series 
A o f the quantitative muscle 
function assessment in Chapter 
9: The distal tendon o f the fully 
dissected medial gastrocnemius 
muscle is connected to  a force 
transducer (white arrow); the 
proximal tendon is left intact. 
Contractions were induced by 
electrical stimulation o f the 
sciatic nerve (grey arrow). Force 
measurements were performed 
by a transducer attached to the 
distal tendon.
F: Experimental set up o f the 
quantitative measurements 
in TNX-deficient EDS patients 
in Chapter 10: Knee extension 
and flexion torques were 
measured w ith the subjects 
seated on a custom-built 
computer-controlled lower limb 
dynamometer. The lower leg was 
connected to the lever arm of 
the dynamometer (white arrow) 
w ith the knee flexed at different 
angles. Padded straps around the 
pelvis and upper body minimized 
undesired movements o f the hip.
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278 Table 1 Summary and combination o f findings o f experimental studies in TNX-deficient EDS patients and Tnxb KO mice.
Chapter M ost im p o rta n t find ings In te rp re ta tio n H ypothesis
Chapter 7 
TNX-deficient 
EDS patients
Voluntary and  stim ulated knee extension a t 90° 
knee flexion:
1) Reduced maximal torques at voluntary 
contraction;
2) Normal delay between stimulation and 
contraction, increased torque rise, and normal 
relaxation rate.
At Iona muscle length.
1) Changes are not due to  reduced physical 
activity, muscle atrophy or changes in 
myotendinous force transmission.
1) Changes are most likely caused by changes in 
myofascial force transmission 
(Continued in Chapter 9. series B).
Chapter 9:
Series A 
Tnxb KO mice
Stim ulated isometric GM contraction a t various 
lengths:
3) Lower normalized active isometric force;
4) Longer delay between stimulation and 
contraction, normal rise o f active force, and 
reduced relaxation rate.
Only at short muscle length.
2) Altered series elastic component (i.e. higher 
compliance) w ith in the maximally dissected 
GM muscle-tendon complex 
(both the ECM network o f endo- and 
perimysium and the myotendinous pathway).
Discrepancy between finding 1) at long muscle 
length and 3) only at short muscle length:
2) Reduced activation capacity may contribute 
to  muscle weakness in EDS 
(Continued in Chanter 10).
Chapter 9:
Series B 
Tnxb KO mice
Sim ultaneously stim ulated TA+EHL, EDL and  TS 
contractions a t various lengths
5) TNX deficiency limited the antagonists 
length-dependent decrease in active force;
6) TNX deficiency significantly affected net 
(direction and magnitude) epimuscular 
myofascial force transmission.
Only at short muscle length.
3) Reduced myofascial force transmission in TNX 
deficiency between the muscles in the lower 
leg, probably due to  increased compliance o f 
connective tissue surrounding the individual 
muscles: muscles in Tnxb KO mice act more 
independently than VVT muscles.
3) Alterations in myofascial force transmission 
probably require adapted patterns o f 
muscular coordination to  allow effective 
physiological movements 
(To be continued).
Chapter 10: 
TNX-deficient 
EDS patients
Voluntary and  stim ulated knee extension and
flexion a t 30°, 60°, and  90° knee flexion:
1) Reduced maximal voluntary torque o f the 
knee-extensors across all jo in t angles tested ( 
30° 60° 90°)
2) Normal normalized torques at 30°;
3) Longer delay between stimulation and 
contraction;
4) Reduced voluntary activation on voluntary 
contraction, particularly at low muscle length.
Reduced isometric voluntary peak torque in
TNX-deficient EDS patients due to:
4) The compliance o f the series elastic 
component o f the muscle tissue is increased.
5) Reduced voluntary activation: failure to 
maximally voluntarily activate the muscles;
6) Muscle length at 30° might not be short 
enough to  detect the changes in the series 
elastic component.
4) Reduced voluntary activation has been 
demonstrated in various neuromuscular 
disorders and in chronic fatigue syndrome. 
Future research could focus on central and 
peripheral components o f experienced 
fatigue in EDS 
(To be continued).
o f RNA micro array analysis pointed to  a significant upregulation o f genes encoding structural 
ECM components as well as genes involved in synthesis and degradation o f the ECM. 
Additionally, a sciatic nerve sample showed mildly reduced collagen fibril density o f the 
endoneurium, few  signs o f degeneration and regeneration, and smaller inner and outer 
diameters o f the myelinated fibres in the Tnxb KO mouse.18
The results o f this animal study reinforced the finding o f mild to  moderate neuromuscular 
involvement in patients w ith various types o f EDS (Chapter 4)12. The observations in the sciatic 
nerve m ight relate to the occurrence o f axonal polyneuropathy in TNX-deficient EDS patients.12 
Chapter 9: Quantitative muscle strength measurements o f tenascin-XB knockout mice 
The quantitative muscle strength measurements in Tnxb KO mice consisted o f tw o  parts.171920 
First, intramuscular aspects o f muscle force were studied in isometric contractions o f the 
maximally dissected medial gastrocnemius (GM) muscle (Series A). Second, intermuscular 
aspects o f muscle force were explored by testing the force characteristics o f the triceps surae 
muscle (TS) and anterior crural muscles (EDL: extensor digitorum longus; EHL: extensor 
hallucis longus; and TA: anterior tibial muscles) w itho u t major dissection. In this way, 
mechanical interaction between these muscle groups remained intact and changes in this 
interaction during contraction could be detected (Series B).17
The first series o f experiments w ith in the maximally dissected GM showed differences 
only at low muscle lengths (optimum length - 4, - 3.5, - 3 mm): lower normalized active 
isometric force, a longer delay between stimulus and force rise, and reduced relaxation rate. 
This pointed to changes in the series elastic com ponent w ith in the maximally dissected GM 
muscle-tendon complex. This complex includes both the ECM network o f endo- and 
perimysium w ithin the muscle and the myotendinous pathway.17
These animal experiments at short muscle length added tw o  im portant findings to the 
results o f the pilot study. First, the series elastic com ponent is altered at short muscle length, 
whereas in the pilot study in tw o  TNX-deficient EDS patients w ith  measurements no such 
observations were made at relatively long muscle length .16 Changes o f the series elastic 
components would indeed be expected to manifest first at short muscle length, since more 
slack has to be taken up before the series elastic component can transmit forces. Second, 
normalized active isometric force in Tnxb KO mice was normal at optim um  length and above, 
whereas maximal torque at voluntary contraction in TNX-deficient EDS patients was reduced 
also at relatively long muscle length. This difference at optim um  length between stimulated 
active isometric force (normal in mice) and maximal torque at voluntary contraction (reduced 
in patients) raised the question whether reduced activation capacity contributes to  muscle 
weakness in EDS patients.17
The second series o f experiments in the Tnxb KO mice (Series B) focussed on the changes 
o f the series elastic com ponent between muscles (consisting o f epimysium, neurovascular 
tracts, and fascia).17 It showed differences also only at low muscle lengths. In normal mice,
279
C
ha
pt
er
 
13 
S
um
m
ar
y,
 g
en
er
al
 d
is
cu
ss
io
n,
 a
nd
 
di
re
ct
io
ns
 
fo
r 
fu
rt
he
r 
re
se
ar
ch
distal active force in the agonistic muscle (TA + EHL and TS respectively) decreased with 
increasing length o f the antagonistic muscle (TS and TA+EHL respectively); this results from 
myofascial force transmission between these muscle groups.21 TNX deficiency limited this 
antagonists length-dependent decrease in active force, which points to  reduced myofascial 
force transmission in TNX deficiency. This is probably due to increased compliance o f 
connective tissue surrounding the individual muscles. Furthermore, TNX deficiency 
significantly affected net epimuscular myofascial force transmission (measured by difference 
in force exerted at proximal and distal tendons o f the EDL), both in magnitude o f the 
myofascial load and in the direction o f loading. Together, these results entail that 
TNX-deficient muscles are less capable o f transmitting forces in other ways than via 
myotendinous force transmission. In other words, muscles in Tnxb KO mice act more 
independently than w ild type muscles in comparable experimental conditions. Such altered 
function probably requires adapted patterns o f muscular coordination to  allow effective 
physiological movements.17
Chapter 10: Quantitative muscle strength measurements in TNX-deficient Ehlers-Danlos syndrome 
patients
The first step to confirm the findings o f series A in a non-invasive manner in TNX-deficient 
patients was to test knee extension torques at short muscle length and to  measure voluntary 
activation capacity. We therefore performed a quantitative muscle function study in seven 
TNX-deficient EDS patients and five age- and sex-matched control subjects, w ith  assessment 
o f isometric voluntary and electrically elicited contractions (both knee extension and flexion) 
at 30°, 60° and 90° knee flexion (Chapter 10).22 We controlled for the level o f physical activity 
w ith  a standardized questionnaire in all subjects.
The main findings o f this study were that: 1) TNX-deficient EDS patients exhibited 
reduced maximal voluntary torque o f the knee-extensors across all jo in t angles tested (at 30°, 
60°, and 90° knee flexion); 2) normalized torques (normalized to the highest torque at 60°) 
were not different at 30° and tended to be higher in EDS patients at 90°; 3) the delay between 
stimulus and torque development was prolonged; and 4) EDS patients exhibited reduced 
voluntary activation on voluntary contraction, particularly at low muscle length.
Together, these results showed that isometric voluntary peak torque is reduced in 
TNX-deficient EDS patients, confirming the finding o f the pilot study (Chapter 7). The 
increased delay between stimulus and torque development as well as the observation that 
voluntary activation is radically reduced w ith  low knee-flexion may indicate that the 
compliance o f the series elastic com ponent o f the muscle tissue is increased as expected. 
However, such possible increased compliance seemed not to  result in obvious normalized 
torque reduction at low  knee-flexion angle (i.e. short muscle length), although measurements 
o f full torque-angle relations may be required to provide conclusive evidence. Moreover, the
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results suggest that an im portant part o f the observed muscle weakness can be explained 
by failure to  maximally voluntarily activate the muscles in addition to  these intrinsic changes 
in the muscle itself.22 Table 1 summarizes and combines the findings o f the experimental 
studies.
Part III: Neuromuscular features o f M arfan syndrome 
Clinical evaluation o f M arfan syndrome patients
In order to  find ou t whether the neuromuscular features are specific for EDS or can also be 
found in other ICTDs6 we examined the occurrence o f neuromuscular features in Marfan 
syndrome.23
Chapter 11: Systematic clinical observational study on neuromuscular features in Marfan syndrome 
A systematic observational study on neuromuscular features in Marfan syndrome was 
performed consisting o f a standardized questionnaire, physical examination, nerve 
conduction studies, needle electromyography, muscle ultrasound, laboratory investigation, 
and muscle biopsy (Chapter 11)23 In addition, previously performed neuroimages were 
screened for presence o f dural ectasia (i.e. widening or ballooning o f the dural sac surrounding 
the spinal cord, mostly at lumbosacral level) and spinal meningeal cysts.23
Various neuromuscular symptoms occur more frequently in Marfan patients than in 
controls. The four older patients (> 50 years) reported muscle weakness and had functional 
impairments. Five patients had a m ild-to-moderate reduction o f vibration sense. The nerve 
conduction studies showed an axonal polyneuropathy in four patients and needle electro­
myography revealed myopathic and neurogenic changes in all. Increased echo intensity and 
muscle atrophy was found in more than one half o f the patients on muscle ultrasound. The 
muscle biopsies obtained in tw o  patients showed myopathic changes in the older, female 
patient.23 In addition, signs o f lumbosacral radiculopathy were found, which co-occurred 
w ith dural ectasia and spinal meningeal cysts.23 Overall, symptoms were most pronounced 
in the older patients. These findings should be confirmed in a larger group o f patients, but 
already now indicate a need to further the awareness o f neuromuscular involvement and 
radicular symptoms in this population.
Chapter 12: Subsequent clinical observations o f lumbosacral radiculopathy in Marfan syndrome 
Since the occurrence o f lumbosacral radiculopathy associated w ith dural ectasia was not 
encountered in EDS and had only sporadically been reported in literature, this was further 
investigated in three Marfan patients (Chapter 12).24 Previous studies had shown that dural 
ectasia occurs in approximately 90% o f adult Marfan patients, and that its severity increases 
w ith aging.25 It is probably caused by ongoing hydrostatic pressure and transmitted pulsation 
o f cerebrospinal fluid, which progressively dilates the dural sac.25 In addition to  dural ectasia,
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other lumbosacral spinal deformities may contribute to  lower back or sacral pain in Marfan 
syndrome; these include narrow pedicles, thin laminae, vertebral scalloping, and wide 
transverse processes, as well as kyphoscoliosis and spondylolisthesis.2627
We reported three patients w ith  moderate to  severe lumbosacral radiculopathy due to 
(kypho)scoliosis and dural ectasia w ith spinal meningeal cysts (Chapter 12).24 The pain, muscle 
weakness, muscle atrophy, and sensory disturbances illustrate the severe neurological 
complications which may occur in Marfan syndrome, especially at a later age. Awareness o f 
these complications and the development o f management protocols are essential since life 
expectancy o f Marfan patients has increased. Marfan syndrome m ight gradually become 
recognized as an ICTD w ith potentially severe neurological and neuromuscular complications 
during ageing.2428
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General discussion and directions for future research
After the summary o f our results, we here discuss the findings in the context o f the other 
earlier and recent studies; and explore future research possibilities.
Part IIA: Clinical evaluation o f Ehlers-Danlos syndrome patients 
Part III: Clinical evaluation o f M arfan syndrome patients
Neuromuscular fea tures in Ehlers-Danlos syndrome and Marfan syndrome (Chapter 3-4 and 11-12) 
The occurrence o f muscular symptoms in EDS was already observed by Beighton in 1970, who 
mentioned weak, hypotonic muscles in his comprehensive thesis on EDS.1 He discussed the 
findings o f previous reports,2930 including hypotonia, progressive muscle weakness, poorly 
developed musculature, and scapular winging, all w ithou t signs o f concomitant myopathy. 
Beighton therefore interpreted the findings as secondary to avoidance o f exercise because of 
the hypermobility and instability o f jo ints .1 Nevertheless, he did discuss the suggestion that the 
muscle hypotonia might have a basis in an abnormality o f the collagen in muscle sheaths 
rather than in the muscle fibres itself, an idea that was originally reported by Froelich in 1949.31 
This idea was supported by the observation by Melnikov that the connective tissue in the 
muscles o f EDS patients was very sparse, so that the muscle bundles were hardly held 
together.132 However, since then this concept has gradually received less attention, a 
development which might be related to the evolution o f medical specialities w ith an exclusively 
narrowing o f the focus o f these specialists to the organ or tissue o f their specialism.
Similarly, Marfan himself reported muscle hypoplasia in his initial description o f the 
syndrome.33 It has long been acknowledged as a significant clinical feature and was reported in 
up to 80% o f cases.3435 Furthermore, the handbook o f McKusick reported in 1966 that "Muscular 
underdevelopment and hypotonia is a frequent but by no means invariable feature. This feature has 
been so striking as to suggest a primary disorder o f muscle in some instances"'36 However, these 
features gradually received less attention, and in refining the nosology o f Marfan's syndrome in 
1979, Pyeritz and McKusick did no longer mention muscular involvement.37
Only recently, neuromuscular features in Marfan syndrome have received renewed 
attention .3839 Behan reported a family w ith Marfan syndrome and mild proximal and distal 
muscle weakness and respiratory failure.38 Electromyography showed myopathic units. 
Muscle biopsy revealed no myopathic changes, but the fibrillin immunostaining was reduced 
in endo- and perimysium, and the fibrillin present appeared to  be a truncated form  o f the 
protein. It was suggested that this contributed to the myopathy in this family and that muscle 
features should be borne in mind when assessing Marfan patients.38
Our findings in Marfan patients are in accordance w ith  a recent experimental study on 
muscle regeneration in a mice model o f Marfan syndrome.39 The results o f this study shed 
light on the pathophysiological mechanism o f myopathy in Marfan syndrome: the patho­
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physiology o f Marfan syndrome involves excessive signalling by transforming growth factor 
(TGF)-p, which is known to inhibit the terminal differentiation o f cultured myoblasts into 
myocytes. Increased TGF-p activity in Marfan syndrome impairs muscle regeneration in 
fibrillin-1-deficient mice. This study also showed that systemic antagonism o f TGF-p through 
administration o f the angiotensin II type 1 receptor blocker losartan normalizes muscle 
architecture, repair and function in vivo.39
We expect that the findings o f this thesis will enhance recognition o f the neuromuscular 
phenotype o f both disorders, and possibly also o f other ICTDs. Follow-up o f EDS and Marfan 
patients at outpatient's clinics calls for a multi-disciplinary approach that preferably includes 
neurological examination and attention for neuromuscular and radicular symptoms. Muscle 
biopsies to  exclude the presence o f a co-existent myopathy m ight not be necessary if typical 
clinical and neurophysiological findings are encountered. Box4 and Figure 1 summarize the 
clinical features that should prompt the neuro(myo)logist to  include EDS in the differential 
diagnosis, and Box 5 illustrates how to measure jo in t hypermobility. Vice versa, neuro(myo) 
logists could add a standardized assessment o f jo in t m obility w ith  a goniom eter to  the 
physical examination o f patients suspected o f myopathies, since jo in t hypermobility can be 
a clue in the differential diagnosis o f myopathies.7
Neuromuscular symptoms in other inherited connective tissue disorders and myopathies 
The clinical and molecular overlap between ICTDs and certain myopathies as well as the 
presence o f neuromuscular symptoms in EDS and Marfan syndrome m ight suggest that 
other ICTDs are also associated w ith neuromuscular symptoms, and subsequently, that this is 
also related to  the underlying ECM defect. This could be investigated systematically in a 
number o f patients w ith osteogenesis imperfecta, due to collagen I defects or cutis laxa due 
to  elastin defects. Muscle weakness has been reported in both disorders.640-42
In parallel, experimental studies (neuromuscular assessment and quantitative muscle 
function measurements) could be extended to include other animal models o f ICTDs. Mice 
models o f the vascular type and the kyphoscoliotic type EDS and o f Marfan syndrome are 
available, o f which the latter tw o  have been characterized w ith  muscle weakness.394344 To 
find ou t if altered ECM composition in these animals also reduces myofascial force 
transmission in these mice, more detailed studies are needed.21 This would further support 
the concept that the ECM composition influences muscle function.
Another extension o f our current study population would be to include patients with 
collagen VI myopathies. Quantitative muscle function studies in these patients could 
generate further support for the hypothesis o f reduced myofascial force transmission in 
patients w ith  an altered muscle ECM. This would preferably be tested in patients w ith 
Bethlem myopathy, since muscle histology is relatively normal in Bethlem myopathy 
compared w ith Ullrich congenital muscular dystrophy.
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Peripheral nerve function in Ehlers-Danlos syndrome
The clinical and experimental studies in this thesis focused primarily on muscle symptoms 
and muscle function in EDS and Marfan syndrome. In addition, various findings suggested 
that peripheral nerve function is also affected by the ECM defect: the case report o f an EDS 
patient w ith  subsequent compression neuropathies (Chapter 3), the finding o f axonal 
polyneuropathy in five EDS patients (Chapter4) and four Marfan patients (Chapter 11), and the 
observation o f reduced collagen fibril density o f the endoneurium, few  signs o f degeneration 
and regeneration, and smaller inner and outer diameters o f the myelinated fibres in a Tnxb 
KO mouse (Chapter8). A systematic analysis o f peripheral nerve function in a larger number 
o f Tnxb KO mice is therefore warranted. Moreover, the study o f neuromuscular symptoms in 
other ICTDs mentioned above should focus on both muscle and peripheral nerve function.
Causes o f so far unsolved myopathies and a predominant role o f fibroblasts 
The search for causes o f so far unsolved cases o f myopathy might include other ECM molecules. 
This is especially important if clinical features include dermal, vascular, articular or skeletal 
features. For example, in a number o f patients w ith a phenotype o f UCMD or Bethlem 
myopathy, no COL6A mutations are found, and other ECM molecules may be involved in their 
pathophysiology. This also accounts for unexplained cases o f ICTDs, such as the hypermobility 
type EDS. Results o f previous interaction studies have suggested ECM molecules that might be 
involved: e.g. collagen XII,46 fibronectin,47 biglycan, and decorin.648
It has recently been shown that muscle interstitial fibroblasts and not myocytes are the 
main source o f collagen VI synthesis in skeletal muscle.49 This implies major roles o f this cell type 
and the ECM in the pathogenesis o f Bethlem myopathy and Ullrich congenital muscular 
dystrophy. Fibroblasts may similarly be the providers o f other ECM components. This might be 
investigated further and should be taken into account in future studies on diseases caused by 
ECM defects.
Fatigue and pain are predominant features o f Ehlers-Danlos syndrome 
The neuromuscular questionnaires included in the clinical studies (Chapter 4 and 11) had 
revealed that fatigue and (muscle) pain were common among both EDS and Marfan 
patients.1223 However, both symptoms had received only little  attention in medical literature 
for long .4550 We therefore analysed these symptoms in an extensive questionnaire study 
among members o f the Dutch patient support group for EDS. This study has added that 
severe fatigue (77% o f EDS patients) and pain (90% o f EDS patients) are debilitating features 
in EDS.1314 These results may support EDS patients not only in medical recognition but also in 
social acceptation o f their impairments.5152
The observation that fatigue and pain drastically interfere w ith  daily life is vividly 
illustrated by a recent patients' account on EDS in the British Medical Journal.51. These case
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Figure 1 Clin ica l fea tures o f  EDS.
A, B, and C:Joint hypermobility and skin hyperextensibility in a patient w ith the TNX-deficient type EDS. 
D: Wide, atrophic scarring in a patient w ith the classical type EDS. E, F and H: Thin translucent skin, jo int 
hypermobility, and typical facial appearance in a patient w ith the vascular type EDS: (large eyes), small 
chin, and th in  lips. G: Atrophic scarring (cigarette paper like scar) in a patient w ith the classical type EDS.
A B
C
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BOX 4  When to  th ink  o f EDS.7-12-45
General history
Medical history
Family history 
Physical examination
Neurological
examination
Ancillary
investigations
Delayed gross motor milestones
Double-jointed in sports; being proficient at ballet and gymnastics during childhood 
Showing hypermobility ‘ tricks" during childhood
Giving up sports during the teens due to  recurrent injuries, pain, and fatigue
Mild generalized muscle weakness
Musculoskeletal pain
Easy fatigability
Paresthesias
Recurrent (sub)luxation
Tendon and muscle rupture
Anal prolaps in childhood
Reduced effect o f local anaesthesia
Complications o f surgery, e.g. hernia
Easy bruising, sometimes w ith incorrect suspicion o f child abuse
Abnormal wound healing w ith wide atrophic scars
Uterus prolaps or cervical insufficiency w ith premature delivery
Early onset varicose veins
Pneumothorax or pneumohematothorax
Spontaneous arterial rupture (vascular or kyphoscoliotic type)
Clubfoot (vascular type)
Intestinal or uterine fragility or rupture (vascular type)
Severe scoliosis at birth (kyphoscoliotic type)
Congenital bilateral hip dislocation (arthrochalasia type)
Hypermobility
Sudden death (vascular type)
Generalized jo in t hypermobility (Beighton score > 5)
Increased skin hyperextensibility (> 4 cm on volar side o f lower arm)
Smooth, velvety skin 
Wide, atrophic scars
Molluscoid pseudotumors (calcifications o f superficial hematomas that frequently 
develop at pressure points like heels, knees, and elbows or are associated w ith scars) 
Piezogenic papules (pressure-induced lesions that appear on the heels while bearing 
weight, due to  herniation o f fat tissue into the dermis)
Sferoids (small subcutaneous hard bodies, frequently mobile and palpable on 
forearms and shins)
Thin, translucent skin, characteristic facial appearance, and acrogeria (vascular type) 
Gingival recession (vascular type)
Microcornea (kyphoscoliotic type)
Kyphoscoliosis (kyphoscoliotic or arthrochalasia type)
Mild proximal weakness
Mild reduction o f vibration sense (measured w ith Rydell-Seiffer tuning fork) 
Reduction but no absence o f tendon reflexes
Nerve conduction studies: reduction o f compound muscle action potential (CMAP) of 
distal muscles, mild axonal sensomotor polyneuropathy
Electromyography: mixed pattern o f both small (myopathic) and larger (neurogenic)
units, or predominantly myopathic units
CK: normal or mildly elevated (generally < 500 U/l)
Muscle biopsy: normal or mild myopathic features (increase o f fibre diameter variance 
and internal nuclei)
Im aging (MR, CT, ultrasound): mitral valve prolaps (common) or proximal aortic 
dilatation (uncommon)
Bone densitometry: osteopenia (kyphoscoliotic type)
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BOX 5 How to measure joint hypermobility.
Beighton score
Degree of mobility by passive 
manoeuvres in 5 joints.
Total score: 0-9. 
Hypermobility:
score > 5.
Bulbena score
Degree of mobility by passive 
manoeuvres in 9 joints.
Total score: 0-10. 
Hypermobility:
> 5 (women);
> 4 (men).
1) Dorsiflexion of the little fingers beyond 90°; one point for each hand;
2) Apposition of the thumbs to the flexor aspect of 
the forearm; one point for each hand;
3) Hyperextension of the elbows beyond 10°; one point for each elbow;
4) Hyperextension of the knees beyond 10°; one point for each knee;
5) Forward flexion of the trunk with knees fully extended so that the palms of the hand 
rest flat on the floor; one point.
One point for each hypermobile joint.
Upper extremity:
1) Thumb: passive apposition of the thumb to the flexor aspect of the forearm < 21 mm;
2) Metacarpophalangeal: with the palm of the hand resting on the table, the passive 
dorsiflexion of the fifth finger is > 90°;
3) Elbow hyperextension: passive hyperextension of the elbow > 10°;
4) External shoulder rotation; with the upper arm touching the body, and the elbow fixed at 
90°; the forearm is taken in external rotation to > 85° of the sagittal plane (shoulder line); 
Lower extrem ity - supine position:
5) Hip abduction: passive hip abduction > 85°;
6) Patellar hypermobility: holding with one hand the proximal end of the tibia, the patella 
can be moved well to the sides with the other hand;
7) Ankle and feet hypermobility: an excess range of passive dorsiflexion of the ankle 
everslon of the foot can be produced;
8) Metatarsophalangeal: dorsal flexion of the toe over the diaphysis of the first metatarsal 
is > 90°;
Lower extrem ity - prone position:
9) Knee hyperflexion: knee flexion allows the heel to make contact with the buttock. 
General:
Presence or absence of ecchymoses (1 point for the presence of ecchymoses).
One point for each hypermobile joint.
Illustration of goniometer used 
for measurement of angles of joint 
mobility
histories by a mother of a patient and two patients themselves illustrate the many problems 
facing patients with EDS in its various forms, among which are frequent (sub)luxations, 
delayed wound healing, pain, fatigue, delayed diagnosis, and the experience of being 
ignored by health-care professionals.51 Moreover, a number of studies on quality of life, pain 
and fatigue in EDS have been published in parallel with our studies or since then.53-57 We will 
shortly discuss this below.
In response to our study on neuromuscular features in EDS, Castori et al. reported a high 
level of bodily pain, and stressed the importance of differentiating between nociceptive and 
neuropathic pain in order to develop efficient treatment strategies.53 In a subsequent study 
on natural history and manifestations of the hypermobility type EDS, the same author 
reported high frequency of fatigue (86%).54 The authors also proposed to delineate three 
phases in the natural course of the hypermobility type of EDS: a "hypermobility" phase, a 
"pain" phase, and a "stiffness" phase.54 This classification has proven very useful in explaining 
the disease course to patients in our centre. Treatment strategies might be most effective 
when starting in the first phase, to prevent pain and stiffness.54 Their group also reported that 
neuropathic pain is a common feature in EDS.56 Next, Rombaut et al. investigated 32 female 
hypermobility type EDS and showed a significant presence of joint pain, joint dislocations, 
muscle cramps, tendinitis, fatigue and headache, with reduction of level of physical activity 
and health related quality of life.55 Furthermore, the memory of not being respected or of not 
taken seriously is substantial for individuals with EDS and can last for years.52 This results in 
lack of trust for the health-care system and difficulties in future encounters with health care.52
A multidisciplinary treatment approach of fatigue and pain in Ehlers-Danlos syndrome 
The five possible determinants involved in fatigue could form a starting point for the 
development of an effective cognitive behavioural intervention for fatigue in EDS, preferably 
within a multidisciplinary approach including cognitive behaviour therapy, physical exercise 
training program, and symptomatic treatment of pain.1314
For the design of such an approach, we can use the expertise of our centre on the 
treatment of fatigue in various neuromuscular disorders. A recent longitudinal study in 
various neuromuscular disorders has shown that muscle strength, self-reported physical 
activity, sleep disturbances, and pain at baseline contributed directly or indirectly to fatigue 
and impairment at follow-up.58 Lower muscle strength contributed to lower levels of physical 
activity, which, in turn, contributed to fatigue severity (Figure 2). In facioscapulohumeral 
dystrophy, pain also contributed to physical activity.5859 Furthermore, we recently showed 
that muscle weakness contributes to fatigue also independently of level of activity.60 Fatigue 
in EDS may be reduced even more if muscle weakness can also be addressed in the physical 
exercise training program, in addition to the level of activity.
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A multidisciplinary treatment trial of fatigue and pain in EDS could consist of the 
following three arms (in parallel with a recently designed trial for treatment of chronic fatigue 
in patients with facioscapulohumeral dystrophy59):
1) aerobic exercise training (+ usual care) to improve physical capacity;
2) cognitive behavioural therapy to stimulate an active life-style yet avoiding excessive 
physical strain (+ usual care); or
3) usual care alone, which consists of no therapy at all or occasional conventional physical 
therapy.59 Preferably, adequate symptomatic treatment of pain should also be considered.
Figure 2 A hypothetical model of perpetuating factors of experienced fatigue in EDS, and 
the multidisciplinary treatment options.
This theoretical model is based on the results of our cross-sectional study on fatigue, in which we 
identified five possible determinants of fatigue in EDS: sleep disturbances, concentration problems, 
social functioning, self efficacy concerning fatigue, and pain. Since we used cross sectional data, we 
were only able to show that these factors are possible determinants, and a follow-up study would allow 
analyzing whether these possible determinants are a cause or a consequence of fatigue. Most likely, 
sleep disturbances, low self-efficacy concerning fatigue, and pain contribute to persistence of severe 
fatigue. Concentration problems may rather be a result of fatigue, whereas social impairment might be 
either a perpetuating factor or a consequence of fatigue: increase of pain severity and fatigue negatively 
influences social participation, whereas strong social support might contribute to persistence of fatigue.
Hypothetical 
model of 
fatigue in EDS
Trea tm ent 
o f pain
Pain
+"/ V
Sleep d isturbances and dys- + Social fu n c tion in g
regu la tion  o f sleep-wake cycle >
Self e fficiacy 
concern ing fa tigue
Cognitive
behavioral
therapy
290
Part IIB: Quantitative muscle function measurements o f tenascin-X-deficient 
EDS patients and tenascin-XB KO mice
Standardized neuromuscular assessment of Tnxb knockout mice
The clinical studies focussed on the occurrence of neuromuscular features in EDS and Marfan 
syndrome (Chapter4 and //).U23 We continued our research with experimental studies in a 
animal model of EDS: the Tnxb KO mouse.
We choose this mice model of EDS for several reasons. First, it is the model of the 
TNX-deficient type EDS, the type of which we had recruited and were going to investigate 
ten patients. In contrast with the classical and hypermobility type EDS, the TNX-deficient 
type can be confirmed by genetic (TNXB mutation or deletion) or biochemical analysis 
(complete absence of TNX in serum). The diagnosis of the vascular type EDS can also be 
confirmed by genetic or biochemical testing; however, a mouse model has become available 
only recently.4461 Furthermore, the phenotype of the Tnxb KO mice had already been 
investigated at our centre,6263 the mice were still available at our animal laboratory, and we 
were given the opportunity to investigate their neuromuscular phenotype.
The results of our studies in Tnxb KO mice (Chapter8)18 confirm the observations in the 
TNX-deficient patients and are in accordance with the findings in a mice model of the 
kyphoscoliotic type of EDS.43 These lysyl hydroxylase-1 KO mice were passive and floppy 
when being handled, with reduction of frequency and strength of spontaneous movements.43
Quantitative muscle strength measurements in tenascin-X-deficient Ehlers-Danlos syndrome 
patients and tenascin-XB knockout mice
The quantitative muscle force measurements in Tnxb KO mice point to alterations of the 
series elastic component (i.e. higher compliance) within the muscle, and to reduced 
myofascial force transmission (Chapter 9).17 This may drastically affect muscular coordination 
required for physiological movements. A reduction of the compliance of intra- and 
extramuscular connective tissue due to the ECM defect results in a contraction in which 
more slack has to be taken up at the onset of contraction, which will be most prominent at 
short muscle length. We could not confirm this with the measurements in TNX-deficient EDS 
patients at 30° (Chapter /0), but the muscle might be not short enough in this position to 
detect this. This study in EDS patients has added that an important part of the observed 
muscle weakness can probably be explained by failure to maximally voluntarily activate the 
muscles.
Such a central activation failure has also been demonstrated in various neuromuscular 
disorders and chronic fatigue syndrome, in which the degree of central activation failure was 
related to experienced fatigue severity.64-66 Reduced central activation in EDS and 
neuromuscular disorders might be a compensatory mechanism in case of abnormal muscle 
function, i.e. that central activation reduces to prevent overloading of muscles which are
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limited in their force generating possibilities. This is a hypothesis that has to be investigated 
in various neuromuscular disorders and also in EDS.
How  can an extracellular matrix defect cause myopathic changes?
The finding of reduced myofascial force transmission, and the suggested altered muscle 
coordination required for physiological movements probably accounts to some extent for 
the muscle weakness in EDS. However, we also observed mild myopathic features both in 
EDS and Marfan patients and in Tnxb KO mice. Most likely, an additional pathophysiological 
mechanism underlying myopathic changes in TNX deficiency is involved. In parallel, how the 
ECM defect within peripheral nerve alters axonal transport has not been elucidated either.
In Box6, we discuss the concept of cellular tensegrity; it offers a model which might help 
to understand the effects of extracellular processes on intracellular functioning and vice 
versa: this concept may support and direct future research questions in this field and may be 
of assistance in the design of possible investigations.
Changes in intracellular processes in collagen VI myopathies and in Marfan syndrome 
In this tensegrity model, defects of ECM molecules logically have direct intracellular effects 
through a chain of interconnected structural elements. This is illustrated by mitochondrial 
dysfunction due to defective autophagy in collagen VI myopathies69 and increased TGF-p 
activation and signalling in Marfan syndrome.3969 Although the collagen VI and the fibrillin 
deficiency were considered crucial in the pathophysiology of both disorders for a long time, 
recent research has shown that these ECM defects also have important intracellular effects, 
which may be the decisive step in the pathophysiological process.3969-71 We will discuss these 
findings below.
Muscle biopsies of patients with collagen VI myopathies show dysfunctional mitochondria 
and spontaneous apoptosis, leading to myofibre degeneration.69 Defects in autophagy of 
mitochondria were shown to be the cause. Forced activation of autophagy (by genetic, dietary 
and pharmacological approaches) restored myofibre survival and improved the dystrophic 
phenotype of COL6A1 KO mice. In addition, in the first part of this discussion we described the 
increased TGF-p activity in Marfan syndrome which leads to failed muscle regeneration.39 The 
effect of losartan on neuromuscular function in Marfan syndrome should be addressed in 
upcoming clinical trials, preferably both at clinical and at histological level.
Changes in intracellular processes in Ehlers-Danlos syndrome: Titin function 
We recently started to investigate intracellular function in EDS patients by studying titin 
expression and function in muscle biopsies of TNX-deficient EDS patients. Titin (or connectin) 
is the third myofilament of striated muscle after myosin and actin (Figure3 below and Figure 
2  in Chapter 1). It is composed of 244 individually folded protein domains which unfold when
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BOX 6 Cellular tensegrity.
Cellular tensegrity is a concept that refers to the balance between tension and structural integrity of 
living cells. It suggests that a (muscle) cell is a prestressed tensegrity structure; this is that the shape 
of the (muscle) cell results from the balance of the tension of its various structural components. 
Tensegrity is a form of tensile architecture that uses tension and compression in a combination 
that yields strength and resilience beyond the sum of their components. In the cell, stiff hollow 
fibres within the cytoskeleton called microtubules act as struts, while contractile microfilaments 
provide tension, acting like stretched rubber bands that compress the microtubules and pull on 
the ECM through adhesion points. The inward pull of the contractile microfilaments is resisted by 
microtubules and by the ECM. This matrix is a semi flexible meshwork of large protein filaments 
that cells anchor to their environment. (http://www.childrenshospital.org/research/cell_tensegrity/ 
index.html).67,68
Cellular tensegrity: Cells attach and spread on the ECM by applying traction forces to their 
adhesion to the matrix.
Making the ECM less rigid (images from left to right side) decreases one of the forces that balances 
in the microfilaments. The matrix buckles and the whole cell contracts to take on a more round 
shape. Because the internal microfilaments are unable to bear the forces previously borne by the 
matrix, they first buckle and then bend around the nucleus as the entire cell membrane retracts 
and rounds.
the protein is stretched and refold when the tension is removed. Mutations in the gene 
encoding titin (TTN 2q31) are associated with a variety of (cardio)myopathies, among which 
are dilated cardiomyopathy 1G, hypertrophic cardiomyopathy, tibial distal myopathy, and 
limb girdle muscular dystrophy 2J.72
293
C
ha
pt
er
 
13 
S
um
m
ar
y,
 g
en
er
al
 d
is
cu
ss
io
n,
 a
nd
 
di
re
ct
io
ns
 
fo
r 
fu
rt
he
r 
re
se
ar
ch
It is the largest protein known (molecular weight 3,960 kD) and underlies the passive and 
restorative forces that maintain the structural integrity of the sarcomere and bring about 
intracellular passive muscle stiffness.72 As such, it can be considered to be the intracellular 
counterpart of the elastic components of the ECM which cause the extracellular passive 
muscle stiffness.
In preliminary studies we found that titin-based stiffness is greatly increased in single 
muscle fibres from TNX-deficient patients, an increase that might be viewed as an adaptive 
response to compensate for the reduced ECM stiffness (personal communication with C. 
Ottenheijm, 2011). In fact, adaptations in titin (becoming more stiff) that counteract opposite 
changes in the ECM (more loose due to defects of collagen) have been documented 
previously in dilated cardiomyopathy patients.73 These exciting findings suggest crosstalk 
between the ECM and titin, with adaptations in titin that might be beneficial for muscle 
function. These findings illustrate the tensegrity concept. Vice versa, myopathies with 
decreased titin-based stiffness may have opposing adaptations of the compliance of the 
muscle ECM. This might subsequently influence myofascial force transmission. It would be 
interesting to study this further with quantitative muscle function measurements.
Limitations
The studies in this thesis have several limitations, which have been discussed in the various 
chapters and are summarized below.
First, Chapter3 contains case-reports of individual patients, and Chapter 7 and 12 are case 
series of respectively 2 and 3 patients. A case report is a type of anecdotal evidence. As such, 
it is less scientifically rigorous than controlled clinical data involving a larger sample size. 
However, advocates argue that case reports and case series have their own role in the 
progress of medical science.74 They permit discovery of new diseases and unexpected effects 
(adverse or beneficial) as well as the study of mechanisms, and they play an important role in 
medical education. Case reports and series have a high sensitivity for detecting novelty and 
therefore remain one of the cornerstones of medical progress; they provide many new ideas 
in medicine.74 The case reports on EDS patients (Chapter 3) and the case series on three 
Marfan patients (Chapter 12) in this thesis illustrate this role in reporting novel observations, 
and were the starting point for the subsequent studies. The pilot study in two EDS patients 
(Chapter 7) had a role in the study of the mechanism of muscle weakness in EDS, which was 
subsequently tested in a mouse model (Chapter 9) and in a larger group of TNX-deficient EDS 
patients (Chapter 10). As such, these case reports and case series have contributed the 
development of the research on this topic.
Another major limitation is that the questionnaire study (Chapter5 a n d 6) was performed 
among members of the national EDS patient organisation, and that we only used the 
questionnaires which were returned. In this way, we were able to include a large number of
294
Figure 3 Titin is a giant protein that functions as a molecular spring which is responsible 
for the intracellular passive elasticity of muscle.
As such, titin is important in the contraction of striated muscle tissues. It connects the Z line to the M 
line in the sarcomere. The protein contributes to force transmission at the Z line and resting tension in 
the I band region. It limits the range of motion of the sarcomere in tension, thus contributing to the 
passive stiffness of muscle. Variations in the sequence of titin between different types of muscle (e.g., 
cardiac or skeletal) has been correlated with differences in the mechanical properties of these muscles.
Nebulin
>. ..........  52
___
Thick filam ent (m yosin) Tropo- Titin Thin filam ent (actin) 
m odulin
Sarcomere
patients; however, this method includes a selection bias. First, both patients who are not 
severely impacted by the disease and busy with their work and family, and patients who are 
severely affected with major impairment might not get involved in a patient support group 
and tend not to complete questionnaires. Second, we were unable to perform a 
non-responders analysis, since the patient support group took care of the mailing of the 
questionnaires and did not send us the names and addresses of their members for privacy 
reasons. Furthermore, although we only included patients in whom EDS had been diagnosed 
by a medical specialist, we have not verified these diagnoses ourselves. This included an 
uncertainty about the diagnosis of the participants of this questionnaire study. However, 
recruitment of a large number of consecutive EDS patients at an outpatients department 
would have been complicated, since the care for EDS patients is multidisciplinary, and most 
hospitals do not have a specialized EDS centre.
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Next, the study on mild muscular features in Tnxb KO mice (Chapter 8) has other 
limitations. First, we used animals of an advanced age, which raises doubt whether the 
abnormalities are of pathological or of biological interest. Furthermore, use of animals of 
different age and different gender for various investigations in the first of these studies may 
have complicated the interpretation of the results. However, we concluded that due to its 
explorative design, these results could serve as a starting point for further physiological 
studies on muscle function in Tnxb KO mice. The second experimental animal study (Chapter 
9) has also used mice of an advanced age, with the same restriction as mentioned above. 
However, in human, hypermobility generally reduces in aging, and tissues become stiffer; 
hence, the differences between Tnxb KO mice and WT mice might have been larger at a 
younger age.
Finally, the study on neuromuscular features in Marfan syndrome has been performed in 
a small group of Marfan patients. This should preferably be confirmed in a larger series. 
Nevertheless, the findings point to a substantial neuromuscular and radicular involvement in 
Marfan syndrome. This serves the goal of showing that neuromuscular involvement is not 
restricted to EDS but also occurs in other ICTDs.
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BOX 7 Final conclusions and recommendations.
Final conclusions
1) A clinical and molecular overlap exists between ICTDs and certain myopathies due to defects 
in molecules of the muscle ECM.
2) Both EDS and Marfan syndrome are associated with various neuromuscular features:
• Mild neuromuscular features with signs of myopathy and polyneuropathy are part of the 
phenotype of EDS.
• Mild neuromuscular features with signs of myopathy, polyneuropathy, and lumbosacral 
radiculopathy are part of the phenotype of Marfan syndrome.
3) Severe fatigue and chronic pain are highly prevalent among EDS patients (77% and 90% 
respectively).
• The five possible determinants involved in fatigue in EDS are sleep disturbances, concentration 
problems, social functioning, self efficacy concerning fatigue, and pain severity.
• Pain is related to hypermobility, dislocations, and previous surgery and associated with 
moderate to severe impairment in daily functioning.
4) Muscle weakness in EDS is not caused by reduced physical activity but results from:
• Alterations of the series elastic component of myotendinous pathways (i.e. a higher 
compliance).
• A reduction of myofascial force transmission between muscles, due to which muscles act more 
independently (in Tnxb KO mice).
• A failure to maximally voluntarily activate the muscles (in TNX-deficient patients).
Recommendations for clinical practice
1) Clinical geneticists should pay attention to neuromuscular and radicular symptoms in ICTDs. 
Vice versa, neuromyologists should look for 'connective tissue symptoms' (joint hypermobility, 
abnormal scar formation, vascular fragility) in patients with myopathies caused by mutations 
in genes encoding ECM molecules.7 They should preferably use a goniometer to measure joint 
hypermobility.
2) If mild neuromuscular features are encountered in EDS or Marfan syndrome, similarly as what 
we have described and without other signs of a concomitant myopathy, a muscle biopsy does 
not have to performed.
3) The five possible determinants involved in fatigue could form a starting point for the 
development of an effective cognitive behavioural intervention for fatigue in EDS. Treatment of 
pain should be a prominent aspect of symptomatic management of EDS.
Recommendations for future research
1) Investigate the occurrence of neuromuscular symptoms in other ICTDs.
2) Investigate quantitative muscle function in collagen VI myopathies, preferably in patients with 
Bethlem myopathy.
4) Consider ECM molecules as causative agents of so far unsolved myopathies.
3) Study the occurrence and pathophysiological mechanisms of peripheral nerve function in EDS 
and Marfan syndrome in more detail.
5) Investigate how the ECM defects in various types of EDS cause intracellular - both myopathic 
and axonal - changes. This includes further study of the function of titin in EDS.
6) Explore why central activation capacity is reduced in EDS.
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Nederlandse samenvatting
Het laatste deel van dit proefschrift bevat een samenvatting van de belangrijkste bevindingen.
Samenvatting
Dit proefschrift is het resultaat van het eerste systematische onderzoek naar neuromusculaire 
symptomen in een ongeselecteerde groep patiënten met Ehlers-Danlos syndroom (EDS) en 
Marfan syndroom. Dit zijn de twee meest voorkomende erfelijke bindweefselaandoeningen. 
Het onderzoek richt zich zowel op de aard en frequentie als op het pathofysiologisch 
mechanisme van deze symptomen. Een aantal neuromusculaire symptomen zoals spier­
zwakte, inspanningsintolerantie, snelle vermoeidheid en spierkrampen is eerder beschreven 
in individuele patiënten of families met EDS of Marfan syndroom. Tot nu toe werd dit 
geweten aan de verminderde fysieke activiteit van patiënten ten gevolge van pijn en angst 
voor dislocaties (zie ook Tabel I in Hoofdstuk4).
Deel I: Inleiding en opzet van dit onderzoek
In het eerste deel van dit proefschrift wordt toegelicht wat bindweefsel en extracellulaire 
matrix (ECM) is en waar dit gelokaliseerd is in de spier. De belangrijkste kenmerken van EDS 
en Marfan syndroom worden besproken, en er wordt uitgelegd hoe dit onderzoek tot stand 
is gekomen en is opgezet (Hoofdstuk I). Verder wordt er een overzicht gegeven van de 
moleculen waaruit het bindweefsel in spier is opgebouwd, en welke ziekten veroorzaakt 
kunnen worden door afwijkingen hiervan.
Hoofdstuk I: Algemene inleiding
Onze interesse in de neuromusculaire symptomen van patiënten met EDS en Marfan 
syndroom komt voort uit het contact met een aantal patiënten dat naar onze polikliniek 
werd verwezen met een verdenking op een spier- of zenuwziekte. Zij hadden last van 
spierpijn, vermoeidheid of pijn. Aanvullend onderzoek liet geen aanwijzingen zien voor een 
primaire spier- of zenuwziekte, maar wel voor EDS of Marfan syndroom. Inmiddels is bekend 
dat de moleculen die veranderd of verminderd aanwezig zijn bij patiënten met EDS en 
Marfan syndroom ook aanwezig zijn in het bindweefsel in de spieren. Dit zou de functie van 
de spieren kunnen beïnvloeden.
Een aantal jaren geleden werd ontdekt dat bepaalde spierziekten (Bethlem myopathie 
en Ullrich congenitale spierdystrofie (UCMD)) veroorzaakt worden door een defect in 
collageen VI, een molecuul in het bindweefsel van spier. Blijkbaar kan een primair bind- 
weefseldefect het functioneren van die spier beïnvloeden. Geleidelijk aan is er ook meer 
aandacht gekomen voor de huid- en gewrichtskenmerken (toegenomen beweeglijkheid 
van de distale gewrichten en een abnormale littekenvorming) van deze collageen VI 
myopathieën. Het voorkomen van deze symptomen bij patiënten met een spierziekte 
vestigt de aandacht op het klinische en moleculaire continuüm van erfelijke bindweefsel­
aandoeningen en bepaalde spierziekten. Verder heeft recent onderzoek in proefdieren en
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patiënten laten zien dat het bindweefsel in en tussen de spieren een rol speelt in de 
overdracht van kracht die gegenereerd wordt door de individuele spiercellen. Dit wordt 
myofasciale krachtstransmissie genoemd. Hierdoor is onze interesse in de neuromusculaire 
symptomen van patiënten met een erfelijke bindweefselziekte nog verder toegenomen.
Door de bovengenoemde interesses heeft dit onderzoek twee doelen; 1) om te 
onderzoeken hoe vaak en welke neuromusculaire symptomen voorkomen in EDS en Marfan 
syndroom; en 2) om na te gaan hoe spierzwakte in EDS ontstaat en zo ook duidelijker te 
maken welke rol bindweefsel speelt in het functioneren van spieren. Dit heeft geleidt tot de 
volgende subdoelen (de nummering komt overeen met de delen van dit proefschrift):
(I) een overzicht te geven van het klinische en moleculaire continuüm van erfelijke bind- 
weefselziekten en spierziekten veroorzaakt door bindweefseldefecten;
(IIA) te onderzoeken welke neuromusculaire klachten voorkomen bij EDS patiënten, en hoe 
vaak;
(IIB) te onderzoeken welke pathofysiologische mechanismen een rol spelen in het ontstaan 
van spierzwakte in EDS om beter te begrijpen waarom EDS gepaard kan gaan met 
spierzwakte en om meer te leren over de rol van de extracellular matrix in spier;
(III) te onderzoeken welke neuromusculaire klachten voorkomen bij Marfan syndroom 
patiënten, en hoe vaak om na te gaan of de bevindingen specifiek zijn voor EDS of 
gegeneraliseerd kunnen worden naar andere erfelijke bindweefselziekten.
De belangrijkste bevindingen worden in dit hoofdstuk samengevat.
Hoofdstuk 2: Overzicht van de literatuur
In hoofdstuk 2 wordt een overzicht gepresenteerd van de literatuur over het moleculaire en 
klinische continuüm van erfelijke bindweefselziekten en spierziekten veroorzaakt door een 
defect in de ECM in spier. Er zijn verschillende erfelijke bindweefselziekten die gepaard gaan 
met lichte tot matige spier- en zenuwbetrokkenheid, naast de bekende huid- en gewrichts- 
en vasculaire problemen. Deze aandoeningen worden veroorzaakt door defecten van ECM 
moleculen die ook aanwezig zijn in het bindweefsel in spieren (collageen I, III, V, IX, lysylhy- 
droxylase, tenascine-X (TNX), fibrillin, fibuline, elastine, en perlecan), of die direct of indirect 
contact maken met de eiwitcomplexen op de oppervlakte van spiercellen (dystroglycan, 
integrine, sarcoglycan). Hiervan uitgaande zou verwacht kunnen worden dat neuromuscu­
laire symptomen van deze erfelijke bindweefselziekten vaker gerapporteerd worden dan 
feitelijk het geval is.
Daarnaast wordt een aantal myopathieën (o.a. congenital muscular dystrophy 1A, 1B of 
1C, en Bethlem myopathy / UCMD) veroorzaakt door defecten van moleculen die contact 
maken met de membraan van spiercellen (a-dystroglycan, sarcoglycan, integrine, en laminin), 
of door defecten van moleculen die meer in de matrix verweven zijn (collageen VI, XIII, en 
XV). Deze moleculen vormen een netwerk met uitgebreide onderlinge interacties. Beide
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groepen van aandoeningen gaan gepaard met een enerzijds 'bindweefselsymptomen' (hy- 
permobiliteit, contracturen, huidafwijkingen, algehele kwetsbaarheid van weefsels) en 
anderzijds 'spiersymptomen' (spierzwakte, inspanningsintolerantie, snelle vermoeibaarheid, 
spierkrampen). Dit overzichtsartikel beschrijft de structuur, functie en onderlinge interactie 
van de genoemde ECM moleculen, en wijst zo naar de gemeenschappelijke moleculaire 
achtergrond van deze aandoeningen. Dokters en onderzoekers die zich bezighouden met 
deze spierziekten en erfelijke bindweefselziekten moeten zich hier bewust van zijn. Het 
brede scala aan klachten van deze patiënten vraagt om een multidisciplinaire benadering. 
Daarnaast is het voor neurologen van belang om bij patiënten met neuromusculaire klachten 
te letten op gewrichtshypermobiliteit, omdat dit kan bijdragen aan het stellen van een 
specifieke diagnose.
Dit overzichtsartikel heeft zo de basis gelegd voor het verdere onderzoek in dit 
proefschrift.
Deel II: Neuromusculaire kenmerken van Ehlers-Danlos syndroom 
Deel IIA: Klinische beoordeling van Ehlers-Danlos syndroom patiënten
Deel IIA begint met een klinische beschrijving van drie individuele EDS patiënten met 
bijzondere neuromusculaire symptomen. Daarna worden de resultaten van het klinische 
onderzoek in 40 EDS patiënten en van het vragenlijst onderzoek in 273 EDS patiënten 
beschreven.
Hoofdstuk 3: Eerste klinische observaties in Ehlers-Danlos syndroom
De eerste patiënte is een 30-jarige vrouw met het hypermobiele type EDS die meerdere 
drukneuropathieën heeft doorgemaakt: van de n.axillaris, van de plexus brachialis, van de 
n.peroneus, en van de n.ischiadicus. Deze drukneuropathieën werden allen bevestigd met 
neurofysiologisch onderzoek, en genetisch onderzoek naar een erfelijke drukneuropathie 
liet geen PMP22 mutatie zien. Het pathofysiologisch mechanisme van herhaaldelijke 
drukneuropathieën bij een patiënt met EDS lijkt voor de hand te liggen: door abnormale rek 
of druk ten gevolge van de hypermobiliteit zouden zenuwen kunnen beschadigen. Het zou 
echter ook kunnen zijn dat het bindweefsel in en om de perifere zenuwen minder stevig is, 
waardoor de zenuwen kwetsbaarder zijn voor abnormale druk of rek. Dokters die betrokken 
zijn bij de zorg voor EDS patiënten zouden hier rekening mee moeten houden.
De tweede patiënt is een 16-jarige jongeman met het kyfoscoliotische type van EDS 
veroorzaakt door een homozygote deletie van PLODl (lysine hydroxylase 1; 1p36.3-p36.2), 
met proximale en distale spierzwakte, en hypotonie. Spierzwakte en hypotonie was in dit 
type EDS wel beschreven in de neonatale fase, maar niet op latere leeftijd. Bij aanvullend 
onderzoek werden aanwijzingen gevonden voor een myopathie en een lichte axonale poly­
neuropathie, die waarschijnlijk beiden hebben bijgedragen aan de spierzwakte. Deze kennis
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is van belang voor de tijdige herkenning van klachten en voor het opzetten van revalidatie- 
programma's voor patiënten met dit type EDS.
De derde patiënt is een 50-jarige vrouw met het TNX-deficiënte type EDS, die verwezen 
werd met ernstige distale spierzwakte, atrofie van de spieren in haar handen en contracturen. 
Ze had eveneens een gegeneraliseerde hypermobiliteit. Ze was jaren geleden ook al eens 
verwezen naar de polikliniek neurologie in verband met deze klachten, en het spierbiopt was 
destijds normaal. Het tweede spierbiopt uit de m.vastus lateralis liet evenmin myopathische 
afwijkingen zien, maar wel een licht verminderde aankleuring van het endomysium met 
collageen VI antilichamen. De combinatie van spierzwakte, hypermobiliteit en contracturen 
komt ook voor bij collageen VI myopathieën, en interactie tussen collageen VI en TNX is 
belangrijk voor een normale functie van deze moleculen. De beschrijving van deze patiënte 
illustreert het klinische en moleculaire continuüm van de erfelijke bindweefselziekten en 
bepaalde spierziekten.
Hoofdstuk 4: Systematische klinische observationele studie naar neuromusculaire kenmerken van 
Ehlers-Danlos syndroom
De verscheidenheid aan klachten in de drie patiënten beschreven in Hoofdstuk 3 heeft 
bijgedragen aan de opzet van de studie beschreven in Hoofdstuk4. Dit onderzoek bestaat 
uit: een korte gestandaardiseerde vragenlijst, lichamelijk onderzoek, zenuwgeleidingsonder- 
zoek en elektromyografisch onderzoek (EMG), spierecho en spierbiopsie in 40 EDS patiënten 
van het vaattype, het klassieke type, het TNX-deficiënte type, en het hypermobiele type 
veroorzaakt door haploinsufficiëntie van TNXB (n = 10 van ieder type).
Het merendeel van de patiënten meldde de volgende klachten: spierzwakte, spierpijn, en 
snelle vermoeibaarheid (respectievelijk 65%, 73%, en 60%). Lichte tot matige spierzwakte (85%) 
en vermindering van de vibratiezin (60%) kwam vaak voor. Zenuwgeleidingsonderzoek liet 
een axonale polyneuropathie zien in vijf patiënten (13%), zonder dat hiervoor een metabole 
oorzaak werd gevonden. Naald EMG liet overwegend myopatische kenmerken zien in 23% van 
de patiënten, en een gemengd neurogeen - myopathisch patroon in 53% van de patiënten. 
Spierecho liet een verhoogde echo intensiteit en spieratrofie zien in de helft van de patiënten 
(50% en 48%). In vijf van de 18 spierbiopten werden lichte myopatische afwijkingen gevonden 
(28%). Bij aanvullend elektronmicroscopisch onderzoek van het spierbiopt werd gezien dat de 
dichtheid en de lengte van de collageen vezels in de EDS patiënten verminderd was. 
Gemiddeld hadden de patiënten met het hypermobiele type EDS ten gevolge van TNXB 
haploinsufficiëntie (en verminderde aanwezigheid van TNX in serum) de minste klachten en 
symptomen. Dit kan wijzen op een dosis-effect relatie van de resterende hoeveelheid TNX 
(en daarmee de ernst van de ECM stoornis) en de ernst van het neuromusculaire fenotype. 
Verder vonden we in een deel van de patiënten ook aanwijzingen dat niet alleen de functie 
van spieren gestoord was, maar ook die van de perifere zenuwen.
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Hoofdstuk 5 en 6: Vragenlijstonderzoek naar vermoeidheid en pijn in Ehlers-Danlos syndroom  
Om te kunnen beoordelen hoe vaak pijn en vermoeidheid voorkomen bij patiënten met 
EDS, en om de invloed van deze klachten op het dagelijks leven te kunnen beoordelen, is 
vervolgens een schriftelijk vragenlijst onderzoek verricht onder 273 leden van de EDS 
patiëntenvereniging.
Meer dan driekwart van de EDS patiënten (77%) had last van ernstige vermoeidheid. 
Patiënten die erg vermoeid waren, hadden ook meer beperkingen in het dagelijks leven en 
meer psychische klachten. De vijf mogelijke determinanten die betrokken zijn in 
vermoeidheid bij EDS waren slaapstoornissen, concentratieproblemen, sociaal functioneren, 
de indruk de vermoeidheid zelf te kunnen beïnvloeden en ernst van de pijn. Omdat dit 
onderzoek een cross-sectionele opzet had, is niet bepaald of deze determinanten oorzaak of 
gevolg van de ernstige vermoeidheid zijn. Aan de hand van eerder longitudinaal onderzoek 
valt dit wel te beredeneren (zie ook Figuur2 in Hoofdstuk 13). Zo zouden deze determinanten 
een beginpunt kunnen vormen voor cognitieve gedragstherapie in EDS.
Omdat pijn een van de belangrijke determinanten van vermoeidheid was, is hier in het 
vragenlijstonderzoek verder naar gekeken (Hoofdstuk 6). Hieruit kwam naar voren dat 
chronische pijn veel voorkomt bij patiënten met EDS (90%) en dat het vaak gepaard gaat met 
het gebruik van pijnstillers. Verder kwam pijn vaker voor en was het ernstiger in het 
hypermobiele type EDS. De ernst van de pijn was gecorreleerd aan de hypermobiliteit, 
dislocaties, eerdere operaties, en aan slechte slaapkwaliteit. Pijn bleek ook bij te dragen aan 
functionele beperkingen in het dagelijkse leven, onafhankelijk van het nivo van vermoeidheid. 
Deze resultaten laten zien dat behandeling van pijn een belangrijk onderdeel van de 
symptomatische aanpak van EDS zou moeten zijn.
Deel IIB: Kwantitatief spierfunctie onderzoek van tenascine-X-deficiënte Ehlers- 
Danlos syndroom patiënten en tenascine-XB knockout muizen
De studies in deel IIB richten zich op het pathofysiologisch mechanisme van spierzwakte in 
EDS. Door dit onderzoek is duidelijker geworden hoe spierzwakte in EDS ontstaat en komen 
we meer te weten over de rol van de ECM in het functioneren van spieren. Deze onderzoeken 
zijn uitgevoerd in TNX-deficiënte EDS patiënten en Tnxb knockout (KO) muizen, een 
diermodel van EDS. Tabel 1 in Hoofdstuk 9 en Tabel 1 van Hoofdstuk 10 geven een overzicht 
van de gebruikte concepten, en in Box3 van Hoofdstuk 13 wordt een overzicht gegeven van 
de verschillende onderzoeksmethoden. In Tabel 1 van Hoofdstuk 13 worden de resultaten van 
deze studies samengevat en met elkaar in verband gebracht.
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Hoofdstuk 7 Kwantitatief spierfunctie onderzoek van twee tenascine-X-deficiënte Ehlers-Danlos 
syndroom patiënten
In dit hoofdstuk zijn de resultaten van kwantitatieve spierfunctie onderzoeken in twee 
TNX-deficiënte EDS patiënten beschreven. De krachtmomenten (= maat voor het 
rotatie-effect van een kracht; de grootte van een moment is bepaald als het product van 
kracht en krachtarm) werden gemeten bij relatief lange spierlengte. De TNX-deficiënte 
patiënten hadden verminderde maximale krachtmomenten bij vrijwillige contractie, relatief 
hoge twitch-momenten (krachtmomenten na enkelvoudige stimuli), een normaal interval 
tussen elektrische stimulatie en de krachtsopbouw, een snellere krachtsopbouw, en een 
normale relaxatie.
Het is onwaarschijnlijk dat deze afwijkingen zijn toe te schrijven aan verminderde fysieke 
activiteit of spieratrofie. Bij lichamelijk onderzoek, spierecho en spierbiopsie van deze 
patiënten werden namelijk geen tekenen gevonden van atrofie, en de twee patiënten 
hadden overeenkomstige afwijkingen, terwijl de ene patiënt fysiek veel actiever was dan de 
andere. De resultaten kunnen ook niet geheel verklaard worden door veranderingen van de 
krachtsoverdracht via de pees door een hogere compliantie (= de mate van elasticiteit) van 
die pees. Dan zou immers verwacht worden dat het krachtmoment dat opgebouwd wordt 
lager is en dat de relaxatie vertraagd zou zijn, en dat werd niet gevonden. Het zou daarentegen 
mogelijk kunnen zijn dat de TNX deficiëntie de stijfheid van de myofasciale verbindingen 
(gevormd door het bindweefsel in en om de spieren en rond de vaat-zenuwstreng) 
vermindert, en dat deze daardoor minder goed in staat zijn om onderling krachten over te 
dragen. Dit is in de volgende studies verder onderzocht (Hoofdstuk 9 en 10).
Hoofdstuk 8: Gestandaardiseerde neuromusculaire beoordeling van de tenascine-XB knockout muizen 
Voorafgaand aan het kwantitatieve spierfunctie onderzoek in het muismodel van EDS 
(Hoofdstuk9) is een aantal onderzoeken verricht om na te gaan of en zo ja welke neuromus­
culaire symptomen deze muizen hebben (Hoofdstuk 8). Er werden twee gestandaardiseerde 
functionele krachttesten gedaan ('hangtime' en 'paw-fall-through test'). Daarnaast werd een 
langdurige meting van de spontane bewegingen van deze muizen verricht, en zijn spier- en 
zenuwbiopten genomen.
Bij de functionele testen werd een lichte spierzwakte van de Tnxb KO muizen vastgesteld. 
Dit ging niet gepaard met een vermindering van de spontane motoriek in een kooi 
gedurende de observatie van een week. De spierbiopten lieten lichte myopatische 
veranderingen zien, en bij RNA micro array analyse van spier werd gevonden dat een aantal 
genen betrokken bij de aanmaak en afbraak van ECM eiwitten sterker tot expressie komt. Een 
n.ischiadicus biopsie liet een vermindering van de dichtheid en lengte van de collageenve- 
zels tussen de zenuwvezels zien, met tekenen van de- en regeneratie en kleinere diameters 
van de gemyeliniseerde vezels.
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Deze bevindingen sluiten aan bij de bevindingen in TNX-deficiënte EDS patiënten 
(Hoofdstuk 4), bij wie ook zowel myopathische als neuropathische afwijkingen werden 
gevonden. Deze Tnxb KO muis lijkt dus een goed model te vormen voor TNX-deficiënte vorm 
van EDS.
Hoofdstuk 9: Kwantitatief spierfunctie onderzoek van tenascine-XB knockout muizen 
Het doel van de studie beschreven in dit hoofdstuk is om vast te stellen of TNX deficiëntie 
inderdaad de stijfheid van de myofasciale verbindingen vermindert, zodat deze minder 
goed in staat zijn om krachten over te dragen. Het onderzoek bestaat uit twee delen: in het 
eerste deel worden intramusculaire aspecten van spierkracht onderzocht tijdens isometrische 
contracties van de maximaal vrijgeprepareerde m. gastrocnemius mediale (GM)(Serie A); in 
het tweede deel worden juist de intermusculaire aspecten van spierkracht gemeten aan de 
hand van kracht gemeten in de m. triceps surae (TS), de m.extensor digitorum longus (EDL); 
de m.extensor hallucis longus (EHL); en de m.tibialis anterior (TA) - dit terwijl de anatomische 
verhoudingen tussen deze spieren intact zijn (Serie B). Op deze manier kunnen de interacties 
tussen de genoemde spieren gemeten worden.
Bij serieA werden alleen verschillen gevonden bij korte spierlengte (optimum lengte - 4, 
- 3.5, - 3 mm): verminderde genormaliseerde actieve isometrische kracht, een langer interval 
tussen elektrische stimulus en het bereiken van 2%  van de maximale kracht, en vertraagde 
relaxatie in de Tnxb KO muis. Deze resultaten worden veroorzaakt door veranderingen van de 
serie elastische component binnen het maximaal vrijgeprepareerde GM spier-peescomplex. 
Het is niet vreemd dat dit alleen gevonden werd bij korte spierlengte, omdat juist dan meer 
'slack' opgenomen moet worden voordat de serie elastische component opgespannen is en 
kracht kan overdragen. Verder is het opvallend dat de genormaliseerde actieve isometrische 
kracht bij optimum spierlengte en daarboven normaal was, terwijl bij de twee TNX-deficiënte 
EDS patiënten in de pilot studie het krachtmoment wel verminderd was bij een vergelijkbare 
spierlengte. Dit verschil tussen kracht na elektrische stimulatie bij muizen en het 
krachtmoment tijdens vrijwillige contractie bij patiënten roept de vraag op of een 
verminderding van de activatie capaciteit wellicht bijdraagt aan de spierzwakte bij EDS 
patiënten.
De tweede serie experimenten in Tnxb KO muizen (Serie B) is gericht op de verandering 
van de serie elastische component tussen de spieren. Hierbij zijn ook alleen verschillen 
gevonden bij korte spierlengte. Normaal neemt de distal actieve kracht in de agonist (res­
pectievelijk TA+EHL en TS) af als de antagonist langer wordt (respectievelijk TS en TA+EHL). 
Dit komt doordat er tussen spieren onderling kracht wordt overgedragen; dit wordt 
myofasciale krachtstransmissie genoemd. De TNX deficiëntie beperkt deze antagonist-leng- 
te afhankelijke afname in actieve kracht van de agonist. Dit geeft aan dat de myofasciale 
krachtstransmissie verminderd is in de Tnxb KO muizen, waarschijnlijk ten gevolge van de
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toegenomen compliantie van het bindweefsel rondom en tussen de individuele spieren. 
Ook de netto epimusculaire myofasciale krachtsoverdracht was verminderd in de Tnxb KO 
muizen (gemeten als verschil van kracht tussen de proximale en distale pezen van de EDL). 
Blijkbaar zijn de TNX-deficiënte spieren minder goed in staat om onderling krachten over te 
dragen, en functioneren ze meer zelfstandig. Dit kan van invloed zijn op de onderlinge 
afstemming van spiercontracties in complexe fysiologische omstandigheden, waardoor 
bewegingen minder efficiënt verlopen.
Hoofdstuk 10: Kwantitatiefspierfunctie onderzoek van tenascine-X-deficiënte Ehlers-Danlos 
syndroom patiënten
De eerste stap om de bovenbeschreven resultaten te verifiëren in patiënten is om te kijken 
naar knie extensie in TNX-deficiënte patiënten bij relatief korte spierlengte, en om de activatie 
capaciteit te meten.
Dit is gedaan in zeven TNX-deficiënte EDS patiënten, met meting van de isometrische 
vrijwillige en elektrisch gestimuleerde contracties (van zowel knie extensie als knie flexie) bij 
verschillende spierlengtes (30°, 60° en 90° knie flexie) (Hoofdstuk 10).23 De mate van fysieke 
activiteit verschilde niet tussen de patiënten en controle proefpersonen.
De belangrijkste bevindingen van deze studie zijn: 1) TNX-deficiënte EDS patiënten 
hadden een verminderd maximaal krachtmoment van knie extensoren bij alle spierlengtes;
2) de genormaliseerde krachtmomenten waren niet verschillend tussen patiënten en 
controles (genormaliseerd naar het hoogste krachtmoment bij 60%); 3) het interval tussen 
elektrische stimulus en opbouw van kracht was verlengd met name bij korte spierlengte; en
4) EDS patiënten hadden een verminderde vrijwillige activatie met name bij korte spierlengte.
Samen laten deze resultaten zien dat het isometrische vrijwillige maximale krachtmoment 
verminderd is in EDS, en bevestigen daarmee de bevindingen van de pilot studie in twee 
TNX-deficiënte EDS patiënten (Hoofdstuk 7). De verlenging van het interval tussen elektrische 
stimulus en de opbouw van kracht en de verminderde centrale activatie bij korte spierlengte 
wijzen in de richting van een toegenomen compliantie van de serie elastische component 
van het spier-peescomplex. Echter, dit heeft blijkbaar niet geleid tot duidelijke vermindering 
van het genormaliseerde krachtmoment bij korte spierlengte (ook al zouden er eigenlijk 
meer meetpunten nodig zijn om hier een meer definitieve uitspraak over te doen). Verder 
geven de resultaten aan dat een belangrijk deel van de spierzwakte verklaard kan worden 
door een onvermogen om de spieren maximaal aan te spannen.
D eelIII: Neuromusculaire kenmerken van Marfan syndroom 
Klinische evaluatie van Marfan syndroom patienten
Om na te gaan of de bevindingen beschreven in deel IIA specifiek zijn voor EDS, of ook 
gevonden kunnen worden bij andere erfelijke bindweefselaandoeningen (zoals beschreven
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in het overzichtsartikel in Hoofdstuk2), is tenslotte gekeken naar het voorkomen van neuro­
musculaire symptomen in Marfan syndroom.
Hoofdstuk 11: Systematische klinische observationele studie naar neuromusculaire kenmerken 
van Marfan syndroom
Het onderzoek naar de neuromusculaire symptomen van Marfan syndroom bestaat uit een 
gestandaardiseerde vragenlijst, neurologisch onderzoek, zenuwgeleidingsonderzoek, naald 
EMG, laboratorium onderzoek en een spierbiopsie. Verder is gekeken naar de aanwezigheid 
van durale ectasie en meningospinale cysten aan de hand van eerder verricht beeldvormend 
onderzoek van de lumbosacrale wervelkolom.
Het bleek dat diverse neuromusculaire symptomen vaker voorkomen bij patiënten met 
Marfan syndroom dan bij controle proefpersonen (spierzwakte, spierpijn, snelle vermoei­
baarheid, beperkte loopafstand). De vier oudste patiënten (> 50 jaar) rapporteerden 
spierzwakte en hadden functionele beperkingen. Vijf patiënten hadden een lichte 
vermindering van de vibratiezin. Het zenuwgeleidingsonderzoek liet aanwijzingen zien voor 
een axonale polyneuropathie bij vier patiënten, en bij elektromyografie werd bij alle 
patiënten een gemengd myopathisch - neurogeen patroon gezien. Het klinisch neurofysio­
logisch onderzoek liet tevens aanwijzingen voor radiculopathie op één of meer lumbosacrale 
nivo's, welke gerelateerd leken aan de durale ectasieën en spinale meningeale cystes bij 
beeldvormend onderzoek. De spierecho liet bij meer dan de helft van de patiënten een 
toegenomen echo intensiteit en spieratrofie zien. Een spierbiopt kon slecht bij twee 
patiënten verricht worden; in één van hen liet dit myopathische afwijkingen zien.
Samengevat had het merendeel van de Marfan patiënten neuromusculaire symptomen 
met bij aanvullend onderzoek een lichte myopathie of polyneuropathie of beiden, met 
daarnaast aanwijzingen voor lumbosacrale radiculopathie. De oudere patiënten hadden de 
meeste klachten en symptomen.
Hoofdstuk 12: Symptomen van durale ectasie en/of spinale meningeale cysten 
Omdat aanwijzingen voor lumbosacrale radiculopathie niet zijn aangetroffen bij patiënten 
met EDS is hier in drie Marfan patiënten uitgebreider naar gekeken. Durale ectasieën komen 
voor bij 90% van de volwassen Marfan patiënten en hebben de neiging om groter te worden 
bij het ouder worden. De durale ectasie ontstaat waarschijnlijk door de voortdurende 
hydrostatische druk van de liquor op het slappere dura weefsel. Omdat de dura slapper is, 
wordt er in het algemeen van uitgegaan dat deze geen radiculaire compressie kan 
veroorzaken. Benige afwijkingen aan de wervelkolom zouden wel kunnen bijdragen aan het 
ontstaan van radiculopathie bij Marfan syndroom.
In dit hoofdstuk worden drie patiënten met matige tot ernstige radiculopathie 
beschreven; de patiënten presenteerden zich met pijn, spierzwakte en -atrofie, en gevoels-
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stoornissen. Beeldvormend onderzoek (MRI van de lumbosacrale wervelkolom) liet een 
nauw contact tussen de zenuwwortels en de durale ectasia en / of spinale meningeale cyste 
zien, waarbij de zenuwwortels zijn afgeplat en niet langer omgeven worden door vetweefsel. 
Meest waarschijnlijk werd de radiculaire prikkeling veroorzaakt door benige en durale 
compressie bij (kyfo)scoliose en durale ectasie met spinale meningeale cysten. Deze casus 
laten zien dat Marfan syndroom gepaard kan gaan met diverse neurologische symptomen, 
met name bij de oudere patiënten.
Box 7 in Hoofdstuk 13 geeft een puntsgewijze samenvatting van de belangrijkste conclusies 
van dit onderzoek en aanwijzingen voor toekomstig onderzoek.
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Appendix

Abbrevations
EDS Ehlers-Danlos syndrome
ICTD Inherited connective tissue disorder
ECM Extracellular matrix
UCMD Ullrich Congenital Muscular Dystrophy
TNX Tenascin-X
MRC Medical Research Council
KO Knockout
W T  W ild type
DGC Dystrophin glycoprotein complex
MDC Congenital muscular dystrophy
LGMD Limb girdle muscular dystrophy
W W S Walker-Warburg syndrome
MEB Muscle-eye-brain disease
FCMD Fukuyama congenital muscular dystrophy
SJS Schwartz-Jampel syndrome
SHS Silverman Handmaker syndrome
OI Osteogenesis imperfecta
MED Multiple epiphyseal dysplasia
TGF-p Transforming growth factor p
CCA Congenital contractural arachnodactyly
LH1 Lysyl hydroxylase 1
CK Creatine kinase
NCV Nerve conduction velocity
NCS Nerve conduction studies
CMAP Compound muscle action potential
MUAP Motor unit action potential
SNAP Sensory nerve action potential
T/A Turns / Amplitude analysis
EI Echo intensity
EM Electronmicroscopy
SD Standard deviation
Clas Classical type Ehlers-Danlos syndrome
Vasc Vascular type Ehlers-Danlos syndrome
TNXd Tenascin-X-deficient type Ehlers-Danlos syndrome
TNXh Happloinsufficiency of TNXB, associated with hypermobility type Ehlers-Danlos 
syndrome
Hyper Hypermobility type Ehlers-Danlos syndrome
CIS Checklist Individual Strength
SIP Sickness Impact Profile
SF-36 ShortForm-36
BDI-pc Beck Depression Inventory
SCL-90 Symptom Check List
SES Self Efficacy Scale
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VAS Visual analogous scale
PFT 1 min Number of paw fall through events in 1 minute
HT dur Hang time duration in sec
MMP Matrixmetalloproteinases
IPAQ International Physical Activity Questionnaire
TA Tibial anterior muscle
GM Medial gastrocnemius muscle
EHL Extensor hallucis longus muscle
EDL Extensor digitorum brevis muscle
TS Triceps surae muscle
l 0 (mm) Optimum length
Fmp Passive force
Fma Active muscle force
%Fm a Normalized active force
Fmt Total force
Fo Optimum force
peakFma Active peak force
%M RR Normalized maximal rate of relaxation
%M RFR Normalized maximal rate of force rise
MET Metabolic equivalent
MVT Maximal voluntary torque
nMVT Normalized MVT
VA Voluntary activation capacity en voluntary activation index
MTC Maximal torque capacity
MRTD Maximal rate of torque development
nMRTD Normalized MRTD
tMRTD Time to reach MRTD
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Ehlers-Danlos syndrome (EDS) and Marfan syndrome are two of the most frequent inherited 
connective tissue disorders, characterized by joint hypermobility, tissue fragility and easy 
bruising, skin hyperextensibility, and / or arterial aneurysmata with ruptures. Neuromuscular 
features have been reported in incidental cases, and are generally ascribed to reduced 
physical activity.
Inspired by patients referred to us and by recent developments in neuromuscular 
research, we presented an overview of the clinical and molecular continuum of the inherited 
connective tissue disorders and certain myopathies. Next, we studied the occurrence and 
nature of neuromuscular features in EDS and Marfan syndrome, and showed that both 
disorders are associated with mild neuromuscular features, with signs of myopathy and 
polyneuropathy in EDS; and signs of myopathy, polyneuropathy, and lumbosacral 
radiculopathy in Marfan syndrome. Furthermore, we showed that severe fatigue and chronic 
pain are highly prevalent among EDS patients. The five possible determinants involved in 
fatigue in EDS are sleep disturbances, concentration problems, social functioning, self 
efficacy concerning fatigue, and pain severity. Pain is related to hypermobility, dislocations, 
and previous surgery and associated with moderate to severe impairment in daily functioning. 
Finally, we investigated the pathophysiological mechanisms of muscle weakness in EDS in 
order to explore the role of the extracellular matrix in muscle function. The results showed 
that muscle weakness in EDS is not caused by reduced physical activity but results from 
(1) alterations of the series elastic component of the myotendinous pathways (due to 
increased compliance of connective tissue of muscle and tendon); (2) a reduction of 
myofascial force transmission (due to increased compliance of connective tissue between 
muscles and fascia), due to which muscles act more independently; and (3) a failure to 
maximally voluntarily activate the muscles.
This study will probably increase awareness of the various neuromuscular features of 
these and other inherited connective tissue disorders among clinicians and researchers, and 
thus improve the clinical recognition of these symptoms. The results of the studies on fatigue 
and pain could form a starting point for the development of an effective cognitive behavioral 
intervention for fatigue in EDS. Treatment of pain should be a prominent aspect of the 
symptomatic management of EDS. The results have also raised new research questions, e.g. 
what is the occurrence of neuromuscular symptoms in other inherited connective tissue 
disorders; which pathophysiological mechanisms cause peripheral nerve dysfunction in EDS 
and Marfan syndrome; how do ECM defects in various types of EDS result in intracellular - 
both myopathic and axonal - changes; and why is central activation capacity reduced in EDS.
